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Kurzfassung 
Tuberkulose (Tb), hervorgerufen durch das Mycobacterium tuberculosis (Mtb), ist weltweit die 
am häufigsten zum Tode führende bakterielle Infektionskrankheit. Erschwert wird die Therapie 
dieser Erkrankung durch das zunehmende Auftreten antibiotikaresistenter Mtb-Stämme und 
dem Mangel an Testsystemen, die eine schnelle und spezifische Diagnose der Tb 
ermöglichen. Die Zellhülle der Mtb-Bakterien trägt dabei wesentlich zur Virulenz des Erregers 
bei und stellt bislang ein besonderes Hindernis bei der Tb-Bekämpfung dar. Die Einzigartigkeit 
dieser mykobakteriellen Zellhülle kann jedoch auch als Vorteil verstanden werden und dazu 
beitragen, neue Methoden für die spezifische Diagnostik und gezielte Therapie von Tb zu 
entwickeln. In der hier vorliegenden Arbeit wurden die besonderen Eigenschaften der 
Mtb-Zellhülle gezielt ausgenutzt, um Mykobakterien aus einer Lösung anzureichern und 
verschiedene klinische Mtb-Isolate metabolisch zu markieren.  
Bei der Untersuchung der bislang kaum erforschten kohlenhydratbindenden Eigenschaften 
der Mykobakterien stellte sich heraus, dass die Adhäsion sowohl vom verwendeten 
Kohlenhydrat, als auch von der Konfiguration der glykosidischen Bindung und von der Struktur 
des Aglykons beeinflusst wird. In einem Mikrotiterplatten-basierten Testsystem zeigte der 
Mykobakterien-Impfstamm Bacillus Calmette Guérin (BCG) eine starke Adhäsion an 
Oberflächen, die mit dem α-D-Arabinofuranosid 1, dem α-D-Mannopyranosid 4 oder dem 
β-D-Glucopyranosid 7 beschichtet waren. Für den pathogenen Mtb-Stamm H37Rv wurde 
hingegen eine starke Bindung an p-Aminophenyl-α-D-galactopyranosid (8) und 6-Amino-
6-desoxy-α,α-D-trehalose (3) nachgewiesen. Magnetische Mikropartikel, die mit 
p-Aminophenyl-α-D-mannopyranosid (4) oder dem Trehalose-Derivat 3 funktionalisiert waren, 
wurden erfolgreich eingesetzt, um Mtb-Bakterien aus einer Lösung anzureichern. 
Mikropartikel, die mit dem Lipid-Liganden 36 oder dem zum Trehalose-Monomykolat analogen 
Derivat 37 modifiziert waren, zeigten jedoch deutlich höhere Bindungseffizienzen, die sich auf 
die hydrophoben Eigenschaften der mykobakteriellen Zellhülle zurückführen lassen. Die 
Ergebnisse dieser Adhäsionsstudien sollen zukünftig zur Entwicklung einer neuen Methode 
beitragen, die eine Anreicherung der Mtb-Bakterien aus Patientenproben (z.B. aus Speichel) 
ermöglicht und zur verbesserten Detektion des Erregers beiträgt.    
Die einzigartigen Kohlenhydrate der mykobakteriellen Zellhülle bilden die Grundlage für eine 
spezifische Markierung des Erregers. Synthetisierte Kohlenhydrat-Derivate können 
aufgenommen, metabolisiert und in die Zellhülle der Bakterien eingebaut werden. In der hier 
vorliegenden Arbeit wurden drei neue Azido-Pentosen, 3-Azido-3-desoxy-α,β-D-arabinose 
(3AraAz, 38), 3-Azido-3-desoxy-α,β-D-ribose (3RiboAz, 39) und 5-Azido-5-desoxy-
α,β-D-arabinofuranose (5AraAz, 40), synthetisiert und erfolgreich für die metabolische 
Markierung von Mtb eingesetzt. Der Einbau der Kohlenhydrat-Derivate in die mykobakterielle 
Zellhülle ermöglicht völlig neue Einblicke in bisher unerforschte Bereiche der Biologie des 
Erregers. Die Ergebnisse der metabolischen Markierung deuten stark auf das Vorhandensein 
von Transportmolekülen für Arabinosen und Ribosen in der Mtb-Zellhülle und auf die Existenz 
bisher unbekannter Biosynthesewege für Arabinose-Derivate hin. Die eingesetzten 
Azido-Zucker, insbesondere 5AraAz, zeigten keine toxischen Eigenschaften und eine hohe 
Markierungseffizienz, auch in klinischen Mtb-Isolaten. Diese Methode auf Grundlage 
metabolischer Prozesse ermöglichte die Fluoreszenzmarkierung verschiedener Mtb-Stämme 
ohne zeitaufwendige genetische Modifikationen. Die markierten Mtb-Bakterien wurden in 
Infektionsstudien mit humanen Makrophagen verwendet. Hierbei zeigten sich vergleichbare 
erregerspezifische Virulenzeigenschaften für 5AraAz-markierte und unmarkierte 
Mtb-Bakterien. Die neuen Azido-Pentosen können zukünftig zur Aufklärung noch unbekannter 
Mechanismen der Kohlenhydrataufnahme und -biosynthese beitragen. Ferner ermöglichen sie 
die Untersuchung der stammspezifischen Pathogenität in Wirtszellen, die mit dem klinischen 
Verlauf einer Tuberkuloseerkrankung in engem Zusammenhang steht. Des Weiteren kann der 
Einbau der Kohlenhydrat-Derivate auch die Grundlage für die Entwicklung einer neuartigen 
Methode darstellen, die es ermöglicht, Mtb-Bakterien gezielt anzugreifen und zu markieren. 
Es ist zu hoffen, dass die metabolische Markierung der Mtb-Zellhülle zukünftig zu einer 
Verbesserung der Tb-Therapie beitragen wird.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
Tuberculosis (Tb), caused by Mycobacterium tuberculosis (Mtb), is the single leading bacterial 
cause of death from infectious diseases worldwide. Tb therapy is complicated by an increase 
in antibiotic resistant Mtb strains and the lack of fast and specific diagnostic tools. The cell 
envelope of Mtb bacteria represents a major virulence factor and contributes to the intrinsic 
difficulties of eradicating the pathogen. However, the uniqueness of the Mtb cell envelope can 
also be seen as an advantage and could bear the chance to develop novel tuberculosis-
specific diagnostic and therapeutic tools. In this thesis the unique features of the Mtb cell 
envelope were utilized to enrich mycobacteria from solution and to metabolically label different 
Mtb clinical isolates.  
The widely unknown carbohydrate-binding characteristics of mycobacteria were investigated 
showing different adhesion efficiencies dependent on the applied sugar, the configuration of 
the glycosidic linkage and the structure of the aglycon. While the vaccine strain 
Bacillus Calmette-Guérin (BCG) strongly adhered to surfaces functionalized with 
α-D-arabinofuranoside 1, α-D-mannopyranoside 4 and β-D-glucopyranoside 7 containing an 
aromatic aglycon, the pathogenic Mtb strain H37Rv showed strong binding to 
p-aminophenyl α-D-galactopyranoside (8) and 6-amino-6-deoxy-α,α-D-trehalose (3) in a 
microtiter plate-based assay system. Magnetic beads functionalized with 
p-aminophenyl α-D-mannopyranoside (4) and the trehalose derivative 3, respectively, could be 
used to capture Mtb bacteria from solution. However, binding efficiencies were strongly 
surpassed by beads functionalized with the lipid ligand 36 and the trehalose 6-monomycolate-
analog derivative 37 addressing the high hydrophobicity of the Mtb cell envelope. The results 
of these adhesion studies will prospectively contribute to the development of a novel tool to 
enrich and more easily detect Mtb bacteria in patient specimen (e.g. in easy accessible saliva). 
The unique carbohydrate constituents of the mycobacterial cell envelope provide the possibility 
to specifically target Mtb. Synthesized derivatives of selected carbohydrates can be taken up, 
metabolized and subsequently be introduced into the cell envelope of Mtb bacteria. In this 
thesis three new azido pentoses, 3-azido-3-deoxy-α,β-D-arabinose (3AraAz, 38), 3-azido-
3-deoxy-α,β-D-ribose (3RiboAz, 39) and 5-azido-5-deoxy-α,β-D-arabinofuranose (5AraAz, 40), 
were synthesized and successfully used for metabolic labeling, thus shedding light on so far 
unknown Mtb biology. The data strongly suggest the presence of arabinose and ribose 
transporters in the Mtb cell envelope and as well the existence of yet unknown biosynthetic 
pathways for arabinose derivatives. The investigated azido sugars, in particular 5AraAz, 
exhibited no toxicity and high labeling efficiency, also in Mtb clinical isolates. This metabolic 
method enables to fluorescently label different Mtb strains without time consuming genetic 
modifications. Metabolically labeled Mtb bacteria were further used in infection studies with 
human macrophages, showing comparable pathogen-specific virulence characteristics to 
untreated Mtb bacteria. The new azido pentoses can now be employed to identify unknown 
uptake and metabolic mechanisms of Mtb bacteria and to study strain-specific pathogenicity 
in host cells, which is strongly associated with the clinical outcome of tuberculosis. In addition, 
the introduced carbohydrate derivatives may form the basis for a new and unexpected way to 
specifically reach and target Mtb bacteria, which might hopefully facilitate the improvement of 
tuberculosis therapy in future. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A guide to this thesis 
The work described in this thesis was carried out at the interface of chemistry and biology. 
New carbohydrate derivatives were synthesized and analyzed in the group of 
Prof. Dr. Thisbe K. Lindhorst (Organic Chemistry, Christiana Albertina University of Kiel, 
Germany).  The synthesized compounds were further applied in the group of PD Dr. Norbert 
Reiling (Microbial Interface Biology, Research Center Borstel, Germany) to facilitate the 
development of new tools to specifically capture and target Mycobacterium tuberculosis (Mtb), 
the main causative agent of tuberculosis.  
The thesis starts with a general introduction on current challenges in the fight against this 
infectious disease and on the uniqueness and relevancy of the mycobacterial cell envelope in 
this context. The following first part of this thesis focuses on the enrichment of mycobacteria 
from solution using carbohydrate derivatives or lipid ligands. The second part of this thesis 
deals with the application of carbohydrate derivatives as tools to metabolically label different 
Mtb clinical isolates. Both chapters are structured into a short specific introduction, the 
objectives of the study, a description of the obtained results and a subsequent detailed 
discussion of the results. The used methods are listed at the end of each part. NMR spectra 
of new compounds and known molecules, which were used for metabolic labeling, are depicted 
in the appendix. 
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1.  Introduction 
1.1 Tuberculosis – a global emergency 
Tuberculosis (Tb) is an infectious bacterial disease mainly caused by Mycobacterium 
tuberculosis (Mtb), which typically affects the lung (pulmonary Tb), but can also be present in 
other parts of the body (extra pulmonary Tb). It remains one of the world’s deadliest 
communicable diseases and was responsible for an estimated 1.5 million fatalities in 2014. 
The World Health Organization (WHO) reports almost 10 million new cases every year and 
overall more than 2 billion infected people.1 In the majority of infected people the bacterium is 
controlled by the immune system and does not cause disease (latent Tb). Only 10% of the 
infected individuals develop clinical symptoms (active Tb). However, the quantity of latent 
infections is a major risk. Compromised immune functions can result in a re-emergence of an 
active, transmittable disease. A STOP TB initiative organized by the WHO was initiated in the 
early 1990’s to provide standardized treatment and supervision and expand diagnostic tools 
and therapies. Furthermore, an overall goal of worldwide reduction of deaths due to Tb by 50% 
until 2015 and total elimination of disease by 2050 was envisaged.2 Because of these efforts, 
worldwide Tb is slowly declining each year and it is estimated that 43 million lives were saved 
between 2000 and 2014. However, the annual case rate remains unacceptably high.1 The fact 
that the amount of multi-drug resistant (MDR) and extensively-drug resistant (XDR) strains 
increases rapidly represents a severe problem in the fight against Tb and underlines the 
necessity to identify new drug targets and to come up with new anti-Mtb strategies. 
Furthermore, the development of rapid, accurate and inexpensive diagnostic tools is essential 
to fully reach the goals set by the STOP TB global initiative. 
 
1.2 Tuberculosis diagnostics  
Early detection of Tb infections and identification of drug resistances are crucial for tuberculosis 
prevention and control, but global case detection rates still remain low. In 2014 only 63% of 
the estimated 10 million people, who developed Tb, were registered as newly diagnosed cases 
before.1 The most common methods for detection of active Tb are direct microscopy of patient 
sputa and culturing of Mtb.3 In high burden countries the “gold standard” of Tb diagnosis is the 
direct microscopic examination of non-concentrated sputum samples.4 The bacteria are 
visualized by acid-fast staining procedures, such as the Ziehl-Neelsen stain or the auramine 
fluorescence stain. The microscopic analysis is not as sensitive as culture-based techniques. 
Less than 50% of cases detected as positive by culture are also positive by smear microscopy.1 
However, culturing the bacteria from sputum is more costly, requires specialized biosafety 
infrastructure and takes weeks to obtain results, because of the extremely slow growth rate of 
Mtb bacteria. In addition, high sensitivity can also be reached by nucleic acid-based diagnostic 
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strategies. With an Mtb-specific polymerase chain reaction (PCR) it is thought that Tb can be 
diagnosed with 98% reliability.5,6 Genetic methods further allow more precise detection of drug 
resistances7–9 and mutations correlating with Tb pathogenicity. However, they require a high 
technical competence. New methods increasing sensitivity and being at the same time cheap 
and easy applicable would strongly improve detection of active Tb. 
 
Beside the diagnosis of active Tb, detection of latent infected people is extremely important 
being aware of the fact that at least one half of all tuberculosis cases are the result of 
reactivation.1 Immunological-based strategies, like the tuberculin skin test (TST) and 
blood-based interferon-γ (IFN-γ) release assays (IGRAs), are currently applied.10 While in the 
TST the immune response to a protein mixture, purified from the filtrate of a mycobacteria 
culture, is visualized by skin induration,11 IGRAs are based on immune responses of isolated 
T-lymphocytes to Mtb-specific antigens.12,13 These antigens are absent in most 
non-tuberculosis mycobacteria. Thus, IGRAs, in contrast to the tuberculin assay, can 
distinguish between Mtb infected and Bacillus Calmette-Guérin (BCG) vaccinated people. 
However, both TST and IGRAs have limitations as they cannot distinguish between latent 
infected people and successfully cured individuals. Therefore, much work has been done on 
discovery of specific biomarkers in Tb infection14 that might provide an indication of treatment 
efficacy. Components of the mycobacterial cell envelope, for example, were directly detected 
in sputum or urine during active and latent infection, showed a treatment-dependent 
concentration in- or decrease and vanished after successful therapy.15–18 However, poor 
sensitivity has led to limited use of biomarker-based diagnostic tools.19 In addition, a new 
strategy was recently developed to analyze treatment efficacy by direct visualization of infected 
regions within the lung.20,21 This imaging method relies on an increased uptake of radiolabeled 
tracers, like 2-deoxy-2-(18F)fluoro-D-glucose (FDG), by activated inflammatory cells.20 
Accumulation of radioactivity is detected by positron emission tomography (PET), while 
morphological information is obtained by computed tomography (CT) high resolution X-ray 
images. Simultaneously performing PET/CT scans can monitor Mtb infections over time 
(Figure 1).21 This method gives the possibility to quantitatively measure drug efficacy and will 
further enable to explain why some Tb lesions do not respond to certain drugs. PET/CT scans 
are a major step forward in Tb diagnostics and will hopefully lead to an improvement of 
Tb therapy. However, both the currently used PET/CT scans and the biomarker-based 
methods do not directly detect Mtb bacteria. Thus, novel strategies that might allow to 
specifically visualize the bacterium within the body would strongly improve detection of latent 
Tb and analysis of drug efficacy. Furthermore, Mtb-specific labeling methods will lead to 
deeper insights into Mtb pathogenicity, which will facilitate the development of novel diagnostic 
and therapeutic tools. 
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1.3 Tuberculosis therapy  
The major problem in Tb control is the fact that more and more strains develop resistances to 
the drugs used for therapy. The emergence of drug resistance was first observed in the 
1940’s.23 Ultimately the use of antibiotic monotherapy was replaced by a four-drug (isoniazid, 
rifampicin, pyrazinamide and ethambutol) regimen for two months, followed by four months of 
therapy with rifampin and isoniazid (for chemical structures see Figure 3). However, 
non-compliance and relatively limited availability of drugs have resulted in the major problems 
of today. 480 000 new cases of MDR Tb, resistant to at least isoniazid and rifampin, were 
notified in 2014 and even 10% of them were detected as extensively drug-resistant (XDR) 
strains, which are not only resistant to first- but also to second-line drugs.1 In high burden 
regions (e.g. Russian Federation, Latvia and China) between 20% and 30% of the new Tb 
cases and 50% of the retreated cases are infected by MDR strains.1 Clinical outcomes of 
MDR/XDR Tb are largely suboptimal and their treatment is very long, toxic and expensive.24 
Especially in developing countries increasing resistances are a particular dilemma, because 
the susceptibility testing and second-line agents are usually insufficient. Fortunately, 2015 a 
novel drug was described, where preliminary data indicate high antibacterial activity in the 
absence of resistance development. Teixobactin (Figure 2) was obtained as a natural product 
from uncultured soil bacteria and is a multistep inhibitor of the bacterial cell envelope 
biosynthesis.25 Although teixobactin still has to pass the clinical trials, the first results make it 
reasonable that antibiotics might be developed, which do not lead to resistance formation. 
 
                                 
 
Figure 1. PET/CT images of a patient’s lung prior and two months after antibiotic treatment. PET/CT is a 
promising method, which enables live imaging of infected regions within the lung. In a non-treated patient’s lung 
intense FDG uptake in regions with activated inflammatory cells (“hot spots”) is visualized (A). Disease 
improvement after two months of antibiotic therapy is shown by a reduction of radioactivity within the lung. 
However, response to antibiotic therapy is lesion dependent (B). The images underline the potential application 
of PET/CT as a diagnostic tool to study drug efficiency and therapy outcomes. These PET/CT images were 
originally published in Russell, D. G. et al. Science 328, 852-856 (2010) and was adapted by permission from 
Science.22  
“Hot spots“ 
A) Prior to treatment B) After two month therapy 
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Figure 2: Chemical structure of the novel antibiotic teixobactin. First data indicate high antibacterial activity 
in the absence of resistance development.   
 
In addition to the increasing prevalence of MDR/XDR cases caused by genetic resistance 
mechanisms, drug therapy is complicated due to changes in the physiological and metabolic 
state of the bacterium. The ability of Mtb bacteria to enter into a non-replicating dormant 
lifestyle leads to an additional challenge.26,27 Currently applied drugs (Figure 3) can mainly 
attack bacteria, which are actively replicating and are metabolically active.28 Isoniazid and 
ethambutol are inhibitors of the cell envelope biosynthesis. Isoniazid is a prodrug that is 
activated by the mycobacterial catalase-peroxidase KatG forming the isonicotinic acyl-NADH 
complex. This complex competitively inhibits the fatty acid synthase and therefore the 
mycolic acid formation, an essential fatty acid of the Mtb cell envelope.29 Ethambutol inhibits 
the arabinosyltransferase disrupting the arabinogalactan synthesis.30 This 
heteropolysaccharide is essential for the structure of the mycobacterial cell envelope. Beside 
inhibition of cell envelope formation, anti-Tb drugs interrupt, for example, the RNA synthesis 
by inhibition of bacterial DNA-dependent RNA polymerase (rifampicin)31 and protein translation 
by inhibition of the ribosomal protein S1 (pyrazinamide).32 New drugs or even novel 
antibacterial strategies, which act against Tb during varying physiological stages and show 
limited resistance formation, are urgently required. 
              
 
 
Figure 3. Chemical structures of first-line drugs used for Tb therapy.  
Ethambutol Isoniazid Rifampicin Pyrazinamide
e 
Rifampicin 
Fatty acid synthase Arabinosyltransferase Ribosomal protein S1 RNA polymerase 
Teixobactin 
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1.4 Mycobacterium tuberculosis 
1.4.1 The bacterium 
Mtb was already discovered 1882 by Robert Koch33 as the causative agent of Tb. Since then 
a group of phylogenetically closely related mycobacteria, collectively known as the 
Mycobacterium tuberculosis complex (MTBC), were identified to cause Tb.34 The MTBC 
comprises seven closely related species. Tb in humans is primarily caused by Mtb and 
Mycobacterium africanum, which is currently limited to West Africa.35 Furthermore, 
Mycobacterium canettii can also infect humans. However, this pathogen widely differs from the 
other members of the MTBC.36 M. canettii mainly leads to extra pulmonary forms of Tb and 
seems to lack the capability of human-to-human transmission. The rare clinical cases caused 
by this species are confined to the Horn of Africa.37 In addition to human pathogens, several 
animal-adapted members of MTBC exist, including Mycobacterium bovis (bovine), 
Mycobacterium caprae (sheep and goats), Mycobacterium microti (rodents) and 
Mycobacterium pinnipedii (seals).38 Human Tb infections caused by M. bovis were detected.39 
However, there is currently no evidence of transmission between humans. The different 
members of MTBC appear to be strongly adapted to their particular host species.40  
Mtb comprises a large amount of different strains, which can be classified into families and 
further into five lineages (lineage 1, 2, 3, 4, 7) based on phylogenetic studies (Figure 4).41 
These lineages are grouped based on their ancientness into “modern” lineages (Clade 1) and 
“ancient” lineages (Clade 2).42,43 The major Mtb families (Beijing, Central Asian (CAS), 
Haarlem, Latin American Mediterranean (LAM), T and X) belong to lineages identified as 
“modern”.44,45 Strains of the Mtb family East African Indian (EAI) are ancient strains and deviate 
genetically from modern strains. The pathogenicity of Mtb bacteria differs been the two Clades, 
the different lineages and even the strains, which is strongly associated with the clinical 
outcome of Tb.41,46,47 
 
Figure 4. Phylogeny of the MTBC based on genome 
analysis. The eight human pathogenic lineages are 
represented including the five Mtb lineages (lineages 1, 
2, 3, 4 and 7), the two lines of M. africanum (lineages 5 
and 6) and M. canettii. The animal lineages represent a 
monophyletic branch in the complex. The “modern” 
lineages are located in the grey oval, as opposed to all 
the other lineages, which are called “ancient”. The major 
Mtb families are assigned to the lineages and shown in 
brackets. (scale bar: nucleotide substitutions per site) 
This phylogenetic tree was originally published in 
Comas, I. et al. Nat Genet 45, 1176‑1182 (2013) and 
was adapted by permission from Nature.48 
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Despite distinct genetic differences between the various species, all mycobacteria share a rod 
shaped appearance, long lifecycles up to 24 hours and an idiosyncratic hydrophobic cell 
envelope. Mycobacteria withstand weak disinfectants and can survive in a dry state for weeks. 
Its unusual cell envelope, rich in lipids, is likely responsible for this resistance, the failure of 
many antibiotics and is a key virulence factor.49 Since the mycobacterial cell envelope is 
essential for viability and virulence of Mtb, it is an important drug target.28 Understanding the 
uniqueness of the cell envelope structures in further detail will provide the basis for the 
development of new diagnostic tools and novel antibacterial strategies. 
1.4.2 The unique cell envelope of Mtb bacteria 
Mycobacteria were classified as Gram-positive bacteria based on 16S ribosomal RNA 
sequence comparison50,51 and a weakly positive Gram stain.52 The cell envelope of 
Gram-positive bacteria is composed of a plasma membrane followed by a thick layer of 
peptidoglycan and membrane- or peptidoglycan-attached glycopolymers. The mycobacterial 
cell envelope, however, contains an outer lipid layer53,54 and is more reminiscent of 
Gram-negative bacteria whose thinner peptidoglycan layer is followed by an outer membrane. 
Although there are some structural similarities to Gram-positive and Gram-negative bacteria, 
the structure in detail contains many unique features only found in the bacterial suborder of 
the Corynebacterineae, to which the mycobacteria belong. The mycobacterial cell envelope 
(Figure 5) consists of three major compartments: 
1. The “inner layer” is localized beyond a typical plasma membrane. This “inner layer” 
consists of proteins, lipid linked polysaccharides, like lipoarabinomannan (LAM) and its 
precursors lipomannan (LM) and phosphatidylinositol mannosides (PIM), and a 
mycolyl-arabinogalactan-peptidoglycan (mAGP) complex composed of a 
peptidoglycan (PG)-layer connected to arabinogalactan (AG), which is further 
conjugated with mycolic acids (MA). These long fatty acids are responsible for the 
connection to the second compartment, the “outer layer”.  
 
2. The “outer layer” consists of lipids and proteins. The lipids are freely associated with 
the “inner layer” by hydrophobic interactions. The lipid-linked polysaccharides consist 
of LAM and LM. Additional glycolipids are present like phenolic glycolipids (PGL), 
sulfolipids (SL) and mycolic acid containing glycolipids (e.g. trehalose 6-monomycolate 
(TMM) and trehalose 6,6'-dimycolate (TDM)). 
 
3. The “capsule” is loosely attached and mainly composed of the glycogen-like 
polysaccharide α-D-glucan, few lipids and proteins, including lipases and proteases. 
 
Subsequently the chemical structures and biological roles of the polysaccharides AG, LM and 
LAM and the glycolipids TMM and TDM are described in further detail.   
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Figure 5. Illustration of the unique mycobacterial cell envelope. The cell envelope consists of three major 
compartments: “inner layer”, “outer layer” and “capsule”. The “outer layer” sticks to the “inner layer” through 
hydrophobic interactions supported by the enormous length (C60-90) of mycolic acids. While bacteria-specific 
D-arabinofuranosides are located in the “inner layer” and “outer layer” as a component of lipoarabinomannan 
(LAM) and arabinogalactan (AG), trehalose is mainly a constituent of trehalose 6,6'-dimycolate (TDM) and 
trehalose 6-monomycolate (TMM), which are intercalated into the “outer layer”. β-D-Galf: β-D-galactofuranoside, 
α-D-Glcp: α-D-glucopyranoside, α-D-Manp: α-D-mannopyranoside, α-D-Araf: α-D-arabinofuranoside, 
α/β-D-GlcNAc: N-acetyl-α/β-D-glucosamine, β-D-MurNAc/Gc: N-acetyl-/N-glycolyl-β-D-muramic acid, 
α-L-Rhap: α-L-rhamnopyranoside. Figure based on Brennan, P. J. et al. Curr Top Med Chem 7, 475-488 
(2007).55  
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Mycolyl-arabinogalactan-peptidoglycan complex                                                                  
The peptidoglycan (PG) in mycobacteria (Figure 6) follows the structure of the most common 
type of peptidoglycan in bacteria, the A1γ class. The glycan chains of PG consist of alternating 
subunits of N-acetyl-β-D-glucosamine (GlcNAc) and N-acetyl- or N-glycolyl-β-D-muramic acid 
(MurNAc/Gc).56 Two glycan chains are cross-linked by tetrapeptides consisting of L-alanine, 
D-isoglutamine, meso-diaminopimelate and D-alanine.57 The cross-linking occurs between two 
meso-diaminopimelic acid units either by an alanine or directly.  
 
Figure 6. Chemical structure of the peptidoglycan in mycobacteria. The glycan chains of PG consist of 
alternating N-acetyl-β-D-glucosamine (GlcNAc) and N-acetyl- or N-glycolyl-β-D-muramic acid (MurNAc/Gc). 
MurNAc/Gc is connected to a tetrapeptide. The peptides of two glycan chains are cross-linked between two 
meso-diaminopimelic acids either by an alanine or directly, as depicted. (R: acetyl (Ac)/ glycolyl (Gc), 
L-Ala: L-alanine, D-IsoGln: D-isoglutamine, DAP: meso-diaminopimelate, D-Ala: D-alanine) 
 
The peptidoglycan is covalently linked to the galactan chain of arabinogalactan (AG) by a 
unique linker (Figure 7) consisting of a phosphodiester, α-D-GlcNAc and 
α-L-rhamnopyranoside (Rhap).58 AG (Figure 7) is the major polysaccharide of the 
mycobacterial cell envelope and connects the PG layer to the mycolic acid layer. AG is 
composed of D-arabinose and D-galactose, both in the relatively uncommon furanose form. 
The galactofuranosyl (D-Galf) residues are connected in alternating β(1→5) and β(1→3) 
linkages of approximately 30 residues forming the galactan polysaccharide. Galactan is 
attached to three arabinan polysaccharides by α(1→5) linkages.59 The α-D-arabinofuranosyl 
(α-D-Araf) residues of arabinan are connected by (1→2), (1→3) and (1→5) linkages. Terminal 
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Araf residues are functionalized with mycolic acids (MA) forming an ester bond between the 
acid and the primary hydroxyl group of Araf.59,60 MAs are α-alkyl-β-hydroxyl-fatty acids ranging 
from 60 to 90 carbons per chain and representing the longest fatty acids produced by an 
organism to date.61 While the short α-chain is saturated, the longer β-chain can be modified 
with different functional units, such as double bonds, methoxy or keto groups, cyclopropanes 
and epoxides, which vary in different Tb strains.62,63 MAs contribute to the intercalation of 
further glycolipids forming the “outer layer”.64  
 
Figure 7. Chemical structure of the mycolyl-arabinogalactan-peptidoglycan complex. The mAGP consists 
of peptidoglycan, which is covalently attached to galactan of the AG heteropolysaccharide by a unique linker. 
The arabinofuranosyl residues are terminally functionalized with mycolic acids. β-D-Galf: β-D-galactofuranoside, 
α-D-Araf: α-D-arabinofuranoside, α-D-GlcNAc: N-acetyl-α-D-glucosamine, α-L-Rhap: α-L-rhamnopyranoside.   
  
Mycobacterial lipoglycans and glycolipids  
LAM (Figure 8) and its precursor LM are the major lipoglycans found in the mycobacterial cell 
envelope. They contain a phosphatidyl-myo-inositol moiety (PI), which is connected to a 
diacylglyceride attaching the molecule non-covalently to the plasma membrane or to the 
“outer layer”.65 The smallest glycolipid precursor of LAM is PIM1, which has one 
α-D-mannopyranosyl (Manp) residue bound to the 2-position of myo-inositol.66,67 Addition of 
another Manp residue to the 6-position of the myo-inositol ring of PIM1 results in the formation 
of PIM2, which can be further elongated forming PIM6.68 Is the backbone extended with 
additional 20-30 Manp residues the polysaccharide is called LM. The mannan core of LM 
consists of linear α(1→6)-linked Manp residues and is further supplemented by α(1→2)-Manp 
side branches. LAM, based on the structure of LM, has a highly branched arabinan polymer 
attached to mannan by α(1→6) linkage.69 The α-D-arabinofuranosyl (α-D-Araf) residues of 
arabinan are connected by (1→2), (1→3) and (1→5) linkages. LAM is classified based on 
peripheral attachment of further molecules, “capping”. In pathogenic species, such as Mtb, 
LAM is capped to various degrees with short mannopyranosyl chains consisting of one to three 
residues,70 inositol phosphate-capped LAM (PILAM) is found in fast growing non-pathogenic 
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Mycobacterium smegmatis, and AraLAM,71 which has neither mannoside nor inositol 
phosphate caps, could be detected in Mycobacterium chelonae.72  
 
Figure 8. Chemical structure of lipoarabinomannan. The lipoglycan LAM is attached to the plasma membrane 
or the “outer layer” by the diacylglyceride moiety of the PI anchor. Myo-inositol of the PI anchor is glycosylated 
at the 2- and 6-position and thereby connected to mannan. Terminal mannosides of this polysaccharide are 
linked to arabinan. In pathogenic mycobacteria (e.g. Mtb) arabinofuranosides of arabinan are terminally 
connected to mannosides by α-(1→5) linkages. α-D-Manp: α-D-mannopyranoside, 
α-D-Araf: α-D-arabinofuranoside, PI: phosphatidyl-myo-inositol. 
 
Various free, noncovalently associated glycolipids are present in the mycobacterial cell 
envelope. The mycolic acid diester TDM and its precursor TMM were ubiquitous detected 
among mycobacterial species.73 TDM (Figure 9) is composed of trehalose functionalized with 
mycolic acids at the primary hydroxyl groups. The mycolic acids can possess different Tb 
strain-dependent modifications and chain lengths.62  
 
Figure 9. Chemical structure of a trehalose 6,6'-dimycolate molecule. TDM is a mycolic acid diester of 
trehalose. The depicted mycolic acids are only an example for a variety of mycolic acids present in mycobacteria. 
The 60 to 90 carbon long fatty acids exhibit Mtb strain-dependent functional units (double bonds, methoxy or 
keto groups, cyclopropanes and epoxides) and chain lengths.  
 
The described lipoglycans and glycolipids are only a part of the free lipids forming the 
“outer layer” of the Mtb cell envelope. The high amount of lipids has a strong impact on cell 
envelope fluidity and permeability. While hydrophobic molecules can pass through the thick 
and dense cell envelope, hydrophilic substances have to be actively transported or can 
passively diffuse through porins. The thickness and hydrophobicity of the mycobacterial cell 
envelope are linked to the considerable resistance of Mtb bacteria to many drugs.74  
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The carbohydrates of the lipoglycans and glycolipids contribute to the pathogenicity of Mtb68  
and are part of the uniqueness of the mycobacterial cell envelope. While some of the 
carbohydrate components, such as mannopyranosides and glucopyranosides, are widely 
prevalent in cell envelopes of bacteria and eukaryotic cells, D-trehalose and 
D-arabinofuranosides are mainly found in the cell envelope of Corynebacterineae.75,76 These 
unique sugars have the potential to promote the development of novel specific diagnostic and 
therapeutic strategies and are the focus of this thesis.  
 
1.4.3 The rare carbohydrates of the mycobacterial cell envelope 
D-Trehalose 
Trehalose is a non-reducing disaccharide of α(1→1)-linked glucose. It is present in several 
eukaryotic organisms (e.g. fungi, insects and plants, but not in mammals) and in both 
Gram-positive bacteria (e.g. Propionibacterium freudenreichii) and Gram-negative bacteria 
(e.g. Pseudomonas aeruginosa, Escherichia coli).75 In these organisms trehalose is mainly 
located in the cytoplasm. Intracellular trehalose is considered to act as a stress protector 
molecule, as it was shown to shield proteins, membranes or whole cells from heat-induced 
denaturation, freezing or γ-radiation.77–79 In mycobacteria trehalose is not only present as a 
free disaccharide in the cytoplasm but is also a prominent constituent of several cell envelope 
glycolipids, such as TDM and TMM. While the essential role of membrane-bound trehalose for 
cell envelope integrity and pathogenicity of Mtb is proven,80 the contribution of intracellular 
trehalose on dehydration tolerance is only hypothetical.81  
 
Biosynthesis of trehalose 6,6'-dimycolate 
The biosynthesis (Figure 10) of the unique trehalose-containing glycolipids is localized in the 
cytoplasm, where free trehalose is mainly synthesized from activated glucose derivatives. 
Uracil-diphosphate(UDP)-glucose and glucose-6-phosphate are converted into trehalose-
6-phosphate (T6P), catalyzed by the trehalose-6-phosphate synthase (OtsA). This 
intermediate is subsequently dephosphorylated into trehalose by the specific trehalose-
6-phosphate phosphatase (OtsB).82,83 Beside the biosynthesis from glucose, trehalose can 
also be generated from glycogen. Maltooligosyltrehalose synthase (TreY) catalyzes the 
isomerization of the α(1→4)-linkage of the terminal disaccharide at the reducing end of 
glycogen into a α(1→1)-linkage, followed by the release of trehalose by maltooligosyltrehalose 
trehalohydrolase (TreZ).75 If trehalose-6-phosphate or trehalose is the substrate for the TMM 
synthesis remains to be confirmed. TMM is translocated across the plasma membrane by the 
mycobacterial membrane protein large 3 (MmpL3).84,85 The antigen 85 (Ag85) complex is 
essential to transfer mycolate from TMM to either AG or another molecule of TMM generating 
TDM.86 Both transesterification processes release free trehalose, which is recycled by a 
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trehalose-specific ATP-dependent transporter SugABC-LpqY.87 While mycolated 
arabinogalactan connected with the PG layer is a constituent of the “inner layer” of the Mtb cell 
envelope, TMM and TDM are intercalated into the “outer layer”. 
 
Figure 10. Illustration of the TDM metabolism. Trehalose is either derived from activated glucose derivatives 
or through glycogen degradation. Cytosolic trehalose can be acylated forming TMM, which is a precursor for 
TDM. TDM is obtained by mycolic acid transfer in the “inner layer”. Trehalose derivatives located in the cell 
envelope are unique constituents of mycobacteria. (   : α-D-glucopyranoside (α-D-Glcp)) Figure based on 
Swarts, B. M. et al. J Am Chem Soc 134, 16123-15126 (2012).88  
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D-Arabinofuranoside 
D-Arabinose is a very rare sugar in nature. While D-arabinopyranose (Arap) occurs in some 
eukaryotes, such as plants89 and some parasitic protozoa like the trypanosomatid parasite 
Leishmania major,90–94 D-arabinofuranose (Araf) can only be found in prokaryotes. Araf is a 
cytoplasmic intermediate in the biosynthesis of 3-deoxy-D-manno-octulosonic acid (Kdo),95 an 
essential carbohydrate of the lipopolysaccharide (LPS) in Gram-negative bacteria. In addition 
Araf is an unique component of cell surface polysaccharides and glycolipids of mainly 
Corynebacterineae.96 In mycobacteria, including pathogenic Mtb, Araf is a prominent 
constituent of the two major cell envelope polysaccharides AG and LAM.  
 
Biosynthesis of the arabinofuranosyl components of AG and LAM 
The biosynthesis of arabinose-containing polysaccharides (Figure 11) has been characterized 
in detail for Mycobacterium smegmatis (Msg), while for Mtb several steps remain uncertain.97 
In the LAM/AG-metabolism activated D-glucose-6-phosphate is transformed to D-ribulose-
5-phosphate catalyzed by two dehydrogenases and a lactonase. This intermediate can also 
be derived from exogenous D-arabinose via a fungal-like pathway.97–99 D-Arabinose is taken 
up and reduced to D-arabinitol, which is further oxidized to D-xylulose. This pentose is 
phosphorylated to D-xylulose-5-phosphate and epimerized to D-ribulose-5-phosphate. 
D-ribose-5-phosphate is either obtained by an isomerization of activated D-ribulose or directly 
from D-xylulose-5-phosphate with sedoheptulose-7-phosphate as an intermediate. 
Subsequently activated D-ribose is further converted to decaprenyl-phospho-ribose. The last 
metabolic steps contain a 2-epimerization of decaprenyl-phospho-ribose to decaprenyl-
phospho-arabinose, which serves as the donor of D-arabinofuranosyl residues for the LAM and 
AG formation.97 In contrast to Msg, for which the biosynthesis of arabinan from external 
D-arabinose was described and a specific ATP-dependent (ABC) arabinose transporter is 
known, in Mtb only a few enzymes of the arabinan metabolism have been defined to date97 
and the carbohydrate transport systems are poorly characterized.100  
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Figure 11. Illustration of the arabinan metabolism. The biosynthetic pathway for LAM and AG is mainly 
studied for Msg. For Mtb a few genes (shown in brackets) encoding for metabolic enzymes were identified to be 
essential for the arabinan metabolism. While the uptake of environmental arabinose is described for Msg and an 
ABC-transporter is known, no pentose transport systems were identified for Mtb to date. The donor for the 
arabinan synthesis is decaprenyl-phospho-D-arabinose, other precursors have never been identified. 
D-Arabinofuranosides are mainly present in the cell envelopes of Corynebacterineae. Figure based on 
Wolucka, B. A. FEBS J 275, 2691-2711 (2008).97  
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1.4.4 Mycobacterial carbohydrates connected to Mtb pathogenicity 
The carbohydrates of the Mtb cell envelope are strongly associated with mycobacterial 
pathogenicity. Mtb bacteria are mainly transmitted by inhalation of aerosolized droplets 
released from infected patients by coughing. The initial step in the infection process is the 
contact between inhaled bacteria and primarily alveolar macrophages, which internalize the 
bacterium through phagocytosis. Following recognition and uptake the host cell initiates a 
number of responses to limit bacteria replication and spread with the ultimate goal of 
eradicating the pathogen. Mtb, however, has evolved successful strategies to survive, replicate 
and persist within macrophages for days, months or years and needs host cells for nutrient 
acquisition and protection against the immune system. The polysaccharides and glycolipids of 
the Mtb cell envelope strongly contribute to the manipulation of host cells and the survival of 
Mtb bacteria within phagosomes.68,101,102  
 
Initial recognition of mycobacteria by the innate immune system is triggered by several pattern 
recognition receptors (PRRs).103,104 These PRRs comprise humoral receptors, such as 
surfactant proteins105 and the mannose-binding lectin (MBL).106 In addition a variety of 
membranous receptors belong to the PRRs including toll-like receptors (TLRs) and C-type 
lectins, such as the DC-specific intercellular adhesion molecule 3-grabbing nonintegrin 
(DC-SIGN),107,108 the dendritic cell-specific C-type lectins (Dectin-1, Dectin-2),109–111 the 
macrophage inducible C-type lectin (Mincle),80,112 the macrophage C-type lectin (MCL)113,114 
and the mannose receptor (MR)115,116 (Figure 12). Several of the PRRs are lectins, which 
recognize carbohydrate structures on the mycobacterial cell surface. The soluble collectin 
surfactant proteins A (SP-A), for example, interacts with ManLAM and LM and acts as an 
opsonin, enhancing binding and uptake of Mtb bacteria by macrophages.105 The most 
prominent membranous receptor involved in phagocytosis of Mtb bacteria by macrophages is 
the MR.115,116 The main ligand of MR is ManLAM.115 The binding affinity of the MR to LAM 
dependents on mannosylation.117 While ManLAM from pathogenic Mtb strains show intense 
binding, PILAM from Msg does not bind to the MR. Higher-order PIMs (PIM5 and PIM6) were 
identified as additional ligands.118 The MR is distinguished by the fact that it mediates 
internalization without triggering pro-inflammatory response.119 Thus, phagocytosis via the MR 
can be regarded as a strategy of Mtb to escape immune surveillance.119 In addition to direct 
pathogen uptake, other classes of PRRs, such as TLRs, play essential roles in activating signal 
transduction pathways.104 The TLR1/TLR2 complex was identified to recognize LM and to a 
lesser degree PIM6.120,121 This interaction, in contrast to the MR, leads to an activation of the 
macrophage resulting in the transcription of pro-inflammatory cytokines.121 However, the 
importance of TLRs in immunity to tuberculosis is controversially discussed and might be less 
significant than originally assigned.122 Additional carbohydrates involved in host-pathogen 
interactions are the α-glucan of the capsule and trehalose of the unique TDM of the “outer 
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layer”. While α-glucan is one of the variety of ligands recognized by DC-SIGN123–125 and might 
also interact with Dectin-1,126 TDM is the main mycobacterial ligand for Mincle and MCL and 
strongly contributes to the survival of Mtb bacteria within phagosomes.80,112–114  
 
Figure 12. Illustration of the pattern recognition receptors present on the cell surface of macrophages, 
which recognize carbohydrate structures of the Mtb cell envelope. Several C-type lectins (DC-specific 
intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN), dendritic cell-specific C-type lectins 
(Dectin-1, Dectin-2), macrophage inducible C-type lectin (Mincle), macrophage C-type lectin (MCL), mannose 
receptor (MR)) and the toll-like receptor 1 (TLR1)/TLR2 complex were identified as receptors for polysaccharides 
(α-glucan), glycolipids (TDM, PIM) and lipoglycans (LM, ManLAM) of the Mtb cell envelope.   
 
Mycobacterial glycolipids and lipoglycans play an important role in regulating phagocytosis 
(Figure 13). Macrophages engulf pathogens forming a phagosome, which then matures into a 
phagolysosome involving a series of fusion reactions with the endocytic and secretory 
pathways and ultimately fusion with lysosomes. Phagolysosomes have an acidic pH of 4.5, 
hydrolase activities through lysosomal enzymes (e.g. proteases, lipases and glycoside 
hydrolases) and contain antimicrobial peptides. Phagosome maturation is crucial for killing of 
engulfed microbes as well as for antigen presentation to T-lymphocytes. Mtb bacteria are able 
to inhibit phagosome maturation triggered by different cell envelope carbohydrate 
structures.127,128 ManLAM limits influx of calcium ions (Ca2+) into the cytosol presumably by 
binding to the MR.129 A decreased Ca2+ concentration reduces the binding of Ca2+/calmodulin 
to Ca2+/calmodulin-dependent protein kinase (CAMK II), a serine-threonine kinase, which 
activates the phosphatidylinositol 3 kinase (PI3K).130,131 PI3K catalyzes the phosphorylation of 
phosphatidylinositol at the 3-position of the inositol ring leading to the formation of 
phosphatidylinositol 3-phosphate (PI3P) on the phagosomal membrane. PI3P and the GTPase 
Ras-related in brain 5 (Rab5), which is an important marker of early endosomes and involved 
in endosomal fusion, are important mediators of the recruitment of the early endosome 
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antigene 1 (EEA1) to the phagosomal membrane. EEA1 is necessary to deliver hydrolases 
such as cathepsin D and H+-ATPase subunit Vo from the trans-Golgi network (TGN) to the 
phagosome and promotes the fusion of phagosomes with vesicles of the endosomal-lysosomal 
pathway.132 Therefore, inhibition of Ca2+ influx directly correlates with inhibition of phagosome 
maturation. In addition, PIMs can also inhibit phagosome acidification, not by preventing EEA1 
recruitment, but by promoting fusion between the phagosome and early endosomes.133 Other 
host receptors that are involved are the TDM recognizing lectins Mincle112 and MCL.113 TDM-
coated beads are sufficient to delay phagosome maturation in macrophages.134 Different 
carbohydrate-lectin interactions contribute to the fact that Mtb bacteria reside in phagosomes 
with incomplete luminal acidification (pH 6.5) and absence of mature lysosomal hydrolases, 
containing early endosomal markers like Rab5, only a transient localization of the late 
endosomal marker Rab7 and low levels of the lysosome-associated membrane protein 1 
(LAMP-1).127,135,136  
 
Figure 13. Illustration how glycolipids and lipoglycans of the Mtb cell envelope contribute to the 
inhibition of the phagosome maturation. ManLAM contributes to the inhibition of the phagosome maturation 
by reduction of the influx of calcium ions (Ca2+) into the cytosol. A limited Ca2+ concentration results ultimately in 
a reduced phosphorylation of phosphatidylinositol (PI). Phosphatidylinositol 3-phosphate (PI3P) and the GTPase 
Ras-related in brain 5 (Rab5) are important mediators of the recruitment of the early endosome antigene 1 
(EEA1) to the phagosomal membrane, which induces the delivery of hydrolases such as cathepsin D and 
H+-ATPase subunit Vo from the golgi to the phagosome and promotes the fusion of phagosomes with vesicles 
of the endosomal-lysosomal pathway leading to a phagosome maturation. PIMs induce fusion with early 
endosomes. In addition TDM contributes to the fact that Mtb resides in phagosomes with incomplete luminal 
acidification (pH 6.5) and absence of mature lysosomal hydrolases. (CAMK II: Ca2+/calmodulin-dependent 
protein kinase, PI3K: the phosphatidylinositol 3 kinase, LAMP-1: lysosome-associated membrane protein 1) 
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Mtb bacteria can also regulate processes of cell death in macrophages. Inhibition of apoptosis 
is regarded to be beneficial for the pathogen during early stage of infection for maintaining its 
replicative niche, while lysis of the host cell at a later stage reaching a certain bacterial load 
enables spreading and entering new host cells. Apoptosis inhibition can be induced by 
ManLAM. Reduction of Ca2+ signaling, as described for inhibition of phagosome maturation, 
appears to be an important step in blocking infection-induced apoptosis.137 Beside regulation 
of the cytosolic Ca2+ concentration, ManLAM can activate the serine-threonine kinase Akt 
leading to a phosphorylation of Bcl-2-associated death promoter (Bad) and release of the anti-
apoptotic protein B-cell lymphoma 2 (Bcl-2).138  
 
While ManLAM strongly reduces phagosome maturation and apoptosis,119 LM binds to TLR2 
and induces pro-inflammatory responses139,140 and an activation of the macrophage121 
(Figure 14). As LAM and LM are both part of the mycobacterial cell envelope, one might expect 
a direct correlation between mycobacterial virulence and a LAM/LM ratio.68 However, the 
biological significance of the LAM/LM balance or even more importantly of the whole 
carbohydrate composition of the mycobacterial cell envelope are only rarely studied119,141 and 
remain to be investigated in further detail. Therefore, a fast and easy tool that might allow to 
visualize the carbohydrate composition on cell surfaces of different Mtb strains will facilitate 
the identification of the strain-specific cell envelope heterogeneity, which might further enable 
to correlate carbohydrate composition to Mtb pathogenicity.  
 
Figure 14. Illustration of the immunomodulative properties of the carbohydrate structures of the 
mycobacterial cell envelope. While ManLAM and PIMs show mainly anti-inflammatory activity, LM can induce 
the secretion of pro-inflammatory cytokines. This figure shows only a part of functions induced by mycobacterial 
glycolipids and lipoglycans. (TLR: toll-like receptor, SP-A: surfactant protein-A, MR: mannose receptor, 
Mincle: macrophage inducible C-type lectin, Akt is a serine-threonine kinase, Bcl-2: B-cell lymphoma-2). 
 
The unique carbohydrates of the Mtb cell envelope, trehalose and arabinofuranoside, 
contribute to a varying extent to the virulence of Mtb bacteria. Trehalose as a constituent of 
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TDM is strongly involved in inhibition of phagosome maturation.134 The physiological role of 
arabinans was thought to be exclusively structural.97 However, the arabinofuranosides are 
essential, since inhibition of the arabinan synthesis is lethal in Mtb.142,143 Unconsidered their 
biological functions, both carbohydrates represent good targets for new diagnostic and 
therapeutic tools, since they are not synthesized in mammals and seldom localized on cell 
surfaces of other microorganisms. 
1.4.5 Mycobacterial lectins 
Lectins on host cells recognizing carbohydrates of the Mtb cell envelope strongly contribute to 
mycobacteria recognition and uptake and have an influence on the immune response. The 
importance of bacterial lectins for adhesion, pathogenicity and biofilm formation is known for 
many Gram-positive and Gram-negative bacteria.144 However, there is very little information 
available about mycobacterial lectins. Their impact on host-pathogen interactions and the 
adhesion among mycobacteria is rarely studied. In 1989 an extracellular lectin, “mycotin”, was 
isolated from Msg, which was able to agglutinate human A, B and O erythrocytes.145 This 
agglutination could be inhibited by different carbohydrates. Apart from D-arabinose, mannan 
and p-nitrophenyl α-D-mannopyranoside showed high inhibitory potency. Other mycobacteria, 
like Mtb, were found to contain molecules immunologically related to mycotin.146 However, the 
potential lectin of Mtb was not isolated until now and it is still unclear where it is encoded in the 
bacterial genome. That lectins are involved in mycobacterial aggregation was shown by 
V. Anton et al..147 In this case D-arabinose was identified to inhibit aggregation of Mtb bacteria. 
The arabinose-specific lectin, which mediates self-aggregation, has also not been isolated or 
further characterized to date. After the genome of Mtb was completely deciphered a few years 
ago, D. D. Singh et al. identified ten potential lectins present in the mycobacterial genome by 
bioinformatic analysis.148 Those proteins span a wide range in length and functional 
annotations and can be classified to belong to families like haemagglutinins, mannose-
sensitive agglutinins or C-type lectins, which bind carbohydrates in a calcium-dependent 
manner.148,149 Although this genetic analysis strongly indicates that mycobacterial lectins are 
present, little is known about carbohydrate specificity, localization and biological functions. 
Identification of membranous mycobacterial lectins and their biological role might give new 
insights into Mtb pathogenicity. Carbohydrate-lectin interactions might further be utilized to 
develop new diagnostic tools.  
In this thesis the presence of rare carbohydrates and possibly of specific mycobacterial lectins 
in the Mtb cell envelope and the high hydrophobicity of the mycobacterial cell surface formed 
the basis for the development of new tools to enrich mycobacteria from solution (part 1) and 
to specifically label different Mtb clinical isolates (part 2) - firsts steps towards new diagnostic 
and therapeutic tools. 
  
 
 
Exploitation of mycobacterial adhesion characteristics to improve detection of 
Mycobacterium tuberculosis  
 
 
 
 
 
               
 
Part 1 
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2 Exploitation of mycobacterial adhesion characteristics to improve 
detection of Mycobacterium tuberculosis  
The concentration of mycobacteria in patient specimen is a limiting factor in Tb diagnostics. 
The first part of the thesis focuses on enrichment of mycobacteria from solution. 
2.1 Introduction 
Low bacteria numbers contribute to false negative results from sputum samples.150 In addition 
an alternative patient specimen, such as saliva, was excluded for diagnostics, because it 
contains even lower amounts of mycobacteria compared to the commonly used sputum.151 
Sputum, however, has several disadvantages. Children and cachectic patients usually cannot 
cough up enough phlegm to allow laboratory evaluations. Furthermore, children tend to 
swallow the specimen rather than expectorate it. In order to enrich samples, sputum induction, 
where a child inhales a saline solution to help them cough up sputum, and gastric or 
nasopharyngeal aspiration, where a tube is inserted into the stomach or nose to suction out a 
sputum sample, are applied.152–154 These procedures are very unpleasant and may also require 
hospitalization and trained personnel, which can be hard to come by in resource-limited 
settings. Saliva might represent a good alternative, because of its easy accessibility. Recent 
visualization of Mtb bacteria in saliva using auramine rhodamine as staining method instead 
of the common Ziehl-Neelsen stain underlines the potency of saliva as an alternative biological 
sample for diagnosis.155,156 Detection of Mtb bacteria in saliva by PCR is also possible as 
recently proven.157 Although Mtb bacteria were detected in saliva, development of diagnostic 
tests based on oral samples remained unsuccessful due to the low bacteria numbers.158,159 
Thus, mycobacteria enrichment is necessary to increase the detection rate.  
 
The development of a new tool to capture Mtb bacteria from solution might enable to use saliva 
as an alternative specimen for detection of Mtb. Therefore, a ligand, which binds Mtb bacteria 
with high efficiency, has to be identified. Previously surfaces functionalized with peptides, 
proteins or antibodies have been used to capture mycobacteria with high specificity.160–165 
However, such ligands are quite susceptible to proteolytic degradation and denaturation and 
are too expensive for extensive use. A more promising approach was published 2010 by 
Microsens Medtech Ltd..166 The “Tb-Beads” are paramagnetic beads coated with the 
hydrophobic poly-diallyldimethyl ammonium chloride (pDADMAC). The “Tb-Beads” are applied 
to captured Mtb bacteria from sputum facilitating existing laboratory practice, such as 
microscopy and cultivation.167,168 In addition to hydrophobic interactions, diagnostic tools can 
be based on carbohydrate-lectin interactions. Recently, magnetic nanobeads coated with the 
mannose-binding lectin (MBL) were used to clean blood from
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 pathogens, an extracorporeal device for sepsis therapy.169 Furthermore, beads functionalized 
with carbohydrate derivatives were used as ligands for microbial lectins leading to bacteria 
detection in water, food, urine or even saliva.170–173 Carbohydrate derivatives and lipid-based 
ligands are cheaper to produce and more stable than proteins and antibodies. Thus, they 
represent good ligands to develop a new diagnostic tool. While the use of hydrophobic ligands 
to capture Mtb bacteria is based on the high hydrophobicity of the mycobacterial cell envelope, 
carbohydrate derivatives are targeted on mycobacterial lectins, which are rarely studied. 
Previous results indicate that mycobacteria contain lectins, which recognize carbohydrate 
structures of the Mtb cell envelope and are involved in mycobacterial aggregation. A lectin 
specific for the rare arabinofuranoside was suggested.147 Only a limited number of D-trehalose- 
or D-arabinofuranoside-specific lectins are described in other organisms to date.114,174–176 Thus, 
capture of Mtb bacteria with derivatives of the unique trehalose or arabinofuranoside might 
allow to preferentially enrich mycobacteria from patient specimen. 
 
2.2 Objectives 
In order to develop a new tool to enrich Mtb bacteria from solution, adhesion characteristics of 
mycobacteria have to be analyzed. In the current study different carbohydrate derivatives and 
lipid ligands were chosen as potential ligands to bind Mtb bacteria. The molecules were 
immobilized on microtiter plates and magnetic beads. Adhesion of mycobacteria to the 
functionalized surfaces was studied to address the following questions:  
 
1. Do Mtb bacteria have carbohydrate-specific adhesion characteristics? 
2. Can carbohydrates be applied to capture Mtb bacteria from solution? 
3. Can ligands with a hydrophobic moiety be applied to capture Mtb bacteria from 
solution? 
 
The adhesion studies might prospectively contribute to the development of a mouth rinse or 
chewing gum to enrich and diagnose Mtb from easy accessible saliva as envisaged in the 
project “Development of a sorbent chewing gum for the detection of pulmonary tuberculosis”. 
This project was supported by a grant of the VolkswagenStiftung given to Dr. Christian 
Herzmann of the Research Center Borstel, Germany. 
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2.3 Results 
Prior to the analysis of the adhesion characteristics of mycobacteria suitable ligands 
(Figure 15) had to be synthesized. Different carbohydrate derivatives were synthesized based 
on the sugar constituents of the mycobacterial lipoglycans LM and ManLAM 
(α-D-arabinofuranosides, α-D-mannopyranosides), glycolipids TMM and TDM (trehalose) and 
the polysaccharide α-glucan (α-D-glucopyranoside). Lectins recognizing these carbohydrates 
might be involved in mycobacterial aggregation. α-D-Mannopyranosides and 
α-D-glucopyranosides are also present in the glycocalyx of host cells. Therefore, lectins 
recognizing these two glycosides might also be involved in adhesion of mycobacteria to host 
cells. Additional glycoside derivatives based on host carbohydrates177 (α-D-galactopyranoside, 
β-D-glucopyranoside) were synthesized to further address host-pathogen interactions and to 
study the influence of the configuration of the hydroxyl groups at the sugar ring and of the 
glycosidic linkage on mycobacterial adhesion.  
 
α-D-Arabinofuranosides           D-Trehalose derivative 
          
α-D-Mannopyranosides     α-D-Glucopyranoside      
         
     
β-D-Glucopyranoside and α-D-galactopyranoside  
      
 
 
Figure 15. Chemical structures of the synthesized carbohydrate derivatives, which were used to study 
the adhesion characteristics of mycobacteria. 
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The nature of the aglycon of the glycoside ligands may further affect the strength of the 
glycoside-lectin interaction. As previously shown for many lectins, such as the fimbrial lectin 
FimH of Escherichia coli (E. coli),178,179 aromatic aglycons contribute to a stronger adhesion of 
the glycoside to the lectin. This increased adhesion is based on the structure of the lectin 
containing aromatic amino acids near the carbohydrate binding side. Since no crystal structure 
of any membranous mycobacterial lectin is analyzed to date, an optimal aglycon could not be 
predicted. Thus, the arabinosides 1 and 2 and the mannosides 4 and 5 with aliphatic and 
aromatic aglycons, respectively, were synthesized. All synthesized sugar derivatives 
contained an amino group, which enabled covalent immobilization of the respective ligands on 
microtiter plates or magnetic beads. Functionalization of the surfaces with the carbohydrate 
derivatives 1-8 could be achieved for instance via amide coupling. In all glycosides the amino 
group was part of the aglycon leaving the carbohydrate unaffected by the immobilization 
process. In the case of the trehalose derivative 3 one primary hydroxyl group was replaced by 
an amino group due to the fact that in the mycobacterial cell envelope trehalose is a constituent 
of TMM and TDM. These glycolipids are trehalose derivatives, which are esterified with mycolic 
acids at one or at both primary hydroxyl groups of the disaccharide. Thus, lectins recognizing 
TMM or TDM might most likely tolerate functionalization at the 6-position of trehalose. 
 
2.3.1 Syntheses 
In analogy to the carbohydrate constituents of ManLAM, present in the Mtb cell envelope, 
(2-aminoethyl) α-D-mannopyranoside (5)180 and (2-aminoethyl) α-D-arabinofuranoside (2) 
were synthesized. D-Mannose was acetylated181 and subsequently functionalized at the 
anomeric position mediated by the Lewis acid boron trifluoride (BF3) giving the α-glycoside 10 
in 56% yield.182 The bromoethyl mannoside 10 was converted into the iodoethyl derivative as 
an intermediate. Iodine represents a better leaving group for the following nucleophilic 
substitution with sodium azide leading to the glycoside 11.180 This acetylated 
azidoethyl mannoside was deprotected according to Zemplén's method.183 The desired 
product 5 was received by palladium-catalyzed reduction (Scheme 1).180  
 
 
Scheme 1. Synthesis of the mannopyranoside 5. a) NaOAc, Ac2O, reflux, 1 h, 99%; b) HOEtBr, BF3∙Et2O, 
DCM, ice-cooling, 30 min → rt, overnight, 56%; c) NaN3, TBAI, DMF, 70°C, 8 h → rt, overnight, 92%; d) NaOMe, 
MeOH, rt, overnight, 98%; e) H2, Pd/C, MeOH, rt, overnight, 98%. 
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The arabinose derivative 2 was synthesized similarly to the mannopyranoside 5. D-Arabinose, 
which was used as starting material, is present in two isomeric forms, as D-arabinopyranose 
(Arap) and D-arabinofuranose (Araf). To avoid pyranosides, previous fixation of the sugar in its 
furanose form was required. Therefore, D-arabinose was reacted with tert-butyl-
dimethylsilyl chloride (TBDMSCl), which due to its steric hindrance selectively protects primary 
hydroxyl groups, only present in the furanose form. After fixation of the furanose isomer, 
unprotected secondary hydroxyl groups were acetylated giving the product 13 in 57% yield.184 
Under acidic conditions TBDMS was removed and the primary hydroxyl group was also 
acetylated. The tretraacetate 15185 was used as a glycosyl donor and was converted with 
2-chloroethanol catalyzed by tin tetrachloride (SnCl4) to give the α-glycoside 16 in 64% yield.186 
Separation of the anomers could only be accomplished by column chromatography using a 
solvent composition of n-hexane and ethyl acetate, mixtures of cyclohexane/ethyl acetate and 
methylene chloride/methanol were ineffective. Subsequently, nucleophilic substitution with 
sodium azide gave the glycoside 17 in 89% yield.186 Deacetylation followed by azide reduction 
resulted in the desired aminoethyl derivative 2. This amino sugar was not stable enough to 
store probably forming a cyclic amine, thus it was directly used without further characterization 
(Scheme 2).  
 
 
Scheme 2. Synthesis of the arabinofuranoside 2. a) TBDMSCl, pyridine, rt, 4 h, Ac2O, rt, overnight, 57%; 
b) HOAc/dH2O, rt, overnight, 98%; c) Ac2O, pyridine, rt, overnight, 94%; d) SnCl4, acetonitrile, rt, 30 min, HOEtCl, 
rt, 45 min, 64%; e) NaN3, TBAI, DMF, 70°C, 7 h → rt, overnight, 89%; f) NaOMe, MeOH, rt, overnight; 91% g) H2, 
Pd/C, MeOH, rt, 2.5 h.  
 
Beside glycosides with aliphatic aglycons, carbohydrates carrying aromatic aglycons were 
synthesized. While the p-aminophenyl mannoside 4187 was directly obtained by palladium-
catalyzed reduction of the commercial available nitrophenyl derivative, p-aminophenyl 
α-D-arabinofuranoside (1) was synthesized with D-arabinose as starting material. As 
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mentioned before the C-5-deprotected arabinofuranose 14188 was received in two synthetic 
steps (Scheme 2). Subsequently, the primary hydroxyl group was protected with 
benzoylchloride under basic conditions resulting in the arabinofuranose derivative 19. 
Anomeric deprotection was carried out by synthesizing the classical glycosyl donor of the 
Koenigs Knorr reaction,189 a glycosyl bromide, which was immediately converted to the 
reducing sugar 20 due to its high reactivity even with low quantities of water. Reaction of 20 
with trichloroacetonitrile and 1,8-diazabicycloundec-7-ene (DBU) as a base yielded the 
arabinofuranosyl trichloroacetimidate 21, which was directly employed for glycosylation of 
p-nitrophenol, because of its low stability. p-Nitrophenyl α-D-arabinofuranoside 22 was 
obtained over two steps from the reducing sugar 20 in 53% yield. The arabinofuranoside 22 
was deprotected according to Zemplén's method183 and reduced with hydrogen catalyzed by 
palladium giving the product 1 (Scheme 3). 
 
 
Scheme 3. Synthesis of the arabinofuranoside 1. a) BzCl, pyridine, rt, overnight, 96%; b) HBr, Ac2O, DCM, 
ice cooling, 30 min → rt, overnight, dH2O, 98%; c,d) Cl3CN, DBU, DCM, ice cooling, 15 min; pNO2PhOH, 
BF3∙Et2O, DCM, ice cooling, 30 min → rt, overnight, 53%; e) NaOMe, MeOH, rt, overnight, 97%; f) H2, Pd/C, 
MeOH, rt, 3 h.   
 
Beside the arabinose and mannose derivatives 1, 2, 4187 and 5180 the glucosides 6 and 7  and 
the galactoside 8 with p-aminophenyl as aglycon were synthesized. Derivatives of those 
carbohydrates address mainly bacteria-host interactions instead of adhesion among 
mycobacteria. All three compounds were directly obtained by palladium-catalyzed reduction of 
the respective commercially available nitrophenyl glycosides.  
 
Another important carbohydrate, solely found in mycobacterial cell envelopes, is trehalose. 
The trehalose mycolic acid ester TDM is also named cord factor and was previously related to 
the cording process of Mtb.190 Although nowadays it is assumed that the presence of 
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cyclopropane rings in mycolic acids is responsible for the cord-like appearance of Mtb 
bacteria,191 trehalose might also be involved in adhesion processes between mycobacteria. To 
analyze whether mycobacteria have trehalose-specific adhesion characteristics, 
amino trehalose 3 was synthesized. α,α-D-Trehalose was protected with TBDMSCl and acetic 
anhydride under basic conditions resulting in the desired product 24 containing one 
TBDMS group (44%) and the byproducts, where none or both primary hydroxyl groups were 
functionalized with bulky silyl ethers.192 TBDMS was removed under acidic conditions.192 The 
unprotected hydroxyl group of the trehalose derivative 25 was activated by tosylation, followed 
by a nucleophilic substitution with sodium azide. Azido trehalose 27193,194 was deprotected 
using sodium methoxide and subsequently reduced giving the trehalose derivative 3 in 97% 
yield over the final two steps (Scheme 4).195  
 
 
Scheme 4. Synthesis of the trehalose derivative 3. a) 1. TBDMSCl, pyridine, ice cooling → rt, overnight; 
2. Ac2O, rt, 6 h, 44%; b) DMF/dH2O/AcOH: 1:1:4, rt, overnight, 79%; c) TsCl, pyridine, rt, overnight, 80%; 
d) NaN3, DMF, 80°C, 6 h, 91%; e) NaOMe, MeOH, rt, overnight, 97%; f) H2, Pd/C, MeOH, rt, 3 h, quant.  
 
 
Results 2.3.1: Summary 
• The carbohydrate derivatives 2-8 were synthesized according to literature including 
minor synthetic modifications.  
• p-Aminophenyl α-D-arabinofuranoside (1) was synthesized as a new compound.  
• All final products contained an amino group facilitating immobilization on microtiter 
plates or magnetic beads. 
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2.3.2 Mycobacterial adhesion assay 
An adhesion assay on microtiter plates was established in order to study mycobacterial 
adhesion to the synthesized carbohydrate derivatives.  
Immobilization of the synthesized carbohydrate derivatives on microtiter plates  
Initially the ligands were immobilized on microtiter plates. All sugar derivatives contained an 
amino group, which enabled functionalization of Nunc Immobilizer Amino 96 well microtiter 
plates under basic conditions. The reactive groups on the surface of the microtiter plates are 
not declared by the company. However, it can be assumed that epoxides, isothiocyanates or, 
even more likely, active esters, as depicted in Figure 16, are present. The functionalization 
method applied is commonly used in the Lindhorst group to study adhesion characteristics of 
E. coli, as previously published.196 Therefore, no further control experiments demonstrating 
successful immobilization were implemented. 
 
Adhesion assay 
Serially diluted concentrations of GFP-expressing mycobacteria, with 4∙108 bacteria/ml as the 
highest and 2∙105 bacteria/ml as the lowest concentration, were incubated in functionalized 
microtiter plates for one hour at 37°C while gently shaking. After two washing steps the 
adhered bacteria were detected using a fluorescence reader (Figure 16). 
 
Figure 16. Illustration of the microtiter plate-based adhesion assay. The synthesized carbohydrate 
derivatives were immobilized via the amino group. GFP-expressing mycobacteria were added to the 
functionalized surfaces and adhered bacteria were detected by fluorescence-based read-out systems.   
 
Data analysis  
In all adhesion assays the mannoside 4 was used as a reference substance. Differences 
between fluorescence intensity of adhered bacteria to functionalized wells and fluorescence 
intensity of adhered bacteria to non-modified wells are depicted in the graphs (Figure 17-21). 
Data are normalized with measured relative fluorescence intensity 125 000 set as 100. 
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2.3.3 Adhesion characteristics of M. bovis Bacillus Calmette-Guérin bacteria  
First adhesion assays were carried out using M. bovis Bacillus Calmette-Guérin (BCG) 
bacteria. M. bovis BCG is a Tb vaccine strain derived from an attenuated M. bovis strain by 
subculturing.1,197 Here it is used as an avirulent mycobacterial model system simplifying the 
establishment of an adhesion assay for mycobacteria.  
 
Adhesion of M. bovis BCG bacteria to sugar derivatives containing an aromatic aglycon 
The synthesized and immobilized glycosides 1, 4, 6, 7 and 8 with aromatic aglycons were 
tested regarding their potency to bind M. bovis BCG bacteria (Figure 17) using the adhesion 
assay in microtiter plates, as described before. 
 
Incubation with M. bovis BCG bacteria resulted in an enhanced fluorescence intensity in wells 
functionalized with the α-glycosides 1, 4 and 8, respectively, or the β-glycoside 7 compared to 
non-modified wells at a concentration of 2∙107 bacteria/ml. Wells functionalized with the 
α-arabinofuranoside 1, the α-mannopyranoside 4 or the β-glucopyranoside 7 showed stronger 
signals than wells functionalized with the α-galactopyranoside 8 after incubation with 
mycobacteria. The fluorescence intensities in wells functionalized with the glycosides 1, 4 or 7 
were 1.5fold higher (Figure 17 A, B and D) compared to the galactoside 8 (Figure 17 E) at a 
concentration of 2∙108 bacteria/ml. In all cases an increase of the bacteria concentration, up to 
2∙108 bacteria/ml, was in line with an increase of fluorescence intensity. At the highest 
M. bovis BCG concentration (4∙108 bacteria/ml) a lower fluorescence intensity was measured 
compared to the second highest bacteria concentration. Supplementation of M. bovis BCG 
bacteria to wells functionalized with the α-glucopyranoside 6 led to similar fluorescence 
intensities as measured for non-modified surfaces (Figure 17 C).  
 
Since fluorescence signals correlate with adhered bacteria, the results indicate that 
M. bovis BCG bacteria have carbohydrate-dependent adhesion characteristics. M. bovis BCG 
bacteria adhered to surfaces functionalized with the α-arabinofuranoside 1, the 
α-mannopyranoside 4, the β-glucopyranoside 7 or the α-galactopyranoside 8. Mycobacterial 
adhesion is influenced by the configuration of the hydroxyl groups at the sugar ring and also 
by the configuration of the anomeric linkage of the aglycon.  
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Figure 17. Adhesion of M. bovis BCG bacteria to surfaces functionalized with carbohydrate derivatives, 
which contain an aromatic aglycon. Microtiter plates were functionalized with the carbohydrate derivatives 1, 
4, 6, 7 and 8. Serially diluted suspensions of GFP-expressing M. bovis BCG bacteria (4∙108 bacteria/ml → 
2∙105 bacteria/ml) were incubated for 1 h, 37°C, gentle agitation. Adhered bacteria were detected using a 
fluorescence reader. Data represent differences between fluorescence intensity of adhered bacteria to 
functionalized wells and fluorescence intensity of adhered bacteria to non-modified wells; three technical 
replicates (+/- SD); one of at least two independent experiments shown; relative fluorescence intensity 
normalized with measured relative fluorescence intensity of 125 000 = 100. (RFI: relative fluorescence intensity). 
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Adhesion of M. bovis BCG bacteria to sugar derivatives containing an aliphatic aglycon 
Beside the glycon moiety of a glycoside its aglycon might be involved in interactions with 
mycobacterial lectins. To address this question mannopyranosides and arabinofuranosides 
containing aromatic and aliphatic aglycons, respectively, were tested. Microtiter plates were 
modified with the glycosides 1, 2, 4 and 5 and applied for mycobacterial adhesion assays 
(Figure 18).  
 
 
 
Figure 18. Adhesion of M. bovis BCG bacteria to surfaces functionalized with carbohydrate derivatives, 
which contain aromatic and aliphatic aglycons, respectively. Microtiter plates were functionalized with the 
carbohydrates derivatives 1 and 4, which contain aromatic aglycons, and the glycosides 2 and 5 with aliphatic 
aglycons. Serially diluted suspensions of GFP-expressing M. bovis BCG bacteria (4∙108 bacteria/ml → 
2∙105 bacteria/ml) were incubated for 1 h, 37°C, gentle agitation. Adhered bacteria were detected using a 
fluorescence reader. Data represent differences between fluorescence intensity of adhered bacteria to 
functionalized wells and fluorescence intensity of adhered bacteria to non-modified wells; three technical 
replicates (+/- SD); one of at least two independent experiments shown; relative fluorescence intensity 
normalized with measured relative fluorescence intensity of 125 000 = 100. (RFI: relative fluorescence intensity).  
 
After incubation with M. bovis BCG bacteria enhanced fluorescence intensity was measured 
in wells functionalized with the glycosides 2 or 5 compared to non-modified wells at a 
concentration of 5∙107 bacteria/ml. Increased bacteria concentrations, up to 2∙108 bacteria/ml, 
were in line with an increase in fluorescence intensity. At the highest bacteria concentration 
(4∙108 bacteria/ml) the fluorescence intensity was lower compared to the second highest 
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concentration (2∙108 bacteria/ml) (Figure 18 B and D). The overall fluorescence in wells 
functionalized with the glycosides  2 or 5, which have aliphatic aglycons, (Figure 18 B and D) 
was lower compared to wells modified with the derivatives 1 or 4 with aromatic aglycons 
(Figure 18 A and C). At a concentration of 2∙108 bacteria/ml the fluorescence signals derived 
from adhered bacteria were roughly three times more intense in the case of the derivatives 1 
and 4.  
 
These results indicate that the adhesion of M. bovis BCG bacteria is influenced by the structure 
of the aglycon.  
 
Ca2+-dependency of the adhesion of M. bovis BCG bacteria  
Carbohydrate-lectin interactions can be influenced by calcium ions. Lectins, which show Ca2+-
dependent binding efficiencies, are C-type lectins. Previous comparative genome analysis 
indicates that mycobacteria might express C-type lectins.149 Thus, it was tested if Ca2+ 
influences the adhesion of M. bovis BCG bacteria to surfaces functionalized with the 
arabinofuranoside 1 or the mannopyranoside 4. GFP-expressing M. bovis BCG bacteria were 
incubated in functionalized microtiter plates in the presence or absence of Ca2+. Adhered 
bacteria were detected using a fluorescence reader. Normalized fluorescence at a 
mycobacteria concentration of 4∙108 bacteria/ml shown (Figure 19). 
 
 
 
Figure 19. Ca2+-dependency of M. bovis BCG adhesion. Microtiter plates were functionalized with the 
glycosides 1 and 4. GFP-expressing M. bovis BCG bacteria were incubated in functionalized microtiter plates in 
the presence or absence of Ca2+ (5 mM), Mg2+ (5 mM) or Ca2+ (5 mM)/EDTA (15 mM) for 1 h, 37°C, gentle 
agitation. Adhered bacteria were detected using a fluorescence reader. Data represent differences between 
fluorescence intensity of adhered bacteria (4∙108 bacteria/ml) to functionalized wells and fluorescence intensity 
of adhered bacteria (4∙108 bacteria/ml) to non-modified wells; two technical replicates (+SD); one of at least two 
independent experiments shown; relative fluorescence intensity normalized with measured relative fluorescence 
intensity of 125 000 = 100. (RFI: relative fluorescence intensity). 
 
In both cases, surfaces functionalized with the arabinofuranoside 1 (Figure 19 A) or the 
mannopyranoside 4 (Figure 19 B), Ca2+ supplementation to the M. bovis BCG bacteria 
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suspension resulted in two times higher fluorescence intensity compared to the untreated 
bacteria. In contrast addition of magnesium ions (Mg2+) had only minor effect on the 
fluorescence signal. Supplementation of Ca2+ and ethylenediaminetetraacetate (EDTA) led to 
no increased fluorescence intensity. In fact, the fluorescence signal was even lower compared 
to untreated bacteria.  
 
These data suggest that the adhesion of M. bovis BCG bacteria to surfaces functionalized with 
the arabinofuranoside 1 or the mannopyranoside 4 is Ca2+-dependent.  
  
Adhesion of M. bovis BCG bacteria to the disaccharide trehalose 
So far, monosaccharides were examined regarding their mycobacterial binding efficiency, but 
frequently di- or oligosaccharides represent the optimal ligands for lectins. A unique 
disaccharide of the mycobacterial cell envelope is trehalose. Beside its immunomodulative 
properties80 it might also be involved in adhesion among mycobacteria. To address whether 
M. bovis BCG bacteria bind to the mycobacterial disaccharide trehalose, amino trehalose 3 
was immobilized and incubated with GFP-expressing M. bovis BCG bacteria (Figure 20) as 
described before.  
 
 
Figure 20. Adhesion of M. bovis BCG bacteria to surfaces functionalized with the trehalose derivative 3. 
Microtiter plates were functionalized with the disaccharide 3. Serially diluted suspensions of GFP-expressing 
M. bovis BCG bacteria (4∙108 bacteria/ml → 2∙105 bacteria/ml) were incubated for 1 h, 37°C, gentle agitation. 
Adhered bacteria were detected using a fluorescence reader. Data represent differences between fluorescence 
intensity of adhered bacteria to functionalized wells and fluorescence intensity of adhered bacteria to 
non-modified wells; three technical replicates (+/- SD); one of two independent experiments shown; relative 
fluorescence intensity normalized with measured relative fluorescence intensity of 125 000 = 100. 
(RFI: relative fluorescence intensity). 
 
Similar to the glycosides 1, 4, 7 and 8 (Figure 17) increased fluorescence intensity was 
detectable in wells functionalized with the trehalose derivative 3 at a concentration of 
2∙107 bacteria/ml and the highest fluorescence intensity was measured at a concentration of 
2∙108 bacteria/ml. At the highest bacteria concentration (4∙108 bacteria/ml) the fluorescence 
intensity was lower than at the second highest concentration. 
 
These results suggest trehalose-specific adhesion characteristics of M. bovis BCG bacteria.   
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Results 2.3.3: Summary 
• A mycobacterial adhesion assay in microtiter plates was established using 
GFP-expressing M. bovis BCG bacteria. 
• Carbohydrate-dependent adhesion of M. bovis BCG bacteria was detected. 
• The arabinofuranoside 1, the mannopyranoside 4 and the glucopyranoside 7 were the 
most potent glycosides of the tested ligands resulting in adhesion of M. bovis BCG 
bacteria.  
• Adhesion of M. bovis BCG bacteria to surfaces functionalized with the 
arabinofuranoside 1 or the mannopyranoside 4 was Ca2+-dependent. 
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2.3.4 Adhesion characteristics of Mtb H37Rv bacteria 
In the case of M. bovis BCG three different carbohydrate derivatives were identified as most 
potent ligands to bind mycobacteria: the arabinofuranoside 1, the mannopyranoside 4 and the 
glucopyranoside 7. Furthermore, the trehalose derivative 3 and the galactopyranoside 8 
showed promising influence on the adhesion of M. bovis BCG bacteria (Figure 17 and 
Figure 20). These five compounds were further applied to investigate adhesion characteristics 
of the pathogenic Mtb strain H37Rv. Adhesion assays were carried out as described before 
for M. bovis BCG bacteria. 
 
Figure 21. Adhesion of Mtb H37Rv bacteria to surfaces functionalized with carbohydrate derivatives, 
which were identified as effective ligands for adhesion of M. bovis BCG bacteria. Microtiter plates were 
functionalized with the carbohydrate derivatives 1, 3, 4, 7 and 8. Serially diluted suspensions of GFP-expressing 
Mtb H37Rv (4∙108 bacteria/ml → 2∙105 bacteria/ml) were incubated for 1 h, 37°C, gentle agitation. Adhered 
bacteria were detected using a fluorescence reader. Data represent differences between fluorescence intensity 
of adhered bacteria to functionalized wells and fluorescence intensity of adhered bacteria to non-modified wells; 
two technical replicates (+/- SD); one of two independent experiments shown; relative fluorescence intensity 
normalized with measured relative fluorescence intensity of 125 000 = 100. (RFI: relative fluorescence intensity). 
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Incubation with Mtb H37Rv bacteria resulted in higher fluorescence intensities in wells 
functionalized with the carbohydrate derivatives 3, 4 or 8 compared to non-modified wells 
(Figure 21). Surfaces functionalized with the glycoside 4 showed enhanced fluorescence 
signals at a concentration of 5∙107 bacteria/ml. Increase of the bacteria concentration was in 
line with an increase of fluorescence intensity. However, at high bacteria concentrations a 
fluorescence decrease was measured. In the case of the galacopyranoside 8 fluorescence 
derived from adhered mycobacteria increased at a concentration of 5∙106 bacteria/ml and 
reached a fluorescence maximum at 2∙108 bacteria/ml, which was almost nine times stronger 
compared to the mannopyranoside 4. Functionalization with the trehalose derivative 3 resulted 
in detectable fluorescence signals at a concentration of 1∙106 bacteria/ml and led to as high 
fluorescence intensities as measured on surfaces functionalized with the derivative 8, but 
already at a lower concentration (1∙108 bacteria/ml). In both cases the fluorescence intensity 
increased with higher mycobacteria concentrations followed by a decrease at the highest 
concentrations. The overall fluorescence intensity detected in wells modified with the 
galactoside 8 or the trehalose derivative 3 was higher compared to fluorescence signals 
detected after incubation with M. bovis BCG bacteria (trehalose derivative 3: 5.5fold at 
1∙108 bacteria/ml; galactoside 8: 6fold at 2∙108 bacteria/ml) (Figure 20; Figure 17). 
 
These data indicate that Mtb H37Rv bacteria have carbohydrate-dependent adhesion 
characteristics. Binding intensities varied compared to M. bovis BCG bacteria. Most intense 
adhesion was detected on surfaces functionalized with the trehalose derivative 3 and the 
galactoside 8. Therefore, these two compounds were identified as promising candidates to 
capture Mtb bacteria.  
 
 
Results 2.3.4: Summary 
• Carbohydrate-dependent adhesion of the pathogenic Mtb strain H37Rv was detected. 
• The trehalose derivative 3 and the galactopyranoside 8 were the most potent 
carbohydrate derivatives of the tested ligands resulting in adhesion of Mtb bacteria. 
• Mtb H37Rv bacteria showed stronger adhesion to surfaces functionalized with the 
carbohydrate derivatives 3 and 8 compared to M. bovis BCG bacteria. 
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2.3.5 Capture of Mtb with beads functionalized with carbohydrate derivatives 
To develop a diagnostic tool binding of Mtb bacteria has to work out not only in microtiter plates 
but also with a more applicable system. Here magnetic polyethylene glycol (PEG) beads, 
suitable for a mouth rinse, were used to capture Mtb bacteria from solution. The magnetic 
properties of the beads facilitate fast and easy extraction of the beads from solutions avoiding 
time consuming centrifugation. The pegylation of the beads is beneficial due to its bio-repulsive 
properties and prevents unspecific adhesion of mycobacteria. Thus, the detected adhesion is 
ligand-dependent, which is necessary in order to identify a new potential ligand to capture Mtb 
bacteria. Furthermore, carboxyl functional groups enable to easily immobilize amino-
functionalized molecules on the bead surface. 
 
Functionalization of the beads with the synthesized carbohydrate derivatives 
Formally, a carboxylic acid can react with an amine forming an amide with the release of one 
equivalent of water. However, this nucleophilic substitution reaction competes with the 
acid-base reaction resulting in unreactive carboxylate and ammonium groups. To facilitate the 
formation of an amide the carboxyl group was converted to an active ester. Carbodiimides are 
widely used to activate carboxyl groups by the formation of highly reactive O-acylisourea 
intermediates. Here the water soluble 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) 
was applied. To avoid undesirable side reactions of the O-acylisourea intermediates, 
N-hydroxysuccinimide (NHS) was added to form the more stable NHS ester derivative. 
NHS ester-activated beads were reacted with the primary amino groups of the synthesized 
ligands resulting in a covalent immobilization of the carbohydrate derivatives via amide bonds 
(Figure 22).   
 
Figure 22. Functionalization of magnetic PEG beads with the synthesized carbohydrate derivatives. 
Functionalization of the beads is based on EDC/NHS activation of the carboxyl groups forming NHS-esters. 
These active esters can react with amino groups of the synthesized carbohydrate derivatives leading to a 
covalent immobilization of the ligands by an amide bond. (R = carbohydrate derivatives)   
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Bead-based adhesion assay 
Functionalized beads (2∙107 beads) were added to GFP-expressing Mtb H37Rv bacteria, which 
were suspended in PBS in desired concentrations. After incubation for one hour at 37°C while 
gently shaking beads were extracted and washed. Adhered bacteria were detected using a 
fluorescence reader (Figure 23). 
 
 
 
Figure 23. Illustration of the bead-based 
adhesion assay. GFP-expressing Mtb H37Rv 
bacteria were added to the functionalized beads. 
Subsequently, adhered bacteria were detected by a 
fluorescence-based read-out systems.   
Data analysis  
In all adhesion assays the mannoside 4 was used as a reference substance. Normalized 
fluorescence intensity shown (auto-fluorescence of beads subtracted). Fluorescence intensity 
of non-modified beads, incubated with GFP-expressing Mtb H37Rv bacteria, shown in order 
to quantify the amount of unspecific adhesion.  
Verification of a successful bead functionalization 
To verify bead functionalization, beads modified with the mannopyranoside 4, as positive 
control, and beads functionalized with the arabinofuranoside 1, as a negative control, were 
incubated with Concanavalin A (ConA). ConA is a α-mannoside and α-glucoside specific lectin, 
originally extracted from the jack-bean Canavalia ensiformis.198 The ConA applied carries 
fluorescein, which enables visualization of bound lectins. Functionalized beads were incubated 
with ConA. Bound ConA was detected using a fluorescence reader (Figure 24). 
 
 
Figure 24. Verifying bead functionalization using the lectin ConA. Magnetic PEG beads were functionalized 
with the carbohydrate derivatives 1 and 4. Beads were incubated with ConA-fluorescein (250 µg/ml) for 1.5 h, rt, 
gentle agitation. Bound ConA was detected using a fluorescence reader. Data represent difference between 
fluorescence intensity of bound ConA to functionalized beads and fluorescence intensity of bound ConA to 
non-modified beads; three technical replicates (+SD); one of two independent experiments shown; fluorescence 
normalized with measured highest fluorescence of the derivative 4 = 100. (RFI: relative fluorescence intensity). 
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Beads functionalized with the mannopyranoside 4 showed an eight times stronger 
fluorescence intensity compared to beads functionalized with the arabinofuranoside 1.  
 
Fluorescence directly correlates with the amount of bound ConA. Since ConA specifically 
interacts with mannopyranosides, these results verify the presence of mannosides on the bead 
surface and thereby a successful functionalization of the PEG beads.  
 
Adhesion of Mtb bacteria to magnetic PEG beads, which were functionalized with carbohydrate 
derivatives 
In order to analyze whether beads functionalized with carbohydrate derivatives can be used to 
capture Mtb bacteria from solution, magnetic beads were modified with the carbohydrate 
derivatives 3 and 4, respectively, and subsequently applied in the bead-based adhesion assay 
with GFP-expressing Mtb H37Rv bacteria (Figure 25). 
 
   
Figure 25. Adhesion characteristics of Mtb H37Rv bacteria to PEG beads functionalized with the 
carbohydrate derivatives 3 and 4. Magnetic PEG beads were functionalized with the carbohydrate derivatives 
3 and 4. Functionalized and non-modified (control) beads were incubated with GFP-expressing Mtb H37Rv 
bacteria (1∙108 bacteria/ml) for 1 h, 37°C, gentle agitation. Adhered bacteria were detected using a fluorescence 
reader. Data represent differences between fluorescence intensity of adhered bacteria (1∙108 bacteria/ml) to 
functionalized beads and auto-fluorescence of non-modified beads (+SEM); duplicates of at least three 
independent experiments; fluorescence intensity normalized with measured fluorescence intensity of 
125 000 = 100. (FI: fluorescence intensity).   
 
Non-modified beads incubated with GFP-expressing Mtb H37Rv bacteria showed slightly 
increased fluorescence signals compared to beads, which were not incubated with 
mycobacteria. Addition of Mtb H37Rv bacteria to magnetic beads functionalized with 
carbohydrate derivatives, led to three times and seven times higher fluorescence intensities, 
respectively, compared to non-modified beads. Beads functionalized with the 
trehalose derivative 3 showed about two times higher fluorescence intensity after incubation 
with mycobacteria compared to beads functionalized with the mannopyranoside 4. The 
fluorescence difference (RFI) between beads functionalized with the trehalose derivative 3 and 
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non-modified beads (control) was 14 times lower compared to the microtiter plate-based 
system at the same bacteria concentration (1∙108 bacteria/ml).  
 
These results indicate that beads functionalized with the carbohydrate derivatives 3 and 4, 
respectively, can be used to capture Mtb bacteria from solution. However, the modified beads 
show lower binding efficiencies compared to microtiter plates, which were functionalized with 
the same carbohydrate derivatives.  
 
 
Results 2.3.5: Summary 
• Magnetic beads functionalized with the carbohydrate derivatives 3 and 4, respectively, 
can be used to capture Mtb H37Rv bacteria from solution. 
• Lower amounts of Mtb H37Rv bacteria adhered to the functionalized magnetic beads 
compared to the microtiter plate-based system. 
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2.3.6 Adhesion of Mtb to magnetic PEG beads functionalized with lipid ligands  
Beside carbohydrate derivatives, molecules with long chain alkyl groups were considered as 
appropriate ligands to capture Mtb bacteria from solution. Using hydrophobic ligands for 
mycobacteria enrichment is based on the high hydrophobicity of the Mtb cell envelope. Eight 
different ligands, containing two to eight alkyl chains (red), were obtained from 
Prof. Dr. Karl-Heinz Wiesmüller of the EMC Microcollections GmbH, Germany. Water 
solubility, necessary for surface functionalization, was either achieved by pegylation 
(ligand 29-35) or positively charged lysines (ligand 36). In addition, a TMM-analog derivative 
was synthesized by the group of Prof. Dr. Mark S. Baird from Bangor University, UK. This 
molecule combines both types of potential Mtb ligands, carbohydrate and fatty acid.  
 
 
PEG-containing ligands  
2 alkyl chains 
 
  
 
3 alkyl chains 
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4 alkyl chains 
 
 
  
6 alkyl chains 
 
 
 
8 alkyl chains 
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Lysine-rich ligand 
3 alkyl chains 
 
TMM-analog derivative 
                                                         
Figure 26. Lipid ligands applied to capture Mtb bacteria from solution. Nine ligands, containing one to eight 
alkyl chains, were immobilized on magnetic beads by an amino group. Functionalized beads were used in a 
bead-based adhesion assay with Mtb H37Rv bacteria. (n: 2700-3300)   
 
The nine different lipid ligands contained one or more amino groups, which enabled 
immobilization of the molecules on magnetic PEG beads, as described for the carbohydrate 
derivatives. Functionalized beads were applied in the bead-based adhesion assay. 
 
 
 
Figure 27. Adhesion of Mtb H37Rv bacteria to PEG beads functionalized with lipid ligands. Magnetic 
PEG beads were functionalized with the derivatives 29-37. Functionalized und non-modified (control) beads were 
incubated with GFP-expressing Mtb H37Rv bacteria for 1 h, 37°C, gentle agitation. Adhered bacteria were 
detected using a fluorescence reader. Data represent differences between fluorescence intensity of adhered 
bacteria (1∙108 bacteria/ml) to functionalized beads and auto-fluorescence of non-modified beads (+SEM); 
duplicates of at least three independent experiments; fluorescence intensity normalized with measured 
fluorescence intensity of 125 000 = 100. (FI: relative fluorescence intensity). (For comparison glycosylated 
beads 3 and 4 included from Figure 25) 
Lipid ligands 
Sugar 
derivatives 
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Incubation of the beads, which were functionalized with the ligands 29-35, with Mtb H37Rv 
bacteria resulted in enhanced fluorescence signals compared to non-modified beads. While 
fluorescence intensity was increased fivefold using ligand 29, ligand 33 led to seven times, 
ligand 32 and 34 to twelve times, ligand 31 and 35 to 17 times and ligand 30 to 24 times higher 
fluorescence signals. The detected fluorescence enhancement was in range with the 
increased fluorescence signals measured for the beads functionalized with the carbohydrate 
derivatives 3 and 4. On the other hand after incubation of the beads functionalized with the 
ligand 36 or the TMM-analog ligand 37 with the mycobacteria much more intensive 
fluorescence was detected with an 180fold and 220fold increase, respectively, compared to 
non-modified beads.  
 
Based on these data the ligand 36 and the TMM-analog derivative 37 were identified as potent 
ligands to capture Mtb bacteria from solution using functionalized magnetic beads. 
 
2.3.7 Verifying adhesion of Mtb bacteria by polymerase chain reaction  
To detect captured Mtb bacteria by a system applicable for Tb diagnostics, mycobacteria 
enrichment was analyzed by PCR. Therefore, DNA was extracted from captured Mtb bacteria 
and quantified by real-time PCR (RT-PCR). RT-PCR studies were carried out in cooperation 
with Daniela Sievert from the group of Prof. Dr. Katharina Kranzer, National Reference Center 
(NRC) for Mycobacteria of the Research Center Borstel, Germany.   
 
Extraction of mycobacterial DNA 
The bead-based adhesion assay with Mtb H37Rv bacteria was carried out as described before. 
Subsequently, beads were suspended in TRIzol, which contains phenol and guanidine 
isothiocyanate and leads to cell lysis and DNA release. After addition of ethanol, mycobacterial 
DNA was isolated using the DirectZol RNA MiniPrep kit (Zymo Research) excluding the DNase 
step. 
 
Real-time PCR  
An RT-PCR (Figure 28) enables to amplify and detect specific mycobacterial DNA regions and 
to quantify the initial concentration of mycobacterial DNA. In a first step, the denaturation, the 
DNA-containing sample is heated to 95°C, which causes disruption of the hydrogen bonds 
between complementary bases within double-stranded DNA and yielding single-stranded DNA 
molecules. Subsequently, in the annealing step the reaction temperature is lowered to 55°C 
allowing annealing of the primers, specific for mycobacterial DNA, to the single-stranded DNA 
template. In a real-time PCR, additionally, fluorescence resonance energy transfer (FRET) 
probes are used, which are oligonucleotides linked to a fluorescent molecule (e.g. fluorescein 
(FAM) or YakimaYellow (YAK)) and a quencher (e.g. BlackBerry (BBQ)), which absorbs the 
fluorescence of the fluorophore. The close proximity of the fluorescent molecule to the 
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quencher prevents detection of the fluorescence. The FRET probe binds to a complementary 
DNA region within the target DNA that is to be amplified. After annealing of primer and FRET-
probe the DNA-elongation step is started. The DNA polymerase of the bacterium Thermus 
aquaticus (Taq polymerase) is commonly used to catalyze the linkage of deoxynucleoside 
triphosphates (dNTPs) and thereby the synthesis of a new DNA strand complementary to the 
DNA template strand. During DNA elongation the Taq polymerase, which further contains 
exonuclease activity, removes the FRET-probe. Cleavage of the FRET-probe results in a 
disruption of the reporter-quencher proximity and a detectable fluorescence emission. The 
denaturation, annealing and elongation steps are repeated several times leading to an 
amplification of the DNA and a proportional breakdown of the FRET-probe. An increase in the 
targeted DNA by each PCR cycle causes an increase in fluorescence intensity. The amount 
of PCR cycles (cyle threshold (ct)), necessary to induce a detectable fluorescence signal, 
depends on the initial concentration of the mycobacterial DNA. Thus, ct values correlate 
inversely proportional with the concentration of the target DNA and can be used to quantify 
mycobacterial DNA.  
 
Figure 28. Illustration of RT-PCR, which was used to quantify DNA of captured mycobacteria. In a PCR 
mycobacterial DNA is specifically amplified. A FRET-probe, containing a fluorescent dye and a quencher, binds 
to a complementary DNA region within the target DNA that is to be amplified. The Taq polymerase catalyzes the 
synthesis of a new DNA strand complementary to the DNA template strand and thereby removes the 
FRET-probe. Disruption of the reporter-quencher proximity results in a detectable fluorescence emission. The 
measured fluorescence intensity correlates with the amount of amplification cycles and the initial concentration 
of mycobacterial DNA. (FAM: fluorescein; YAK: YakimaYellow (fluorescent dyes); BBQ: BlackBerry (quencher); 
Taq: Thermus aquaticus polymerase)  
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Detection of captured Mtb bacteria by RT-PCR 
Magnetic beads functionalized with the ligand 36 and the ligand 37, respectively, and 
non-modified beads were incubated with Mtb H37Rv bacteria as described in the bead-based 
adhesion assay. DNA was extracted from captured mycobacteria and quantified by RT-PCR. 
For comparison DNA was also isolated from determined amounts of mycobacteria and 
analyzed by RT-PCR. 
 
 
 
Figure 29. Detection of captured Mtb bacteria by real-time PCR. DNA was isolated from captured Mtb H37Rv 
bacteria and quantified by real-time PCR. Data represent ct values (median with range) of at least three 
independent experiments; one to three technical replicates each. Ct values also determined of known bacteria 
concentrations. (n.d.: no DNA detected)  
 
DNA extracted from 107 bacteria resulted in an averaged ct value of 27 and from 106 bacteria 
in a ct value of roughly 29. Deviations of up to 4 ct values were detected. DNA quantification 
of mycobacteria captured by beads functionalized with the ligand 36 showed similar ct values: 
DNA isolated from the beads, after incubation with 107 bacteria, led to a ct value of roughly 26 
and after incubation with 106 bacteria to a ct value of roughly 30. While deviations of up to 5 
ct values were measured for the higher bacteria concentration, almost homogeneous data 
were detected for 106 bacteria. Analysis of isolated DNA of Mtb bacteria captured with beads 
coated with the TMM-analog derivative 37 resulted in mean ct values slightly higher as those 
detected for the beads modified with the ligand 36. Also in this case mycobacteria 
concentration and ct values were inversely proportional. Adhesion assays with unmodified 
beads led in most of the cases to no DNA detection in the bead fractions. The related 
supernatant showed ct values of 29, which were identical with those detected for DNA isolated 
from 106 bacteria alone. In the control experiments with unmodified beads strong variations of 
ct values were measured for a couple of samples.   
 
These data demonstrate that DNA isolated from mycobacteria, which were captured by 
functionalized beads, can be detected by RT-PCR in a concentration-dependent manner. 
 
Without beads Ligand 36 Ligand 37 
Beads Supernatant 
Non-modified beads 
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Results 2.3.6 and Results 2.3.7: Summary 
• The lysine-rich ligand 36 and the TMM-analog derivative 37 were identified as potent 
lipid ligands to capture Mtb bacteria from solution. 
• DNA of adhered mycobacteria was detected by RT-PCR in a concentration-dependent 
manner. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Capture of mycobacteria 
Discussion  
48 
 
2.4 Discussion 
Tb diagnostic is complicated by limited concentrations of Mtb bacteria in patient specimen. In 
this thesis it was envisaged to identify new ligands to enrich mycobacteria from solution. A 
potential existence of lectins on the mycobacterial cell surface and the highly hydrophobic 
character of the mycobacterial cell envelope led to the synthesis of (i) different 
carbohydrate derivatives and the application of (ii) several lipid ligands. The different 
molecules were immobilized on microtiter plates or on magnetic PEG-beads and tested for 
their ability to capture Mtb bacteria.  
 
2.4.1 Carbohydrate-specific adhesion characteristics of mycobacteria 
Capturing bacteria with carbohydrate-functionalized surfaces presume the presence of lectins 
in the bacterial cell envelope. So far, there were only minor indications that mycobacteria might 
express carbohydrate-binding proteins.145,147–149,199 From one single Mtb lectin200 and a Msg 
lectin domain201 crystallization and preliminary X-ray studies were reported. The crystallized 
13 kDa large lectin from Mtb, sMTL-13, is a secreted protein, which natural ligand was not 
identified yet. Although this lectin was detected in patients during Mtb infections,199 it cannot 
be addressed for mycobacteria enrichment from patient specimen, since it is not membranous. 
Indications for membranous mycobacterial lectins and their corresponding ligands were 
received from previous studies of V. Anton et al..147 Several monosaccharides were identified 
as inhibitors for mycobacterial aggregation. Mycobacteria are known to form large clumps, 
especially in stationary liquid culture. In the case of Mtb H37Rv bacteria these aggregates were 
dispersed by addition of D-arabinose, while D-glucose, D-mannose and D-xylose were 
ineffective. In contrast adhesion among Msg bacteria was not only inhibited by D-arabinose, 
but also by D-xylose, inositol and D-glucose. The impact of D-glucose was studied even more 
precisely showing an inhibitory effect of methyl-β-D-glucoside but not methyl-α-D-glucoside.147 
Further indications for potential ligands for mycobacterial lectins were obtained from M. Kundu 
et al., who isolated a lectin from Msg, mycotin, which was able to agglutinate human A, B and 
O erythrocytes. This haemagglutination could be inhibited by D-arabinose, mannan and 
p-nitrophenyl α-D-mannopyranoside.145  
 
Based on these first indications the mannosides 4 and 5, the arabinosides 1 and 2, the 
β-glucoside 7 and the α-glucoside 6 were synthesized and applied in adhesion assays with 
M. bovis BCG bacteria and Mtb H37Rv bacteria. Since mycobacterial aggregation is probably 
based on lectin binding to carbohydrates present in the mycobacterial cell envelope, a 
derivative of the rare disaccharide, trehalose, was also included. Furthermore, 
p-aminophenyl α-D-galactopyranoside (8) was synthesized to expand the configurational 
variety of the hydroxyl groups at the sugar scaffold and to address pathogen-host interactions. 
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In contrast to the results described by V. Anton et al., Mtb H37Rv bacteria did not adhere to 
surfaces functionalized with the arabinoside derivative 1. However, in this synthesized 
molecule arabinose is fixed in the furanose form, while the unmodified D-arabinose, applied by 
V. Anton et al., is mainly present in the pyranose form. Thus, the results might not be 
contradictory, but rather suggest that an arabinopyranose-, but not arabinofuranoside-binding 
lectin might be present in the mycobacterial cell envelope. While Mtb H37Rv bacteria showed 
no adhesion, M. bovis BCG bacteria strongly adhered to microtiter plates functionalized with 
the D-arabinofuranoside 1. Carbohydrate-dependent adhesion of M. bovis BCG has never 
been addressed before. In accordance to the inhibitory results of Msg aggregation, 
M. bovis BCG bacteria adhered to surfaces functionalized with the β-glucopyranoside 7, but 
not to the immobilized α-glucopyranoside 6. Thus, a similar lectin might be present in Msg and 
M. bovis BCG. Adhesion to wells modified with the trehalose derivative 3 or the 
galactopyranoside 8 was detected for both, M. bovis BCG bacteria and Mtb H37Rv bacteria. 
However, adhesion efficiency was much higher for Mtb H37Rv bacteria. This stronger 
adhesion might either be based on a larger number of lectins present on the Mtb surface or 
might be based on higher affinity of the addressed Mtb lectins to the carbohydrate derivatives 
3 and 8 compared to the lectins of M. bovis BCG. None of the two carbohydrates were 
analyzed regarding their capability to bind these two mycobacterial species before. Taken 
together, the adhesion experiments, implemented in the current study, unambiguously verified 
carbohydrate-dependent adhesion characteristics of M. bovis BCG bacteria and Mtb H37Rv 
bacteria. Specific adhesion to both mycobacterial and host carbohydrates was detected 
indicating that lectins involved in interactions among the bacteria and also between pathogen 
and host cells might be present in the mycobacterial cell envelope. The carbohydrate specificity 
strongly varied between the two investigated mycobacterial species. Thus, the lectin 
composition might be species or even strain dependent. This heterogeneity is in line with the 
results reported by V. Anton et al., as described before, and is further supported by previous 
computer-based genome analysis. A computational search of lectins in all fully or partially 
sequenced mycobacterial genomes identified 94 potential carbohydrate-binding proteins. The 
number of detected lectins and their potential association to lectin families strongly varied 
dependent on the analyzed strain.149 This carbohydrate specificity bears the chance to 
distinguish between different mycobacteria and to preferentially capture Mtb bacteria.  
Trehalose, detected as a potent ligand for Mtb H37Rv bacteria, is absent in non-mycobacterial 
cell envelopes. Thus, trehalose-dependent adhesion might be involved in mycobacterial 
aggregation. This presumption is further supported by the fact that the amount of adhered 
mycobacteria increased with the use of higher mycobacteria concentrations, but then 
decreased when the concentration exceeds a threshold of approximately 2∙108 bacteria/ml. 
This reduction might be explained by a competitive process, where Mtb bacteria either binds 
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to the glycosylated surface or to surrounding mycobacteria. Lower adhesion at the highest 
bacteria load was determined for all tested carbohydrate derivatives. Thus, carbohydrate-
dependent binding, investigated in this study, might mainly address lectins involved in 
mycobacteria aggregation. Although the β-D-glucopyranoside 7 and the 
α-D-galactopyranoside derivative 8 do not represent glycosides present in the mycobacterial 
cell envelope, they seem to interact with mycobacterial lectins involved in aggregation 
processes. This might be based on a broad ligand tolerance by the addressed lectins.  
As described the configuration of the hydroxyl groups at the sugar scaffold and the 
configuration of the linkage at the anomeric centre strongly influence mycobacterial adhesion. 
Furthermore, also the aglycon itself had an impact on the binding efficiency of M. bovis BCG 
bacteria. While the derivatives 2 and 5 with aliphatic aglycons led to low amounts of adhered 
mycobacteria, the derivatives 1 and 4 with aromatic aglycons increased the bacterial load by 
a factor of three. These results are similar to previous observations with other lectins. Adhesion 
and inhibition studies with the fimbrial lectin FimH of E. coli bacteria, for example, also revealed 
higher binding efficiencies of carbohydrates carrying an aromatic aglycon compared to 
derivatives with aliphatic aglycons.178,179 These findings can be explained by the protein 
structure of FimH. Increased adhesion is based on π-π interactions between the aromatic 
aglycon and tyrosine residues located at the outer region of the carbohydrate binding 
pocket.178,179 Although no structure of a membranous mycobacterial lectin is known to date, 
aglycon-dependent adhesion variations might give first indications about the binding pocket of 
a potential mycobacterial lectin. Hydrophobic or aromatic amino acids might be localized in or 
close to the sugar binding region of arabinofuranoside- and mannopyranoside-specific 
mycobacterial lectins. Only two of four carbohydrates were analyzed regarding the influence 
of the aglycon so far. Thus, experiments should be extended including galactoside and 
glucoside derivatives to get deeper insights into mycobacterial adhesion characteristics.  
Adhesion of M. bovis BCG bacteria to the arabinoside derivative 1 and the mannoside 4 could 
be further increased by addition of calcium ions. This increase was not observed when Ca2+ 
was previously complexed by EDTA. The amount of adhered bacteria was even reduced by 
EDTA supplementation, which can be explained by additional complexation of ions, naturally 
present on the mycobacterial surface and relevant for binding processes. These results 
suggest that C-type lectins might be involved in mycobacterial adhesion to surfaces 
functionalized with mannoside and arabinoside derivatives, respectively. Mycobacterial lectins 
identified by computer-based genome analysis showed homologies to β-prism-II lectins 
present in plants, R-type lectins, a unique lectin from cyanobacterium Microcystis viridis (MVL) 
and also C-type lectins.149 Gene sequences similar to those encoding for C-type lectins were 
detected in all analyzed strains of Mtb, M. marinum and M. canettii, but not M. bovis BCG. 
Therefore, calcium-dependent adhesion of M. bovis BCG bacteria, as shown in the current 
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study, is not in line with the results received by K. V. Abhinav et al.149 and no potent gene 
region could be associated so far. Furthermore, Ca2+-depend binding of mycobacterial lectins 
might be a disadvantage for diagnostic applications. Human saliva mainly consists of water 
(99.5%), but also contains mucus, enzymes, immunoglobulins, such as IgA, and ions. Ca2+ is 
present in a 1 mM concentration.202 Therefore, capturing Mtb bacteria based on mycobacterial 
C-type lectins might be possible but not favorable, since patient-specific ion concentrations 
might have a strong impact on binding efficiencies.   
In the microtiter plate-based adhesion assay bacteria concentrations of at least 
1∙106 bacteria/ml were necessary to detect carbohydrate-dependent adhesion. This might be 
explained by a limited detection level of fluorescent bacteria (ca. 1∙105 bacteria) using a 
fluorescence reader. However, the synthesized molecules might also not represent the optimal 
ligands and therefore exhibit low binding affinities. It is conceivable that the natural ligand is 
not even a monosaccharide, but a di- or oligosaccharide. To address this question it might be 
necessary to identify and characterize the related protein. Single knockdown of the ten 
potential Mtb lectins, detected by genome analysis, will help to identify the related gene region 
of a mycobacterial lectin.148 Furthermore, transformation of a selected gene region into Msg 
bacteria followed by overexpression of the related protein might enable to construct a less 
pathogenic model organism to study lectin-dependent adhesion or to isolate and characterize 
the mycobacterial lectin. Beside these biological approaches, it might also be convenient to 
apply photoaffinity labeling (PAL) to target mycobacterial lectins.203–206 For PAL carbohydrate 
derivatives can be designed carrying a diazirine group.207–213 This nitrogen containing 
cyclopropene-like ring is activated at a wavelength of light (~355 nm) that is not damaging to 
proteins. Upon photo-activation of the diazirine moiety a carbene intermediate is formed, which 
rapidly inserts into X-H bonds (X = C, N, S, O) in the near proximity forming stable covalent 
insertion products.207,209 In the case of sugar-lectin interactions, amino acids near the 
carbohydrate binding pocket of the lectin will react with the carbene of the sugar derivative.210 
Thereby, carbohydrate ligands will be covalently connected to the target protein, which can 
subsequently be identified by mass spectrometry.214 PAL represents a useful method for target 
identification in complex protein mixtures or even within whole cells.208,210–213 Here, it might be 
used to identify potential mycobacterial lectins.  
 
In this thesis new carbohydrate derivatives were identified as potential ligands to bind Mtb 
bacteria, thus shedding light on the so far barely studied carbohydrate-binding characteristics 
of mycobacteria. Based on these results it will be highly fascinating not only to characterize 
the structure and natural ligand of the potential lectin, but also to analyze distribution and 
function of mycobacterial lectins. A largely unexplored area, that might allow deeper insights 
into virulence characteristics of the pathogen and will hopefully help to develop new specific 
diagnostic tools for tuberculosis infections.     
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2.4.2 Capture of Mtb bacteria with functionalized magnetic beads 
Carbohydrate-dependent mycobacterial adhesion was unambiguously detected in a 
microtiter plate-based assay. Especially the trehalose 3-specific adhesion was highly 
promising.  The uniqueness of trehalose as a cell envelopes constituent might correlate with a 
limited number of membranous trehalose-specific lectins in other organisms. Thus, trehalose 
derivatives might represent potent molecules to specifically capture mycobacteria. To develop 
a diagnostic tool, based on trehalose-specific adhesion of mycobacteria, binding of Mtb has to 
work out not only in microtiter plates but also with a system applicable for Tb diagnostics. 
Therefore, beads were functionalized suitable for a mouth rinse. However, the magnetic 
PEG beads functionalized with the trehalose derivative 3 did not show high binding efficiency. 
This drawback might be caused by carbohydrate arrangement and accessibility. Bead size and 
ligand density should be varied in future studies in order to possibly enhance binding affinity 
of Mtb bacteria towards the functionalized beads. In addition, the low binding efficiency might 
also be a consequence of the structural properties of the related mycobacterial lectin. 
Catch bond characteristics of the lectin would explain the higher affinity to static compared to 
mobile surfaces. In case of static surfaces shear forces can be provoked for example by 
solvent flow, which normally would reduce adhesion (slip bond). Proteins with catch bond 
characteristics do not show weaker but even stronger binding under increased flow 
conditions.215 This untypical binding behavior was previously detected for the von Willebrand 
factor, cadherins, selectins and the mannose-specific lectin FimH.215–219 In the case of FimH 
change of binding efficiency is based on a lengthening of the protein structure combined with 
a conformational change of a β-sheet in the binding pocket due to shear-originated mechanical 
force.216,220 A catch-bond character of mycobacterial lectins might be an advantage for the 
bacterium to attach to the lung surface or to already adhered bacteria within the lung resisting 
the strong air flow through. However, here it would be a disadvantage for the development of 
a diagnostic mouth rinse.  
While beads functionalized with carbohydrate derivatives failed to effectively capture Mtb 
bacteria from solution, strong mycobacterial adhesion could be obtained by the application of 
beads functionalized with the lipid ligands 36 and 37, respectively. Although the other ligands, 
received from Prof. Dr. Karl-Heinz Wiesmüller, had hydrophobic regions comparable to the 
ligand 36, minor binding affinities were detected. This might be explained by the fact that the 
lysines, which were important for immobilization, are located between the hydrophobic moiety 
and the hydrophilic-PEG region. Therefore, functionalized beads might have alternating 
hydrophobic and hydrophilic parts instead of a complete hydrophobic surface. Furthermore, 
an insufficient functionalization of the beads using the ligands 29-35 might be the reason for 
the low Mtb affinity. Thus, in future studies functionalization efficiency should be examined. 
Successful ligand immobilization can be detected by investigating changes in surface charge 
between functionalized and non-modified beads using Zeta potential analysis.221 In addition, 
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the amount of unreacted carboxyl groups and thereby functionalization degree can be 
quantified by UV titration with toluidine blue O (TBO).222  
Capturing mycobacteria due to hydrophobic interactions was previously shown by Microsens 
Medtech Ltd..166 The developed “Tb-Beads” are paramagnetic particles coated with 
pDADMAC, a charged and hydrophobic ligand, which is believed to have a high affinity for 
LAM and mycolic acids. The beads were applied to enrich Mtb bacteria from sputum and 
subsequently analyze bound bacteria by microscopy, cultivation or PCR.167,168,223 Beside this 
diagnostic tool, Steinhäuser et al. exploited the hydrophobic character of the mycobacterial cell 
envelope to label Mtb bacteria with magnetic nanoparticles. This magnetic tag enabled a 
specific isolation and investigation of mycobacteria-containing phagosomes.136 The magnetic 
nanoparticles were immobilized in the mycobacterial cell envelope using the same lipid ligand 
36, as applied in the current study. Thus, successful capturing of Mtb bacteria by this molecule 
was expectable. The TMM-analog molecule 37, synthesized by the group of Prof. Dr. Mark S. 
Baird, has never been applied for binding studies with Mtb bacteria before. The high binding 
affinity of ligand 37 might be based on hydrophobic interactions, but can also be explained by 
lectin-dependent adhesion. A mycobacterial lectin similar to Mincle is conceivable. This 
macrophage inducible C-type lectin is assumed to be involved in mycobacteria-dependent 
inhibition of phagosome maturation.80 The main ligand of Mincle is TDM.112 X-ray 
crystallography and mutagenesis studies have revealed an extended ligand-binding site that 
interacts with both trehalose and one mycolic acid of the glycolipid.224 Binding affinity of 
6-octanoyl-trehalose was up to 50 times higher compared to trehalose.224 In analogy, adhesion 
of Mtb H37Rv bacteria to beads functionalized with the TMM-analog ligand 37 compared to 
beads modified with the trehalose derivative 3 was increased by roughly twelvefold. This 
enhancement could be based on a mycobacterial lectin with a binding pocket recognizing 
trehalose and a neighboring hydrophobic binding site. However, since no membranous lectin 
has been published to date, an Mtb lectin similar to Mincle is only speculation. 
Binding of mycobacteria due to carbohydrate-lectin interactions would enable to specifically 
capture Mtb bacteria, while hydrophobic ligands might target a wide range of different bacteria 
or apoptotic host cells. The low specificity of the ligand 36 was already shown by Steinhäuser 
et al. This lipid ligand could not only be used to magnetically tag Mtb bacteria, but also other 
mycobacteria (e.g. M. avium), Gram-positive bacteria (e.g. Listeria monocytogenes) and 
Gram-negative bacteria (e.g. E. coli).136 Thus, capturing Mtb bacteria using a mouth rinse with 
hydrophobic particles might also result in binding of commensal oral bacteria and fungi. 
However, analytical methods like PCR will enable the specific detection of Mtb bacteria even 
within a mixture of isolated microorganisms. High binding selectivity is favorable, but not 
obligatory necessary.  
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In this study, RT-PCR was used to verify and quantify mycobacterial adhesion to hydrophobic 
beads. It was shown that the ligand 36 and the TMM-analog derivative 37 bind Mtb bacteria 
with high efficiency. Similar numbers of amplification cycles were necessary to detect 
mycobacterial DNA isolated from either ligand 36-captured Mtb bacteria or from the total 
bacteria amount. Thus, a comparable DNA concentration must have been present. It can be 
assumed that beads functionalized with the ligand 36 capture nearly all mycobacteria from 
solution. Slightly higher mean ct values were detected for beads functionalized with the 
ligand 37. This might not be due to minor binding efficiency, but can rather be explained by 
strong variations of detected ct values. Differences of up to five ct values were measured for 
DNA isolates from Mtb bacteria captured by functionalized beads or untreated bacteria. This 
limited accuracy might be caused by a loss of sample material during the adhesion assay or 
by the DNA-extraction procedure. Detection of ct values in experiments with unmodified beads 
might be based on insufficient washing steps. To obtain more reliable data, the current method 
should be further optimized. However, concentration dependent detection of Mtb bacteria by 
PCR verified that both, ligands 36 and 37, are suitable to effectively extract mycobacteria from 
solution.   
Comparison of the three hydrophobic ligands, derivative 36, 37 and pDADMAC, revealed a 
strong Mtb binding efficiency for all of them. However, while pDADMAC is immobilized by ionic 
interactions, the other two molecules are covalently attached, which might be an advantage 
for the stability of the functionalization. The primary amino groups of ligand 36 and 37 facilitate 
a fast and easy immobilization by peptide-coupling or thiourea formation to a variety of 
surfaces. The TMM-analog derivative 37 has a big advantage over the ligand 36. The 
carbohydrate scaffold will enable easy modifications of this molecule. Further structures can 
be selectively introduced at any position of the six unmodified hydroxyl groups. Derivatization 
might help to optimize the ligand and further increase binding efficiency. Also the functional 
amino group can be easily replaced facilitating alternative immobilization methods and 
prospective polymerization reactions. It might be conceivable to attach butadiene to the 
molecule 37 and then include this new ligand by radical or anionic polymerization into a 
polybutadiene structure suitable for a chewing gum. The potential structural variety based on 
the TMM-analog derivative 37 will positively contribute to finally reach the goal of developing 
a diagnostic mouth rinse or chewing gum.  
2.4.3 Development of a diagnostic mouth rinse or chewing gum 
The most common methods for Tb detection are direct microscopy of patient sputa and 
culturing of Mtb bacteria.3,4 However, children and cachectic patients usually cannot cough up 
enough phlegm to allow laboratory evaluations. One of the most important advantages for 
using saliva as a diagnostic tool is its simple, non-invasive sampling process. Mycobacteria 
were detected in saliva earlier, but the development of a diagnostic test remained unsuccessful 
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due to the low bacteria numbers.158,159 The amount of mycobacteria in saliva is between 
100 and 5000 times lower compared to sputum.151 However, A. G. Holani et al. successfully 
visualized Mtb bacteria from oral samples using fluorochrome staining.156 Additionally, 
detection of Mtb bacteria in saliva using PCR was recently shown by G. G. Mediero et al..157 
These results identified saliva as an alternative biological sample for rapid diagnosis of 
pulmonary Tb.  
Nevertheless, bacteria enrichment is necessary to increase the detection rate. Methods to 
capture mycobacteria to solid surfaces have previously been proposed, including immobilized 
phage or phage derived binding peptides,160,162 antibody coated beads161,163–165 or the 
hydrophobic Tb-Beads described before.166 Finally, only the Tb-Beads found their way into a 
diagnostic application. Antibodies are highly specific, but too expensive for extensive use, 
especially in less developed countries, and are susceptible to denaturation. Tb-Beads were 
designed to isolate mycobacteria from sputum, applications in saliva have not been described 
so far. The hydrophobic beads, investigated in the current study, might be used in analogy to 
the known Tb-Beads. The newly identified ligands 36 and 37 show high affinity for Mtb bacteria 
and high stability, are good to immobilize and cheap and easy to synthesize. Moreover, binding 
capacity of the applied beads might be further improved by an increase of the surface area. 
As shown by M. Behra et al. porous magnetic PEG beads have three times higher bacteria 
binding efficiency than nonporous particles.225 However, to develop a mouth rinse further 
biomedical standards have to be fulfilled. The oral rinse should not be toxic and has to be 
applicable also for children and cachectic patients, which are the main target group. Oral 
solutions for dental health are mainly approved for children older than six years. Thus, a 
diagnostic mouth rinse might not be suitable for babies and children younger than six, because 
they may swallow the rinse.  
Alternatively, a chewing gum or even better a non-dissolving lollipop could be designed. 
Chewing gums have been used for therapeutic applications since decades.226 Already during 
the late 19th century Dr. Edward Beeman incorporated pepsin powder into a chewing gum and 
1924 aspirin containing chewing gums were introduced in the US.227 One of the best known 
examples is the nicotine containing chewing gum used to help patients break the smoking 
habit.226 However, diagnostic chewing gums have only been rarely studied. 
Prof. Dr. Lorenz Meinel from the Julius Maximilian University of Würzburg developed a 
chewing gum detecting biomarkers of pathogens present in the mouth cavity. Thereby, a 
peptide is released from the gum matrix and cleaved by a pathogen-specific protease resulting 
in a bitter taste. This diagnostic system was designed for patient self-monitoring.228 Another 
diagnostic chewing gum is currently under investigation by Andrew Fung. He combines both 
magnetic particles and a gum matrix to isolate Malaria-specific proteins from saliva.229 Neither 
an Mtb-specific chewing gum nor mouth rinse have ever been developed before.  
Capture of mycobacteria 
Discussion  
56 
 
In analogy to the described diagnostic chewing gums, mycobacteria might also be detected in 
saliva by Mtb-specific molecules. Much work has been done on discovery of biomarkers in 
active and latent Tb infections.14 One of the most promising antigens that were evaluated is 
LAM. It is known that this lipoglycan is shedded from the Mtb cell envelope and released by 
exocytosis.230 Enzyme-linked immunosorbent (ELISA)-based assays were used to reveal LAM 
in sputum and urine.16–18 Furthermore, Ag85 was directly measured in sputum.15 Mtb-specific 
biomarkers in saliva were not investigated so far. 
To finally analyze bead- or chewing gum-captured mycobacteria, even in less developed 
countries, microscopy, cultivation or PCR can be applied. All three methods were successfully 
tested using the known Tb-Beads.167,168,223 Microscopy is not as sensitive as culture-based 
techniques.1 At least 3000 bacteria/ml are required, whereas Mtb concentrations of 
10 bacteria/ml can be detected by liquid culture. However, culturing bacteria is more costly, 
requires specialized biosafety infrastructure and takes weeks to obtain results, because of the 
extremely slow growth rate of Mtb bacteria. Nucleic acid-based diagnostic strategies can detect 
approximately 100 bacteria/ml, making them less sensitive than culture, but significantly more 
sensitive than microscopy. With DNA amplification systems it is thought that Tb can be 
diagnosed from sputum with 98% reliability.5,6 Genetic methods further allow more precise 
detection of drug resistances7–9 and mutations correlating with Tb pathogenicity. However, they 
require a high technical competence. Alternatively, a fast an easy method is conceivable, that 
might enable patient self-monitoring. A novel method for sensitive and rapid Mtb detection was 
recently developed by the chemist Jianghong Rao and the microbiologist Jeffrey Cirillo.231–233 
They took advantage of the high specificity of the β-lactamase BlaC, naturally surface-localized 
and secreted by Mtb bacteria. The β-lactamase activity was used to cleave cephalosporin-
based fluorogenic substrates generating fluorescence and leading to direct and rapid detection 
of mycobacteria. By this chemical method 90% of casas detected as positive by culture were 
identified correctly.231–233 Based on this strategy a new method can be developed, which might 
combine capturing of mycobacteria and Mtb detection by color appearance. After capture of 
Mtb bacteria by a diagnostic chewing gum or lollipop this diagnostic tool might be placed into 
a solution containing a cephalosporin-based substrate. This substrate should be cleaved by 
mycobacterial BlaC activity realizing a molecule, which turns the solvent colorful. This color 
appearance might be directly detected by patients and might allow patient self-monitoring. 
 
Although two potent ligands for enrichment of Mtb bacteria, the lipid ligands 36 and 37, were 
identified in this study, for the development of a diagnostic tool it is still a long way to go. A 
perfectly applicable material, a suitable chemistry for ligand introduction, a strategy for 
subsequent Mtb bacteria release and a cheap and easy, but highly sensitive analytical method 
need to be investigated. However, developing a chewing gum, lollipop or mouth rinse for 
detection Mtb bacteria will certainly contribute to improved Tb diagnostics in future.  
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2.5 Concluding remarks 
In order to develop a new tool to enrich and detect Mtb bacteria, carbohydrate derivatives and 
lipid ligands were applied to capture Mtb bacteria from solution. With the synthesized sugar 
derivatives 1-8 a largely unexplored area of mycobacterial lectins was addressed. Findings of 
the current study revealed carbohydrate-specific adhesion of M. bovis BCG bacteria and 
Mtb H37Rv bacteria indicating that lectins might indeed be present in the mycobacterial cell 
envelope. Lectin composition seems to vary between the two investigated species, which 
might be utilized to distinguish between different mycobacteria and preferentially capture Mtb 
bacteria. Microtiter plates and magnetic PEG-beads functionalized with the carbohydrate 
derivatives 1-8 could be used to enrich Mtb bacteria from solution. However, the adhesion 
efficiency of the Mtb strain H37Rv to beads functionalized with the α-D-mannopyranoside 4 
and amino trehalose 3 was strongly surpassed by beads carrying the lipid ligands 36 and 37, 
respectively. These adhesion studies will prospectively contribute to the development of a 
chewing gum or mouth rinse for Tb diagnostics.  
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2.6 Materials and methods 
2.6.1 Reagents 
 
Acetic acid Merck KGaA, Darmstadt, Germany 
Acetic anhydride Thermo  Fisher Scientific, Waltham, USA 
Acetone Thermo  Fisher Scientific, Waltham, USA 
Acetonitrile Sigma-Aldrich, St. Louis, USA 
Amberlite IR120 ion exchange resin Sigma-Aldrich, St. Louis, USA 
D-Arabinose VWR International, Radnor, USA 
Benzoylchloride Thermo  Fisher Scientific, Waltham, USA 
2-Bromoethanol Sigma-Aldrich, St. Louis, USA 
Boron trifluoride diethyl etherate  abcr GmbH, Karlsruhe, Germany 
Calcium chloride Sigma-Aldrich, St. Louis, USA 
Calcium hydride Thermo  Fisher Scientific, Waltham, USA 
Celite 545 Thermo  Fisher Scientific, Waltham, USA 
2-Chloroethanol Sigma-Aldrich, St. Louis, USA 
Chloroform-d1 Deutero GmbH, Kastellaun, Germany 
Concanavalin A, FITC-labeled Sigma-Aldrich, St. Louis, USA 
Cyclohexane Sigma-Aldrich, St. Louis, USA 
Deuterium oxide Deutero GmbH, Kastellaun, Germany 
1,8-Diazabicycloundec-7-ene (DBU) Alfa Aesar, Ward Hill, USA 
Dichloromethane (DCM) Merck KGaA, Darmstadt, Germany 
Diethyl ether Merck KGaA, Darmstadt, Germany 
Dimethylformamide (anhydrous) (DMF) Thermo  Fisher Scientific, Waltham, USA 
Dulbecco’s PBS (10x) Merck KGaA, Darmstadt, Germany 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, St. Louis, USA 
Ethanol VWR International, Radnor, USA 
Ethanolamine TOKYO CHEMICAL INDUSTRY CO., Tokyo, 
Japan 
Ethyl acetate Merck KGaA, Darmstadt, Germany 
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) Sigma-Aldrich, St. Louis, USA 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich, St. Louis, USA 
Glycerol Serva Electrophoresis GmbH, Heidelberg, 
Germany 
n-Hexane Thermo  Fisher Scientific, Waltham, USA 
Hydrochloric acid, 37% Sigma-Aldrich, St. Louis, USA 
Hydrogen bromide/ glacial acetic acid, 33% Sigma-Aldrich, St. Louis, USA 
4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) 
Sigma-Aldrich, St. Louis, USA 
Lithium aluminium hydride Thermo  Fisher Scientific, Waltham, USA 
Manganese chloride Alfa Aesar, Ward Hill, USA 
Magnesium chloride Sigma-Aldrich, St. Louis, USA 
Magnesium sulfate Thermo  Fisher Scientific, Waltham, USA 
Magnesium turnings Sigma-Aldrich, St. Louis, USA 
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D-Mannose Thermo  Fisher Scientific, Waltham, USA 
Methanol (MeOH) Sigma-Aldrich, St. Louis, USA 
Methanol-d4 Deutero GmbH, Kastellaun, Germany 
Middlebrook 7H9 broth Becton Dickinson, Franklin Lakes, USA 
N-Hydroxysuccinimide (NHS) Sigma-Aldrich, St. Louis, USA 
p-Nitrophenol Alfa Aesar, Ward Hill, USA 
p-Nitrophenyl α-D-galactopyranoside abcr GmbH, Karlsruhe, Germany 
p-Nitrophenyl α-D-glucopyranoside TOKYO CHEMICAL INDUSTRY CO., Tokyo, 
Japan 
p-Nitrophenyl α-D-manopyranoside Iris Biotech GmbH, Marktredwitz, Germany 
2-(N-morpholino)ethanesulfonic acid (MES) VWR International, Radnor, USA 
OADC (oleic acid, albumin, dextrose, catalase) Becton Dickinson, Franklin Lakes, USA 
Palladium/charcoal activated, 10% Sigma-Aldrich, St. Louis, USA 
Phosphorus pentoxide Sigma-Aldrich, St. Louis, USA 
Potassium hydroxide Merck KGaA, Darmstadt, Germany 
Pyridine Thermo  Fisher Scientific, Waltham, USA 
Sodium acetate Merck KGaA, Darmstadt, Germany 
Sodium azide Sigma-Aldrich, St. Louis, USA 
Sodium carbonate Sigma-Aldrich, St. Louis, USA 
Sodium chloride Sigma-Aldrich, St. Louis, USA 
Sodium hydrogen carbonate Sigma-Aldrich, St. Louis, USA 
Sodium hydroxide Sigma-Aldrich, St. Louis, USA 
Sodium methoxide Thermo  Fisher Scientific, Waltham, USA 
TaqMan Universal PCR Master Mix Thermo  Fisher Scientific, Waltham, USA 
Terahydrofuran (THF) Merck KGaA, Darmstadt, Germany 
tert-Butyldimethylsilyl chloride (TBDMSCl) Sigma-Aldrich, St. Louis, USA 
Tetrabutylammonium iodide (TBAI) Sigma-Aldrich, St. Louis, USA 
Tin tetrachloride Sigma-Aldrich, St. Louis, USA 
Toluene Thermo  Fisher Scientific, Waltham, USA 
p-Toluenesulfonyl chloride Sigma-Aldrich, St. Louis, USA 
Trichloroacetonitrile Alfa Aesar, Ward Hill, USA 
Triethylamine  Thermo  Fisher Scientific, Waltham, USA 
Tris(hydroxymethyl)aminomethane (Tris) Serva Electrophoresis GmbH, Heidelberg, 
Germany 
TRIzol Thermo  Fisher Scientific, Waltham, USA 
Tween 80 Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
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2.6.2 Buffer and media 
pH-Values were adjusted with aqueous HCl (100 mM) or NaOH (100 mM) solutions, respectively, unless otherwise 
described. All buffer and media were autoclaved prior use. 
 
Carbonate buffer, pH 9.4 Sodium carbonate (1.59 g, 15.0 mmol) and sodium 
hydrogen carbonate (2.52 g, 30.0 mmol) were 
dissolved in double dist. water (1.00 l) with 
subsequent pH adjustment. 
 
Lectin binding buffer (LBB), pH 7.0 HEPES (238 mg, 1.00 mmol), sodium chloride 
(292 mg, 5.00 mmol), manganese chloride 
(12.6 mg, 100 µmol) and calcium chloride (11.1 mg, 
100 µmol) were dissolved in double dist. water 
(100 ml) with subsequent pH adjustment. 
 
2-(N-morpholino)ethanesulfonic acid(MES) buffer, 
pH 6.3 
MES (9.76 g, 50.0 mmol) was dissolved in double 
dist. water (100 ml) with subsequent pH adjustment 
using a sodium carbonate solution (2.5 M). 
 
Middelebrook 7H9 medium Middlebrook 7H9 broth (4.70 g) were dissolved in 
double dist. water (900 ml) and Tween 80 (500 µl, 
412 µmol) and glycerol (2.00 ml, 27.4 mmol) were 
added. 
 
Phosphate-buffered saline (PBS), pH 7.0 Dulbecco’s PBS (10x) was diluted 1:10 with double 
dist. water 
 
Tris-buffered saline (TBS), pH 7.6  (adhesion assay) Tris (2.42 g, 20.0 mmol) and sodium chloride 
(8.00 g, 137 mmol) were dissolved in double 
dist. water (1.00 l) with subsequent pH adjustment. 
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2.6.3 Biological assays 
Mycobacterial strains used in this study  
All bacterial strains (Table 1) were grown in Middlebrook 7H9 medium containing 
oleic acid-albumin-dextrose-catalase (OADC, 10%), Tween 80 (0.05%) and glycerol (0.2%).  
At mid-log phase (OD600 = 0.4) cultures were harvested and frozen at -80°C as previously 
described.46 For adhesion assays frozen stocks (2.5∙108 bacteria/ml) were thawed (37°C) and 
centrifuged (3629 x g, 4°C, 10 min). Bacteria were re-suspended in PBS or TBS (with or 
without supplementation of Ca2+ (5 mM), Mg2+ (5 mM) or Ca2+ (5 mM)/ EDTA (15 mM)), the 
concentration was adjusted to 4∙108 bacteria/ml and the bacterial suspension homogenized 
using a sterile 1 ml syringe with a 26 gauge needle. 
Table 1: Mycobacterial strains used in this study. 
Sample name Description Source 
GFP-expressing 
M. bovis BCG 
M. bovis BCG Pasteur strain (1173P2) 
 
Strain carrying a GFP-expressing plasmid 
(pMN437)234 
 
Plasmid (pMN437)234 
kindly provided by 
Prof. Dr. M. Niederweis, 
University of Alabama at 
Birmingham, USA 
GFP-expressing 
Mtb H37Rv  
In order to obtain stable GFP expression in Mtb 
H37Rv, codon usage, fluorescence and folding 
optimized gfpm2+ from pMN437234 was cloned into 
the integrative mycobacterial plasmid pMV306235 
giving pSvM4 which was used to transform Mtb 
H37Rv (ATCC 27294). 
Plasmid (pMN437)234 
kindly provided by 
Prof. Dr. M. Niederweis, 
University of Alabama at 
Birmingham, USA 
 
Functionalization of microtiter plates196 
Black Immobilizer Amino™ F96 MicroWell™ plates (Nunc) were incubated with a solution of 
the carbohydrate derivatives 1-8 (10 mM in carbonate buffer, pH 9.4, 100 μl/well) overnight at 
rt and under gentle agitation (100 rpm). Wells were washed with PBS (2∙150 μl/well) and 
unreacted functional groups on the microtiter plate surface were blocked with ethanolamine 
(10 mM in carbonate buffer, pH 9.4, 120 μl/well) for 2 h at rt under gentle agitation (100 rpm). 
The wells were washed with PBS (2∙150 μl/well) and the microtiter plates were directly applied 
to adhesion assays or stored overnight at 4°C. 
Functionalization of magnetic PEG beads 
Beads (micromer-M, polystyrol core, surface: PEG-COOH, 5 µm, micromod; 800 µl, 
5.6∙108 beads) were supplemented with N-hydroxysuccinimide (NHS, 12.8 mg) and 1-ethyl-3-
(3-dimethylaminopropyl)carbodiimide (EDC, 6.40 mg) dissolved in MES buffer (pH 6.3, 200 µl) 
and incubated for 1.5 h at rt while intensely shaking (600 rpm). The activated beads were 
washed twice with PBS (1.00 ml each) and partitioned (3 batches, 1.87∙108 beads each). Each 
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batch was incubated with a solution of the carbohydrate derivatives 1, 3 or 4 (10 mM in 
carbonate buffer, pH 9.4, 1.00 ml) or the lipid ligands 29-37 (1.00 mg/ml carbonate buffer, 
pH 9.4; lipid 37: 1.00 mg/ 200 µl DMSO, 20.0 µl Et3N, 780 µl carbonate buffer, pH 9.4 (in the 
described order)) for 4.5 h at rt while intensely shaking (600 rpm). The functionalized beads 
were washed twice with PBS (1.00 ml/batch each) and unreacted NHS esters on the bead 
surface were blocked with ethanolamine (10 mM in carbonate buffer, pH 9.4, 1.00 ml/batch) 
for 1 h at rt, intense shaking (600 rpm). The beads were washed twice with PBS (1.00 ml/batch 
each), re-suspended in PBS (1.00 ml) and stored at 4°C. All steps were carried out in 
eppendorf tubes. A magnetic rack (DynaMag-2 magnet, Life technologies) was used for bead 
extraction. 
ConA-assay 
The beads were functionalized as described before in the method “Functionalization of 
magnetic PEG beads”. ConA-fluorescein was dissolved in LBB (250 µg/ml). The beads 
(2∙107 beads) were removed from PBS, suspended in the ConA-fluorescein solution (200 µl) 
and incubated for 1.5 h at rt while gently shaking (100 rpm) in the dark. The beads were 
washed twice with PBS (200 µl/batch each), re-suspended in PBS (100 µl), transferred to 
black microtiter plates (Nunc Maxisorp) and analyzed using a fluorescence microplate reader 
(Synergy 2, Biotek, excitation: 485 nm /emission: 528 nm). All steps were carried out in 
eppendorf tubes. A magnetic rack (DynaMag-2 magnet, Life technologies) was used for bead 
extraction. 
Mycobacterial adhesion assay on microtiter plates 
GFP-expressing mycobacteria (Mtb H37Rv or M. bovis BCG, 4∙108 bacteria/ml in PBS) were 
serial diluted (1:2) with PBS in functionalized microtiter plates (100 µl/well, highest 
concentration: 4∙108 bacteria/ml, lowest concentration: 2∙105 bacteria/ml) and incubated for 1 h 
at 37°C while gently shaking (100 rpm) in the dark. Wells were washed twice with PBS 
(150 µl/well each) followed by addition of PBS (100 µl/well). The bacterial adhesion was 
analyzed using a fluorescence microplate reader (Synergy 2, Biotek, excitation: 485 
nm/emission: 528 nm).   
Mycobacterial adhesion assay studying Ca2+ dependency 
The adhesion assay was carried out analog as described before in method “Mycobacterial 
adhesion assay on microtiter plates”. Variations: Bacteria were suspended and diluted in TBS 
(with or without supplementation of Ca2+ (5 mM), Mg2+ (5 mM) or Ca2+ (5 mM)/EDTA (15 mM)); 
for washing steps the same TBS buffer was used.  
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Mycobacterial adhesion assay using functionalized magnetic PEG beads 
The beads were functionalized as described before in the method “Functionalization of 
magnetic PEG beads”. Functionalized or unmodified beads (2∙107 beads, 100 µl), PBS (300 µl) 
and GFP-expressing Mtb H37Rv bacteria (4∙108 bacteria/ml, 100µl) were incubated for 1 h at 
rt while gently shaking in the dark. The beads were washed twice (500 µl/batch) and re-
suspended in PBS (100 µl). The suspension was transferred to black microtiter plates (Nunc 
Maxisorp) and analyzed using a fluorescence microplate reader (Synergy 2, Biotek, 
excitation: 485 nm/emission: 528 nm).  
   
Verifying mycobacterial adhesion by PCR                                        
The beads were functionalized as described before in method “Functionalization of magnetic 
PEG beads”. Functionalized or unmodified beads (5∙106 beads, 25.0 µl), PBS (375 µl) and Mtb 
H37Rv bacteria in desired concentrations (100 µl) were combined and incubated for 1 h at rt 
while gently shaking in the dark. Beads were washed twice (500 µl/batch), centrifuged and 
re-suspended in PBS (50.0 µl). For comparison Mtb H37Rv bacteria in desired concentrations 
were centrifuged and re-suspended in PBS (50.0 µl). All samples were equally treated in the 
following steps.  
 
TRIzol (250 µl) and ethanol (250 µl) were added and mixed. The suspension was transferred 
to a spin column in a collection tube of the DirectZol RNA MiniPrep kit (Zymo Research) 
followed by centrifugation (13000 x g, 1 min). The column was transferred into a new collection 
tube and the flow-through discarded. Pre-washing buffer (400 μl) was added to the column, 
which was subsequently centrifuged (13000 x g, 1 min). Flow-through was discarded and the 
pre-washing step was repeated. Washing buffer (700 μl) was added to the column followed by 
centrifugation (13000 x g, 2 min). The column was transferred into an RNase-free tube. To 
elute DNA, DNase/RNase-free water (50 μl) was added and finally centrifuged (13000 x g, 
1 min). Isolated DNA was stored at -80°C. 
 
 For quantitative real-time PCR (qRT-PCR) analysis TaqMan Universal PCR Master Mix 
(10.0 µl), Beijing primer (sense and antisense, 200 µM, 1.0 µl each), non-Beijing primer (sense 
and antisense, 200 µM, 1.0 µl each), fluorescein (FAM)-BlackBerry (BBQ) non-Beijing probe 
(4 µM, 1.0 µl), YakimaYellow (YAK)-BlackBerry (BBQ) Beijing probe (4 µM, 1.0 µl), double 
dist. water (2.0 µl) and isolated DNA (2.0 µl) were combined. The samples were transferred to 
a white 96 well plate, which was sealed, centrifuged (180 x g, 2 min, 4°C) and subjected to the 
Rotor-Gene system (Qiagen). The used qRT-PCR protocol is given in table 4. 
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Table 2: Primers used in this study.236 
Primer pair Name Forward primer Reverse primer 
Non-Beijing nBjF/nBjR 5’-aagcattcccttgacagtcgaa 5’-ggcgcatgactcgaaagaag 
Beijing BjF/BjR 5’-ctcggcagcttcctcgat 5’-cgaactcgaggctgcctactac 
 
 
Table 3: FRET-probes used in this study.236 
FRET-probe  Sequence 
Non-Beijing 5’-6FAM-tcatcaaagaccctcttggaaggccc-BBQ 
Beijing 5’-YAK-aacgccagagaccagccgccggct-BBQ 
 
 
Table 4: qRT-PCR protocol (55 cycles) 
Program Temperature Time 
Denaturation 95°C 15 min 
Annealing 55°C 60 sec 
Elongation 72°C 20 sec 
End 25°C 5 min 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Capture of mycobacteria 
Materials and methods  
65 
 
2.6.4 Syntheses 
General methods for synthesis                 
Commercially available starting materials and reagents were used without further purification. 
Anhydrous dimethylformamide (DMF) was purchased, all other solvents used were dried for 
reactions (acetone over phosphorus pentoxide, acetonitrile over calcium hydride, 
dichloromethane (DCM) over calcium hydride, methanol (MeOH) over magnesium turnings, 
pyridine over potassium hydroxide, tetrahydrofuran (THF) over lithium aluminium hydride). 
Air- and/or moisture-sensitive reactions were carried out under an atmosphere of nitrogen. 
Thin layer chromatography (TLC) was performed on silica gel plates (GF 254, Merck). 
Detection was effected by UV irradiation and/or charring with sulfuric acid in ethanol (10%) 
followed by heat treatment. Flash chromatography was performed on silica gel 60 (particle size 
0.040-0.063 mm, Merck). 1H and 13C NMR spectra were recorded on a DRX-500 or 
AV-600 instrument (Bruker). Chemical shifts are referenced to internal tetramethylsilane 
(TMS, 1H: δ 0.00 ppm) or to the residual proton of the NMR solvent: CDCl3 (1H: δ 7.26 ppm, 
13C: δ 77.00 ppm), MeOH-d4 (1H: δ 3.31 ppm; 13C: δ 49.05 ppm) or D2O (1H: δ 4.65 ppm). 
Data are presented as follows: chemical shift, multiplicity (s: singlet, d: doublet, t: triplet, 
q: quartet, m: multiplet), coupling constant in Hertz (Hz) and integration of the respective 
signals. Full assignment was achieved with 2D NMR techniques (1H-1H COSY, 1H-13C HSQC 
and 1H-13C HMBC). ESI-MS measurements were recorded on a LCQ Classic (Thermo 
Finnigan) and HRMS ESI spectra on an Agilent 6224 ESI-TOF. Optical rotation was measured 
on a polarimeter 341 (Perkin-Elmer) (Na-D-line: 589 nm, length of cell 1 dm, concentration 
listed: g/100ml). IR spectra were recorded on a Paragon 1000 FT-IR instrument 
(Perkin-Elmer). Melting points (m.p.) were determined on a Büchi 510 apparatus (Flawil).      
p-Aminophenyl α-D-arabinofuranoside (1)                        
p-Nitrophenyl α-D-arabinofuranoside (23, 700 mg, 2.56 mmol) was dissolved in methanol 
(50.0 ml) and 10% palladium on charcoal (spatula tip) was added. The reaction was stirred for 
3 h at rt under a hydrogen atmosphere, purified using a syringe filter (Satorius), concentrated 
in vacuo and lyophilized. The product 1 was obtained as a colorless solid (600 mg, 2.49 mmol, 
97%). TLC (cyclohexane/ethyl acetate/methanol, 1:1:0.25): Rf = 0.07; rotation value: [α]22𝐷  = 
+ 176.0° (c = 1.0, MeOH); m.p.: 158.5-160.2°C; 1H NMR (500 MHz, MeOH-d4, 300 K): 
δ = 6.91-6.88 (m, 2H, aryl-Hmeta), 6.73-6.70 (m, 2H, aryl-Hortho), 5.39 (d, 3J1,2 = 1.9 Hz, 1H, H-1), 
4.22 (dd, 3J1,2 = 2.0 Hz, 3J2,3 = 4.1 Hz, 1H, H-2), 4.09 (ddd, 3J3,4 = 6.5 Hz, 3J4,5a = 3.2 Hz, 
3J4,5b = 5.1 Hz, 1H, H-4), 3.97 (dd, 3J2,3 = 4.0 Hz, 3J3,4 = 6.5 Hz, 1H, H-3), 3.80 (dd, 
3J4,5a = 3.2 Hz, 2J5a,5b = 12.0 Hz, 1H, H-5a), 3.69 (dd, 3J4,5b = 5.1 Hz, 2J5a,5b = 12.0 Hz, 1H, 
H-5b) ppm; 13C NMR (125 MHz, MeOH-d4, 300 K): δ = 151.4 (aryl-Cipso), 143.2 (aryl-Cpara), 
119.4 (aryl-Cmeta), 117.8 (aryl-Cortho), 109.0 (C-1), 85.9 (C-4), 83.8 (C-2), 78.4 (C-3), 62.9 (C-5) 
ppm; HRMS (ESI-MS): m/z = 264.0886, [M+Na]+ (calc. 264.0848 for C11H15NO5+Na).  
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(2-Aminoethyl) α-D-arabinofuranoside (2)                                          
The arabinofuranoside derivative 18 (11.0 mg, 50.2 µmol) was dissolved in methanol (3.00 ml) 
and 10% palladium on charcoal (spatula tip) was added. The reaction was stirred for 2.5 h at 
rt under a hydrogen atmosphere, purified using a syringe filter (Satorius) and concentrated in 
vacuo. TLC (methanol/ethyl acetate, 5:1): Rf = 0.07. The instable product 2 was not further 
analyzed and directly used for surface functionalization.  
6-Amino-6-deoxy-α,α-D-trehalose (3)195                                          
The trehalose derivative 28 (120 mg, 323 µmol) was dissolved in methanol (25.0 ml) and 
10% palladium on charcoal (spatula tip) was added. The reaction was stirred for 3 h at rt under 
a hydrogen atmosphere, purified using a syringe filter (Satorius), concentrated in vacuo and 
lyophilized. The product 3 was obtained as a white solid (110 mg, 323 µmol, quant.). 
TLC (methanol/H2O/Et3N, 4:1:0.1): Rf = 0.12.; 1H NMR (500 MHz, D2O, 300 K): δ = 5.14 (d, 
3J1’,2’ = 4.0 Hz, 1H, H-1’), 5.13 (d, 3J1,2 = 3.9 Hz, 1H, H-1), 3.82-3.68 (m, 4H, H-4, H-4’, H-5’, H-
6’a), 3.70 (ddd, 3J4,5 = 6.5 Hz, 3J5,6a = 2.5 Hz, 3J5,6b = 7.3 Hz, 1H, H-5), 3.70 (dd, 3J5’,6’b = 5.2 Hz, 
2J6’a,6’b = 12.0 Hz, 1H, H-6’b), 3.59 (dd, 3J1,2 = 3.9 Hz, 3J2,3 = 9.9 Hz, 3J1’,2’ = 3.9 Hz, 
3J2’,3’ = 9.9 Hz, 2H, H-2, H-2’), 3.39 (dd~t, 3J2’,3’ = 9.5 Hz, 3J3’,4’ = 9.5 Hz, 1H, H-3’), 3.28 (dd~t, 
3J2,3 = 9.5 Hz, 3J3,4 = 9.5 Hz, 1H, H-3), 2.95 (dd, 3J5,6a = 2.7 Hz, 2J6a,6b = 13.7 Hz, 1H, H-6a), 
2.70 (dd, 3J5,6b = 7.8 Hz, 2J6a,6b = 13.7 Hz, 1H, H-6b) ppm.   
p-Aminophenyl α-D-mannopyranoside (4)187                       
p-Nitrophenyl α-D-mannopyranoside (1.00 g, 3.32 mmol) was dissolved in methanol (50.0 ml) 
and 10% palladium on charcoal (spatula tip) was added. The reaction was stirred for 4 h at rt 
under a hydrogen atmosphere, purified using a syringe filter (Satorius), concentrated in vacuo 
and lyophilized. The product 4 was obtained as a white solid (900 mg, 3.32 mmol, quant.). 
TLC (cyclohexane/ethyl acetate/methanol, 1:1:0.2): Rf = 0.10; 1H NMR (500 MHz, MeOH-d4, 
300 K): δ = 6.92-6.88 (m, 2H, aryl-Hmeta), 6.70-6.67 (m, 2H, aryl-Hortho), 5.28 (d, 3J1,2 = 1.8 Hz, 
1H, H-1), 3.97 (dd, 3J1,2 = 1.9 Hz, 3J2,3 = 3.4 Hz, 1H, H-2), 3.87 (dd, 3J2,3 = 3.4 Hz, 3J3,4 = 9.2 Hz, 
1H, H-3), 3.78 (dd, 3J5,6a = 2.4 Hz, 2J6a,6b = 11.9 Hz, 1H, H-6a), 3.73 (dd, 3J3,4 = 8.0 Hz, 
3J4,5 = 10.9 Hz, 1H, H-4), 3.72 (dd, 3J5,6b = 5.1 Hz, 2J6a,6b = 12.0 Hz, 1H, H-6b), 3.67 (ddd, 
3J4,5 = 9.8 Hz, 3J5,6a = 2.3 Hz, 3J5,6b = 4.8 Hz, 1H, H-5) ppm.  
(2-Aminoethyl) α-D-mannopyranoside (5)180                
The azido sugar 12 (900 mg, 3.61 mmol) was dissolved in methanol (50.0 ml) and 
10% palladium on charcoal (spatula tip) was added. The reaction was stirred overnight at rt 
under a hydrogen atmosphere, purified using a syringe filter (Satorius) and concentrated in 
vacuo. The product 5 was obtained as a white foam (790 mg, 3.54 mmol, 98%). 
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TLC (methanol/ethyl acetate, 5:1): Rf = 0.06; 1H NMR (500 MHz, MeOH-d4, 300 K): 
δ = 4.77 (d, 3J1,2 = 1.7 Hz, 1H, H-1), 3.84 (dd, 3J5,6a = 2.4 Hz, 2J6a,6b = 11.7 Hz, 1H, H-6a), 3.83 
(dd, 3J1,2 = 1.8 Hz, 3J2,3 = 3.2 Hz, 1H, H-2), 3.77 (ddd, 3J = 4.8 Hz, 3J = 6.0 Hz, 2J = 10.1 Hz, 1H, 
OCH2CH2NH2), 3.71 (dd, 3J2,3 = 3.4 Hz, 3J3,4 = 9.2 Hz, 1H, H-3), 3.70 (dd, 3J5,6b = 6.0 Hz, 
2J6a,6b = 11.7 Hz, 1H, H-6b), 3.60 (dd~t, 3J3,4 = 9.5 Hz, 3J4,5 = 9.5 Hz, 1H, H-4), 3.54 (ddd, 
3J = 2.1 Hz, 3J = 6.0 Hz, 2J = 9.7 Hz, 1H, OCH2CH2NH2), 3.46 (ddd, 3J4,5 = 10.0 Hz, 
3J5,6a = 4.7 Hz, 3J5,6b = 6.1 Hz, 1H, H-5), 2.86-3.77 (m, 2H, OCH2CH2NH2) ppm. 
p-Aminophenyl α-D-glucopyranoside (6)237                           
p-Nitrophenyl α-D-glucopyranoside (1.00 g, 3.32 mmol) was dissolved in methanol (50.0 ml) 
and 10% palladium on charcoal (spatula tip) was added. The reaction was stirred overnight at 
rt under a hydrogen atmosphere, purified using a syringe filter (Satorius), concentrated in 
vacuo and lyophilized. The product 6 was obtained as a colorless foam (890 mg, 3.28 mmol, 
99%). TLC (ethyl acetate/methanol, 2:1): Rf = 0.36; 1H NMR (500 MHz, MeOH-d4, 300 K): 
δ = 6.98-6.94 (m, 2H, aryl-Hmeta), 6.71-6.67 (m, 2H, aryl-Hortho), 5.27 (d, 3J1,2 = 3.7 Hz, 1H, H-1), 
3.82 (dd~t, 3J2,3 = 9.4 Hz, 3J3,4 = 9.4 Hz, 1H, H-3), 3.76 (dd, 3J5,6a = 1.8 Hz, 2J6a,6b = 12.6 Hz, 
1H, H-6a), 3.76-3.71 (m, 1H, H-5), 3.70 (dd, 3J5,6b = 6.1 Hz, 2J6a,6b = 12.5 Hz, 1H, H-6b), 3.51 
(dd, 3J1,2 = 3.7 Hz, 3J2,3 = 9.7 Hz, 1H, H-2), 3.41 (dd~t, 3J3,4 = 9.1 Hz, 3J4,5 = 9.1 Hz, 1H, H-4) 
ppm.  
p-Aminophenyl β-D-glucopyranoside (7)237                                   
p-Nitrophenyl β-D-glucopyranoside (260 mg, 864 mmol) was dissolved in methanol (13.0 ml) 
and 10% palladium on charcoal (spatula tip) was added. The reaction was stirred overnight at 
rt under a hydrogen atmosphere, purified using a syringe filter (Satorius), concentrated in 
vacuo and lyophilized. The product 7 was obtained as a colorless foam (224 mg, 827 mmol, 
96%). TLC (ethyl acetate/methanol, 2:1): Rf = 0.35; 1H NMR (500 MHz, MeOH-d4, 300 K): 
δ = 6.94-6.91 (m, 2H, aryl-Hmeta), 6.70-6.67 (m, 2H, aryl-Hortho), 4.72 (d, 3J1,2 = 7.4 Hz, 1H, H-1), 
3.88 (dd, 3J5,6a = 1.6 Hz, 2J6a,6b = 12.0 Hz, 1H, H-6a), 3.69 (dd, 3J5,6b = 5.2 Hz, 2J6a,6b = 12.0 Hz, 
1H, H-6b), 3.48-3.39 (m, 3H, H-3, H-4, H-5), 3.40 (dd, 3J1,2 = 7.3 Hz, 3J2,3 = 2.7 Hz, 1H, H-2) 
ppm.  
p-Aminophenyl α-D-galactopyranoside (8)187                                   
p-Nitrophenyl α-D-galactopyranoside (1.00 g, 3.32 mmol) was dissolved in methanol (50.0 ml) 
and 10% palladium on charcoal (spatula tip) was added. The reaction was stirred for 2.5 h at 
rt under a hydrogen atmosphere, purified using a syringe filter (Satorius), concentrated in 
vacuo and lyophilized. The product 8 was obtained as a colorless solid (897 mg, 3.31 mmol, 
quant.). TLC (ethyl acetate/methanol, 2:1): Rf = 0.38; 1H NMR (200 MHz, MeOH-d4, 300 K): 
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δ = 7.06-6.97 (m, 2H, aryl-Hmeta), 6.78-6.69 (m, 2H, aryl-Hortho), 5.33 (d, 3J1,2 = 2.7 Hz, 1H, H-1), 
4.10-3.93 (m, 4H, H-3, H-5, H-6a, H-6b), 3.78-3.70 (m, 2H, H-2, H-4) ppm. 
1,2,3,4,6-Penta-O-acetyl-α,β-D-mannopyranose (9)181              
A suspension of sodium acetate (4.10 g, 50.0 mmol) in acetic anhydride (Ac2O, 45 ml) was 
refluxed. The heating source was removed and D-mannose (9.00 g, 50.0 mmol, 1 eq.) was 
slowly added. The reaction mixture was stirred for 30 min at rt and for 30 min under reflux. 
After addition of ice (200 ml) it was stirred 1 h and extracted with DCM. The organic phases 
were dried over MgSO4, filtered and concentrated in vacuo. The product 9 was co-evaporated 
with toluene and a colorless oil was obtained (19.2 g, 49.3 mmol, 99%) (α:β ratio = 3:1 by 
integration of the 1H NMR spectrum). TLC (cyclohexane/acetone, 3:2): Rf = 0.35; 
1H NMR (200 MHz, CDCl3, 300 K, TMS): δ = 6.09 (d, 3J1,2 = 1.9 Hz, 1H, H-1 (α)), 5.86 (d, 
3J1,2 = 1.2 Hz, 1H, H-1 (β)), 5.49 (dd, 3J1,2 = 1.2 Hz, 3J2,3 = 3.2 Hz, 1H, H-2 (β)), 5.38-5.24 (m, 
4H, H-2 (α), H-3 (α), H-4 (α), H-4 (β)), 5.13 (dd, 3J2,3 = 3.2 Hz, 3J3,4 = 10.0 Hz, 1H, H-3 (β)), 
4.31 (dd, 3J5,6a = 5.4 Hz, 2J6a,6b = 12.4 Hz, 1H, H-6a (α)), 4.29 (dd, 3J5,6b = 4.9 Hz, 
2J6a,6b = 12.3 Hz, 1H, H-6b (α)), 4.16 (dd, 3J5,6a = 2.5 Hz, 2J6a,6b = 8.0 Hz, 1H, H-6a (β)), 
4.18-4.00 (m, 2H, H-5α, H-6b (β)), 3.81 (ddd, 3J4,5 = 9.7 Hz, 3J5,6a = 5.3 Hz, 3J5,6b = 2.5 Hz, 1H, 
H-5 (β)), 2.18, 2.17, 2.09, 2.06, 2.01 (s each, 3H each, 5 COCH3 (α,β)) ppm.    
(2-Bromoethyl) 2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside (10)182                  
Acetyl protected mannose 9 (1.50 g, 3.85 mmol) and 2-bromoethanol (330 µl, 4.64 mmol, 
1.2 eq.) were dissolved in dry DCM (15.0 ml). Boron trifluoride diethyl etherate (BF3∙Et2O, 
2.70 ml, 21.3 mmol, 5.5 eq.) was added slowly within 30 min under cooling with an ice bath 
and the reaction was stirred overnight at rt. Dist. water was added and the aqueous phase 
extracted with DCM. The combined organic phases were dried over MgSO4, filtered and 
concentrated in vacuo. The crude product was chromatographed on silica gel 
(cyclohexane/ethyl acetate, 2:1) and recrystallized from diethyl ether to give the pure 
α-anomere 10 as colorless solid (986 mg, 2.16 mmol, 56%). TLC (cyclohexane/ethyl acetate, 
1:1): Rf = 0.48; 1H NMR (500 MHz, CDCl3, 300 K, TMS): δ = 5.35 (dd, 3J2,3 = 3.4 Hz, 
3J3,4 = 10.1 Hz, 1H, H-3), 5.31-5.27 (m, 2H, H-2, H-4), 4.88 (d, 3J1,2 = 1.7 Hz, 1H, H-1), 4.27 (dd, 
3J5,6a = 6.0 Hz, 2J6a,6b = 12.7 Hz, 1H, H-6a), 4.16-4.12 (m, 2H, H-5, H-6b), 3.98 (dt, 3J = 6.3 Hz, 
2J = 11.2 Hz, 1H, OCH2CH2Br), 3.89 (dt, 3J = 5.8 Hz, 2J = 11.3 Hz, 1H, OCH2CH2Br), 3.52 (t, 
3J = 6.0 Hz, 3J = 6.0 Hz, 2H, OCH2CH2Br), 2.16, 2.11, 2.05, 2.00 (s each, 3H each, 4 COCH3) 
ppm. 
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(2-Azidoethyl) 2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside (11)180         
To a solution of bromoethyl mannopyranoside 10 (3.00 g, 6.59 mmol) in dry DMF (50.0 ml) 
sodium azide (2.13 g, 32.7 mmol, 5 eq.) and tetrabutylammonium iodide (TBAI, 490 mg, 
1.32 mmol, 0.2 eq.) were added. The reaction mixture was stirred under a nitrogen atmosphere 
for 8 h at 70°C and overnight at rt. Dist. water was added and the aqueous phase was extracted 
with DCM. The combined organic layers were dried over MgSO4, filtered and concentrated in 
vacuo. The crude product was chromatographed on silica gel (cyclohexane/ethyl acetate, 2:1) 
to give the azido sugar 11 (2.54 g, 6.09 mmol, 92%) as colorless crystals. 
TLC (cyclohexane/ethyl acetate, 2:1): Rf = 0.16; 1H NMR (500 MHz, CDCl3, 300 K, TMS): δ = 
5.37 (dd, 3J2,3 = 3.5 Hz, 3J3,4 = 10.0 Hz, 1H, H-3), 5.30 (dd~t, 3J3,4 = 10.0 Hz, 3J4,5 = 10.0 Hz, 1H, 
H-4), 5.28 (dd, 3J1,2 = 1.8 Hz, 3J2,3 = 3.4 Hz, 1H, H-2), 4.87 (d, 3J1,2 = 1.7 Hz, 1H, H-1), 4.29 (dd, 
3J5,6a = 5.4 Hz, 2J6a,6b = 12.3 Hz, 1H, H-6a), 4.13 (dd, 3J5,6b = 2.4 Hz, 2J6a,6b = 12.3 Hz, 1H, H-6b), 
4.05 (ddd, 3J4,5 = 9.9 Hz, 3J5,6a = 5.3 Hz, 3J5,6b = 2.4 Hz, 1H, H-5), 3.87 (ddd, 3J = 3.8 Hz, 3J = 6.9 
Hz, 2J = 10.7 Hz, 1H, OCH2CH2N3), 3.68 (ddd, 3J = 3.7 Hz, 3J = 6.0 Hz, 2J = 10.6 Hz, 1H, 
OCH2CH2N3), 3.50 (ddd, 3J = 3.6 Hz, 3J = 6.9 Hz, 2J = 13.3 Hz, 1H, OCH2CH2N3), 3.45 (ddd, 
3J = 3.8 Hz, 3J = 6.0 Hz, 2J = 13.3 Hz, 1H, OCH2CH2N3), 2.16, 2.10, 2.05, 1.99 (s each, 3H 
each, 4 COCH3) ppm. 
(2-Azidoethyl) α-D-mannopyranoside (12)180                 
The acetyl-protected mannopyranoside derivative 11 (2.10 g, 5.04 mmol) was suspended in 
dry methanol and sodium methoxide (spatula tip) was added. The reaction mixture was stirred 
overnight at rt under a nitrogen atmosphere. After neutralization with Amberlite IR120 ion 
exchange resin and concentration in vacuo, the crude product was chromatographed on silica 
gel (ethyl acetate/methanol, 7:1) and lyophilized to give the product 12 (1.23 g, 4.93 mmol, 
98%) as a white solid. TLC (ethyl acetate/methanol, 2:1): Rf = 0.50; 1H NMR (500 MHz, 
MeOH-d4, 300 K): δ = 4.85 (d, 3J1,2 = 1.7 Hz, 1H, H-1), 3.95 (ddd, 3J = 4.6 Hz, 3J = 4.6 Hz, 2J = 
9.8 Hz, 1H, OCH2CH2N3), 3.87 (dd, 3J1,2 = 1.7 Hz, 3J2,3 = 3.5 Hz, 1H, H-2), 3.88 (dd, 
3J5,6a = 2.4 Hz, 2J6a,6b = 11.6 Hz, 1H, H-6a), 3.76 (dd, 3J2,3 = 3.4 Hz, 3J3,4 = 9.1 Hz,  1H, H-3), 
3.75 (dd, 3J5,6b = 5.7 Hz, 2J6a,6b = 11.8 Hz, 1H, H-6b), 3.69-3.63 (m, 2H, H-4, H-5), 3.60 (ddd, 
3J = 2.3 Hz, 3J = 5.8 Hz, 2J = 9.8 Hz, 1H, OCH2CH2N3), 3.46-3.42 (m, 2H, OCH2CH2N3) ppm. 
5-O-tert-Butyldimethylsilyl-1,2,3-tri-O-acetyl-α,β-D-arabinofurose (13)184          
D-Arabinose (5.00 g, 33.3 mmol) was suspended in dry pyridine (50.0 ml) and tert-butyl-
dimethylsilyl chloride (TBDMSCl, 5.50 g, 36.5 mmol, 1.1 eq.) was added. The reaction mixture 
was stirred for 4 h at rt under a nitrogen atmosphere. Acetic anhydride (Ac2O, 15.0 ml, 
136 mmol, 4 eq.) was added and the reaction was stirred overnight. After addition of a 
saturated aqueous NaHCO3 solution (150 ml) the resulting mixture was extracted with DCM. 
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The combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. The 
crude product was chromatographed on silica gel (cyclohexane/ethyl acetate 4:1) to give the 
arabinofuranose derivative 13 (7.32 g, 18.8 mmol, 57%) as a colorless oil (α:β ratio = 2:1 by 
integration of the 1H NMR spectrum). TLC (cyclohexane/ethyl acetate, 2:1): Rf = 0.50; rotation 
value: [α]22
𝐷
 = + 12.8° (c = 0.5, CH2Cl2); 1H NMR (500 MHz, CDCl3, 300 K): δ = 6.34 (d, 
3J1,2 = 4.7 Hz, 1H, H-1 (β)), 6.16 (d~s, 1H, H-1 (α)), 5.48 (dd, 3J3,4 = 5.9 Hz, 3J2,3 = 7.1 Hz, 1H, 
H-3 (β)), 5.33 (dd, 3J1,2 = 4.7 Hz, 3J2,3 = 7.1 Hz, 1H, H-2 (β)), 5.20 (dd, 3J2,3 = 1.7 Hz, 
3J3,4 = 4.9 Hz, 1H, H-3 (α)), 5.18 (dd~d, 3J2,3 = 1.7 Hz, 1H, H-2 (α)), 4.20 (ddd~q, 3J3,4 = 4.3 Hz, 
3J4,5a = 4.3 Hz, 3J4,5b= 4.3 Hz, 1H, H-4 (α)), 4.06 (ddd~q, 3J3,4 = 5.7 Hz, 3J4,5a = 5.7 Hz, 
3J4,5b = 5.7 Hz, 1H, H-4 (β)), 3.85 (dd, 3J4,5a = 4.2 Hz, 2J5a,5b = 11.2 Hz, 1H, H-5a (α)), 3.81 (dd, 
3J4,5b = 4.3 Hz, 2J5a,5b = 11.2 Hz, 1H, H-5b (α)), 3.79 (dd, 3J4,5a = 5.7 Hz, 2J5a,5b = 12.0 Hz, 1H, 
H-5a (β)), 3.77 (dd, 3J4,5b = 5.7 Hz, 2J5a,5b = 12.1 Hz, 1H, H-5b (β)), 2.11, 2.10, 2.09 (s each, 3H 
each, 3 COCH3 (α)), 2.08, 2.07, 2.06 (s each, 3H each, 3 COCH3 (β)), 0.90 (s, 9H, 
OSi(CH3)2C(CH3)3 (α)), 0.89 (s, 9H, OSi(CH3)2C(CH3)3 (β)), 0.07, 0.067, 0.065, 0.06 (s each, 
3H each, OSi(CH3)2C(CH3)3 (α,β)) ppm; 13C NMR (125 MHz, CDCl3, 300 K): δ = 169.7, 169.6, 
169.6, 169.3, 169.1, 169.1 (6 COCH3 (α,β)), 99.3 (C-1 (α)), 93.5 (C-1 (β)), 84.6 (C-4 (α)), 81.6 
(C-4 (β)), 81.0 (C-2 (α)), 76.5 (C-3 (α)), 75.4 (C-2 (β)), 74.2 (C-3 (β)), 63.7 (C-5 (β)), 61.9 
(C-5 (α)), 25.5 (2 OSi(CH3)2C(CH3)3 (α,β)), 20.8, 20.5, 20.2 (3 COCH3 (β)), 20.8, 20.5, 20.4 
(3 COCH3 (α)),  18.0 (OSi(CH3)2C(CH3)3 (α, β)), -5.6 (OSi(CH3)2C(CH3)3 (β)), -5.7 
(OSi(CH3)2C(CH3)3 (α)) ppm; ESI-MS: m/z = 413.078, [M+Na]+ (calc. 413.161 for 
C17H30O5Si+Na).  
1,2,3-Tri-O-acetyl-α,β-D-arabinofurose (14)                      
The product 14 was obtained by a different synthetic route as described in literature:188 The 
arabinofuranose derivative 13 (10.7 g, 27.4 mmol) was stirred in acetic acid (120 ml) and dist. 
water (60.0 ml) overnight at rt. A saturated aqueous NaHCO3 solution was added and the 
resulting mixture was extracted with DCM. The combined organic layers were dried over 
MgSO4, filtered and concentrated in vacuo. The crude product was chromatographed on silica 
gel (cyclohexane/ethyl acetate, 1:1) to give 14 (7.41 g, 26.8 mmol, 98%) as a colorless oil. 
(α:β ratio = 2:1 by integration of the 1H NMR spectrum). TLC (cyclohexane/ethyl acetate, 2:1): 
Rf = 0.08; 1H NMR (500 MHz, CDCl3, 300 K, TMS): δ = 6.39-6.38 (m, 1H, H-1 (β)), 6.18 (d~s, 
1H, H-1 (α)), 5.40-5.39 (m, 2H, H-2 (β), H-3 (β)), 5.25 (dd~d, 3J2,3 = 1.9 Hz, 1H, H-2 (α)), 5.12 
(dd, 3J2,3 = 1.8 Hz, 3J3,4 = 5.2 Hz, 1H, H-3 (α)), 4.23 (ddd, 3J3,4 = 5.2 Hz, 3J4,5a = 3.4 Hz, 
3J4,5b= 4.2 Hz, 1H, H-4 (α)), 4.11-4.07 (m, 1H, H-4 (β)), 3.89 (dd, 3J4,5a = 3.4 Hz, 
2J5a,5b = 12.3 Hz, 1H, H-5a (α)), 3.86 (dd, 3J4,5a = 4.4 Hz, 2J5a,5b = 12.2 Hz, 1H, H-5a (β)), 
3.81 (dd, 3J4,5b = 4.2 Hz, 2J5a,5b = 12.3 Hz, 1H, H-5b (α)), 3.74 (dd, 3J4,5b = 5.3 Hz, 
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2J5a,5b = 12.2 Hz, 1H, H-5b (β)), 2.14, 2.13, 2.12 (s each, 3H each, 3 COCH3 (α)), 2.12, 2.10, 
2.00 (s each, 3H each, 3 COCH3 (β)) ppm. 
1,2,3,5-Tetra-O-acetyl-α,β-D-arabinofurose (15)                      
The product 15 was obtained by a different synthetic route as described in literature:185 The 
arabinofurose derivative 14 (4.00 g, 14.5 mmol) was dissolved in dry pyridine (40.0 ml) and 
acetic anhydride (2.80 ml, 29.6 mmol, 2 eq.) was added. The reaction mixture was stirred 
overnight at rt under a nitrogen atmosphere. After addition of a saturated aqueous NaHCO3 
solution (100 ml) the resulting mixture was extracted with DCM. The combined organic layers 
were washed with dist. water, dried over MgSO4, filtered and concentrated in vacuo. The crude 
product was co-evaporated with toluene and chromatographed on silica gel 
(cyclohexane/ethyl acetate, 2:1) to give the tetraacetylated sugar 15 (4.32 g, 13.6 mmol, 94%) 
as a colorless oil (α:β ratio = 2:1 by integration of the 1H NMR spectrum). 
TLC (cyclohexane/ethyl acetate, 2:1): Rf = 0.20; 1H NMR (500 MHz, CDCl3, 300 K, TMS): 
δ = 6.39 (d, 3J1,2 = 3.9 Hz, 1H, H-1 (β)), 6.20 (d~s, 1H, H-1 (α)), 5.36-5.35 (m, 2H, H-2 (β), 
H-3 (β)), 5.22 (dd, 3J1,2 = 0.5 Hz, 3J2,3 = 1.3 Hz, 1H, H-2 (α)), 5.07-5.04 (ddd, 3J2,3 = 1.8 Hz, 
3J3,4 = 4.6 Hz, 4J = 0.6 Hz, 1H, H-3 (α)), 4.40 (dd, 3J4,5a = 4.0 Hz, 2J5a,5b = 14.6 Hz, 1H, H-5a (α)), 
4.40-4.36 (m, 1H, H-4 (α)), 4.36 (dd, 3J4,5a = 4.2 Hz, 2J5a,5b = 11.7 Hz, 1H, H-5a (β)), 4.27 (dd, 
3J4,5b = 7.2 Hz, 2J5a,5b = 11.6 Hz, 1H, H-5b (β)), 4.25-4.20 (m, 2H, H-5b (α), H-4 (β)), 2.13 (s, 6H, 
2 COCH3 (α)), 2.12, 2.10 (s each, 3H each, 2 COCH3 (α)), 2.11, 2.10, 2.09, 2.08 (s each, 3H 
each, 4 COCH3 (β)) ppm.                  
(2-Chloroethyl) 2,3,5-tri-O-acetyl-α-D-arabinofuranoside (16)186               
Acetyl protected arabinofuranose derivative 15 (500 mg, 1.57 mmol) was dissolved in dry 
acetonitrile (15.0 ml), tin tetrachloride (1 M in DCM, 6.00 ml, 6.00 mmol, 4 eq.) was slowly 
added and the reaction mixture was stirred for 30 min at rt. 2-Chloroethanol was diluted in dry 
acetonitrile (3.00 ml) and added dropwise. The reaction was stirred 45 min at rt, followed by 
ice-cooling and slowly supplementation of a saturated aqueous NaHCO3 solution. The crude 
product was filtrated through celite, extracted with DCM and washed with brine and dist. water. 
It was further purified by silica gel-chromatography (n-hexane/ethyl acetate, 3:1) giving the 
arabinofuranoside derivative 16 (340 mg, 1.01 mmol, 64%) as colorless oil. 
TLC (n-hexene/ethyl acetate, 2:1): Rf = 0.21; 1H NMR (500 MHz, CDCl3, 300 K, TMS): δ = 5.12 
(dd~d, 3J2,3 = 1.6 Hz, 1H, H-2), 5.09 (d~s, 1H, H-1), 4.99 (dd, 3J2,3 = 1.5 Hz, 3J3,4 = 5.1 Hz, 1H, 
H-3), 4.44 (dd, 3J4,5a = 3.4 Hz, 2J5a,5b = 11.8 Hz, 1H, H-5a), 4.30 (ddd, 3J3,4 = 5.3 Hz, 
3J4,5a = 3.4 Hz, 3J4,5b = 5.4 Hz, 1H, H-4), 4.23 (dd, 3J4,5b = 5.7 Hz, 2J5a,5b = 11.8 Hz, 1H, H-5b), 
3.94 (dt, 3J = 5.9 Hz, 3J = 5.9 Hz, 2J = 11.2 Hz, 1H, OCH2CH2Cl), 3.78 (dt, 3J = 5.7 Hz, 
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3J = 5.7 Hz, 2J = 11.0 Hz, 1H, OCH2CH2Cl), 3.66 (t, 3J = 5.8 Hz, 3J = 5.8 Hz, 2H, OCH2CH2Cl), 
2.12, 2.11, 2.10 (s each, 3H each, 3 COCH3) ppm. 
(2-Azidoethyl) 2,3,5-tri-O-acetyl-α-D-arabinofuranoside (17)186                  
The reported synthesis186 was modified according to the following procedure: To a solution of 
chloroethyl arabinofuranoside 16 (300 mg, 888 µmol) in dry DMF (20.0 ml) sodium azide 
(287 mg, 4.41 mmol, 5 eq.) and TBAI (66.0 mg, 179 µmol, 0.2 eq.) was added. The reaction 
mixture was stirred under a nitrogen atmosphere for 7 h at 70°C and overnight at rt. Dist. water 
was added and the aqueous phase was extracted with DCM. The combined organic layers 
were dried over MgSO4, filtered and concentrated in vacuo. The crude product was 
chromatographed on silica gel (cyclohexane/ethyl acetate, 2:1) to give the azido sugar 17 
(273 mg, 791 µmol, 89%) as colorless oil. TLC (cyclohexane/ethyl acetate, 2:1): Rf = 0.22; 
1H NMR (500 MHz, CDCl3, 300 K, TMS): δ = 5.11 (dd~d, 3J2,3 = 1.5 Hz, 1H, H-2), 5.07 (d~s, 
1H, H-1), 4.99 (ddd, 3J2,3 = 1.5 Hz, 3J3,4 = 5.1 Hz, 4J = 0.6 Hz, 1H, H-3), 4.45 (dd, 3J4,5a = 3.4 Hz, 
2J5a,5b = 11.8 Hz, 1H, H-5a), 4.32-4.29 (m, 1H, H-4), 4.24 (dd, 3J4,5b = 5.7 Hz, 2J5a,5b = 11.8 Hz, 
1H, H-5b), 3.92 (ddd, 3J = 3.4 Hz, 3J = 7.0 Hz, 2J = 10.5 Hz, 1H, OCH2CH2N3), 3.66 (ddd, 
3J = 3.4 Hz, 3J = 6.2 Hz, 2J = 10.6 Hz, 1H, OCH2CH2N3), 3.44 (ddd, 3J = 3.4 Hz, 3J = 7.0 Hz, 2J = 
13.3 Hz, 1H, OCH2CH2N3), 3.36 (ddd, 3J = 3.4 Hz, 3J = 6.2 Hz, 2J = 13.3 Hz, 1H, OCH2CH2N3), 
2.12, 2.11, 2.10 (s each, 3H each, 3 COCH3) ppm. 
(2-Azidoethyl) α-D-arabinofuranoside (18)186                                
The reported synthesis186 was modified according to the following procedure: The 
acetyl-protected arabinofuranoside derivative 17 (250 mg, 725 µmol) was dissolved in dry 
methanol (10.0 ml) and sodium methoxide (a spatula tip) was added. The reaction mixture was 
stirred overnight at rt under a nitrogen atmosphere. The reaction mixture was neutralized with 
Amberlite IR120 ion exchange resin, it was filtered and the solvent removed under reduced 
pressure. Purification of the crude product on silica gel (ethyl acetate/methanol, 8:1) gave the 
product 18 (145 mg, 662 µmol, 91%) as a colorless oil. TLC (ethyl acetate/methanol, 4:1): 
Rf = 0.51; 1H NMR (500 MHz, MeOH-d4, 300 K): δ = 4.91 (d, 3J1,2 = 1.7 Hz, 1H, H-1), 4.00 (dd, 
3J1,2 = 1.7 Hz, 3J2,3 = 3.9 Hz,  1H, H-2), 3.96 (ddd, 3J3,4 = 6.5 Hz, 3J4,5a = 3.2 Hz, 3J4,5b = 5.3 Hz, 
1H, H-4), 3.88 (ddd, 3J = 3.6 Hz, 3J = 6.0 Hz, 2J = 10.9 Hz, 1H, OCH2CH2N3), 3.85 (dd, 
3J2,3 = 3.8 Hz, 3J3,4 = 6.4 Hz, 1H, H-3), 3.76 (dd, 3J4,5a = 3.2 Hz, 2J5a,5b = 11.9 Hz, 1H, H-5a), 
3.64 (dd, 3J4,5b = 5.3 Hz, 2J5a,5b = 11.9 Hz, 1H, H-5b), 3.63 (ddd, 3J = 2.6 Hz, 3J = 5.4 Hz, 2J = 
10.9 Hz, 1H, OCH2CH2N3), 3.46 (ddd, 3J = 3.6 Hz, 3J = 7.1 Hz, 2J = 13.2 Hz, 1H, OCH2CH2N3), 
3.38 (ddd, 3J = 3.7 Hz, 3J = 5.9 Hz, 2J = 13.2 Hz, 1H, OCH2CH2N3) ppm. 
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5-O-Benzoyl-1,2,3-tri-O-acetyl-α,β-D-arabinofurose (19)             
The triacetyl-arabinofuranose derivative 14 (450 mg, 1.63 mmol) was dissolved in dry pyridine 
(10.0 ml), supplemented with benzoylchloride (400 µl, 3.45 mmol, 2 eq.) and stirred overnight 
at rt under a nitrogen atmosphere. A saturated aqueous NaHCO3 solution was added and the 
aqueous phase was extracted with DCM. The combined organic layers were washed with dist. 
water, dried over MgSO4, filtered and concentrated in vacuo. The crude product was 
chromatographed on silica gel (cyclohexane/ethyl acetate, 2:1) giving the 
arabinofuranose derivative 19 (595 mg, 1.57 mmol, 96%) as a colorless oil. (α:β ratio = 2:1 by 
integration of the 1H NMR spectrum) TLC (cyclohexane/ethyl acetate, 2:1): Rf = 0.40; rotation 
value: [α]22
𝐷
 = + 10.4° (c = 1.8, CH2Cl2); 1H NMR (500 MHz, CDCl3, 300 K, TMS): δ = 8.04-7.99 
(m, 2H, aryl-Hortho (α,β)), 7.56-7.48 (m, 1H, aryl-Hpara (α,β)), 7.42-7.35 (m, 2H, aryl-Hmeta (α,β)), 
6.34 (d, 3J1,2 = 4.7 Hz, 1H, H-1 (β)), 6.16 (d~s, 1H, H-1 (α)), 5.47 (dd, 3J2,3 = 6.9 Hz, 
3J3,4 = 5.8 Hz, 1H, H-3 (β)), 5.34 (dd, 3J1,2 = 4.7 Hz, 3J2,3 = 7.0 Hz, 1H, H-2 (β)), 5.18 (dd~d, 
3J1,2 = 1.4 Hz, 1H, H-2 (α)), 5.14-5.13 (m, 1H, H-3 (α)), 4.58 (dd, 3J4,5a = 3.8 Hz, 
2J5a,5b = 11.9 Hz, 1H, H-5a (α,β)), 4.48 (dd, 3J4,5b = 4.9 Hz, 2J5a,5b = 11.9 Hz, 1H, H-5b (α)), 
4.45-4.41 (m, 2H, H-4 (α), H-5b (β)), 4.28 (dt, 3J3,4 = 6.0 Hz, 3J4,5a = 4.2 Hz, 3J4,5b= 6.0 Hz, 1H, 
H-4 (β)), 2.06, 2.07, 1.99 (s each, 3H each, 3 COCH3 (α)), 2.03, 2.04, 1.92 (s each, 3H each, 
3 COCH3 (β)) ppm; 13C NMR (125 MHz, CDCl3, 300 K): δ = 170.3, 169.8, 169.3 (3 COCH3 (α)), 
170.0, 169.5, 169.3 (3 COCH3 (β)), 166.1 (COaryl (α)), 166.0 (COaryl (β)), 133.3 (aryl-Cpara 
(α,β)), 129.8 (aryl-Cortho, aryl-Cipso (α,β)), 128.4 (aryl-Cmeta (β)), 128.4 (aryl-Cmeta (α)), 99.4 
(C-1 (α)), 93.7 (C-1 (β)), 82.8 (C-4 (α)), 80.8 (C-2 (α)), 79.7 (C-4 (β)), 77.1 (C-3 (α)), 75.3 
(C-2 (β)), 74.6 (C-3 (β)), 64.5 (C-5 (β)), 63.4 (C-5 (α)), 21.1, 20.7, 20.6 (3 COCH3 (α)), 20.9, 
20.7, 20.5 (3 COCH3 (β)) ppm; ESI-MS: m/z = 403.105, [M+Na]+ (calc. 403.101 for 
C18H20O9+Na). 
5-O-Benzoyl-2,3-di-O-acetyl-α,β-D-arabinofurose (20)                   
The arabinofuranose derivative 19 (980 mg, 2.58 mmol) was dissolved in dry DCM (50.0 ml), 
cooled with ice and HBr/glacial acetic acid (33%, 2.50 ml, 37.2 mmol HBr, 14 eq.) and acetic 
anhydride (30.0 µl, 272 µmol, 0.1 eq.) were added slowly. The reaction was stirred in the dark 
for half an hour under cooling with an ice bath and overnight at rt. Ice (20.0 ml) was added and 
the mixture was extracted with DCM. The combined organic layers were washed with a 
saturated aqueous NaHCO3 solution and dist. water, dried over MgSO4, filtered and 
concentrated in vacuo. The crude product was chromatographed on silica gel 
(cyclohexane/ethyl acetate, 2:1) to give the C-1-deprotected arabinofuranose derivative 20 
(851 mg, 2.52 mmol, 98%) as a colorless oil (α:β ratio = 2.5:1 by integration of the 1H NMR 
spectrum). TLC (cyclohexane/ethyl acetate, 2:1): Rf = 0.18, 0.12; rotation value: [α]22𝐷  = + 16.9° 
(c = 0.4, CH2Cl2); 1H NMR (500 MHz, CDCl3, 300 K, TMS): δ = 8.10-8.05 (m, 2H, aryl-Hortho 
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(α,β)), 7.59-7.54 (m, 1H, aryl-Hpara (α,β)), 7.46-7.42 (m, 2H, aryl-Hmeta (α,β)), 5.60 (d, 
3J1,2 = 4.3 Hz, 1H, H-1 (β)), 5.45 (d~s, 1H, H-1 (α)), 5.43-5.41 (m, 1H, H-3 (β)), 5.18-5.16 (m, 
1H, H-3 (α)), 5.15 (dd, 3J1,2 = 4.3 Hz, 3J2,3 = 8.9 Hz, 1H, H-2 (β)), 5.14 (dd, 3J1,2 = 1.3 Hz, 
3J2,3 = 4.3 Hz, 1H, H-2 (α)), 4.69 (dd, 3J4,5a = 3.1 Hz, 2J5a,5b = 11.4 Hz, 1H, H-5a (α)), 4.66 (dd, 
3J4,5a = 6.9 Hz, 2J5a,5b = 12.2 Hz, 1H, H-5a (β)), 4.59 (dd, 3J4,5b = 4.2 Hz, 2J5a,5b = 11.7 Hz, 1H, 
H-5b (β)), 4.57-4.53 (m, 1H, H-4 (α)), 4.51 (dd, 3J4,5b = 5.3 Hz, 2J5a,5b = 11.4 Hz, 1H, H-5b (α)), 
4.23 (dt, 3J3,4 = 4.4 Hz, 3J4,5a = 7.0 Hz, 3J4,5b= 4.4 Hz, 1H, H-4 (β)), 3.50 (s, 1H, OH (β)), 3.18 (s, 
1H, OH (α)), 2.14, 2.10 (s each, 3H each, COCH3 (β)), 2.13, 2.04 (s each, 3H each, 
2 COCH3 (α)) ppm; 13C NMR (125 MHz, CDCl3, 300 K): δ = 170.3, 170.1 (2 COCH3 (β)), 170.2, 
169.8 (2 COCH3 (α)), 166.5 (COaryl (β)), 166.2 (COaryl (α)), 133.2 (aryl-Cpara (α,β)), 129.8 
(aryl-Cortho, aryl-Cipso (α)), 129.8 (aryl-Cortho, aryl-Cipso (β)), 128.4 (aryl-Cmeta (β)), 128.4 (aryl-
Cmeta (α)), 100.8 (C-1 (α)), 95.3 (C-1 (β)), 81.8 (C-2 (α)), 81.4 (C-4 (α)), 79.0 (C-4 (β)), 77.4 
(C-3 (α)), 77.0 (C-2 (β)), 76.0 (C-3 (β)), 65.6 (C-5 (β)), 63.7 (C-5 (α)), 20.8, 20.7 (2 COCH3 (α)), 
20.8, 20.6 (2 COCH3 (β)) ppm; ESI-MS: m/z = 361.088, [M+Na]+ (calc. 361.090 for 
C16H18O8+Na). 
p-Nitrophenyl 5-O-benzoyl-2,3-di-O-acetyl-α-D-arabinofuranoside (22)           
The C-1-deprotected arabinofuranose derivative 20 (845 mg, 2.18 mmol) was dissolved in dry 
DCM (10.0 ml), cooled with an ice bath and trichloroacetonitrile (2.60 ml, 26.0 mmol, 12 eq.) 
and 1,8-diazabicycloundec-7-ene (DBU, 26.0 µl, 174 µmol, 0.08 eq.) were added slowly. The 
reaction was stirred 15 min under cooling with an ice bath and concentrated in vacuo at a low 
heat (max. 30°C). The crude product was chromatographed on silica gel 
(cyclohexane/ethyl acetate, 4:1) to give the instable product 21 (1.00 g, 2.08 mmol) as a 
colorless oil. The intermediate and p-nitrophenol (350 mg, 2.52 mmol, 1.2 eq.) were dissolved 
in dry DCM (30.0 ml). Boron trifluoride diethyl etherate (BF3∙Et2O, 450 µl, 3.91 mmol, 1.8 eq.) 
was added slowly within 30 min under cooling with an ice bath and the reaction was stirred 
overnight at rt. DCM was added and the organic layer was washed with a saturated aqueous 
NaHCO3 solution and dist. water, dried over MgSO4, filtered and concentrated in vacuo. The 
crude product was chromatographed on silica gel (cyclohexane/ethyl acetate, 7:1) to give the 
arabinofuranose derivative 22 (534 mg, 1.16 mmol, 53% over two steps) as colorless crystals. 
TLC (cyclohexane/ethyl acetate, 2:1): Rf = 0.28; rotation value: [α]22𝐷  = + 59.7° (c = 1.0, 
CH2Cl2);  1H NMR (500 MHz, CDCl3, 300 K, TMS): δ = 8.22-8.18 (m, 2H, PhNO2meta), 8.09-8.07 
(m, 2H, COPhortho), 7.60-7.56 (m, 1H, COPhpara), 7.47-7.43 (m, 2H, COPhmeta), 7.18-7.14 (m, 
2H, PhNO2ortho), 5.80 (d~s, 1H, H-1), 5.42 (dd~d, 3J2,3 = 1.1 Hz, 1H, H-2), 5.29 (ddd, 
3J2,3 = 1.4 Hz, 3J3,4 = 4.7 Hz, 4J = 0.6 Hz, 1H, H-3), 4.70 (dd, 3J4,5a = 3.4 Hz, 2J5a,5b = 12.1 Hz, 
1H, H-5a), 4.58 (dd, 3J4,5a = 4.7 Hz, 2J5a,5b = 12.1 Hz, 1H, H-5b), 4.51 (dt, 3J3,4 = 4.7 Hz, 
3J4,5a = 3.5 Hz, 3J4,5b= 4.7 Hz, 1H, H-4), 2.16, 2.07 (s each, 3H each, 2 COCH3) ppm; 13C NMR 
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(125 MHz, CDCl3, 300 K): δ = 170.2, 169.6 (2 COCH3), 166.0 (COPh), 160.8 (PhNO2-Cipso), 
142.8 (PhNO2-Cpara), 133.3 (COPh-Cpara), 129.8 (COPh-Cortho), 129.7 (COPh-Cipso), 128.4 
(COPh-Cmeta), 125.8 (PhNO2-Cmeta), 116.6 (PhNO2-Cortho), 100.8 (C-1), 82.5 (C-4), 81.3 (C-2), 
77.0 (C-3), 63.1 (C-5), 20.7, 20.6 (2 COCH3) ppm; ESI-MS: m/z = 482.1, [M+Na]+ (calc. 482.1 
for C22H21NO10+Na). 
p-Nitrophenyl α-D-arabinofuranoside (23)                
The Arabinofuranoside derivative 22 (700 mg, 1.53 mmol) was dissolved in dry methanol and 
sodium methoxide (spatula tip) was added. The reaction mixture was stirred overnight at rt 
under a nitrogen atmosphere. After neutralization with Amberlite IR120 ion exchange resin and 
concentration in vacuo, the crude product was chromatographed on silica gel 
(cyclohexane/ethyl acetate/methanol, 1:1:0.25) to give the product 23 (400 mg, 1.48 mmol, 
97%) as colorless crystals. TLC (cyclohexane/ethyl acetate/methanol, 1:1:0.5): Rf = 0.29; 
rotation value: [α]22
𝐷
 = + 210.7° (c = 1.0, MeOH); m.p.: 158.5-160.2°C; 1H NMR (500 MHz, 
MeOH-d4, 300 K): δ = 8.22-8.19 (m, 2H, aryl-Hmeta), 7.23-7.20 (m, 2H, aryl-Hortho), 5.67 (d, 
3J1,2 = 1.7 Hz, 1H, H-1), 4.30 (dd, 3J1,2 = 1.8 Hz, 3J2,3 = 3.8 Hz, 1H, H-2), 4.06 (ddd, 
3J3,4 = 6.2 Hz, 3J4,5a = 3.2 Hz, 3J4,5b = 5.0 Hz, 1H, H-4), 4.02 (ddd, 3J2,3 = 3.8 Hz, 3J3,4 = 6.4 Hz, 
4J = 0.5 Hz, 1H, H-3), 3.78 (dd, 3J4,5a = 3.2 Hz, 2J5a,5b = 12.1 Hz, 1H, H-5a), 3.68 (dd, 
3J4,5b = 5.0 Hz, 2J5a,5b = 12.1 Hz, 1H, H-5b) ppm; 13C NMR (125 MHz, MeOH-d4, 300 K): 
δ = 163.5 (aryl-Cipso), 143.6 (aryl-Cpara), 126.6 (aryl-Cmeta), 117.7 (aryl-Cortho), 107.8 (C-1), 87.0 
(C-4), 83.6 (C-2), 78.2 (C-3), 62.7 (C-5) ppm; HRMS (ESI-MS): m/z = 294.0643, [M+Na]+ (calc. 
294.0590 for C11H13NO7+Na).  
6-O-tert-Butyldimethylsilyl-2,3,4,2’,3’,4’,6’-hepta-O-acetyl-α,α-D-trehalose (24)192                     
The reported synthesis192 was modified according to the following procedure: D-Trehalose 
(2.00 g, 5.85 mmol) was suspended in dry pyridine (20.0 ml), cooled with an ice bath and 
supplemented with TBDMSCl (1.00 g, 6.63 mmol, 1.1 eq.). The reaction was stirred overnight 
at rt under a nitrogen atmosphere. Ac2O (6.00 ml, 63.6 mmol, 10 eq.) was added and stirring 
was continued for 6 h at rt. After addition of a saturated aqueous NaHCO3 solution the resulting 
mixture was extracted with DCM. The combined organic layers were dried over MgSO4, filtered 
and concentrated in vacuo. The crude product was chromatographed on silica gel 
(cyclohexane/ethyl acetate, 4:1 → 2:1) to give 24 (1.94 g, 2.59 mmol, 44%) as a white solid. 
TLC (cyclohexane/ethyl acetate, 1:1): Rf = 0.29; 1H NMR (500 MHz, CDCl3, 300 K): δ = 5.49 
(dd~d, 3J3,4 = 9.4 Hz, 1H, H-3), 5.47 (dd~d, 3J3’,4’ = 9.4 Hz, 1H, H-3’), 5.28 (d, 3J1,2 = 3.9 Hz, 1H, 
H-1), 5.25 (d, 3J1’,2’ = 3.9 Hz, 1H, H-1’), 5.08 (dd, 3J1,2 = 3.9 Hz, 3J2,3 = 10.2 Hz, 1H, H-2), 5.07-
5.01 (m, 2H, H-4, H-4’), 4.98 (dd, 3J1’,2’ = 3.9 Hz, 3J2’,3’ = 10.3 Hz, 1H, H-2’), 4.23 (dd, 
3J5,6a = 5.7 Hz, 2J6a,6b = 12.2 Hz, 1H, H-6a), 4.06 (ddd, 3J4,5 = 10.3 Hz, 3J5,6a = 5.7 Hz, 
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3J5,6b = 2.1 Hz, 1H, H-5), 4.00 (dd, 3J5,6b = 2.2 Hz, 2J6a,6b = 12.2 Hz, 1H, H-6b), 3.93 (ddd, 
3J4’,5’ = 10.2 Hz, 3J5’,6’a = 4.6 Hz, 3J5’,6’b = 2.9 Hz, 1H, H-5’), 3.63 (dd, 3J5’,6’a = 4.7 Hz, 
2J6’a,6’b = 11.3 Hz, 1H, H-6’a), 3.61 (dd, 3J5’,6’b = 2.7 Hz, 2J6’a,6’b = 11.3 Hz, 1H, H-6’b), 2.08, 2.07, 
2.04, 2.03, 2.02, 2.01 (s each, 1∙6H, 5∙3H, COCH3), 0.86 (s, 9H, OSi(CH3)2C(CH3)3), 0.02, 0.00 
(s each, 3H each, OSi(CH3)2C(CH3)3) ppm.  
2,3,4,2’,3’,4’,6’-Hepta-O-acetyl-α,α-D-trehalose (25)192                               
The reported synthesis192 was modified according to the following procedure: The trehalose 
derivative 24 (1.30 g, 1.73 mmol) was dissolved in DMF (30.0 ml), supplemented with 
dist. water (30.0 ml) and conc. acetic acid (120 ml). The reaction mixture was stirred overnight 
at rt. After addition of a saturated aqueous NaHCO3 solution the resulting mixture was 
extracted with diethyl ether. The combined organic layers were washed with dist. water, dried 
over MgSO4, filtered and concentrated in vacuo. The crude product was chromatographed on 
silica gel (cyclohexane/ethyl acetate, 1:1 → 1:3) to give 25 (864 mg, 1.36 mmol, 79%) as a 
white solid. TLC (cyclohexane/ethyl acetate, 1:1): Rf = 0.07; 1H NMR (500 MHz, CDCl3, 300 K): 
δ = 5.53 (dd~d, 3J3,4 = 9.5 Hz, 1H, H-3), 5.49 (dd~d, 3J3’,4’ = 9.5 Hz, 1H, H-3’), 5.30 (d, 
3J1,2 = 3.4 Hz, 1H, H-1), 5.29 (d, 3J1’,2’ = 3.4 Hz, 1H, H-1’), 5.05 (dd, 3J3,4 = 9.4 Hz, 
3J4,5 = 10.3 Hz, 1H, H-4), 5.03-4.99 (m, 3H, H-2, H-2’, H-4’), 4.26 (dd, 3J5,6a = 5.7 Hz, 
2J6a,6b = 12.2 Hz, 1H, H-6a), 4.09 (ddd, 3J4,5 = 10.4 Hz, 3J5,6a = 5.5 Hz, 3J5,6b = 2.1 Hz, 1H, H-5), 
3.99 (dd, 3J5,6b = 2.2 Hz, 2J6a,6b = 12.2 Hz, 1H, H-6b), 3.91 (ddd, 3J4’,5’ = 10.3 Hz, 
3J5’,6’a = 5.7 Hz, 3J5’,6’b = 2.4 Hz, 1H, H-5’), 3.65-3.59 (m, 2H, H-6a’, H-6b’), 2.08, 2.07, 2.06, 
2.04, 2.03, 2.02, 2.01 (s each, 3H each, COCH3) ppm. 
2,3,4,2’,3’,4’,6’-Hepta-O-acetyl-6-O-tosyl-α,α-D-trehalose (26)         
The product 26 was obtained by a different synthetic route as described in literature:194 The 
trehalose derivative 25 (2.00 g, 3.15 mmol) was dissolved in dry pyridine (50.0 ml). Tosyl 
chloride (TsCl, 1.70 g, 8.93 mmol, 2.8 eq.) was added slowly. The reaction was stirred 
overnight at rt under a nitrogen atmosphere and was concentrated in vacuo. The crude product 
was chromatographed on silica gel (cyclohexane/ethyl acetate, 1:1) to give the the 
tosylated sugar 26 (2.01 g, 2.52 mmol, 80%) as a white solid. TLC (cyclohexane/ethyl acetate, 
1:1): Rf = 0.17; 1H NMR (500 MHz, CDCl3, 300 K): δ = 7.74 (dt, 3Jmeta,ortho = 8.3 Hz, 
4Jmeta,CH3 = 1.7 Hz, 2H, aryl-Hmeta), 7.34 (d, 3Jmeta,ortho = 8.0 Hz, 2H, aryl-Hortho), 5.45 (dd, 
3J2’,3’ = 9.3 Hz, 3J3’,4’ = 10.2 Hz, 1H, H-3’), 5.40 (dd, 3J2,3 = 8.7Hz, 3J3,4 = 9.5 Hz, 1H, H-3), 5.15 
(d, 3J1’,2’ = 3.8 Hz, 1H, H-1’), 5.06 (d, 3J1,2 = 3.8 Hz, 1H, H-1), 5.05-5.01 (m, 2H, H-2, H-2’), 4.93 
(dd, 3J3,4 = 9.3 Hz, 3J4,5 = 10.3 Hz, 1H, H-4), 4.92 (dd, 3J3’,4’ = 10.3 Hz, 3J4’,5’ = 3.9 Hz, 1H, H-4’), 
4.22 (dd, 3J5,6a = 5.4 Hz, 2J6a,6b = 12.0 Hz, 1H, H-6a), 4.13 (ddd, 3J4’,5’ = 4.3 Hz, 3J5’,6’a = 5.4 Hz, 
3J5’,6’b = 2.6 Hz, 1H, H-5'), 4.11-4.04 (m, 2H, H-6’a, H-6’b), 4.02 (ddd, 3J4,5 = 10.2 Hz, 
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3J5,6a = 5.4 Hz, 3J5,6b = 2.2 Hz, 1H, H-5), 3.98 (dd, 3J5,6b = 2.2 Hz, 2J6a,6b = 12.0 Hz, 1H, H-6b), 
2.45 (s, 3H, aryl-CH3), 2.10, 2.07, 2.05, 2.04, 2.03, 2.02, 2.01 (s each, 3H each, COCH3) ppm. 
6-Azido-6-deoxy-2,3,4,2’,3’,4’,6’-hepta-O-acetyl-α,α-D-trehalose (27)                  
The product 27 was obtained by a different synthetic route as described in literature:193,194 To 
a stirring solution of the tosylated molecule 26 (100 mg, 125 µmol) in dry DMF (12.0 ml) 
sodium azide (33.0 mg, 508 µmol, 4 eq.) was added. The reaction mixture was heated to 80°C 
and stirred for 6 h under a nitrogen atmosphere. Dist. water was added and the reaction 
mixture was extracted with diethyl ether. The combined organic layers were dried over MgSO4, 
filtered and concentrated in vacuo. The crude product was chromatographed on silica gel 
(cyclohexane/ethyl acetate, 1:1) to give the azido sugar 27 (75.0 mg, 114 µmol, 91%) as a 
white solid. TLC (cyclohexane/ethyl acetate, 1:1): Rf = 0.175; 1H NMR (500 MHz, CDCl3, 
300 K): δ = 5.49 (dd, 3J2’,3’ = 10.2 Hz, 3J3’,4’ = 9.4 Hz, 1H, H-3’), 5.47 (dd, 3J2,3 = 10.2 Hz, 
3J3,4 = 9.5 Hz, 1H, H-3), 5.33 (d, 3J1’,2’ = 4.0 Hz, 1H, H-1’), 5.31 (d, 3J1,2 = 3.9 Hz, 1H, H-1), 5.08 
(dd, 3J1’,2’ = 3.9 Hz, 3J2’,3’ = 10.3 Hz, 1H, H-2’), 5.06 (dd, 3J3’,4’ = 9.5 Hz, 3J4’,5’ = 10.3 Hz, 1H, 
H-4’), 5.03 (dd, 3J1,2 = 3.9 Hz, 3J2,3 = 10.4 Hz, 1H, H-2), 4.98 (dd, 3J3,4 = 9.3 Hz, 3J4,5 = 10.4 Hz, 
1H, H-4), 4.25 (dd, 3J5,6a = 5.7 Hz, 2J6a,6b = 12.2 Hz, 1H, H-6a), 4.10-4.04 (m, 2H, H-5, H-5’), 
4.00 (dd, 3J5,6b = 2.2 Hz, 2J6a,6b = 12.2 Hz, 1H, H-6b), 3.35 (dd, 3J5’,6’a = 7.2 Hz, 
2J6’a,6’b = 13.4 Hz, 1H, H-6’a), 3.16 (dd, 3J5’,6’b = 2.5 Hz, 2J6’a,6’b = 13.3 Hz, 1H, H-6’b), 2.12, 2.09, 
2.08, 2.06, 2.05, 2.03, 2.02 (s each, 3H each, COCH3) ppm.  
6-Azido-6-deoxy-α,α-D-trehalose (28)193             
The heptaacetate 27 (50.0 mg, 75.8 µmol) was dissolved in dry methanol (8.00 ml). Sodium 
methoxide (spatula tip) was added and the reaction mixture was stirred overnight at rt under a 
nitrogen atmosphere. The reaction was neutralized with Amberlite IR120 ion exchange resin 
and the solvent was removed in vacuo. After lyophilization the product 28 was obtained 
(27.0 mg, 74.6 µmol, 97%) as a white solid. TLC (cyclohexane/ethyl acetate/ methanol, 
1:1:0.5): Rf = 0.07; 1H NMR (500 MHz, D2O, 300 K): δ = 5.14 (d, 3J1’,2’ = 4.1 Hz, 1H, H-1’), 5.13 
(d, 3J1,2 = 4.0 Hz, 1H, H-1), 3.92 (dd, 3J3’,4’ = 5.9 Hz, 3J4’,5’ = 9.8 Hz, 1H, H-4’), 3.91 (dd, 
3J3,4 = 5.9 Hz, 3J4,5 = 9.9 Hz, 1H, H-4), 3.82-3.75 (m, 3H, H-3, H-3’, H-6’a), 3.70 (dd, 
3J5’,6’b = 5.1 Hz, 2J6’a,6’b = 12.1 Hz, 1H, H-6’b), 3.62 (dd, 3J5,6a = 2.6 Hz, 2J6a,6b = 13.6 Hz, 1H, 
H-6a), 3.61 (dd, 3J1’,2’ = 3.9 Hz, 3J2’,3’ = 10.4 Hz, 1H, H-2’), 3.59 (dd, 3J1,2 = 3.8 Hz, 
3J2,3 = 10.3 Hz, 1H, H-2), 3.50 (dd, 3J5,6b = 5.9 Hz, 2J6a,6b = 13.6 Hz, 1H, H-6b), 3.42-3.37 (m, 
2H, H-5, H-5') ppm.   
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3 Azido pentoses, a new tool for specific labeling of 
Mycobacterium tuberculosis 
A major challenge in Tb therapy is the lack of specific probes that can be used to diagnose 
and treat Mtb bacteria in a selective manner while leaving many other microorganisms and 
eukaryotic host cells unaffected. The second part of the thesis focuses on the development of 
a new tool to specifically label Mtb bacteria. 
3.1 Introduction 
Recently, first efforts have been made to selectively target bacteria based on the presence of 
unique carbohydrates in the bacterial cell envelope and the broad substrate tolerance of 
enzymes of the carbohydrate metabolism.88,192,238–240 Chemically modified carbohydrate 
derivatives were added to the bacterial environment to be specifically taken up, pass through 
the natural carbohydrate metabolism and subsequently be incorporated into the bacterial cell 
envelope replacing endogenous sugars (Figure 30).241,242 This strategy enabled to distinguish 
between bacteria and host cells and also between different bacteria classes. This metabolic 
labeling method is also referred to as metabolic oligosaccharide engineering (MOE).241,242  
 
Figure 30. Illustration of metabolic oligosaccharide engineering (MOE). Environmental carbohydrate 
derivatives are transported to the cytoplasm, metabolized and introduced into structures of the cell envelope. 
 
3.1.1 Metabolic oligosaccharide engineering  
MOE was pioneered by C. R. Bertozzi,243,244 W. Reutter245,246 and colleagues to study and 
target eukaryotic glycans. Only recently, it was extended to bacterial cell envelope 
structures.88,192,238,239 The carbohydrate derivatives, used for metabolic labeling, can directly 
carry the whole diagnostic or therapeutic probe or only a small functional group, which can be 
further modified on the cell surface by a selective reaction. Chemical reactions that can occur 
on the cell surface or even within living organisms without interfering with native biochemical 
processes are termed bioorthogonal, as coined by C. R. Bertozzi.247,248 Carbohydrates 
carrying a large functional group are only rarely incorporated into cell envelope structures due 
to the substrate specificity of the metabolic enzymes. Small modifications, however, are often 
tolerated. Furthermore, a two-step approach, based on the incorporation of an unnatural sugar 
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derivative carrying a small function group and a subsequent selective biorthogonal reaction, 
allows to covalently immobilize a large variety of molecules differing in size, charge and 
function.  
 
3.1.2 Bioorthogonal reactions 
Synthetic sugar derivatives incorporated into the bacterial cell envelope should exhibit 
functional groups that are naturally absent from biological systems, stable in water, nonreactive 
with functional groups, which are naturally present on the cell surface, and capable to undergo 
covalent modifications with selective reaction partners under physiological conditions. 
Therefore, several bioorthogonal chemical strategies have been developed (Table 5).249–251 
Ketone-, azide- or alkyne-containing carbohydrates have been used to label bacterial 
glycans.88,238,239 Originally, ketones were explored as chemical reporters being almost absent 
on cell surfaces.243 Ketones specifically react with hydrazide or amino-oxy probes in near 
neutral environment (pH 5-6) forming hydrazone and oxime products, respectively.248 Ketone-
hydrazide chemistry has been successfully used to label both Gram-positive and 
Gram-negative bacteria.239 This biorthogonal reaction is even suitable to target bacteria within 
a host. Unlike ketones, azides are truly absent from biological systems.247 Azides react with 
triarylphosphines via Staudinger ligation to yield amides.252 This selective reaction has already 
been successfully used within mice without unintended side reactions.247 However, 
triarylphosphines are easily inactivated through oxidation and have slow reaction kinetics, 
which can be a drawback for targeting bacteria in vivo.247 An alternative selective azide-based 
reaction was developed by M. Meldal, K. B. Sharpless and coworkers. They demonstrated that 
azides react with alkynes regioselectively at moderate temperature under copper(I) (Cu(I)) 
catalysis forming triazoles.253,254 Although this cycloaddition is highly selective and especially 
fast (k = 1-10 M-1∙s-1),255 in vivo applications are limited due to the high toxicity profile of 
copper.256,257 This disadvantage could be minimized by copper chelators limiting Cu(II) 
formation and oxidative damage of biomolecules.258–263 C. R. Bertozzi and coworkers 
developed the “strain promoted azide-alkyne cycloaddition” (SPAAC) which works completely 
without any catalysis. In SPAAC the azide reacts with a tensioned alkyne, a cyclooctyne.264,265 
The fact that copper is no longer necessary is based on the tension of the alkyne which leads 
to reduction of activation energy of the cycloaddition. This reaction was primarily discovered 
by G. Wittig and A. Krebs in 1961,266 but only recently used for biological applications by the 
Bertozzi group. Most recently developed reagents for SPAAC have reaction rates comparable 
to that of Cu(I)-catalyzed chemistry250,267 and show only minor side reactions.268,269 
Furthermore, this biorthogonal chemistry was successfully used in living animals, such as 
zebrafish,270–272 nematodes273 and mice.274 Taken together, SPAAC offers an attractive choice 
for targeting bacterial glycans. 
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Table 5. Some of the reported bioorthogonal chemistries, which can be used for covalent targeting of 
bacterial glycans. k: reaction rate constant (second order rate), R: rest; based on Tra, V. N. et al. 
Chem Commun 50, 4659-4673 (2014).240  
Function group of the 
sugar derivative 
 Biorthogonal reaction 
 
 
 
 
a)275  
 
b)276  
 
 
 
 
 
 
 
 
c)252  
 
d)255  
 
e)250  
 
 
 
 
 
f)255  
 
g)277  
 
 
 
h)278  
 
 
 
i)279  
 
 
 
 
j)280  
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Beside metabolic labeling methods using specific reactions of keto and azido groups, 
additional bioorthogonal reactions (Table 5) have been developed. Terminal alkynes are rarely 
detectable in biological systems and can react with azides as described before,248 but can also 
undergo covalent modification with indobenzene derivatives in the presence of catalytic 
palladium(II) nitrate (Pd(NO3)2) via Sonogashira cross coupling.277 Furthermore, cylopropenes 
are tolerated by biosynthetic pathways in mammalian cells and react in an inverse electron 
demand Diels-Alder reaction with tetrazine conjugates on the cell surface leading to 
dihydropyrazines.278 To date several new bioorthogonal reactions, such as alkene/tetrazole279 
and vinyl sulfide/o-quinone methide280, expand the repertoire of chemical reporters that could 
be used for probing bacterial glycans. Nevertheless, azide-cyclooctyne reactions are still the 
most commonly used biorthogonal reactions and extremely well established. 
 
3.1.3 Metabolic labeling of bacteria 
The discovery of unique carbohydrates for specific targeting of bacteria remains the bottleneck 
in MOE. Ketone-modified uridine diphosphate N-acetylmuramic acid ((UDP)-MurNAc) (Figure 
31 A), an analoge of a natural occurring peptidoglycan precursor, enabled metabolic labeling 
of many bacterial but not human cells.239 More specifically, a derivative of 3-deoxy-D-manno-
oct-2-ulosonic acid (Kdo), containing an azido group, (Figure 31 B) was used to discriminate 
between Gram-positive and Gram-negative bacteria. Kdo is a monosaccharide present in the 
inner core of the lipopolysaccharide (LPS), thus azide-modified Kdo (KdoAz) is incorporated 
into Gram-negative bacteria (e.g. E. coli, Salmonella typhimurium, Legionella pneumophila) 
but not Gram-positive bacteria (e.g. Staphylococcus aureus, Bacillus subtilis).238 Only recently, 
mycobacteria could be selectively labeled by trehalose derivatives (Figure 31 C).88,192 
Trehalose is part of unique mycobacterial cell envelope components, such as TMM and TDM, 
and absent in cell envelopes of Gram-negative and Gram-positive bacteria. Azide-modified 
trehalose (TreAz) analoges are tolerated in mycobacterial biosynthesis anchoring the 
disaccharide into the mycobacterial cell envelope as mycolic acid esters. The small azido 
functional group was visualized in a subsequent bioorthogonal reaction, employing copper-
free click chemistry with fluorescent cyclooctyne derivatives.88 Beside this two-step approach, 
the mycobacterial cell envelope was directly modified by trehalose derivatives carrying a large 
fluorescein molecule or even quantum dots (QD).192 The possibility to enter these impressively 
large carbohydrate derivatives is based on a broad substrate tolerance of the trehalose 
mycolyltransesterase enzymes (Ag85A, Ag85B, Ag85C). Fluorescein isothiocyanate (FITC)-
modified trehalose and quantum dots functionalized with trehalose derivatives could be used 
to labeled Mtb bacteria even within macrophages.192 These results make it reasonable that 
carbohydrate derivatives can be used to specifically image and target Mtb bacteria and might 
prospectively be applied in Tb diagnostic and therapy. 
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Figure 31. Carbohydrate derivatives used for metabolic labeling of bacteria. UDP-MurNAc-keto-
pentapeptide was metabolically incorporated into peptidoglycan structures of both Gram-positive and 
Gram-negative bacteria (A).239 Azido Kdo was used to specifically target Gram-negative bacteria (B).238 Different 
trehalose derivatives bearing an azido group (C) were incorporated into the cell envelope of Msg bacteria and 
Mtb bacteria and visualized by copper-free click chemistry.88 Mtb bacteria could be fluorescently labeled, in a 
one-step approach, using fluorescein isothiocyanate (FITC)-modified trehalose or quantum dots (QD) 
functionalized with trehalose derivatives (C).192 
 
A) 
B) 
C) 
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3.2 Objectives 
To facilitate the development of Mtb-specific diagnostic and therapeutic tools, new 
carbohydrate derivatives, applicable for MOE, are of special interest. D-Arabinose is a 
non-mammalian sugar and especially rare in nature, but a major component of the 
mycobacterial cell envelope heteropolysaccharides LAM and AG. These features led to the 
following questions:  
 
1. Can Mtb bacteria be labeled based on the arabinan metabolism? 
2. Does arabinose-dependent MOE show unwanted side effects like bacteriostasis, 
cytotoxicity or labeling of host cells? 
3. What can arabinose-dependent MOE be applied for? 
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3.3 Results 
Developing new metabolic labeling strategies for Mtb bacteria is preceded by the synthesis of 
sugar derivatives tolerated by the carbohydrate metabolism and containing a functional group 
that can be addressed by bioorthogonal reactions. In this study three different carbohydrate 
derivatives were designed based on the arabinan metabolism of Msg97 (Figure 11) carrying an 
azido function. D-ribose-5-phosphate and 5-phospho-D-ribosylpyrophosphate are key 
intermediates of this metabolism. Thus, the 1- and 5-position of arabinose or ribose, 
respectively, were excluded from modifications. In a final biosynthetic step, 
1-decaprenylphospho-D-ribofuranose is epimerized at position 2 to form the respective Araf 
substrate.97 Consequently, also the 2-position of the sugar ring was not modified. Based on 
this analysis 3-azido-3-deoxy-D-arabinose (3AraAz, 38) and 3-azido-3-deoxy-D-ribose 
(3RiboAz, 39) were synthesized, with 5-azido-5-deoxy-D-arabinofuranose (5AraAz, 40) as 
negative control compound (Figure 32). 6-Azido-6-deoxy-D-trehalose (6TreAz, 28) was 
synthesized as a positive control compound based on the known metabolic labeling strategies 
for Mtb bacteria (Figure 31).88  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32. Azido compounds synthesized for bioorthogonal labeling of Mtb bacteria. Three different 
azido pentoses (3-azido-3-desoxy-α,β-D-ribose (3RiboAz, 38), 3-azido-3-desoxy-α,β-D-arabinose (3AraAz, 39), 
5-azido-5-desoxy-α,β-D-arabinofuranose (5AraAz, 40)) and 6-azido-6-desoxy-trehalose (6TreAz, 28) as a 
positive control compound were synthesized and applied for metabolic labeling of Mtb bacteria. 
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3.3.1 Syntheses 
3AraAz was synthesized over six reaction steps with D-arabinose as starting material. Initially 
the primary hydroxyl group, only present in the furanose form of D-arabinose, was protected 
with tert-butyl-diphenylsilyl chloride (TBDPSCl) giving the arabinofuranose derivative 41 in 
70% yield.281 The cis-arranged hydroxyl groups at the 1- and 2-position of the sugar ring 
reacted with acetone under acid conditions leading to the formation of a 1,3-dioxolane. 
Consequently, only the hydroxyl group at the 3-position remained unprotected. Substitution of 
a hydroxyl group by an azido function is based on a nucleophilic substitution second order 
(SN2), thus is associated with an epimerization. To avoid the formation of a diastereomer, the 
hydroxyl group itself had to be epimerized prior substitution. The hydroxyl group at the 
3-position was activated by trifluoromethanesulfonic anhydride (Tf2O) under basic conditions 
and subsequently reacted with sodium nitrite giving the epimerized product, 1,2,5-protected 
lyxofurose 43,282 in 50% yield. Finally, the azido function was introduced by activation of the 
unprotected hydroxyl group as a trifluoromethanesulfonic acid ester and a nucleophilic 
substitution with sodium azide.282 The azido sugar 44 was stepwise deprotected. The silyl 
ether was removed by tetra-N-butylammonium fluoride (TBAF) and the isopropylidene group 
under acidic conditions giving 3AraAz (38) in an overall yield of 20% (Scheme 5).  
 
 
Scheme 5. Synthesis of the azido pentose 38 (3AraAz). a) TBDPSCl, pyridine, rt, overnight, 70%; 
b) 2,2-dimethoxypropane, p-TsOH, acetone, rt, 3 h, 87%; c) 1. Tf2O, pyridine, DCM, 0°C, 2 h; 2. NaNO2, DMF, 
70°C, overnight, 50%; d) 1. Tf2O, pyridine, DCM, 0°C, 4.5 h; 2. NaN3, DMF, 80°C, 5 h → rt, overnight, 75%; 
e) TBAF, THF, rt, 45 min, 90%; f) TFA, H2O, DMF, 0°C, 2 h, 98%. 
 
Based on the ribose intermediates in the arabinan metabolism of Msg 3RiboAz (39) was 
designed and synthesized. D-Xylose was protected with acetone under acidic conditions giving 
1,2,3,5-di-O-isopropylidene-α-D-xylofuranose, which could be partial hydrolyzed with high 
selectivity leading to the 1,2-protected xylofuranose 46 in 73% yield.283 The primary 
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hydroxyl group was protected by the sterically demanding TBDPS group, which resulted in the 
compound 47 containing only one unprotected hydroxyl group at the 3-position.284,285 The 
hydroxyl group was activated by Tf2O under basic conditions and subsequently reacted with 
sodium azide giving the azido ribose 48 in 46% yield.284,285 The azido sugar 48 was stepwise 
deprotected. The silyl ether was removed by TBAF284,285 and the isopropylidene group under 
acidic conditions yielding 3RiboAz (39) (Scheme 6). 
 
 
Scheme 6. Synthesis of the azido pentose 39 (3RiboAz). a) 1. Acetone, H2SO4, rt, 30 min; 2. Na2CO3, 0°C → 
rt, 3 h, 73%; b) TBDPSCl, pyridine, rt, 3.5 h, 96%; c) 1. Tf2O, pyridine, DCM, 0°C, 4.5 h; 2. NaN3, DMF, 80°C, 
5 h → rt, overnight, 46%; d) TBAF, THF, rt, 45 min, 85%, e) TFA, H2O, DMF, 0°C, 2 h, 91%. 
 
While 3AraAz and 3RiboAz were regarded as promising candidates for metabolic labeling of 
Mtb bacteria, 5AraAz was synthesized as a negative control. The synthesis started from the 
arabinofuranose derivative 14, which was prepared as described in the first part of this thesis 
(Scheme 2). The unprotected primary hydroxyl group was activated by tosylation followed by 
a nucleophilic substitution with sodium azide.286 The azido arabinofuranose 51 was 
deprotected according to Zemplén's method183 giving 5AraAz (40) in 78% yield over three 
steps (Scheme 7).286  
 
 
Scheme 7. Synthesis of the azido pentose 40 (5AraAz). a) TsCl, pyridine, rt, overnight, 96%; b) NaN3, DMF, 
70°C, 5 h, 85%; c) NaOMe, MeOH, rt, overnight, 96%. 
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The azido trehalose 28 (6TreAz) was synthesized as a positive control compound based on 
the results recently published by B. M. Swarts et al..88 The reaction pathway was the same as 
described for the amino trehalose 3 in the first part of this thesis (Scheme 4). 
 
 
Results 3.3.1: Summary 
• 3AraAz (38) and 3RiboAz (39) were successfully synthesized by protection group-
based chemistry and specific epimerization steps. 
• 5AraAz (40) was synthesized as a negative control based on the arabinan metabolism 
of Msg. 6TreAz (28) was synthesized as a positive control, as shown by B. M. Swarts 
et al..  
• All derivatives carried an azido group, which can be addressed by cyclooctynes in a 
biorthogonal reaction. 
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3.3.2 Metabolic labeling of Mtb bacteria  
For metabolic labeling of Mtb (Figure 32), bacteria in the exponential growth phase were 
cultured in the presence of the azido sugars for three days. Incorporated azido groups in the 
mycobacterial cell envelope were detected using Cu-free click chemistry. Therefore, bacteria 
were incubated with dibenzocyclooctyne (DIBO)-Alexa 488 for one hour at 37°C while gently 
shaking. 
 
Figure 32. Illustration of the method to metabolically label Mtb bacteria using azido sugars and Cu-free 
click chemistry. Mtb bacteria were cultured in the presence of azido sugars. Subsequently, bacteria were 
incubated with DIBO-Alexa 488, which led to azido group-dependent fluorescent labeling of Mtb bacteria. 
 
Detection of labeled Mtb bacteria by flow cytomtry 
Fluorescently labeled Mtb bacteria were detected by flow cytometry and labeling intensity 
quantified. Flow cytometry enables to simultaneously analyze the size (forward scatter) and 
the relative granularity (sideward scatter) of the bacteria287 and to detect emitted fluorescence 
signals on a single cell level (Figure 33).  
 
Figure 33. Illustration of the flow cytometric analysis of metabolically labeled Mtb bacteria. Flow 
cytometric analysis enables to detect fluorescence labeled bacteria on a single cell level and quantify 
fluorescence intensity. Beside detection of fluorescence signals, flow cytometry gives insights into size and 
granularity of the analyzed bacteria by detecting the scattered light. (FSC:forward scatter, SSC: sideward scatter) 
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In a flow cytometer bacteria in suspension are separated passing one at a time through a 
focused laser beam. The monochromatic light can be absorbed by a fluorescent dye 
(e.g. Alexa 488 linked to the bacterial cell envelope) re-emitting light of a specific wavelength. 
In addition, the excitation light is specifically scattered dependent on cell size, shape and 
granularity. Scattered and by a fluorochrome emitted light are collected via optics that direct 
the light to a series of filters and dichroic mirrors isolating particular desired wavelength bands. 
The light signals are detected by photomultiplier tubes and digitized for computer analysis. 
 
Metabolic labeling of Mtb bacteria with the new azido pentoses  
To test metabolic labeling of Mtb bacteria with the azido pentoses 3AraAz (38), 3RiboAz (39) 
and 5AraAz (40), and the known disaccharide 6TreAz (28) as control, the commonly used 
virulent Mtb strain H37Rv was cultured with the azido sugars at different concentrations, 
reacted with DIBO-Alexa 488 and labeled bacteria analyzed by flow cytometry (Figure 34 and 
Figure 35).  
 
Figure 34. Flow cytometric analysis shows the influence of metabolic labeling on the morphology of Mtb 
bacteria. The Mtb strain H37Rv was cultured in the presence of different azido pentoses (3AraAz (38), 3RiboAz 
(39) and 5AraAz (40), concentrations: 5 mM each), reacted with DIBO-Alexa 488, fixed and analyzed by flow 
cytometry. Analysis shown includes 100% of detected events. Dot plot (A) shows the detected forward scatter 
(FSC-A) and sideward scatter (SSC-A) of the analyzed non-modified Mtb bacteria (control), each dot = one 
detected event; the histograms (B and C) show the FSC and SSC, respectively, of non-modified Mtb bacteria 
(control) and of labeled Mtb bacteria. One of two technical replicates of three independent experiments shown. 
(control: without azido sugar, without dye). 
 
Culturing Mtb bacteria in the presence of azido pentoses, followed by click-reaction, led to 
similar forward scatter signals (FSC) and sideward scatter signals (SSC) as detected for 
cultured, but non-modified Mtb bacteria (control) (Figure 34). Supplementation of 3RiboAz (39) 
and 3AraAz (38), respectively, resulted in a dose dependent increase of fluorescence intensity 
reaching a twofold enhancement at a sugar concentration of 5 mM compared to Mtb bacteria 
cultured without azido sugar supplementation, but incubated with DIBO-Alexa 488 (dye only) 
(Figure 35 A and B). Whereas 3RiboAz (39) and 3AraAz (38) performed similarly, incubation 
with 5AraAz (40) resulted in highly intense signals and was about four times more efficient 
than the 3-azido derivatives 38 and 39 (Figure 35 C). The fluorescence increase obtained with 
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5AraAz (40) was similar to that observed with 6-azido-6-deoxy-D-trehalose (6TreAz, 28)88 
(Figure 35 D). However, five times higher concentrations of 5AraAz (40) were required 
compared to 6TreAz (28) to reach fluorescence signals with similar intensity.  
 
      
Figure 35. Flow cytometric analysis of dose-dependent metabolic labeling of Mtb bacteria using the three 
synthesized azido pentoses (3AraAz (A), 3RiboAz (B), 5AraAz (C)) and 6TreAz (D).88 The Mtb strain H37Rv 
was cultured in the presence of the different azido pentoses 38, 39 or 40 (concentrations: 0.5 mM, 1.25 mM, 
2.5 mM, 5 mM) or 6TreAz (28) (concentrations: 0.01 mM, 0.05 mM, 0.1 mM, 1 mM), reacted with DIBO-Alexa 488, 
fixed and analyzed by flow cytometry. Analysis shown includes 100% of detected events. Bar diagram represent 
means (+SD) of duplicates of two independent experiments. (MFI: mean fluorescence intensity; control: without 
azido sugar, without dye; dye only: without azido sugar, with dye).  
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This flow cytometric analysis suggests that metabolic labeling of Mtb bacteria has no impact 
on the bacterial morphology and shows that a fluorescence staining can be observed with all 
three new azido pentoses 38, 39 and 40, but with different efficiencies. 5AraAz (40), which 
was originally synthesized as a negative control compound, was identified as the most potent 
pentose derivative for MOE. 
 
3.3.3 Microscopic analysis of metabolic labeled Mtb bacteria  
To microscopically document the labeling of Mtb bacteria, red fluorescent Mtb H37Rv bacteria 
expressing mCherry (Cherry 10) were cultured in the presence of 5AraAz (40), reacted with 
DIBO-Alexa 488 and analyzed by fluorescence microscopy.  
 
Figure 36. Flow cytometry and fluorescence microscopy of metabolically labeled Cherry 10. mCherry 
expressing Mtb H37Rv bacteria (Cherry 10, red) were cultured in the absence (control) or presence of 5AraAz 
(40, 5 mM), reacted with DIBO-Alexa 488 (green) and analyzed by flow cytometry (A) and fluorescence 
microscopy (B). Shown is one representative experiment of at least three independent experiments performed 
as duplicates. Flow cytometric analysis includes 100% of detected events. (Control: without azido sugar, without 
dye; scale bar: 5 µm).  
  
 
 
Figure 37. Enlarged view of a part (white box) of the 
fluorescence microscopic image of 5AraAz-labeled 
Mtb bacteria (overlay), as shown in Figure 36. 
Intense green fluorescence at the bacterial poles 
(white arrow) shown. 
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Flow cytometric analysis of 5AraAz (40)-labeled Mtb Cherry 10 bacteria showed a broad signal 
with roughly 100 times higher green fluorescence intensity compared to non-modified Mtb 
Cherry 10 bacteria (control). The red fluorescence intensity was similar between labeled and 
non-labeled Mtb bacteria (Figure 36 A). Microscopic analysis visualized green fluorescence 
signals for mycobacteria labeled with 5AraAz (40) and no green fluorescence signals for 
non-modified Mtb Cherry 10 bacteria. The detected green fluorescence was co-localization 
with the red fluorescence derived from the mCherry-expressing Mtb bacteria. The green 
fluorescence intensity was highly diverse. Approximately half of the bacteria show strong green 
fluorescence signals, whereas the other half of the visualized bacteria are less intensely green 
fluorescent or do not emit microscopically detectable green fluorescence. Some of the bacteria 
show more intense green fluorescence at the bacterial poles and less in mid sections 
(Figure 37). Few of the strongly green fluorescent mycobacteria show no detectable red 
fluorescence (Figure 36 B).  
 
The flow cytometric analysis shows that Mtb Cherry 10 bacteria can be labeled similar to 
non-fluorescent Mtb H37Rv bacteria (Figure 36 A). Furthermore, MOE does not influence the 
fluorescence signal of the expressed mCherry protein. Microscopic analysis (Figure 36 B and 
Figure 37) verified the potency to label Mtb bacteria using 5AraAz (40) and gave first insights 
into surface distribution of the incorporated label. Microscopic analysis seemed to be less 
sensitive than flow cytometric analysis resulting probably in an absent visualization of weak 
fluorescence signals. 
 
3.3.4 Influence of azido sugars on mycobacterial growth 
As described before 5AraAz (40) has to be applied in five times higher concentrations 
compared to 6TreAz (28) to reach similar labeling efficiencies (Figure 35). Thus, it was 
analyzed whether these larger amounts of azido sugar have an impact on bacteria replication. 
Bacterial growth analysis performed in 96-well microtiter plates using GFP-expressing Mtb 
bacteria288 was carried out with all three azido pentoses (3AraAz (38), 3RiboAz (39) and 
5AraAz (40)) and 6TreAz (28) for seven days (Figure 38). In this assay bacteria replication is 
linked to an increase of fluorescence intensity, which was detected using a fluorescence 
reader. 
 
A similar increase in fluorescence intensities over seven days was detected for bacteria 
cultured in the presence of the azido pentoses 38, 39 and 40, respectively, and untreated 
bacteria cultures (Figure 38 A-C). Addition of 6TreAz (28, 1 mM) led to a smaller increase and 
no change in fluorescence intensity was detected at 6TreAz (28) concentrations of 5 mM and 
10 mM (Figure 38 D). The low fluorescence intensities measured for high concentrations (5 mM 
and 10 mM) of 6TreAz (28) were similar to those detected in wells containing the antibiotic 
rifampicin (RIFA). 
Labeling of Mtb 
Results  
94 
 
 
Figure 38. Influence of the three synthesized azido pentoses (3AraAz (A), 3RiboAz (B) and 5AraAz (C)) 
and 6TreAz (D) on growth of GFP-expressing Mtb bacteria. Mtb growth analysis was performed as described 
elsewhere.288 All four azido derivatives,28, 38, 39 and 40, were tested regarding their bacteriostatic effects in 
different concentrations (0.1 mM, 1 mM, 5 mM, 10 mM). Rifampicin (RIFA, 1 µg/ml) was used as positive control. 
Data represent means (+/-SD) of three technical replicates. One of three independent experiments shown. 
(RLU: relative light units) 
 
Since fluorescence intensities correlate with mycobacteria quantity, the data indicate that 
neither 3AraAz (38), 3RiboAz (39) nor 5AraAz (40) influence bacteria replication up to a 
concentration of 10 mM. Thus, the toxicity profile of the new azido pentoses is highly favorable. 
In contrast 6TreAz (28) showed growth-limiting effects at a concentration of 1 mM. 
 
3.3.5 Stability of Mtb labeling with 5AraAz 
In order to address the stability of the labeling with 5AraAz (40), metabolically labeled Mtb 
bacteria were cultured for different time periods at 4°C and 37°C and analyzed by flow 
cytometry (Figure 39). 
 
Figure 39. Stability of Mtb labeling with 5AraAz (40). 5AraAz (40)-labeled Mtb H37Rv bacteria were cultured 
for various time periods (1 h, 2 h, 5 h, 18 h) at 4°C and 37°C. Flow cytometric analysis includes 100% of detected 
events. Data represent means (+SD) of duplicates of at least two independent experiments. (MFI: mean 
fluorescence intensity; control: without azido sugar, without dye; dye only: without azido sugar, with dye).  
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At 4°C no major change in fluorescence intensity of the labeled mycobacteria was observed 
and even after 18 hours nearly 70% of the initial signal was detected. At 37°C, on the other 
hand, the fluorescence intensity of the labeled Mtb bacteria was reduced by half within the first 
two hours and vanished completely after 18 hours.  
 
The results indicate a time- and temperature-dependent depletion of the incorporated label.  
 
To analyze whether fluorescence degression is based on bleaching of the dye, 
DIBO-Alexa 488 was dissolved in 7H9 medium and incubated at 37°C for different time 
periods. Fluorescence intensity was detected (Figure 40) using a fluorescence reader. 
 
Figure 40. Stability of the dye DIBO-Alexa 488. DIBO-Alexa 488 (final concentration 4 µM) was added to 7H9 
medium and incubated for various time periods (1 h, 4 h, 7 h, 10 h, 56 h) at 37°C. Fluorescence intensity of the 
solution (100 µl each) was analyzed using a fluorescence reader. Fluorescence intensity normalized with 
measured initial fluorescence intensity = 100. (FI: fluorescence intensity)   
 
Incubation of the dye at 37°C resulted in no major change in fluorescence intensity. After 56 h 
roughly 75% of the initial signal was detected. 
 
The observed depletion of the label, which was incorporated into the Mtb cell envelope, is not 
due to bleaching of the fluorescence dye Alexa 488. 
 
3.3.6 Incorporation of 5AraAz into lipoglycans of the Mtb cell envelope 
5AraAz (40) was highly effective for metabolic labeling of Mtb bacteria (Figure 35). To prove 
that 5AraAz (40) indeed passes the biosynthetic pathway and is finally incorporated into 
mycobacterial cell envelope structures, Mtb lipoglycans and glycolipids were isolated from 
untreated (control) and 5AraAz (40)-treated Mtb H37Rv bacteria. The mycobacteria were 
cultured with or without supplementation of 5AraAz (40), washed and autoclaved. The resulting 
suspensions were further processed according to an established protocol to isolate ManLAM 
and its related precursors, LM and PIM, from the mycobacterial cell envelope.289 The isolation 
of glycolipids and lipoglycans from the Mtb cell envelope was supported by Regina Engel from 
the group of Prof. Dr. Otto Holst of the Research Center Borstel, Germany. Both preparations, 
from 5AraAz (40)-treated and untreated bacteria, were denatured and the components 
separated by size using sodium dodecyl sulfate polyacrylamide gel electrophoresis 
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(SDS-PAGE, for additional information see method section). The separated cell envelope 
structures were analyzed by Periodic acid-Schiff reaction (PAS), coomassie staining and the 
more sensitive silver staining (Figure 42 A-C). PAS (Figure 42 A) was used to investigate, 
whether the isolated cell envelope structures contain carbohydrates and to estimate the sizes 
of the glycoconjugates. Vicinal diols of the sugar ring were oxidized by periodic acid resulting 
in two aldehyde groups. The aldehydes were reacted with Schiff’s fuchsin-sulfite reagent to 
give a deep red-violet product. In a coomassie staining (Figure 42 C) a negative charged 
triphenylmethane dye, Coomassie Brilliant Blue, binds to positive charged molecules. Thereby 
proteins containing basic amino acids, such as arginine, lysine or histidine, can be visualized. 
The silver staining (Figure 42 B) is based on binding of silver ions to negative charged 
molecules. The attached silver ions are subsequently reduced by formaldehyde giving the 
visible elemental silver. To detect not only proteins, but also carbohydrates by this staining 
method the isolated and separated cell envelope structures were oxidized prior to the silver 
staining. 
To analyze whether azido functions were integrated into the isolated cell envelope structures, 
both preparations were incubated with DIBO-biotin. After denaturation and separation by SDS-
PAGE the cell envelope structures were transferred to a polyvinylidene fluoride (PVDF) 
membrane by wet electroblotting. The membrane was incubated with streptavidin-horseradish 
peroxidase (S-HRP), which specifically bound to biotin tagged and therefore azide containing 
cell envelope structures. The linked peroxidase enabled visualization of bound S-HRP via 
chemiluminescence (method Figure 41 and results Figure 42 D). The emitted light was 
detected on an X-ray film. 
 
Figure 41. Illustration of the used method to detect incorporated 5AraAz (40) in isolated cell envelope 
structures. Isolated cell envelope structures (20 µg) were incubated with DIBO-Biotin (4 µM) for 1.5 h at rt, gentle 
agitation. SDS-PAGE, followed by blotting and incubation with streptavidin-horseradish peroxidase (S-HRP) 
enabled visualization of biotin tagged and therefore azide containing cell envelope structures via 
chemiluminescence. (ECL: enhanced chemiluminescence)   
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Figure 42. Verification of the incorporation of 5AraAz (40) into glycolipids and lipoglycans of the Mtb cell 
envelope. Mtb H37Rv bacteria were cultured in the presence of 5AraAz (40, 1 mM) or left untreated (control), 
followed by glycolipid and lipoglycan isolation. Analysis of the composition of the isolated fractions 
(5AraAz: from 5AraAz (40)-labeled Mtb H37Rv cultures; control: from unlabeled Mtb H37Rv cultures): 
Carbohydrates of mycobacterial cell envelope structures (lipoarabinomannan (ManLAM), lipomannan (LM) and 
phosphatidyl-myo-inositol mannosides (PIMs)) and two larger structures (arrows) were visualized with Periodic 
acid-Schiff reaction (PAS) (marker: α-1-acid-glycoprotein) (A). Proteins were detected by coomassie staining 
(marker: low range marker (LRM)) (C). Silver staining was used to enrich the analytic sensitivity detecting 
proteins, carbohydrates or other negative charged molecules (marker: LRM) (B). To visualize incorporated 
azide functions isolated glycolipids were treated with DIBO-Biotin, separated by gel electrophoresis (marker: 
ColorPlus Prestained Protein Marker), blotted and incubated with streptavidine-HRP, followed by detection via 
chemiluminescence (D). 
 
In both preparations, from 5AraAz-treated and untreated Mtb bacteria (control), bands were 
detected by PAS and silver staining (Figure 42 A and B) at molecular weights smaller than 
14 kDa, between 18 and 22 kDa, between 31 and 35 kDa and two bands larger than 45 kDa 
(arrows Figure 42 A and B). No bands were visualized by coomassie staining (Figure 42 C).  
 
Bands visualized by PAS and silver staining were in line with molecular weights of the typical 
mycobacterial glycolipids and lipoglycans known from literature (PIM: < 12 kDa, 
LM: 15-20 kDa, ManLAM: 30-45 kDa).290–292 No proteins were detected by coomassie staining. 
These results indicate a successful glycolipid and lipoglycan preparation from Mtb bacteria and 
suggest that 5AraAz (40) supplementation does not strongly influence cell envelope 
composition.  
 
The blot showed only in the preparation from 5AraAz (40)-treated Mtb bacteria a specific band 
at around 50 kDa (Figure 42 D). 
The band (~50 kDa) detected by chemiluminescence indicates that 5AraAz (40) is indeed 
incorporated into a cell envelope structure of Mtb. The fact that bands in this molecular size 
range were also detected in PAS and silver stain analysis suggests that 5AraAz (40) is 
introduced into a yet unknown non-protein glycoconjugate of the Mtb cell envelope.  
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3.3.7 5AraAz labeling of Mtb bacteria in the presence of D-arabinose 
To investigate whether the incorporation of 5AraAz (40) depends on arabinose uptake 
mechanisms, 5AraAz (40) labeling of Mtb H37Rv bacteria was performed in the presence of 
increasing concentrations of D-arabinose (Figure 43). 
 
Figure 43. 5AraAz (40) labeling of Mtb bacteria in the presence of D-arabinose. Mtb H37Rv bacteria were 
cultured in the presence of 5AraAz (40, 5 mM) and increasing concentrations of D-arabinose (50 mM, 250 mM), 
reacted with DIBO-Alexa 488, fixed and analyzed by flow cytometry. Analysis includes 100% of detected events. 
Data represent means (+SD) of duplicates of two independent experiments. (MFI: mean fluorescence intensity; 
control: without azido sugar, without dye; dye only: without azido sugar, with dye). 
 
Flow cytometric analysis showed a reduction of the fluorescence intensity with increasing 
concentrations of D-arabinose.  
This observation strongly suggests that 5AraAz (40) is integrated into the mycobacterial cell 
envelope by an arabinose-dependent metabolism.  
 
3.3.8 Labeling of Mtb clinical isolates with azido pentoses  
To address whether carbohydrate-based metabolic labeling varies between Mtb clinical 
isolates, staining of four strains of the Mtb complex (H37Rv, Haarlem, Beijing and EAI) was 
carried out using the three new synthesized azido pentoses 5AraAz (40), 3AraAz (38) and 
3RiboAz (39) (Figure 44).  
 
In the case of Mtb H37Rv bacteria and the Mtb Haarlem strain roughly a tenfold increase in 
fluorescence intensity was obtained by addition of 5AraAz (40) and a three- or fourfold increase 
was detected after incubation with the 3-azido derivatives 3AraAz (38) and 3RiboAz (39). 
Fluorescence intensities measured for the Mtb Beijing strain and the Mtb EAI strain were lower, 
but clearly detectable. Similar to the results obtained with Mtb H37Rv bacteria also in these 
strains the addition of 5AraAz (40) led to higher signals compared to any other azido sugar 
applied, however the staining intensity was half as efficient as detected for the other strains. 
 
The results show that all strains can be labeled with the three sugar derivatives 38, 39 and 40, 
but with different intensities dependent on the applied sugar and used strain.  
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Figure 44. Labeling of Mtb clinical isolates with azido pentoses. Mtb H37Rv bacteria and three clinical 
isolates of the Haarlem (2336/02), Beijing (1934/03) and East African Indian (EAI, 1797/03) lineage were 
compared regarding the labeling efficiency of 5AraAz (40), 3AraAz (38) and 3RiboAz (39). Labeled bacteria were 
analyzed by flow cytometry. Analysis includes 100% of detected events. Data represent means (+SEM) of 
duplicates of three independent experiments. (MFI: mean fluorescence intensity; control: without azido sugar, 
without dye; dye only: without azido sugar, with dye). 
 
 
Results 3.3.2 – Results 3.3.8 Summary 
• All three new azido pentoses (3AraAz (38), 3RiboAz (39) and 5AraAz (40)) were 
successfully used for metabolic labeling of different Mtb strains. Intensities varied 
dependent on the applied sugar and used strain. 
• Culturing of Mtb bacteria in the presence of 5AraAz (40) led to most intense labeling. 
• The results suggest that 5AraAz (40) is incorporated by an alternative arabinose-
dependent metabolism into an unknown 50 kDa large glycostructure of the 
Mtb cell envelope.  
• The three azido pentoses 38, 39 and 40 had no influence on bacterial growth.  
• The stability of the incorporated label was time- and temperature-dependent. 
Temperature dependency suggests that enzyme-catalyzed cellular processes of 
actively replicating bacteria may be involved in degression of the incorporated label. 
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3.3.9 Infection of human macrophages with metabolically labeled Mtb bacteria 
Mtb bacteria reside in phagosomes with incomplete luminal acidification (pH 6.5) and absence 
of mature lysosomal hydrolases, containing early endosomal markers like Rab5. Carbohydrate 
structures of the Mtb cell envelope contribute to the inhibition of the phagosome maturation 
(Figure 13). To address whether metabolically labeled Mtb bacteria would show the typical 
virulence characteristics of pathogenic Mtb bacteria, human monocyte-derived macrophages 
(hMDM) were infected with 5AraAz (40)-labeled or untreated red fluorescent Mtb bacteria with 
a multiplicity of infection (MOI) of ten for three hours. Infected hMDMs were fixed with 
paraformaldehyde (PFA) and permeabilized with Triton X. To study the maturation stage of 
Mtb containing phagosomes the cells were incubated with antibodies detecting the early 
endosomal marker protein Rab5 or the late endosomal and lysosomal marker protein 
LAMP-1.293,294 Bound antibodies were detected by secondary antibodies carrying DyLight 680 
and Cy5, respectively (Figure 45). Cells were analyzed by fluorescence microscopy 
(Figure 46) and co-localization of Mtb bacteria with Rab5 or LAMP-1 was quantified 
(Figure 47). 
 
 
Figure 45. Illustration of the infection of human macrophages with metabolically labeled Mtb bacteria 
and the subsequent antibody-based detection of phagosomal marker proteins. Human monocyte-derived 
macrophages (hMDM) were infected with 5AraAz (40)-labeled (green) Mtb bacteria with a MOI of ten for three 
hours. During that time period bacteria are phagocytized and first host-pathogen interactions take place. Infected 
cells were fixed with paraformaldehyde (PFA) and permeabilized with Triton X. Primary antibodies (Ab 1) bound 
to marker proteins on the phagosomal membrane. Secondary antibodies (Ab 2), which carried a fluorescent dye, 
bound to the primary antibodies. Fluorescence signals of labeled bacteria and secondary antibodies were 
visualized by fluorescence microscopy.      
 
Three hours post infection the green fluorescence obtained by metabolic labeling was clearly 
detectable and unambiguously associated with red fluorescent Mtb bacteria within 
macrophages (Figure 46). Metabolically labeled Mtb bacteria were largely localized in 
compartments positive for the Rab5-specific antibody (ca. 80%). In addition, the majority of 
these compartments were not stained by an antibody detecting LAMP-1 (ca. 25%). Moreover, 
no differences were observed when labeled were compared to unlabeled Mtb bacteria 
(Figure 47).  
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Figure 46. Detection of Rab5 and LAMP-1 proteins in human monocyte-derived macrophages infected 
with 5AraAz (40)-labeled and untreated Mtb bacteria, respectively. mCherry expressing Mtb H37Rv bacteria 
(Cherry 10, red) were cultured in the presence of 5AraAz (40, 5 mM) and reacted with DIBO-Alexa 488 (green). 
Human monocyte-derived macrophages (hMDM) were infected with labeled and untreated Mtb (MOI: 10) for 3 h. 
Cells were fixed, permeabilized, blocked, incubated with anti-Rab5 or anti-LAMP-1 antibody and an appropriate 
fluorophore-conjugated secondary antibody (white). Nuclei were stained with 4′,6-diamidino-2-phenylindole 
(DAPI) (blue). Microscopic pictures show Rab5 staining (A) and LAMP-1 staining (B) (antibody control: infected 
with 5AraAz (40)-labeled Cherry 10, without primary antibody, with secondary antibody; scale bar: 20 µm).  
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Figure 47. Quantification of Mtb co-localization with Rab5 and LAMP-1, respectively. Microscopic pictures 
(representative pictures: Figure 25) were analyzed regarding co-localization of Mtb bacteria with fluorescence 
signals derived from anti-Rab5 or anti-LAMP-1 antibodies (blinded evaluation of > 200 phagosomes per 
condition). Bar diagram represents mean percentage (+SEM) of phagosomes positive for Rab5 and LAMP-1, 
respectively. Data of duplicates of three independent experiments analyzed. (Control: without azido sugar, 
without dye). 
 
These data suggest that metabolic labeling of Mtb bacteria with 5AraAz (40) is stable during 
the early phase of infection experiments and it seems not to influence Mtb-induced phagosome 
arrest in primary macrophages. 
 
 
 
Results 2.3.9: Summary 
• Metabolic labeling of Mtb bacteria with 5AraAz (40) is stable during the early phase of 
infection experiments. 
• Labeled as well as untreated Mtb bacteria reside in Rab5 positive early endosomal 
phagosomes. 
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3.3.10 Analysis of putative cytotoxic effects of the azido pentoses on epithelial cells 
Carbohydrate derivatives can not only be used to specifically label bacteria in solution, but 
might also be applied to target bacteria within cells or even whole organisms.192 Therefore, the 
sugar derivatives should neither be cytotoxic nor label mammalian cells, which was 
investigated in cooperation with Dr. Leonhard Möckl from the Ludwig Maximilian University of 
Munich, Germany. To investigate cytotoxic effects of the azido pentoses on mammalian cells, 
human mammary epithelial cells (HMEC-1) were cultured in the presence or absence of the 
new azido sugars 38, 39 and 40, respectively, or 6TreAz (28) at different concentrations and 
analyzed (Figure 49) by a calcein-dependent cell viability assay (Figure 48) using fluorescence 
microscopy. In live cells the non-fluorescent acetomethoxy derivate of calcein (calcein AM) can 
pass through the cellular membrane and is intracellularly converted into a green-fluorescent 
calcein after acetoxymethyl ester hydrolysis by esterases. Calcein in contrast to calcein AM 
cannot cross the plasma membrane and accumulates within the cytoplasm. Dead cells lack 
active esterases, thus, only live cells are labeled.295 
 
Figure 48. Illustration of the calcein-dependent cell viability assay. The non-fluorescent acetomethoxy 
derivate of calcein (Calcein-AM) can pass through the cellular membrane of human mammary epithelial cells 
(HMEC-1). In the cytoplasm the acetoxymethyl ester is hydrolyzed by esterases giving the fluorescent calcein. 
Dead cells lack active esterases, thus, only live cells are labeled.  
 
 
98% of HMECs cultured without azido sugar supplementation and incubated with calcein-AM 
showed green fluorescence signals. The same amount of fluorescent cells was detected for 
HMECs cultured in the presence of azido arabinoses (5AraAz (40) and 3AraAz (38)) and for 
HMECs cultured in the presence of 3RiboAz (39) or 6TreAz (28) at concentrations of 0.01 mM, 
0.1 mM and 1 mM. At a 3RiboAz (39) concentration of 10 mM 80% of the cells showed a green 
fluorescence. After addition of 6TreAz (28) in a final concentration of 10 mM 70% of the cells 
were fluorescent.  
 
Since fluorescence correlates with cell viability the new azido pentoses, especially 5AraAz (40) 
and 3AraAz (38), show a highly favorable toxicity profile with regard to mammalian cells.  
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Figure 49. Cytotoxic effects of the synthesized azido sugars were analyzed by a calcein-dependent cell 
viability assay. HMEC were cultured in the presence of different carbohydrate concentrations (0.01 mM, 0.1 mM, 
1 mM, 10 mM) or without azido sugar supplementation (control) for 2 d and treated with PBS+Ca2+/Mg2+ 
containing calcein AM and ethidium homodimer. Fluorescence was analyzed by confocal microscopy. The 
viability was defined as the number of living cells divided by the total number of cells. Amount of analyzed cells 
(n): more than 1000 cells per condition. One of two independent experiments shown.  
 
3.3.11 Metabolic labeling of epithelial cells with the new azido pentoses 
To analyze whether the synthesized azido derivatives would label mammalian cells, HMEC-1 
was incubated with the azido derivatives 5AraAz (40), 3AraAz (38), 3RiboAz (39) and 
6TreAz (28) or the acetylated analogs Ac5AraAz (51), Ac3AraAz (52), Ac3RiboAz (53) and 
Ac6TreAz (27). Subsequently, cells were stained by Cu-free click chemistry using 
DIBO-Alexa 647 and analyzed by fluorescence microscopy (Figure 51). Acetylated 
compounds were synthesized (Scheme 8) and used for metabolic labeling of HMECs, based 
on the fact that azido sugars, which were previously developed for metabolic labeling of 
eukaryotic cells, are typically administered in the peracetylated form. This acetyl protection 
ensures entry by passive diffusion and is removed intracellularly by cytosolic esterases.242 
Acetylated N-azidoacetyl-mannosamine (AcManNAz) is known to be taken up, deprotected, 
metabolized and subsequently introduced into glycoproteins and glycolipids of HMECs forming 
azide-containing sialic acids on the cell surface (Figure 50).242,244 Thus, AcManNAz was used 
as a positive control.  
 
Scheme 8. Acetylation of 3AraAz (38) and 3RiboAz (39). a) Ac2O, pyridine, rt, 2 h, 82%; 98%. 
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Figure 51. Metabolic labeling of HMECs using the synthesized azido derivatives and their acetylated 
analogs. An epithelial cell line (HMEC-1) was incubated with 5AraAz (40), 3AraAz (38), 3RiboAz (39) or 
6TreAz (28) (5 mM each), the acetylated derivatives Ac5AraAz (51), Ac3AraAz (52), Ac3RiboAz (53) or 
Ac6TreAz (27) (5 mM each) or AcManNAz (100 µM).242,244 After incubation with the azido sugars cells were 
stained with DIBO-Alexa 647 and analyzed by fluorescence microscopy. (dye only: without azido sugar, with dye; 
scale bar: 20 µm).   
 
Figure 50. Illustration of a known method to metabolically label eukaryotic cells.242,244 AcManNAz is 
taken up, deprotected by cytosolic esterases, metabolized and subsequently introduced into glycoproteins and 
glycolipids of HMECs forming azide-containing sialic acids on the cell surface. The azido group can be visualized 
using fluorescent cyclooctyne derivatives (e.g. DIBO-Alexa 647).  
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Culturing HMECs in the presence of AcManNAz (100 µM), followed by click-reaction, resulted 
in intense fluorescence signals located at the cell membranes. After the addition of the 
acetylated or unprotected azido pentoses 38, 39, 40, 51, 52 or 53 in even higher 
concentrations (5 mM instead of 100 µM) almost no fluorescence was detectable. Neither 
6TreAz (28) nor Ac6TreAz (27) supplementation led to detectable fluorescence signals. 
 
These results show that AcManNAz, but none of the applied azido pentoses 38, 39, 40, 51, 52 
and 53 or the trehalose derivatives 27 and 28, can be used to metabolically label epithelial 
cells and underline the specificity of the azido pentose-based labeling of Mtb bacteria. 
 
 
Results 3.3.9 - 3.3.11: Summary 
• The azido arabinoses (3AraAz (38), 5AraAz (40)) showed no cytotoxic effects. 
• 3RiboAz (39) and 6TreAz (28) showed no cytotoxic effects up to 1 mM and had only 
minor effect on cell viability at the highest sugar concentration (10 mM). 
• The tested azido pentoses 38, 39 and 40 and 6TreAz (28) did not label mammalian 
cells, even not in the acetylated, membrane permeable form. 
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3.3.12 Metabolic labeling of Mtb bacteria with 5-deoxy-5-iodo-α,β-D-arabinofuranose 
Fluorescent flow cytometry, as used in this study, is a highly sensitive method to analyze and 
quantify metabolically labeled bacteria at a single-cell level. However, limitations of this 
technique include photobleaching of the fluorescent dye and spectral overlap, when using 
several different fluorescent molecules in the same sample. Cytometry by time of flight 
(CyTOF) analysis combines flow cytometry and mass spectrometry (MS) facilitating 
multiparametric analysis of single cells. To investigate whether MOE can be used to label Mtb 
bacteria with heavy atoms suitable for CyTOF, an iodine analog (5AraI, 55) of 5AraAz (40) 
(Scheme 9) was synthesized. 5AraI (55) was send to Prof Dr. Niaz Banaei of Stanford 
University, USA. The iodo arabinose 55 was applied for metabolic labeling of Mtb bacteria and 
labeling efficiency was subsequently detected by CyTOF analysis. 
 
Synthesis 
The synthesis of 5AraI (55) started from the tosylated arabinofuranose derivative 50, which 
was prepared as described before in the synthesis pathway of 5AraAz (40) (Scheme 7). 
A nucleophilic substitution reaction using sodium iodide gave the iodo derivative 54286 in 79% 
yield. Deprotection according to Zemplén's method183 resulted in the desired 5AraI (55). 
 
 
Scheme 9. Synthesis of iodo arabinofuranose 55 (5AraI). a) NaI, DMF, 80°C, 5 h, 79%; b) NaOMe, MeOH, 
rt, 1 h, 89%. 
 
Metabolic labeling and CyTOF analysis was performed by Dr. Rajiv Lochan Gaur from the 
group of Prof Dr. Niaz Banaei. Mtb bacteria were cultured in the presence of 5AraI (55, 5 mM) 
for three days and subsequently analyzed by CyTOF. At least 44% of the mycobacteria were 
detected as positive for the iodo atome (graph not shown). Further experiments are currently 
carried out including labeling and detection of Mtb bacteria within macrophages. 
  
These results indicate that metabolic labeling of Mtb bacteria with the arabinose derivative 
5AraI (55) offers the opportunity to detect Mtb bacteria by CyTOF analysis. 
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3.3.13 Cysteamine derivatives and their influence on mycobacterial growth 
Successful metabolic labeling is associated with an effective uptake of the sugar derivatives. 
Thus, the sugar part may be used as a “shuttle” for molecules, such as antibiotics, to overcome 
the critical permeability of the Mtb cell envelope. For first insights into targeted antibiotic 
transport, cysteamine derivatives were synthesized (Scheme 10-12) in analogy to the 
azido pentoses 38, 39 and 40 and tested in a mycobacterial growth assay. Cysteamine was 
chosen due to its antibacterial activity, as previously detected,296 and its small size, which might 
be favorable in order to allow carbohydrate-based transport activity. 
 
Syntheses 
The 3AraAz-analog cysteamine derivative 59 was synthesized over four reaction steps with 
the arabinofuranose derivative 42 as starting material (Scheme 10). The unprotected 
hydroxyl group was deprotonated under basic conditions to increase the reactivity and enable 
the nucleophilic substitution reaction with allyl bromide giving the allylated derivative 56 in 68% 
yield. The TBDPS-protecting group was selectively cleaved with TBAF to give the 5-OH free 
derivative 57. tert-Butyloxycarbonyl (Boc)-protected cysteamine 72297 was introduced by a 
photoinduced thiol-ene coupling. This radical addition reaction occurred at room temperature 
by irradiation at λmax 365 nm and in the presence of 2,2-dimethoxy-2-phenyl-acetophenone 
(DPAP) as the sensitizer. The thiahexyl derivative 58 was obtained in 91% yield. 
Isopropylidene- and Boc-protecting groups were removed under acidic conditions, which led 
to the product 59 in an overall yield of 48%. 
 
 
Scheme 10. Synthesis of thiahexyl arabinose 59. a) NaH, DMF, 0°C, 30 min, allyl bromide, rt, 3.5 h, 68%; 
b) TBAF, THF, rt, 1 h, 90%; c) molecule 72, DPAP, MeOH, rt, 1 h, hⱱ, 91%; d) TFA, H2O, DCM, 0°C, 2 h, quant.. 
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The synthesis of the 3RiboAz-analog cysteamine derivative 64 started from the 
arabinofuranose derivative 47, which was prepared as described before (Scheme 6). The 
hydroxyl group at the 3-position was activated by Tf2O under basic conditions and 
subsequently reacted with sodium nitrite giving the epimerized product 60298 in a yield of 40%. 
After allylation with sodium hydride and allyl bromide the fully protected arabinofuranose 61 
was obtained in 80% yield. The TBDPS group was removed with TBAF to provide 62 in almost 
quantitative yield. Boc-protected cysteamine 72297 was introduced in a radical addition reaction 
with azobisisobutyronitrile (AIBN) as radical initiator, which led to the derivative 63 in a yield of 
60%. In a final step the thiahexyl derivative 63 was deprotected under acidic conditions giving 
the desired product 64 (Scheme 11).  
 
 
Scheme 11. Synthesis of thiahexyl ribose 64. a) 1. Tf2O, pyridine, DCM, 0°C, 3 h; 2. NaNO2, DMF, 70°C, 
overnight, 40%; b) NaH, DMF, 0°C, 30 min, allyl bromide, rt, 3.5 h, 80%; c) TBAF, THF, rt, 1 h, 99%; 
d) molecule 72, AIBN, MeOH, 70°C, 6 h, 60%; e) TFA, H2O, DCM, 0°C, 2 h, quant.. 
 
Arabinose derivative 42, the same starting material as used for the synthesis of the 
thiahexyl derivative 59 (Scheme 10), was applied for the synthesis of the 5AraAz-analog 
cysteamine derivative 70. The hydroxyl group at the 3-position was protected under basic 
conditions with chloromethyl methyl ether (MOMCl) giving the fully protected 
arabinofuranose 65 in 87% yield. The primary hydroxyl group was selectively deprotected with 
TBAF and subsequently allylated under basic conditions with allyl bromide. Isopropylidene- 
and MOM-protecting groups were removed under acidic conditions giving the 
allyl arabinofuranose derivative 68 in 84% yield. Boc-protected cysteamine297 was introduced 
by a photoinduced thiol-ene coupling in analogy to the synthesis of the thiahexyl derivative 59 
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(Scheme 10). The Boc-protecting group was subsequently removed under acidic conditions, 
which led to the desired product 70 in an overall yield of 47% over six steps (Scheme 12). 
 
 
Scheme 12. Synthesis of thiahexyl arabinofuranose 70. a) MOMCl, TBAI, DIPEA, 60°C, 2 h, 87%; b) TBAF, 
THF, rt, 1 h, 97%; c) NaH, DMF, 0°C, 30 min, allyl bromide, rt, overnight, 89%; d) TFA, H2O, DCM, 0°C, 1 h → 
40°C, 1 h, 84%; e) molecule 72, DPAP, MeOH, rt, 1 h, hⱱ, 75%; f) TFA, H2O, DCM, 0°C, 2 h, quant.. 
 
Influence of cysteamine on mycobacterial growth 
Anti-microbial activity of cysteamine and cysteamine derivatives was previously shown.296,299 
Cysteamine was active against several bacterial pathogens detected within the lung of patients 
with cystic fibrosis, such as Pseudomonas aeruginosa.296 In addition, different aminothiahexyl 
glycosides showed antibacterial activity against E. coli.299 However, the impact of cysteamine 
and cysteamine derivatives on mycobacteria replication was not studied so far. Therefore, 
bacterial growth analysis performed in 96-well microtiter plates using GFP-expressing Mtb 
bacteria288 was carried out with cysteamine at different concentrations for eight days 
(Figure 52). 
 
Increase of fluorescence intensity over eight days was detected for mycobacteria cultured in 
the presence of lower concentrations (0.1 mM and 1 mM) of cysteamine similar to the increase 
measured for untreated bacteria cultures. Addition of cysteamine in higher concentrations 
(5 mM) led to a reduced increase by half and no change in fluorescence intensity was detected 
at a cysteamine concentration of 10 mM. 
 
Fluorescence intensities correlate with mycobacteria quantity. Thus, the results indicate that 
cysteamine has a negative impact on bacteria replication at concentrations over 1 mM and 
leads to complete growth arrest at a concentration of 10 mM.  
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Figure 52. Influence of cysteamine on mycobacterial growth. Mtb growth analysis was performed as 
described elsewhere.288 Cysteamine was tested regarding the antibacterial effect in different concentrations 
(0.1 mM, 1 mM, 5 mM, 10 mM). Rifampicin (RIFA, 1 µg/ml) was used as positive control. Data represent means 
(+/-SD) of three technical replicates. One of two independent experiments shown. (RLU: relative light units) 
 
 
Influence of the thiahexyl derivatives 59, 64 and 70 on mycobacterial growth 
Thiahexyl sugars 59, 64 and 70 were analyzed regarding their influence on mycobacterial 
growth using the same assay as applied for bacterial growth analysis before.  
 
 
Figure 53. Influence of thiahexyl derivatives 59 (A), 64 (B) and 70 (C) on mycobacterial growth. Mtb growth 
analysis was performed as described elsewhere.288 The thiahexyl pentoses 59, 64 and 70 were tested regarding 
their antibacterial effect in different concentrations (0.1 mM, 1 mM, 5 mM, 10 mM). Rifampicin (RIFA, 1 µg/ml) was 
used as positive control. Data represent means (+/-SD) of three technical replicates. One of at least two 
independent experiments shown. (RLU: relative light units) 
 
Increase of fluorescence intensity over eight days was detected for mycobacteria cultured in 
the presence of the thiahexyl derivatives 59, 64 or 70 similar to the increase measured for 
untreated bacteria cultures. In cultures supplemented with rifampicin no change in 
fluorescence intensity was detected. 
 
The data indicate that none of the synthesized thiahexyl derivatives 59, 64 or 70 has a 
mycobacterial growth-limiting effect at concentrations up to 10 mM.  
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Influence of the acetyl-protected cysteamine derivatives 74 and 75 on mycobacterial growth 
To analyze whether functionalization of the thiol group is responsible for absent growth-limiting 
effects of the carbohydrate derivatives 59, 64 and 70, the amine and thiol group of cysteamine, 
respectively, were acetylated. N-acetylated and S-acetylated cysteamine (Scheme 13) were 
applied for bacterial growth analysis as described before. 
  
The amine group of cysteamine was selectively protected under basic condition using 
di-tert-butyl dicarbonate.297 The Boc-protected derivative 72297 was acetylated under basic 
conditions giving the fully protected cysteamine 73 in 90% yield. Subsequently, the 
Boc-protecting group was removed under acidic conditions, which led to the desired 
product 74. While the S-acetylated cysteamine 74 was synthesized over three steps, the 
N-acetylated cysteamine 75 was purchased (Scheme 13). 
 
 
Scheme 13. Synthesis of acetyl-protected cysteamine derivative 74 and the commercial available 
cysteamine derivative 75. a) Boc2O, Et3N, DCM, rt, 6 h; b) Ac2O, pyridine, rt, overnight; c) TFA, DCM, rt, 1 h, 
99%. 
 
 
Figure 54. Influence of acetyl-protected cysteamine 75 (A) and 74 (B) on mycobacterial growth. Mtb 
growth analysis was performed as described elsewhere.288 The cysteamine derivatives 75 (A) and 74 (B) were 
tested regarding the antibacterial effect in different concentrations (0.1 mM, 1 mM, 5 mM, 10 mM). Rifampicin 
(RIFA, 1 µg/ml) was used as positive control. Data represent means (+/-SD) of three technical replicates. One of 
two independent experiments shown. (RLU: relative light units)  
 
Increase of fluorescence intensity over eight days was detected for mycobacteria cultured in 
the presence of lower concentrations (0.1 mM and 1 mM) of acetylated cysteamine 74 and 75 
similar to the increase measured for untreated bacteria cultures. Addition of the two derivatives 
74 and 75 in higher concentrations (5 mM and 10 mM) led to a smaller increase (Figure 54).  
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The results indicate that the acetylated cysteamine derivatives 74 and 75 have a negative 
impact on bacterial replication at concentrations of 5 mM and 10 mM. The effect is not as strong 
as measured for unprotected cysteamine, but clearly detectable.  
 
 
 
Results 3.3.12 and Results 3.3.13: Summary 
• Four new carbohydrate derivatives, 5AraI (55) and the thiahexyl derivatives 59, 64 and 
70, were synthesized. 
• 5AraI (55) was successfully used for first CyTOF analysis. 
• While cysteamine showed mycobacterial growth-limiting effects in high concentrations 
(5 mM and 10 mM), the cysteamine-modified carbohydrate derivatives 59, 64 and 70 
had no antibacterial activity. 
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3.4 Discussion 
The structures of the mycobacterial cell envelope and the related biosynthetic pathways 
represent targets of many diagnostic tools and therapeutic agents. For example, the lipoglycan 
LAM was discovered as a specific biomarker in Tb infection being measurable in sputum and 
urine.17,300 Furthermore, several anti-Tb drugs, including the first-line drugs isoniazid and 
ethambutol, act as inhibitors of the cell envelope biosynthesis.30,301 Recently, first efforts have 
been made not only to detect or inhibit unique cell wall structures, but to specifically modify 
them using MOE.88,192,302 Based on the absence of D-arabinose in many organisms and the 
high amounts of D-arabinofuranosides in the mycobacterial cell envelope, 
D-arabinose derivatives were identified in this study as potential candidates to target Mtb 
bacteria by MOE. The Mtb bacteria were successfully labeled using the synthesized 
azido pentoses 3AraAz (38), 3RiboAz (39) and 5AraAz (40). Therefore, the azido pentoses 
had to be (i) taken up, (ii) metabolized and subsequently (iii) be introduced into the 
mycobacterial cell envelope.  
 
3.4.1 Arabinose uptake mechanisms 
The initial critical process for a successful metabolic labeling is the transport of the 
carbohydrate derivative into the cytoplasm. Since the azido pentoses used in this study for 
metabolic labeling of Mtb bacteria were not acetylated, they were hydrophilic and had to be 
actively transported across the hydrophobic cell envelope of Mtb. The presence of 
carbohydrate transporters in the cell envelope is often connected to the nutrition requirements 
of the organism. For mycobacteria nutrition requirements have been intensively studied. 
Already 1951 the utilization of several carbohydrates, fatty acids and amino acids by 
mycobacteria was examined by measuring oxygen consumption, which is connected to an 
active aerobic respiration. Glycerol, lactate and fatty acids were proven to be the most effective 
stimulants of respiration. Glucose caused a weaker stimulation and arabinose had no 
significant effects.303 Furthermore, growth analysis of Msg bacteria on various sugars as a sole 
carbon source for seven days revealed that L-arabinose but not D-arabinose can be utilized.304 
However, after a long time lag of eight to ten days, growth of mycobacteria was observed also 
in media containing D-arabinose.99 D-Arabinose uptake activity was further analyzed by the 
use of radioactive 14C-D-arabinose, verifying the transport of this rare pentose through the 
mycobacterial cell envelope.99 D-Arabinose might not be a preferred carbon source of 
mycobacteria, but can verifiably pass through the mycobacterial cell envelope.  
While carbohydrate uptake mechanisms of Msg have been widely studied and eight putative 
pentose transporters were identified, transport systems of Mtb are poorly characterized.100 
Analysis of the genome of Mtb H37Rv bacteria predicts four ABC (ATP-binding cassette)-type 
transporters and one permease for carbohydrates.305,306 Two of the ABC-type transporters are 
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similar (62% and 80% similar amino acids) to those described for Msg but the substrate 
specificity was only recently solved for one of them. The SugABC-LpqY transporter exhibits a 
high specificity for trehalose and is used as a recycling system for this disaccharide, which 
may be extracellularly released by TDM hydrolases or as a byproduct of cell envelope 
biosynthesis (Figure 10).87 Genetic similarities of the other three ABC systems to known 
transporters outside the genus Mycobacterium are so low that potential substrates cannot be 
predicted by comparative analyses.305 Another possible candidate as a pentose uptake system 
may be the permease SugI, because of its sequence similarities to the arabinose transporter 
(AraE, 24%) of E. coli. However, also in this case the substrate has not been identified to 
date.100  
Although it is still unclear by which mechanism the synthesized azido sugars (3AraAz (38), 
3RiboAz (39), 5AraAz (40)) were taken up, the successful metabolic labeling strongly suggests 
that pentose transporters are present in the Mtb cell envelope.  
The azido pentose-based metabolic labeling strategy can now be used to study the widely 
unknown pentose transport mechanisms of Mtb bacteria in further detail. 
 
3.4.2 Arabinose metabolism  
For metabolic labeling the carbohydrate derivatives do not only have to enter the bacterium, 
but also have to pass through the natural carbohydrate metabolism. 3AraAz (38) and 
3RiboAz (39) were designed to be incorporated as arabinofuranoside derivatives into the 
mycobacterial cell envelope. The only known donor of D-arabinofuranosides in mycobacteria 
is decaprenyl-phospho-arabinose, which was isolated from Msg and characterized by mass 
spectrometry and NMR spectroscopy.307 Further activated forms of D-arabinose, such as 
D-arabinose phosphate and D-arabinose nucleotides, have not been demonstrated in 
mycobacteria to date.97 Thus, the azido pentoses 38 and 39 have to be included into the 
decraprenyl-phospho-arabinose biosynthesis pathway, as described in the introduction 
(Figure 11).  
3AraAz (38) might pass the whole metabolism starting with a reduction to D-arabinitol. 
However, the subsequent conversion to D-xylulose derivatives cannot take place, because this 
requires an epimerization at the 3-position. This isomerization is excluded since the 3-position 
is functionalized by the azido group. The formation of xylulose intermediates, however, might 
be important, because the phosphorylation of the primary hydroxyl group, which might be 
essential for the following metabolic steps, is mediated by a D-xylulose kinase.97 Alternative 
enzymes converting D-arabinose directly into further downstream D-ribose derivatives have not 
been identified to date. Thus, it is still unclear, how 3AraAz (38) is included.  
3RiboAz (39) might enter the biosynthesis pathway as a D-ribose 5-phosphate derivative. This 
would require the activity of a ribose kinase. The adenosine kinase (ADK) of Mtb typically 
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catalyzes the phosphorylation of adenosine to adenosine monophosphate (AMP).34,308 
However, Mtb ADK has a very low sequence similarity with other ADKs, which are mainly 
present in eukaryotic organisms, but is genetically more closely related to the ribokinase (RK) 
from E. coli. 25% identity was detected based on the amino acid sequence.309,310 Moreover, 
both Mtb ADK and E. coli RK are dimers, whereas all other known ADKs are monomers.310 In 
E. coli RK catalyzes the phosphorylation of ribose to ribose 5-phosphate. RK activity of the Mtb 
ADK would explain the entry of 3RiboAz (39) into the arabinan metabolism as 3-azido-3-deoxy-
5-phospho-D-ribose. However, this activity has not been demonstrated so far. While the 
introduction of 3RiboAz (39) into the mycobacterial cell envelope by the decraprenyl-phospho-
arabinose biosynthesis pathway is feasible, the entry of 5AraAz (40) is unlikely.  
5AraAz (40) was synthesized as a negative control compound, since intermediates of the 
arabinan metabolism are phosphorylated at the 5-position and this phosphorylation is not 
removed until the pre-final synthetic step.97 Enzymes catalyzing the functionalization of the 
phosphorylated substrates with decaprenyl phosphate are essential as determined by 
transposon mutagenesis.311 If these enzymes might also transfer decaprenyl-phosphate to 
non-phosphorylated ribose or arabinose has not been studied to date. The improbability of the 
incorporation of 5AraAz (40) into the polysaccharides of the mycobacterial cell envelope is 
further supported by the fact that arabinofuranosides in AG and LAM are mainly connected by 
(1→5) linkage and terminally functionalized with mycolic acids and mannosides, respectively. 
The structural details of AG and LAM result in only a few putative positions to be modified by 
5AraAz (40). However, in the current study isolation of cell envelope structures, followed by 
detection of azido functions revealed that 5AraAz (40) is incorporated into the Mtb cell 
envelope. The azide-containing structure was detected on a SDS-gel with a molecular weight 
roughly 10 kDa larger than ManLAM. This shift could be explained by an enhanced size due 
to functionalization with DIBO-biotin. On the other hand, an intercalation into a novel unknown 
glycoconjugate larger than ManLAM is also likely, since bands in the same molecular range 
were visualized by PAS and silver staining even in non DIBO-biotin treated samples. Although 
no bands were detected by coomassie staining, protein origin cannot be fully excluded and 
has to be analyzed more precisely, since the used coomassie imaging method is less 
sensitive.312 More intense signals in the silver staining compared to the PAS staining indicate 
that the main part of the unknown compound may not consist of carbohydrates, but rather of 
highly negative charged molecules. While lipids are mainly neutral even after oxidation, 
proteins containing amino acids with a carboxyl group in the side chain can increase the 
negative charge. Thus, the unknown structure might be a glycoprotein, although it was not 
detected by coomassie staining. Mycobacterial glycoproteins have been detected earlier, but 
full extent and nature of glycosylation as well as the glycosylation pathway remain poorly 
characterized.313–315 Carbohydrate analysis by capillary zone electrophoresis combined with 
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laser induced fluorescence detection of 1-aminopyrene-3,6,8-trisulfonate derivatives revealed 
the presence of glucose, mannose and arabinose in mycobacterial cell surface proteins 
(CSP).313 These observations support the possibility that 5AraAz (40) may be included into the 
carbohydrate part of mycobacterial glycoproteins. However, further studies are needed to 
prove this hypothesis.  
In future experiments, the cell envelope preparations containing the 5AraAz (40)-labeled cell 
envelope structure should be incubated with DIBO-biotin and biotin-tagged molecules 
separated by magnetic beads functionalized with streptavidin. Subsequently, the captured 
compound might be released and analyzed by mass spectrometry. Furthermore, not only the 
LAM/LM/PIM fraction should be examined, but the whole cell lysate, since 5AraAz (40) might 
be incorporated into yet unknown cell envelope structures. The method bears further the 
chance to identify the intermediates of the metabolism, whereby 5AraAz (40) was incorporated 
into the mycobacterial cell envelope, and will give new insights into the biosynthetic pathways 
of Mtb. Finally, characterizing 3AraAz (38) and 3RiboAz (39)-labeled structures will help to 
identify how these derivatives entered the arabinan metabolism and confirm or confute 
predictions.  
Taken together, MOE with the azido pentoses 38, 39 and 40 can not only be used to target 
Mtb bacteria, but moreover enables novel insights into the carbohydrate composition of the 
Mtb cell envelope and into the biosynthetic pathways of pathogenic mycobacteria.  
 
3.4.3 Arabinose derivatives used for MOE  
MOE is a powerful tool to target not only eukaryotic but also prokaryotic cells. To date, only a 
few studies have addressed metabolic labeling of Mtb bacteria. Recently, trehalose derivatives 
were identified as potent compounds to label mycobacteria.88,192,316 These molecules were 
either taken up by the SugABC-LpqY transporter and proceeded through the trehalose 
recycling pathway or were directly anchored into the mycobacterial cell envelope by the 
extracellular proteins Ag85A, Ag85B and Ag85C, which catalyze esterification of the trehalose 
derivatives and the formation of TMM and TDM derivatives (for details of the TDM metabolism 
see Figure 10).88,192 K. M. Backus et al. revealed strong specificity of all Ag85 isoforms for 
trehalose-like disaccharides but a striking variety of trehalose derivatives that were converted. 
Modifications on every position of the sugar scaffold were tolerated and even the large FITC-
trehalose derivative was processed. Labeling experiments with an Ag85C mutant strain 
verified the significance of this extracellular protein for incorporation of FITC-trehalose into the 
mycobacterial cell envelope.192 However, 2-, 4- and 6TreAz labeling required uptake into the 
cytoplasm by the ABC transporter, as shown by B. M. Swarts et al..88 For these labeling 
strategies not only the biosynthetic pathway, but also the modified cell envelope structures 
were identified. Trehalose derivatives were mainly incorporated into TMM and TDM.88,192 
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Efficiency and required concentrations (between 2.5 µM and 250 µM) varied dependent on the 
used trehalose derivative.88 Furthermore, trehalose dependent labeling is highly specific: 
FITC-trehalose led to high fluorescence in Mtb bacteria, whereas neither Staphylococcus 
aureus, Pseudomonas aeruginosa nor Haemophilus influenza showed appreciable labeling 
after incubation with the trehalose derivative.192 Strikingly, FITC-trehalose could also be 
applied for targeting Mtb bacteria within macrophages. In contrast to the uniform staining of 
bacilli observed in vitro, mycobacterial labeling in vivo varied between different macrophages 
or even within a single macrophage.192 This heterogeneity might be explained by the metabolic 
status of the bacterium and the maturation status of the phagosomal compartment. Beside this 
well studied carbohydrate-based labeling method, D-amino acid derivatives were developed to 
label peptidoglycan structures of the mycobacterial cell envelope.302 Azide and alkyne-
functionalized D-alanine, respectively, was successfully used for staining of Mtb bacteria, but 
required much higher concentrations (at least 200 µM) compared to the trehalose derivatives. 
Furthermore, this metabolic method is not specific and leads to cell envelope modification of 
Gram-positive bacteria (e.g. Listeria monocytogenes, Corynebacterium glutamicum), Gram-
negative bacteria (e.g. E. coli) and mycobacteria (e.g. Mtb).302  
In the current study, the azido pentoses 38, 39 and 40 were successfully applied as new 
compounds for MOE of Mtb. D-Arabinose and D-ribose derivatives have never been used for 
metabolic labeling before. Labeling efficiency differed between the applied azido derivatives. 
Whereas 3AraAz (38) and 3RiboAz (39) led to similar low labeling intensities, 5AraAz (40) 
resulted in as strong signals as detected with the known trehalose derivative 6TreAz (28). 
However, five times higher concentrations were required. The applied concentrations were 
similar to those used for D-amino acid labeling.  
That MOE with the azido pentoses 38, 39 and 40 was only detected at sugar concentrations 
of at least 100 µM might be explained by a limited uptake of those derivatives. Recently, 
R. Lowery et al. used deuterated carbohydrates to analyze sugar transport of Msg and 
revealed that trehalose is taken up in three times higher amounts compared to 
L-arabinopyranose.317 Although D-arabinose was not tested, these results indicate that the 
uptake efficiency might vary between different carbohydrates. The more intense labeling by 
5AraAz (40) compared to 3AraAz (38) might also be explained by uptake mechanisms. It is 
conceivable that arabinofuranoses have a preferred entry compared to arabinopyranoses. 
While 5AraAz (40) is fixed in the furanose form 3AraAz (38) is mainly present as a pyranose.  
Furthermore, intracellular degradation or competitive processes during the metabolism can 
influence the amount of cell envelope modifications. Decaprenyl-phospho-arabinose is not only 
synthesized from external D-arabinose, but also from glucose, which is highly present in the 
used 7H9/OADC-culture medium. Thus, the azido pentoses, especially 3AraAz (38) and 
3RiboAz (39), which are assumed to pass through the decaprenyl-phospho-arabinose 
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biosynthesis pathway, might compete with glucose for cell envelope incorporation. This might 
also explain the low labeling efficiency of 3AraAz (38) and 3RiboAz (39) compared to 
5AraAz (40).  
Finally, also the accessibility of the azido function for the click reaction can have a strong 
impact on the detected fluorescence intensity. Therefore, it might be speculated that 
3AraAz (38), 3RiboAz (39) and 5AraAz (40) were present in much higher amounts in the 
mycobacteria envelope, but more closely located to the cell membrane and therefore shielded 
by the “outer layer”. In contrast labeling with trehalose derivatives leads to modifications of 
TMM and TDM, which are mainly components of the “outer layer”. Therefore, 
azido modification of these glycolipids might be easily accessible for applied cyclooctynes.  
The disadvantage of the required higher concentrations is offset by a highly favorable toxicity 
profile. None of the azido pentoses 38, 39 and 40 had any impact on bacterial replication up 
to concentrations of 10 mM. Thus, they can be used as potent agents for metabolic labeling of 
Mtb bacteria in a millimolar range. Moreover, required concentrations might even be lower 
under a changed experimental set-up. As detected for FITC-trehalose, labeling efficiency of 
Mtb bacteria is strongly influenced by the composition of the bacterial environment and the 
metabolic status of Mtb. It is known that Mtb bacteria respond to environmental conditions and 
adjust their metabolism for example by switching their main carbon source from carbohydrates 
to lipids.318 To address whether labeling with the new azido derivatives 38, 39 and 40 is 
influenced by the metabolic status of Mtb, labeling experiments should be carried out not only 
in glucose-rich 7H9/OADC-medium, but also in medium exclusively containing a 
non-carbohydrate carbon source, such as acetate. 
Beside low toxicity and high labeling efficiency the degree of specificity is important for a good 
metabolic labeling tool. Therefore, the new azido derivatives 38, 39 and 40 should label all 
strains of the MTBC, but should not be incorporated into cell envelopes of other bacteria or 
host cells.  
MOE experiments with four different strains of the MTBC (H37Rv, Haarlem, Beijing and EAI) 
led to a successful labeling of all strains with the three azido pentoses 38, 39 and 40, but with 
different efficiency dependent on the used strain. Varying labeling intensities might be 
explained by different glycolipid and lipoglycan compositions of the cell envelope. While these 
particular strains were instrumental in the identification of clade-specific virulence patterns,46 
divergences of their cell envelope composition have never been addressed. However, 
differences in this respect were shown for other Mtb strains.292 Thus, it is feasible that the 
obtained labeling results were based on cell envelope diversity. On the other hand the optical 
density (OD) was only measured and adjusted bevor carbohydrate supplementation. After 
three days of cultivation the OD was not further controlled. Therefore, it cannot be excluded 
that labeling diversity relies on varying bacterial replication rates. However, it seems rather 
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unlikely, since similar replication rates were previously detected for the investigated strains.319 
The new azido pentoses 38, 39 and 40 can be used as fast and easy tools to label different 
Mtb clinical isolates and might also give deeper insights into the structural heterogeneity of the 
MTBC strains.  
Labeling experiments with other bacteria, which do not belong to the MTBC, have not been 
carried out so far. Since arabinofuranosides are present in the cell envelopes of different 
genera of Actinomycetales and a similar arabinan metabolism was described for several 
bacteria of this order,97 one might expect that these bacteria can also be labeled by the new 
azido derivatives 38, 39 and 40. However, 5AraAz (40) labeling seems not to be based on the 
known metabolism and might not be incorporated into the common arabinan 
heteropolysaccharides LAM and AG. Thus, this sugar derivative might be even more specific 
than expected. To finally analyze specificity, other bacteria belonging to the Actinomycetales 
order, such as the non-tuberculosis mycobacteria M. avium, M. leprae and M. marinum or 
other non-mycobacterial human colonizing bacteria (e.g. Rhodococcus equi, Nocardia 
araoensis, Actinomyces israelii), should be examined. Furthermore, Gram-negative bacteria, 
like E. coli or the lung pathogens Pseudomonas aeruginosa, Legionella pneumophila and 
Haemophilus influenza, should be addressed using this metabolic labeling method. In the cell 
envelope of Gram-negative bacteria the monosaccharide Kdo is present as a constituent of 
LPS. This eight-carbon sugar is synthesized based on arabinose-5-phosphate (Ara5P). Ara5P 
is converted with phosphoenolpyruvate (PEP) catalyzed by Kdo synthase to give 
Kdo-8-phosphate. This activated Kdo is subsequently transformed into free Kdo and further 
activated to form the cytidine monophosphate (CMP-Kdo) donor prior to its incorporation into 
LPS.320,321 Thus, labeling of Gram-negative bacteria might be possible by 3AraAz (38), but not 
5AraAz (40). 3RiboAz (39) might also be incorporated as azido Kdo into the cell envelope, 
because it is known that ribose 5-phosphate is converted to ribulose 5-phosphate (Ru5P), 
which is subsequently isomerized to the Kdo precursor Ara5P.322,323  
In addition, labeling with 3AraAz (38) and 3RiboAz (39) might not be limited to prokaryotes, 
since a few eukaryotic pathogens like the trypanosomatid parasite L. major have 
arabinopyranosides in their cell envelope.90–93,324 In L. major these pentoses are part of the 
lipophosphoglycan (LPG). The galactoside residues of LPG are capped by (1→2) linkage with 
β-D-arabinopyranosides, which are strongly associated with parasite release from midgut of 
the sand fly and thus important virulence factors.325,326 It would be highly fascinating to apply 
the synthesized pentose derivative 38 to modify those arabinose structures. L. major has 
never been stained by MOE before. However, radioactive D-arabinose was successfully 
incorporated into LPG and glycosylphosphatidylinositol lipids (GPIL) as shown by 
N. M. Novozhilova et al..327 These results make it reasonable that 3AraAz (38) can be used for 
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metabolic labeling of L. major. To address this question, a cooperation with 
Prof. Dr. Ger van Zandbergen of the Paul Ehrlich Institute, Germany was started.  
To target pathogens within host cells, the azido pentoses 38, 39 and 40 should not be 
incorporated into the glycocalyx of mammalian cells. Therefore, a human epithelial cell line 
was incubated with the new azido sugars and incorporation analyzed by click reaction with 
DIBO-Alexa 647. No labeling was obtained. Thus, all three derivatives have the capability to 
be used as intracellular labeling tools. This was further supported by the fact that none of the 
synthesized sugars 38, 39 and 40 showed any cytotoxic effect up to concentrations of at least 
5 mM.  
Taken together, the applied azido pentoses 38, 39 and 40 represent a new tool to label 
different mycobacterial strains and address their structural heterogeneity. While 5AraAz (40) 
might specifically label mycobacteria, 3AraAz (38) and 3RiboAz (39) might further be applied 
to target Gram-negative bacteria or the trypanosomatid parasite L. major. However, additional 
studies are necessary to prove the assumed labeling specificity of the three azido pentoses 38, 
39 and 40.  
 
3.4.4 Applications of MOE 
MOE has the potential to develop new strategies to study, image or treat Mtb bacteria:  
Trehalose analogs were recently used to localize new cell envelope formation and to identify 
the involved enzymes.328 Both K. M. Backus et al. and B. M. Swarts et al. revealed high levels 
of trehalose derivative incorporation particular at the bacterial poles.88,192 This observation was 
consistent with the polar growth model of mycobacteria.328–330 An irregular distribution of the 
pentose derivative 40 within the cell envelope was not further quantified. However, partial 
higher fluorescence intensity at the mycobacterial poles was visualized by microscopy 
(Figure 37).                                        
In the current study metabolic labeling was used to get deeper insights into cell envelope 
dynamics. Labeling degression was time and temperature dependent. While a fast 
fluorescence reduction was observed at 37°C, fluorescence intensity remained nearly constant 
at 4°C. These findings suggest that enzyme-catalyzed cellular processes may be involved in 
either shedding of cell surface structures or turnover mechanisms. The results are similar to 
previous observations with Msg, where the radioactive labeling with N-acetyl-glucosamine 
(14C-GlcNAc) was reduced to 20% within twelve hours.331 Our results on the time-dependent 
reduction of fluorescent intensity suggest a complete cell envelope turnover within less than 
18 hours. Thus, the half-life of cell envelope constitution may be shorter than previously 
anticipated. Nevertheless, these experiments were carried out in nutrient-rich medium. Natural 
nutrient supply differs and depends on bacterial location within the host,318 thus cell wall 
turnover might also be completely different in vivo.                                                          
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Beside the use of MOE as a method to study biochemical processes, it can also be applied as 
a new tool for fast and easy staining of clinical isolates evading time-consuming genetic 
modifications. Therefore, metabolic labeling should not influence the virulence characteristics 
of the pathogen. To analyze the impact of surface modifications on Mtb pathogenicity, human 
macrophages were infected with 5AraAz (40)-labeled and untreated mycobacteria, 
respectively, for three hours. Fluorescence derived from metabolic labeling was stable under 
early infection conditions and was clearly detectable within the macrophage. The best 
characterized virulence mechanism of Mtb bacteria is the inhibition of phagosome 
maturation.332,333 Thus, antibodies recognizing endosomal or lysosomal marker proteins were 
applied to characterize the phagosomal status. Both, labeled and untreated Mtb bacteria, 
mainly resided in phagosomes positive for the endosome associated protein Rab5 but negative 
for the lysosomal-associated protein LAMP-1.334,335 Thus, also labeled Mtb bacteria seemed to 
be able to inhibit phagosome maturation. These results indicate that MOE does not influence 
Mtb virulence characteristics in primary macrophages during early phase of infection. 
However, only two phagosomal markers were analyzed so far. To get more reliable information 
further marker proteins should be examined.127 For example increased EEA1293 concentrations 
and the appearance of Rab7335 would indicate a late endosomal status, whereas Rab14133 and 
the uncleaved lysosomal aspartyl protease procathepsin D336 would refer to early endosomes. 
Despite the wide use of antibodies to document the degree of maturation, this method provides 
only a static measurement of a dynamic process and provides limited information about the 
environment within the phagosomes. Inhibition of phagosome maturation is connected with a 
reduced acidification.294 This could be visualized by the lack of fluorescence imaging with the 
hydrophobic and acidotropic fluorescent dye LysoTracker.337 So far the stability of the 
introduced label and the influence of MOE on Mtb pathogenicity were investigated during the 
early phase of infection. In a time period of three hours mycobacteria are phagocytosed and 
first host-pathogen interactions, including inhibition of the phagosomal maturation,127 take 
place. To address whether the introduced label might also withstand intracellular mycobacterial 
replication and later stages of infection, the infection studies should be carried out for at least 
24 hours.                                                                                                          
Beside visualization of Mtb bacteria within macrophages, as shown in the current study, MOE 
might also be applied to investigate the bacterial environment within the phagosome. Metabolic 
labeling might be used to functionalize mycobacteria with biosensors. Molecules detecting 
phagosomal maturation by pH measurement, identification of β-galactosidase, protease or 
lipase activity or directly determine lysosomal fusion are conceivable. Specific host immune 
stresses could be detected via measurements of hypoxia, reactive nitrogen species (RNS) or 
reactive oxygen species (ROS). Furthermore, ion concentrations (Ca2+ or Fe3+), nutrient supply 
or the release of specific signaling or virulence factors could be addressed. While the Russell 
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group already genetically developed a panel of reporter strains to analyze the physiology of 
the phagosomes,338,339 introduction of biosensors via MOE would have several advantages. 
This carbohydrate based strategy might enable to easily compare the virulence characteristics 
of different Mtb clinical isolates without time consuming genetic modifications, can be 
introduced even after a normal infection at a specific time point and might also be applicable 
within monkeys. To study the environmental composition of mycobacteria within a macaques’s 
lung is of special interest, since it is known that some bacteria or even whole infected regions 
do not respond to therapy, while others are easily cured.340                                       
First efforts to use MOE to detect therapeutic outcome have been done by the Barry group.21 
They applied the radiolabeled tracer 2-deoxy-2-(18F)fluoro-D-glucose (FDG) to illuminate areas 
of inflammation within the lung.20 While the radioactivity is detected by positron emission 
tomography (PET), morphological information is added by computed tomography (CT) high-
resolution X-ray images. These PET/CT scans (Figure 1) can monitor infections over time. 
Since FDG is mainly taken up by activated inflammatory cells, which have a high glycolytic 
rate, this imaging method detects inflammation but not the mycobacterium itself within the 
lung.21 To directly visualize Mtb bacteria 2-deoxy-2-(18F)fluoro-trehalose (FDT) is currently 
under investigation in the group of Prof. Dr. Clifton E. Barry 3rd.                                    
Beside radioactive fluorine derivatives, carbohydrates carrying iodine isotopes could be 
applied. These molecules might also enable Mtb imaging, but can further be used as 
therapeutic tools. For iodine-based PET/CT imaging the γ-emitting isotopes iodine-123 (I123) 
with a half-life of 13 hours could be chosen, while the β-emitting isotope iodine-131 (I131) with 
a half-life of eight days would be suitable for radiotherapy. In the current work the 
iodo arabinofuranose 5AraI (55) was successfully used for metabolic labeling of Mtb bacteria. 
Although a non-radioactive derivative was synthesized, the results demonstrate that iodine-
functionalized arabinose can be introduced into mycobacteria. Moreover, 5AraI (55) was 
applied in cooperation with Prof. Dr. Niaz Banaei of Stanford University, USA for first CyTOF 
analysis of Mtb bacteria. To analyze and quantify metabolically labeled bacteria at a single-cell 
level often fluorescent flow cytometry is used. However, there are several limitations of this 
technique including photobleaching of the fluorescent dye and spectral overlap, when using 
several different fluorescent molecules in the same sample. CyTOF analysis, combining flow 
cytometry and mass spectrometry (MS), facilitates multiparametric analysis. Therefore, 
bacteria have to be labeled with heavy and good ionizable atoms. Labeled bacteria, solely or 
within a host-cell, can be separated by flow cytometry. Subsequently, the introduced heavy 
atoms, rarely present in the non-labeled bacteria, can be specifically detected after plasma 
treatment by mass spectrometry, such as TOF-MS. Here we used an iodine analog (5AraI, 55) 
of 5AraAz (40) to verify metabolic incorporation of arabinofuranose derivatives into Mtb 
bacteria by CyTOF analysis. In contrast to the azide-cyclooctyne-based labeling method, 
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CyTOF enables detection of metabolic modifications by a one-step approach, excluding the 
biorthogonal reaction. Furthermore, the small iodine group might also be an advantage for 
labeling of Mtb bacteria within macrophages in comparison to large and hydrophobic 
fluorescent dyes like fluorescein.   
MOE might not only be used as an imaging or diagnostic tool, but can also enable the 
development of novel therapeutic strategies. Since metabolic labeling is associated with an 
effective uptake of sugar derivatives, MOE can be used to “smuggle” carbohydrate-linked 
molecules through the highly impermeable cell envelope of Mtb. Here, we used the cysteamine 
derivatives 59, 64 and 70 to get first insights into targeted antibiotic transport. Although 
cysteamine had only Mtb growth limiting effects in high concentrations, this molecule was 
chosen for first experiments. The small size seemed to be an advantage in order to allow 
carbohydrate-based transport activity. Additionally, antibacterial effects of thiahexyl derivatives 
were previously reported by the Lindhorst group.299 A low anti-Mtb activity of the original 
molecule would further allow to easily detect carbohydrate-dependent increase of 
bacteriostatic activity. However, none of the cysteamine-functionalized sugars 59, 64 and 70 
synthesized in analogy to 3AraAz (38), 3RiboAz (39) and 5AraAz (40) had any effect on 
mycobacterial growth even at very high concentrations. These results might be explained by 
an absent uptake of the new thiahexyl derivatives 59, 64 and 70 or a loss of activity due to 
functionalization of the thiol group. To address the question whether a free thiol is responsible 
for the growth limiting effect of cysteamine, the N- and S-acetylated cysteamine 75 and 74, 
respectively, were also tested in the bacterial growth assay. Both had minor, but similar 
bacteriostatic activity, thus functionalization of the thiol seemed not to be responsible for the 
negative results obtained with the sugar derivatives 59, 64 and 70. However, acetyl-protecting 
groups can migrate from the thiol to the amine and thereby re-generate a free thiol. 
Nevertheless, cysteamine derivatives appeared not to be the ideal molecules to study targeted 
antibiotic transport. Thus, further experiments should be carried out with other antibacterial 
agents linked to arabinose or trehalose. Cycloserin, a second-line drug of Mtb, ethambutol or 
other small but maybe less active molecules could be glycosylated and utilized. Furthermore, 
trehalose derivatives of penicillin are conceivable. Although penicillin was reported to be not 
active against Mtb bacteria, recent studies revealed that penicillin can be used for Tb therapy, 
but only in combination with β-lactamase inhibitors.341 It might also be possible to avoid β-
lactam cleavage by a fast and targeted transport of penicillin through the mycobacterial cell 
envelope. It is tempting to speculate that this transport might be achieved by carbohydrate-
functionalization.                                                                                                            
While cycloserin, ethambutol or penicillin would directly inhibit the cell envelope 
biosynthesis,30,341,342 other molecules could be incorporated by MOE and then subsequently 
be activated to exhibit antibacterial characteristics in a second step. This two-step approach 
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might reduce resistance formation, which would be a great benefit since MDR and XDR strains 
are the main challenge in the fight against Tb. Up to now only two examples for incorporating 
therapeutics by MOE into bacterial glycans have been published.343–345 However, huge 
inspiration can be obtained from the area of cancer research.346,347 Novel classes of 
therapeutics such as carbohydrate-linked photosensitizers, NO sensitizer or activatable 
nanoparticles could be developed to catalyze damage to mycobacteria.240 These molecules 
are either activated by light, pH or in a magnetic field. In photodynamic therapy ROS are 
generated by photosensitizers when excited by light.348,349 Formation of singlet oxygen species, 
for example, can result in oxidation and thereby inactivation of essential biomolecules followed 
by cell death. These destructing oxygen species have an incredibly short life span in water,350 
with the result that toxicity is localized and targeted bacteria would be killed with high 
selectivity. Several porphyrin-based photosensitizers are clinically approved in cancer 
therapy348,349 and were already applied for treatment of bacterial infections.351–353 Although 
glycosylated photosensitizers hold a great potential for MOE-based therapy and excitation with 
light is feasible within the lung,348 Mtb might be able to survive this treatment. Pathogenic 
mycobacteria utilize a wide range of mechanisms to defend against ROS and RNS using 
enzymes like catalase and superoxide dismutase (SOD) or the NO detoxifying truncated 
hemoglobin (trHbN). However, the Misra group showed that inhalable microparticles, which 
contain the three nitric oxide donors isosorbide mononitrate (ISMN), sodium nitroprusside 
(SNP) and diethylenetriamine nitric oxide (DETA/NO), significantly reduced Mtb colony forming 
units (cfu) by up to 4-log within a mouse lung.354,355 Carbohydrates could be easily 
functionalized with the small DETA/NO molecule via peptide coupling or thiourea formation. 
After cell envelope incorporation NO would then spontaneously dissociate activated by pH 
reduction (pH < 6). Alternatively, carbohydrates could also be connected to microparticles, 
which might be activated by light or in a magnetic field to dissipate heat. Localized thermal 
changes can disturb biochemical processes and induce cellular lysis.356 First successful 
applications were shown by R. S. Norman et al. using antibody-conjugated gold nanorods to 
trigger targeted photothermal lysis of Gram-negative Pseudomonas aeruginosa.357 Beside 
gold nanoparticels incorporation of magnetic nanostructures could be of interest to induce 
thermal lysis after positioning in a magnetic field.356 Carbohydrate functionalized magnetic 
beads could be used not only for Mtb therapy, but also for mycobacteria detection via magnetic 
resonance tomography (MRT).                                                                                      
Taken together, MOE opens up the possibility to develop novel, specific and local diagnostic 
and therapeutic tools, which might completely change Mtb therapy in future. 
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3.5 Concluding remarks 
In the current study azido pentoses, especially 5AraAz (40), were identified as new molecules 
to efficiently label Mycobacterium tuberculosis. This metabolic strategy verified the presence 
of D-arabinose and D-ribose transporters in the Mtb cell envelope and disclosed putative novel 
biosynthetic pathways for arabinose derivatives. Moreover, the azido sugars 38, 39 and 40 
represent a new tool to identify these widely unknown uptake and metabolic mechanisms in 
further detail. Beside biochemical applications, the new azido derivatives 38, 39 and 40 served 
as powerful reagents to fluorescently label different Mtb clinical isolates without any time 
consuming genetic modifications. Neither mycobacterial growth nor the typical virulence 
characteristics of the pathogen were influenced by this carbohydrate-based strategy. Thus, 
metabolic labeled Mtb strains can be perfectly applied for infection studies. Absence of 
metabolic labeling of epithelial cells and low cytotoxicity indicate that the azido pentoses 38, 
39 and 40 might even be used to target Mtb bacteria within host cells. Furthermore, these new 
molecules form the basis for a potential investigation of targeted antibiotic transport or anti-
Mtb radiotherapy. Two examples of the huge amount of new potential antibacterial or 
diagnostic strategies that might prospectively be developed based on MOE. 
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3.6 Materials and methods 
Reagents, buffer and media, which are listed in part 1 of this thesis, are excluded in the 
following register. 
3.6.1 Reagents 
 
N-Acetylcysteamine Sigma-Aldrich, St. Louis, USA 
Allyl bromide  Sigma-Aldrich, St. Louis, USA 
Ammonia solution (25%) Merck KGaA, Darmstadt, Germany 
Ammonium persulfate Sigma-Aldrich, St. Louis, USA 
Azobisisobutyronitrile (AIBN) Sigma-Aldrich, St. Louis, USA 
Bovine serum albumin (BSA) AppliChem GmbH, Darmstadt, Germany 
Bromophenol blue Sigma-Aldrich, St. Louis, USA 
Calcein AM Sigma-Aldrich, St. Louis, USA 
Chloromethyl methyl ether (MOMCl) Sigma-Aldrich, St. Louis, USA 
Click-IT Alexa Fluor 488 DIBO Alkyne (DIBO-Alexa 488) Thermo Fisher Scientific, Waltham, USA 
Click-IT Alexa Fluor 647 DIBO Alkyne (DIBO-Alexa 647) Thermo Fisher Scientific, Waltham, USA 
Click-IT Biotin DIBO Alkyne (DIBO-Biotin) Thermo Fisher Scientific, Waltham, USA 
Coomassie Brilliant Blue R-250 Thermo Fisher Scientific, Waltham, USA 
Cysteamine hydrochloride Sigma-Aldrich, St. Louis, USA 
4’,6-Diamidino-2-phenylindole (DAPI) Roche Diagnostics, Rotkreuz, Switzerland 
N,N-Diisopropylethylamine (DIPEA) Sigma-Aldrich, St. Louis, USA 
2,2-Dimethoxy-2-phenylacetophenone (DPAP) TOKYO CHEMICAL INDUSTRY CO., Tokyo, 
Japan 
2,2-Dimethoxypropane Sigma-Aldrich, St. Louis, USA 
Di-tert-butyl dicarbonate Sigma-Aldrich, St. Louis, USA 
Dulbecco’s phosphate-buffered saline Thermo Fisher Scientific, Waltham, USA 
Ethidium homodimer Thermo Fisher Scientific, Waltham, USA 
Fetal calf serum (FCS) Merck KGaA, Darmstadt, Germany 
GlutaMAX Thermo Fisher Scientific, Waltham, USA 
Hank’s balanced salt solution (HBSS) Merck KGaA, Darmstadt, Germany 
Human epidermal growth factor (hEGF) Thermo Fisher Scientific, Waltham, USA 
Hydrocortisone Sigma-Aldrich, St. Louis, USA 
Isopropanol Merck KGaA, Darmstadt, Germany 
MCDB-131 medium Thermo Fisher Scientific, Waltham, USA 
Macrophage colony stimulating factor (M-CSF) R&D Systems Inc., Minnneapolis, USA 
Mercaptoethanol Sigma-Aldrich, St. Louis, USA 
Normal goat serum (NGS) Merck KGaA, Darmstadt, Germany 
Pancoll, human PAN-Biotech GmbH, Aidenbach, Germany 
Paraformaldehyde (PFA) Merck KGaA, Darmstadt, Germany 
Penicillin/streptomycin Merck KGaA, Darmstadt, Germany 
Periodic acid Sigma-Aldrich, St. Louis, USA 
Phenol Sigma-Aldrich, St. Louis, USA 
ProLong Gold antifade Reagent Thermo Fisher Scientific, Waltham, USA 
Roti-Immunoblock Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Labeling of Mtb 
Materials and methods 
128 
 
RPMI 1640 (without L-glutamine) GE Healthcare, Little Chalfont, UK 
Silver nitrate Sigma-Aldrich, St. Louis, USA 
Sodium citrate Sigma-Aldrich, St. Louis, USA 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich, St. Louis, USA 
Sodium hydride Sigma-Aldrich, St. Louis, USA 
Sodium hydroxide  Sigma-Aldrich, St. Louis, USA 
Sodium iodine Sigma-Aldrich, St. Louis, USA 
Sodium metabisulfite Sigma-Aldrich, St. Louis, USA 
Sodium nitrite Sigma-Aldrich, St. Louis, USA 
Streptavidin-horseradish peroxidase (HRP) Thermo Fisher Scientific, Waltham, USA 
Sulfuric acid Sigma-Aldrich, St. Louis, USA 
tert-Butyldiphenylsilyl chloride (TBDPSCl) Sigma-Aldrich, St. Louis, USA 
N,N,N′,N′-Tetramethylethylenediamine (TEMED) Thermo Fisher Scientific, Waltham, USA 
Tetra-N-butylammonium fluoride solution in THF (1 M) Sigma-Aldrich, St. Louis, USA 
p-Toluenesulfonic acid (p-TsOH) Sigma-Aldrich, St. Louis, USA 
Trifluoroacetic acid (TFA) Sigma-Aldrich, St. Louis, USA 
Trifluoromethanesulfonic anhydride (Tf2O) Sigma-Aldrich, St. Louis, USA 
Triton X-100 Sigma-Aldrich, St. Louis, USA 
 
3.6.2 Buffer and media 
pH-Values were adjusted with aqueous HCl (100 mM) or NaOH (100 mM) solutions, respectively, unless otherwise 
described. All buffer and media were autoclaved prior use. 
 
APS solution (10%)  Ammonium persulfate (100 mg, 438 µmol) was 
dissolved in double dist. water (1.00 ml). 
 
Blocking buffer (blot) Skim milk powder (5.00 g) was suspended in T-TBS 
(100 ml). 
 
Blocking buffer (fluorescence microscopy) NGS (100 µl) and Triton X-100 (10.0 µl, 16.5 µmol) 
were added to PBS (10.0 ml). 
 
Coomassie solution Coomassie Brilliant Blue R-250 (50.0 mg, 60.5 µmol) 
was dissolved in methanol (11.5 ml) and 
supplemented with double dist. water (11.5 ml) and 
glacial acetic acid (2.50 ml). The solution was filtered 
before use. 
 
Destaining solution (Coomassie staining) Isopropanol (4.50 ml) and glacial acetic acid 
(2.00 ml) were added to double dist. water (18.5 ml). 
 
Fixative/destaining solution (PAS) Methanol (17.5 ml) and acetic acid (5.00 ml) were 
added to double dist. water (27.5 ml). 
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Fixative/destaining solution (silver staining) Ethanol (20.0 ml) and acetic acid (2.50 ml) were 
added to double dist. water (27.5 ml). 
Human macrophage medium (HMM, culturing) RPMI 1640 (450 ml) was supplemented with FCS 
(50.0 ml) and L-glutamine (292 mg, 2.00 mmol) 
 
Human monocyte medium (HMM, differentiation) RPMI 1640 (435 ml) was supplemented with 
L-glutamine (292 mg, 2.00 mmol), M-CSF (1 µg), 
human serum (10.0 ml) and penicillin/streptomycin 
(10000 U/ml / 10000 µg/ml, 5.00 ml) 
 
2 x Lysis buffer , pH 6.8  Tris (15.1 mg, 125 µmol) and SDS (40.0 mg, 
139 µmol) were dissolved in double dist. water 
(800 µl). The Solution was supplemented with 
glycerol (200 µl, 2.74 mmol) and the pH  was 
adjusted. Mercaptoethanol (4.0 µl, 56.8 µmol) was 
added. 
 
MDCB-131 medium MDCB-131 (445 ml) was supplemented with 
GlutaMAX (5.00 ml), FCS (50.0 ml), hEGF (5 µg) 
and hydrocortisone (500 µg). 
 
PFA solution, pH 7.2 (4%) PFA (4.00 g) was suspended in PBS (100 ml) and 
concentrated sodium hydroxide solution (few drops) 
was added. The mixture was heated in order to 
dissolve PFA. Subsequently the pH was adjusted.   
 
PBSB  BSA (250 mg) was dissolved in PBS (50.0 ml) 
 
Periodic acid solution  Periodic acid (175 mg, 768 µmol) was dissolved in 
acetic acid (5%, 25.0 ml). 
 
Reaction buffer  NGS (10.0 µl) and Triton X-100 (10.0 µl, 16.5 µmol) 
were added to PBS (10.0 ml). 
 
Running buffer, pH 8.3  Tris (3.03 g, 25.0 mmol), SDS (1.00 g, 3.47 mmol) 
and glycine (14.4 g, 192 mmol) were dissolved in 
double dist. water (1.00 l). pH was adjusted.  
 
SDS solution (10%) SDS (1.00 g) was dissolved in double dist. water 
(10.0 ml). 
 
Silver nitrate solution  Silver nitrate (500 mg, 2.94 mmol) was dissolved in 
double dist. water (73.5 ml) and sodium hydroxide 
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solution (1 M, 1.40 ml) and ammonia solution (25%, 
1.00 ml) were added. 
Sodium citrate solution  Sodium citrate (1.25 mg, 5.84 mmol) was dissolved 
in double dist. water (25.0 ml) and formaldehyde 
(37%, 12.5 µl, 120 µmol) was added. 
 
Sodium metabisulfite solution  Sodium metabisulfite (50.0 mg, 263 µmol) was 
dissolved in acetic acid (5%, 25.0 ml). 
 
Sodium periodate solution  Sodium periodate (17.5 mg, 81.8 µmol) was 
dissolved in double dist. water (25.0 ml). 
 
TBS, pH 8.0  (blot) Tris (1.21 g, 10.0 mmol) and sodium chloride 
(8.76 g, 150 mmol) were dissolved in 
double dist. water (1.00 l) with subsequent pH 
adjustment. 
 
Transfer buffer, pH 8.3 (blot) Tris (3.03 g, 25.0 mmol), SDS (200 mg, 693 µmol) 
and glycine (14.4 g, 192 mmol) were dissolved in 
double dist. water (800 ml) and the pH was adjusted. 
Methanol (200 ml) was added.  
 
Tris/HCl solution, pH 6.8 (0.5 M) (SDS-PAGE) Tris (6.05 g, 50.0 mmol) was dissolve in double dist. 
water (100 ml) with subsequent pH adjustment. 
 
Tris/HCl solution, pH 8.8 (1.5 M) (SDS-PAGE) Tris (18.2 g, 150 mmol) was dissolve in double dist. 
water (100 ml) with subsequent pH adjustment. 
 
T-TBS (blot) Tween 20 (1.00 ml, 896 µmol) was added to TBS 
(1.00 l) 
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3.6.3 Biological assays  
Mtb strains used in this study                   
Clinical isolates (Table 6) were initially cultured from clinical samples on Löwenstein/Jensen 
medium at the National Reference Center for Mycobacteria in Borstel, Germany. Further 
characterization by genotyping methods and susceptibility testing are described elsewhere.358  
All strains (Table 6 and 7) were grown in Middlebrook 7H9 medium containing oleic acid-
albumin-dextrose-catalase (OADC, 10%), Tween 80 (0.05%) and glycerol (0.2%). At mid-log 
phase (OD600 = 0.4) cultures were harvested and frozen at -80°C as described previously.288  
Table 6. Clinical strains used in this study.  
Sample name Species Superlineage Lineage 
1934/03358 Mtb Clade I Beijing 
2336/02358 Mtb Clade I/Euro-American Haarlem 
1797/03358 Mtb Clade II EAI 
 
Table 7. Laboratory strains used in this study.  
Sample name Description Source 
GFP-expressing Mtb 
H37Rv  
In order to obtain stable GFP expression in Mtb 
H37Rv, codon usage, fluorescence and folding 
optimized gfpm2+ from pMN437234 was cloned into 
the integrative mycobacterial plasmid pMV306235 
giving pSvM4 which was used to transform Mtb 
H37Rv (ATCC 27294). 
Plasmid (pMN437)234 
kindly provided by 
Prof. Dr. M. Niederweis, 
University of Alabama at 
Birmingham, USA 
mCherry-expressing Mtb 
(Cherry 10)359  
Strain carrying a mCherry-expressing plasmid 
(pCherry10),360 derived from H37Rv (ATCC 25618) 
Prof. Dr. U. E. Schaible, 
Research Center Borstel, 
Germany 
  
Bacterial culture conditions               
All bacterial cultures used were derived from frozen stocks (2.5∙108 bacteria/ml). Homogenous 
bacterial suspensions were prepared in 7H9 medium (50.0 ml) supplemented with 
OADC (10%), Tween 80 (0.05%) and glycerol (0.2%). 25.0 ml each were incubated in 30 ml 
square medium bottles (Nalgene) at 37°C without shaking (preculture). Growth (~ 3 d) to 
mid-log phase was monitored by measuring the optical density at 600 nm (OD600 = 0.4) 
(Bio-Tek Synergy).  
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Labeling of Mtb bacteria                       
Precultured bacteria (5.00 ml/batch) were mixed with the azido sugars 28, 38, 39 and 40, 
respectively, in the desired concentration and cultured 3 d at 37°C without shaking. The 
samples (2.00 ml each) were washed twice with PBSB (1.00 ml). Subsequently, bacteria were 
incubated with DIBO-Alexa 488 (1:250 dilution of 1 mM stock solution in DMSO into PBSB, 
1.00 ml) in the dark for 1 h at 37°C gently shaking. The samples were washed (one time PBSB, 
one time PBS, 1.00 ml each) and fixed with PFA (4%, 1.00 ml) in the dark for 1 h at rt without 
shaking. After centrifugation (3629 x g, 10 min, 4°C) the pellet was suspended in PBS (400 µl) 
and fluorescence intensity was analyzed on a FacsCantoII flow cytometer (BD Biosciences) 
using the 488 nm and 633 nm laser, respectively. The analysis was performed using the 
FCSExpress4 program (DeNovo Software).  
Labeling stability                   
Bioorthogonal labeling was performed with 5AraAz (40) as described in method “Labeling of 
Mtb bacteria”. Before fixation bacteria were re-cultured (7H9 medium (50.0 ml) supplemented 
with OADC (10%), Tween 80 (0.05%) and glycerol (0.2%), 1.125 ml/batch) for desired time 
points (1 h, 2 h, 5 h, 18 h) at 4°C or 37°C. The samples (1.00 ml each) were centrifuged 
(3629 x g, 4°C, 10 min) and fixed with PFA (4%, 1.00 ml) in the dark for 1 h at rt without 
shaking. After centrifugation (3629 x g, 10 min, 4°C) the pellet was suspended in PBS (400 µl) 
and fluorescence intensity was analyzed on a FacsCantoII flow cytometer (BD Biosciences) 
using the 488 nm laser. The analysis was performed using the FCSExpress4 program 
(DeNovo Software). 
Microscopic analysis of 5AraAz (40)-labeled Cherry 10               
Bioorthogonal labeling of Mtb Cherry 10 bacteria was performed with 5AraAz (40, 5 mM) as 
described in method “Labeling of Mtb bacteria”. Labeled (with 5AraAz (40)) and unlabeled 
(without 5AraAz (40)) mycobacteria were not fixed in PFA (4%) as described before, instead 
were re-suspended in PFA (1% in PBS; 1.00 ml), transferred to µ-slides (µ-slide VI, ibidi; 
100 µl/channel) and incubated overnight at 4°C. The slides were washed three times with PBS 
(100 µl/channel) and mounted with ProLong Gold Antifade Reagent. Bacteria were analyzed 
by use of an Axio Observed microscope, equipped with an ApoTome and the AxioVision 
Software 4.8 (Carl Zeiss AG). Used excitation and emission filters: for Alexa 488 (excitation: 
BP 470/40 nm, emission: BP 525/50 nm) and for mCherry (excitation: BP 565/30 nm, 
emission: BP 620/60 nm). 
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Mtb growth analysis288                                
GFP-expressing Mtb H37Rv bacteria (1∙106 bacteria) were cultured in 7H9 medium 
(supplemented with OADC (10%), Tween 80 (0.05%) and glycerol (0.2%)) and mixed with the 
azido sugars 28, 38, 39 and 40, respectively, in different concentrations (total volume 100 µl). 
The experiments were performed in black 96-well plates with a clear bottom (Corning Inc) 
sealed with an air-permeable membrane (Porvair Sciences). Growth was measured as relative 
light units at 528 nm after excitation at 485 nm in a fluorescence microplate reader (Synergy 
2, Biotek) at different time points. 
Glycolipid and lipoglycan isolation289                      
Precultured Mtb H37Rv bacteria (300 ml) were mixed with 5AraAz (40, final concentration: 
1 mM) and incubated 3 d at 37°C without shaking. Bacteria were washed twice with PBS 
(30.0 ml each) and suspended in PBS (300 ml). The suspension was autoclaved and the 
solvent was reduced in vacuo to 15.0 ml. The residue was lyophilized, re-suspended in PBS 
(15.0 ml) supplemented with Triton X-100 (0.5%) and sonicated. Bacteria were disrupted by 
three passages through a cell disruption system (40.000 psi; 1psi = 6.89 kPa) (Constant 
Systems Ltd) and centrifuged (17000 x g, 60 min, 4°C). The supernatant was precipitated with 
cold acetone (135 ml) over night at -20°C, centrifuged (3500 x g, 20 min, 4°C) and the obtained 
sediment was washed twice with acetone (30.0 ml each) and dried under a stream of nitrogen. 
The residue was dissolved in dist. water and lyophilized. The lyophilisate was dissolved in 
dist. water (36.0 ml) supplemented with Triton X-114 (10%) and stirred 1 h at rt. Phase 
separation was obtained after 2 h at 37°C and centrifugation (3500 x g, 30 min, 30°C). 
Triton X-114 (1.4 ml) was added to the aqueous layer and the solution was stirred overnight at 
rt. Phase separation was obtained after 2 h at 37°C and centrifugation (3500 x g, 20 min, 
30°C). The two Triton X layers were precipitated with cold acetone (150 ml) for 2 d at -20°C 
and centrifuged (12000 x g, 30 min, 4°C). The combined sediments were washed twice with 
acetone (15.0 ml each) and dried under a stream of nitrogen. The residue was dissolved in 
dist. water and lyophilized. The lyophilisate was dissolved in dist. water (8.00 ml), mixed with 
aqueous phenol (80% w/v phenol/PBS, 8.00 ml) and stirred 25 min at 80°C. Phase separation 
was obtained after 20 min on ice and centrifugation (3500 x g, 60 min, 4°C). The extraction 
was repeated. To remove phenol and low-molecular mass components the aqueous layer was 
dialyzed against dist. water using 3500 MWCO membrane (di = 29 mm) (Spectrum 
Laboratories, 1 d, rt and 1 d, 4°C) and lyophilized. The residue was dissolved in dist. water 
(5.00 ml), precipitated with cold acetone (60.0 ml) for 1 d at -20°C and centrifuged (12000 x g, 
30 min, 4°C). The sediment was lyophilized and re-suspended in dist. water (1.00 ml) resulting 
in the desired isolated glycolipid fraction A (concentration: 2.00 mg/ml).  
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Analysis of the glycolipid and lipoglycan fractions       
Glycolipids and lipoglycans were denaturated and separated by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE). SDS-gels were directly used for Periodic 
acid-Schiff reaction (PAS), silver or coomassie staining. 
SDS-PAGE 
For the SDS-PAGE (Figure 55) a SDS polyacrylamide gel was used composed of a stacking 
gel and a separating gel. The stacking gel with a larger pore size allows the loaded samples 
to be concentrated into a tight band during electrophoresis before entering the resolving portion 
of the gel. 
Table 8. Ingredients of the solutions for the stacking gel and the separating gel. 
Buffer and reagents Stacking gel Separating gel 
5% 15% 17% 
Double dist. water 6.15 ml 6.02 ml 5.175 ml 
Tris/HCl solution, pH 6.8 (0.5 M) 2.50 ml   
Tris/HCl solution, pH 8.8 (1.5 M)  4.25 ml 4.25 ml 
Acrylamide 1.25 ml 6.38 ml 7.225 ml 
SDS solution (10%) 100 µl 170 µl 170 µl 
TEMED 10.0 µl 20.0 µl 20.0 µl 
APS solution (10%) 50.0 µl 100 µl 100 µl 
 
The separating gel solution (7.50 ml) was pipetted into the gap between the glass plates of the 
casting frame (BioRad) and overlaid with ethanol, which led to a straight edge of the gel. The 
gel polymerized within 30 min. Ethanol was removed and the stacking gel solution (4.00 ml) 
was pipetted on top of the polymerized separating gel. A comb was inserted resulting in gel 
pockets in the stacking gel. The stacking gel polymerized within 30 to 45 min. The polymerized 
gel was mounted to the gel electrophoresis chamber (Mini-Protean IV, BioRad), running buffer 
was added, the comb removed and the samples of the cell envelope preparation (20.0 µl each) 
and a protein standard (low range marker (LRM), 14.4 97.4 kDa, BioRad or ColoPlus 
Prestained Protein Marker, broad range 7 175 kDa, New England Biolabs) or α-1-acid-
glycoprotein (Sigma Aldrich)) as a marker (5.0 µl) loaded into the gel pockets. Prior to gel 
electrophoresis the samples were supplemented with the same amount of 2 x lysis buffer and 
incubated for 15 min at 95°C. Thus, the compounds were denaturated and coated with SDS. 
These negative charged and linearized molecules were separated by size in the electric field 
during gel electrophoresis (20 min, 70 V and 1 h, 180 V). 
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Figure 55. Illustration of an SDS-PAGE. 
Denaturated and SDS-coated compounds were 
loaded into the gel pockets of the stacking gel. These 
negative charged and linearized molecules were 
separated by size in the electric field during gel 
electrophoresis. 
Periodic acid-Schiff reaction (PAS)361               
The SDS-gel was incubated in fixative/destaining solution (20.0 ml) for 2 h at rt under gentle 
agitation. Fixative was removed and carbohydrates were oxidized by addition of periodic acid 
solution (20.0 ml) for 1 h at rt under gentle agitation. Oxidized gel was washed five times with 
double dist. water (1 min each, 20.0 ml each) and sodium metabisulfite solution (20.0 ml) was 
added. The gel turned from colorless to yellow and back to colorless. Sodium metabisulfite 
solution was replaced by Schiff reagent (20.0 ml, Microscopy PAS Kit, Merck) and gel was 
incubated for 2 h at 4°C under gentle agitation. The gel was placed into fixative/destaining 
solution (20.0 ml) overnight at 4°C under gentle agitation. The gel was washed (two times 
fixative/destaining solution, 30 min each, 20.0 ml each; two times dist. water, 10 min each, 
20.0 ml each) and scanned. 
Silver staining362                  
The SDS-gel was incubated in fixative (20.0 ml) for 1 h at rt under gentle agitation. After 
washing with double dist. water carbohydrates were oxidized by addition of sodium periodate 
solution (20.0 ml) for 10 min at rt under gentle agitation. Oxidized gel was washed four times 
with double dist. water (5 min each, 20.0 min each), silver nitrate solution (20.0 ml) was added 
and gel incubated for 10 min at rt under gentle agitation. The gel was washed four times with 
double dist. water (5 min each, 20.0 ml each) and developed by sodium citrate solution 
(20.0 ml) for 5 min. Sodium citrate solution was replaced by acetic acid (7%, 20.0 ml) and gel 
incubated 30 min at rt under gentle agitation. The gel was stored in dist. water and scanned.   
Coomassie                  
SDS-gel was incubated in coomassie solution (20.0 ml) for 1 h at rt under gentle agitation. 
After washing with double dist. water gel was placed into destaining solution (20.0 ml) and 
finally scanned.  
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Azide detection in isolated glycolipid/lipoglycan fractions  
Glycolipid/lipoglycan isolate A (2.00 mg/ml; 10.0 µl), prepared from 5AraAz (40)-labeled 
Mtb H37Rv bacterial cultures, and glycolipid/lipoglycan isolate B (5.00 mg/ml; 1.5 µl) prepared 
from unlabeled Mtb H37Rv bacterial cultures, (used concentrations based on previous PAS 
staining) were mixed with DIBO-biotin (1:6 dilution of 25 µM stock solution in DMSO into water, 
final volume 12.0 µl) and incubated 1.5 h at rt and 100 rpm. Reaction mixtures were treated 
with 2 x lysis buffer (12.0 µl) for 15 min at 95°C. The samples (20.0 µl/slot) were separated by 
15% SDS-PAGE as described before with protein standards (ColoPlus Prestained Protein 
Marker, broad range 7-175 kDa, New England Biolabs) as a marker. The SDS-Gel was stored 
in TBS overnight at 4°C. Glycolipids/lipoglycans were transferred to a polyvinylidene fluoride 
(PVDF) membrane (Millipore) at 75 V for 85 min using a wet blot system (Mini Protean II, 
BioRad) under ice cooling. The membrane was blocked in milk (5%) in T-TBS (TBS, Tween 
20 (0.1%)) for 1 h at rt, washed three times in T-TBS (10 min each) and incubated with 
streptavidin-horseradish peroxidase (HRP, 1:6000 dilution of 1.00 mg/ml stock solution in 
dist. water into Roti-Immunoblock (Carl Roth, 10% in T-TBS, 12.0 ml)) for 1 h, at rt and under 
gentle agitation. After three washing steps with T-TBS (10 min each) the blot was developed 
using Amersham ECL Western blotting Detection Reagent (GE Haelthcare, 1.00 ml) and 
Amersham Hyperfilm ECL (GE Healthcare) and analyzed with the X-Omat M35 film processor 
(Kodak). 
Eukaryotic cells used in this study 
For metabolic labeling experiments and cytotoxicity analysis a human epithelial cell line 
(human mammary epithelial cells, HMEC-1, Centers for Disease Control and Prevention 
(CDC)) was used. Infection studies and immunofluorescence analysis were carried out with 
human monocyte-derived macrophages (hMDMs) isolated from venous blood of healthy 
volunteers at the Research Center Borstel, Germany.     
Cell culture conditions HMEC-1                                                                            
HMEC-1 cells were cultured in MDCB-131 medium containg GlutaMAX (1%), fetal bovine 
serum (FCS, 10%), human epidermal growth factor (hEGF, 10 ng/ml) and hydrocortisone 
(1 µg/ml). Cells were kept at 37°C in a 5% humidified CO2-atmosphere. 
Isolation, differentiation and cultivation of hMDMs46    
Ethics statement                           
Experiments with hMDMs were approved by the Ethics Committee of the University of Lübeck, 
Lübeck, Germany (14-032, March 2014). 
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Mononuclear cells were isolated from peripheral blood mononuclear cells (PBMC) of healthy 
volunteers by density gradient centrifugation. Heparinized peripheral blood was collected and 
diluted in PBS (1:1), slowly transferred on top of a polysucrose solution (Pancoll, 10.0 ml) and 
centrifuged in a swing bucket rotor (403 x g, 40 min, rt; without break). The upper layer was 
discarded and the interface transferred to a new 50 ml tube. Cells were washed with PBS 
(50.0 ml) and re-suspended in Hank's Balanced Salt Solution (HBSS) containing 0.1% BSA. 
Cell numbers were adjusted (5∙106 cells/ml) using a cell counter (Casy2, Schärfe System). 
Isolated PBMCs, containing lymphocytes, monocytes and thrombocytes, were separated by 
counterflow elutriation using a centrifuge equipped with an elutriation rotor (JE-5-B rotor, 
Beckman), tubing systems and a peristaltic pump (RTC) (purity consistently greater than 92%). 
Prior to elutration, the rotor was disinfected with ethanol (70%), washed twice with dH2O and 
equilibrated (BSA (0.1%) in HBSS). PBMCs were loaded and separated under centrifugation 
by stepwise increase of the flow rate (24 up to 44 ml/min, Table 9). Received fractions were 
analyzed with a cell counter (Casy2, Schärfe System). Isolated monocytes were centrifuged 
(258 x g, 10 min, 4°C) and cell density was adjusted to 2∙107 cells/ml by addition of RPMI 1640 
containing human serum (2%) and recombinant human macrophage colony-stimulating factor 
(M-CSF, 10 ng/ml). For differentiation of monocytes into macrophage, cells were seeded into 
teflon-coated cell culture bags (VueLifeTM 72, Celgenix) and incubated for 7 d at 37°C in a 5% 
humidified CO2-atmosphere.  To detach macrophages, cell culture bags were placed on ice for 
1 h and subsequently pulled over the edge of a bench. Cells were counted in a counting 
chamber (Neubauer, Brand) using tryptan blue vital staining.  
Table 9. Elutriation protocol. 
Flow rate (ml/min) Volume (ml) Fraction 
24 200 Loading of PBMC 
26 50 Thrombocytes 
28 50 Washing 
30 50 Small lymphocytes 
32 50 Lymphocytes 
33 50 Lymphocytes 
34 50 Lymphocytes 
35 50 Lymphocytes 
36 50 Large lymphocytes 
37 50 Washing 
38 50 Washing 
39 50 Washing 
40 50 Washing 
41 50 Washing 
42 50 Washing 
43 50 Monocytes 
44 (stop) 50 Pure Monocytes 
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For infection studies macrophages (2∙105 cells/chamber) were seeded on chamber slides (Lab 
Tek II, 8 well, Thermo Fischer Scientific) and allowed to attach for 2 h at 37°C in a 5% 
humidified CO2-atmosphere. 
Infection of hMDMs and immunofluorescence analysis              
Bioorthogonal labeling of Mtb Cherry 10 bacteria was performed with 5AraAz (40, 5 mM) as 
described in method “Labeling of Mtb bacteria” (bacteria were not fixed with PFA). 
hMDMs were infected with Cherry 10 (5AraAz (40)-labeled or unlabeled) with a multiplicity of 
infection (MOI) of 10 for 3 h. Subsequently cells were washed twice with PBS (500 µl/chamber) 
and fixed with PFA (1%, 300 µl/chamber) at 4°C overnight. After washing with PBS 
(500 µl/chamber), cells were permeabilized with Triton X in PBS (0.1%, 300 µl/chamber) for 
10 min at rt. Cells were washed with PBS (500 µl/chamber) three times and blocked with 
blocking buffer (300 µl/chamber) for 1 h at rt. To visualize lysosomal-associated membrane 
protein 1 (LAMP-1) or ras-related protein (Rab5) slides were partly incubated with anti-LAMP-1 
IgG mouse antibody (Abcam, 1:100 in reaction buffer, 100 µl/chamber) or anti-Rab5 polyclonal 
rabbit IgG antibody (Santa Cruz Biotechnology, 200 µg/ml, 1:100 in reaction buffer, 100 
µl/chamber) for 1 h at rt. After three washing steps with PBS (500 µl/chamber) the secondary 
antibody, Cy5-conjugated anti-mouse IgG antibody (Jackson, ImmunoResearch, 1:200 in 
reaction buffer, 100 µl/chamber)) and DyLight 680-conjugated goat anti-rabbit IgG antibody 
(Thermo Scientific, 1 mg/ml, 1:200 in reaction buffer, 100 µl/chamber), respectively, was 
added and slides incubated 1.5 h at rt. Cells were washed three times with PBS 
(500 µl/chamber) and once with dist. water (500 µl/chamber). Nuclei were stained with 
4',6-diamidino-2-phenylindole (DAPI, Roche Diagnostics; 1:2000 dist. water, 100 µl/well) 
10 min at rt. Slides were washed twice with dist. water (500 µl/chamber) and mounted with 
ProLong Gold Antifade Reagent, covered with glass coverslips (R. Langenbrink) and analyzed 
by use of an Axio Observed microscope, equipped with an ApoTome and the AxioVision 
Software 4.8 (Carl Zeiss AG). Used excitation and emission filters: for DAPI 
(excitation: 365 nm, emission: BP 445/50 nm), for Alexa 488 (excitation: BP 470/40 nm, 
emission: BP 525/50 nm), for mCherry (excitation: BP 565/30 nm, emission: BP 620/60 nm) 
and for Cy5 (excitation: BP 640/30 nm, emission: BP 690/50 nm). 
Metabolic labeling of eukaryotic cells                   
HMEC-1 cells were seeded in collagen coated LabTek I 8-well slides (Nunc) with a density of 
0.75∙104. After 6 h cell medium was supplemented with azido sugar (Ac5AraAz (51), 
Ac3AraAz (52), Ac3RiboAz (53), Ac6TreAz (27), 5AraAz (40), 3AraAz (38), 3RiboAz (39) or 
6TreAz (28); dissolved in DMSO (acetylated sugars) or dist. water (non-acetylated sugars)) to 
a final sugar concentration of 5 mM in the growth medium. Acetylated N-azidoacetyl-
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mannosamine (AcManNAz, 100 µM final concentration) was used as a positive control. After 
3 d of incubation at 37°C in a 5% humidified CO2-atmosphere, cells were washed three times 
with growth medium, stained for 15 min with DIBO-Alexa 647 (5 µM), and washed twice with 
growth medium. Cells were investigated by use of a Cell Observer SD microscope and the 
ZEN Software (Carl Zeiss AG).  
Cytotoxicity measurements                   
HMEC-1 cells were seeded in collagen coated LabTek II 8-well slides (Nunc) with a density of 
0.5∙104. After 6 h cell medium was supplemented with azido sugar (5AraAz (40), 3AraAz (38), 
3RiboAz (39) or 6TreAz (28)) in different concentrations (final sugar concentration: 10 µM, 
100 µM, 1 mM or 10 mM). After 2 d of incubation, the cells were washed three times with growth 
medium and treated with phosphate-buffered saline (PBS)+Ca2+/Mg2+ containing calcein AM 
(0.5 µM) and ethidium homodimer (3 µM). Upon excitation with 488 nm, the 515 nm 
fluorescence of calcein AM displays living cells whereas the 635 nm fluorescence of ethidium 
homodimer indicates dead cells. Confocal images were taken of more than 1000 cells per 
condition with a Cell Observer SD microscope and the ZEN Software (Carl Zeiss AG). After 
applying a threshold, the number of cells fluorescing in each channel was counted using the 
Objects Counter Plugin of ImageJ. The viability was defined as the number of living cells 
divided by the total number of cells.  
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3.6.4 Syntheses 
General methods for synthesis                  
(as described in part 1) 
3-Azido-3-deoxy-α,β-D-arabinose (38)                     
The arabinofuranose derivative 45 (400 mg, 1.86 mmol) was dissolved in DCM (30.0 ml), 
cooled with ice and supplemented with dist. water (4.00 ml) and trifluoroacetic acid (TFA, 
14.0 ml, 183 mmol, 100 eq.). The reaction mixture was stirred for 2 h and concentrated in 
vacuo. The crude product was chromatographed on silica gel 
(cyclohexane/ethyl acetate/methanol, 1:1:0.25) and lyophilized to give the product 38 
(318 mg, 1.82 mmol, 98%) as a colorless oil (α-pyranose: β-pyranose: furanose ratio = 7:5:1 
by integration of the 1H NMR spectrum). TLC (cyclohexane/ethyl acetate/methanol, 1:1:0.25): 
Rf = 0.2 and 0.15; rotation value:  [α]22𝐷  = - 74.6° (c = 0.24, MeOH);
 1H NMR (only resonances 
of α- and β-pyranose are listed, not the resonances of the minor furanose) (500 MHz, D2O, 
300 K): δ = 5.18 (d, 3J1,2 = 3.6 Hz, 1H, H-1 (β)), 4.51 (d, 3J1,2 = 7.5 Hz, 1H, H-1 (α)), 4.07-4.05 
(m, 1H, H-4(β)), 4.01 (ddd, 3J3,4 = 3.2 Hz, 3J4,5a = 2.0 Hz, 3J4,5b = 1.4 Hz, 1H, H-4 (α)), 3.98 (dd, 
3J4,5a = 1,3 Hz, 2J5a,5b = 12.9 Hz, 1H, H-5a (β)), 3.88 (dd, 3J1,2 = 3.6 Hz, 3J2,3 = 10.5 Hz, 1H, 
H-2 (β)), 3.84 (dd, 3J4,5a = 2.1 Hz, 2J5a,5b = 13.1 Hz, 1H, H-5a (α)), 3.73 (dd, 3J2,3 = 10.5 Hz, 
3J3,4 = 3.2 Hz, 1H, H-3 (β)), 3.64 (dd, 3J4,5b = 1.2 Hz, 2J5a,5b = 13.1 Hz, 1H, H-5b (α)), 3.57 (dd, 
3J1,2 = 7.4 Hz, 3J2,3 = 10.3 Hz, 1H, H-2 (α)), 3.56 (dd, 3J4,5b = 2.4 Hz, 2J5a,5b = 12.9 Hz, 1H, 
H-5b (β)), 3.50 (dd, 3J2,3 = 10.4 Hz, 3J3,4 = 3.2 Hz, 1H, H-3 (α)) ppm; 13C NMR (only 
resonances of α- and β-pyranose are listed, not the resonances of the minor furanose) 
(125 MHz, D2O, 300 K): δ = 96.8 (C-1 (α)), 92.1 (C-1 (β)), 70.4 (C-2 (α)), 67.7 (C-4 (β)), 67.5 
(C-4 (α)), 67.1 (C-2 (β), C-5 (α)), 64.7 (C-3 (α)), 62.4 (C-5 (β)), 61.2 (C-3 (β)) ppm; IR (ATR-
IR): Ṽ = 3335, 2927, 2104, 1674, 1305, 1251, 1134, 1060, 998, 945, 923, 870, 849, 785, 643, 
595, 570, 552; HRMS (ESI-MS): m/z = 198.0486, [M+Na]+ (calc. 198.0491 for C5H9N3O4+ Na). 
3-Azido-3-deoxy-α,β-D-ribose (39)            
The ribofuranose derivative 49 (300 mg, 1.39 mmol) was dissolved in DCM (30.0 ml), cooled 
with an ice bath and supplemented with TFA (12.0 ml, 157 mmol, 113 eq.) and dist. water 
(2.50 ml). The reaction mixture was stirred for 2 h and concentrated in vacuo. The crude 
product was chromatographed on silica gel (cyclohexane/ethyl acetate/methanol, 1:1:0.25) 
and lyophilized to give the product 39 (220 mg, 1.26 mmol, 91%) as a colorless oil 
(α-pyranose: β-pyranose: α-furanose: β-furanose ratio = 1.3:8:1:1.3 by integration of the 
1H NMR spectrum). TLC (cyclohexane/ethyl acetate/methanol, 1:1:0.25): Rf = 0.22 and 0.20; 
rotation value: [α]22
𝐷
 = - 6.00° (c = 0.4, MeOH); 1H NMR (only resonances of β-pyranose are 
listed, minor α-pyranose and furanose resonances are not shown) (500 MHz, D2O, 300 K): δ = 
4.85 (d, 3J1,2 = 7.1 Hz, 1H, H-1 (β)), 4.21 (ddd~dt, 3J2,3 = 3.3 Hz, 3J3,4 = 3.3 Hz, 4J3,5a = 1.0 Hz, 
Labeling of Mtb 
Materials and methods 
141 
 
1H, H-3 (β)), 4.07 (ddd, 3J3,4 = 3.4 Hz, 3J4,5a = 4.6 Hz, 3J4,5b = 9.4 Hz, 1H, H-4 (β)), 3.84 (ddd, 
4J3,5a = 1.0 Hz, 3J4,5a = 4.7 Hz, 2J5a,5b = 11.5 Hz, 1H, H-5a (β)) 3.57 (dd, 3J1,2 = 7.2 Hz, 
3J2,3 = 3.3 Hz, 1H, H-2 (β)), 3.65 (dd, 3J4,5b = 9.3 Hz, 2J5a,5b = 11.6 Hz, 1H, H-5b (β)) ppm; 
13C NMR (only resonances of β-pyranose are listed, minor α-pyranose and furanose 
resonances are not shown) (125 MHz, D2O, 300 K): δ = 93.6 (C-1), 70.2 (C-2), 66.3 (C-4), 64.6 
(C-3), 63.4 (C-5) ppm; IR (ATR-IR): Ṽ = 3342, 2927, 2103, 1674, 1422, 1262, 1203, 1081, 
1038, 991, 954, 915, 870, 802, 711, 611, 552; HRMS (ESI-MS): m/z = 198.0483, [M+Na]+ 
(calc. 198.0491 for C5H9N3O4+ Na). 
5-Azido-5-deoxy-α,β-D-arabinofuranose (40)286           
The reported synthesis286 was modified according to the following procedure: Triacetate 51 
(1.00 g, 3.32 mmol) was dissolved in dry methanol (10.0 ml). Sodium methoxide (a spatula tip) 
was added and the reaction mixture was stirred overnight at rt under a nitrogen atmosphere. 
After neutralization with Amberlite IR120 ion exchange resin and concentration in vacuo, the 
crude product was chromatographed on silica gel (cyclohexane/ethyl acetate/methanol, 
1:1:0.25) and lyophilized to give the product 40 (557 mg, 3.18 mmol, 96%) as a colorless oil 
(α:β ratio = 2:1 by integration of the 1H NMR spectrum). TLC 
(cyclohexane/ethyl acetate/methanol, 1:1:0.5): Rf = 0.44; 1H NMR (500 MHz, D2O, 300 K): δ = 
5.26 (dd, 3J1,2 = 3.2 Hz, 4J = 0.8 Hz, 1H, H-1 (β)), 5.22 (d, 3J1,2 = 2.8 Hz, 1H, H-1 (α)), 4.15 (dt, 
3J3,4 = 6.1 Hz, 3J4,5a = 3.5 Hz, 3J4,5b = 6.1 Hz, 1H, H-4 (α)), 4.07-4.03 (m, 2H, H-2 (β), H-3 (β)), 
3.99 (dd, 3J1,2 = 2.8 Hz, 3J2,3 = 4.7 Hz, 1H, H-2 (α)), 3.95 (dd, 3J2,3 = 4.7 Hz, 3J3,4 = 6.3 Hz, 1H, 
H-3 (α)), 3.86 (dt, 3J3,4 = 6.4 Hz, 3J4,5a = 3.6 Hz, 3J4,5b= 6.5 Hz, 1H, H-4 (β)), 3.62 (dd, 
3J4,5a = 3.5 Hz, 2J5a,5b = 13.5 Hz, 1H, H-5a (α)), 3.57 (dd, 3J4,5a = 3.5 Hz, 2J5a,5b = 13.5 Hz, 1H, 
H-5a (β)), 3.42 (dd, 3J4,5b = 5.9 Hz, 2J5a,5b = 13.6 Hz, 1H, H-5b (α)), 3.40 (dd, 3J4,5b = 6.5 Hz, 
2J5a,5b = 13.5 Hz, 1H, H-5b (β)) ppm.  
5-O-tert-Butyldiphenylsilyl-α,β-D-arabinofuranose (41)281                     
The reported synthesis281 was modified according to the following procedure: D-Arabinose 
(6.50 g, 43.3 mmol) was suspended in dry pyridine (50.0 ml). tert-Butyl-diphenylsilyl chloride 
(TBDPSCl, 11.0 ml, 42.3 mmol, 1 eq.) was added and the reaction was stirred overnight at rt 
under a nitrogen atmosphere. The reaction mixture was concentrated in vacuo. The crude 
product was chromatographed on silica gel (cyclohexane/ethyl acetate, 2:1) to give 
arabinofuranose 41 (11.8 g, 30.4 mmol, 70%) as a colorless oil (α:β ratio = 2:1 by integration 
of the 1H NMR spectrum). TLC (cyclohexane/ethyl acetate, 1:1): Rf = 0.36; 1H NMR (only 
resonances of α-anomer are listed) (500 MHz, CDCl3, 300 K, TMS): δ = 7.70-7.65 (m, 4H, aryl-
Hortho (α)), 7.47-7.38 (m, 6H, aryl-Hmeta, aryl-Hpara (α)),  5.43 (d~s, 1H, H-1 (α)), 4.27 (dd, 
3J1,2 = 3.9 Hz, 3J2,3 = 1.8 Hz, 1H, H-2 (α)), 4.22 (dd~s, 1H, H-3 (α)), 4.05 (ddd~s, 1 H, H-4 (α)), 
Labeling of Mtb 
Materials and methods 
142 
 
3.83 (dd, 3J4,5a = 2.5 Hz, 2J5a,5b = 11.4 Hz, 1H, H-5a (α)), 3.73 (dd, 3J4,5b = 1.7 Hz, 2J5a,5b = 11.5 
Hz, 1H, H-5b (α)), 1.05 (s, 9H, C(CH3)3 (α)) ppm. 
5-O-tert-Butyldiphenylsilyl-1,2-O-isopropylidene-β-D-arabinofuranose (42)281                 
The reported synthesis281 was modified according to the following procedure: The 
arabinofuranose derivative 41 (8.00 g, 20.6 mmol) was dissolved in dry acetone (50.0 ml) and 
supplemented with 2,2-dimethoxypropane (25.0 ml, 204 mmol, 10 eq.) and p-toluenesulfonic 
acid (p-TsOH, 350 mg, 2.03 mmol, 2 eq.). The reaction mixture was stirred for 3 h at rt under 
a nitrogen atmosphere. The reaction was cooled with ice and quenched by addition of dist. 
water. The resulting mixture was extracted with DCM. The combined organic layer was dried 
over MgSO4, filtered and concentrated in vacuo. The crude product was chromatographed on 
silica gel (cyclohexane/ethyl acetate, 4:1) to give 42 (7.77 g, 18.1 mmol, 87%) as a colorless 
oil. TLC (cyclohexane/ethyl acetate, 2:1): Rf = 0.23; 1H NMR (200 MHz, CDCl3, 300 K, TMS): 
δ = 7.70-7.64 (m, 4H, aryl-Hortho), 7.45-7.34 (m, 6H, aryl-Hmeta, aryl-Hpara), 5.88 (d, 
3J1,2 = 4.1 Hz, 1H, H-1), 4.55 (dd~d, 3J1,2 = 4.1 Hz, 1H, H-2), 4.43 (dd~d, 3J3,4 = 2.6 Hz, 1H, 
H-3), 4.05 (ddd~dt, 3J3,4 = 2.5 Hz, 3J4,5a = 6.7 Hz, 3J4,5b = 6.8 Hz, 1H, H-4), 3.90-3.80 (m, 2H, 
H-5a, H-5b), 1.81 (s, 1H, OH), 1.34, 1.29 (s each, 3H each, O2C(CH3)2), 1.07 (s, 9H, C(CH3)3) 
ppm.  
5-O-tert-Butyldiphenylsilyl-1,2-O-isopropylidene-β-D-lyxofuranose (43)282       
The reported synthesis282 was modified according to the following procedure: The 
arabinofuranose derivative 42 (5.00 g, 11.7 mmol) was dissolved in dry DCM (50.0 ml). The 
solution was cooled with an ice bath and supplemented with dry pyridine (3.00 ml, 37.2 mmol, 
3 eq.) and trifluoromethanesulfonic anhydride (Tf2O, 4.00 ml, 23.8 mmol, 2 eq.). The reaction 
mixture was stirred for 2 h under a nitrogen atmosphere. The reaction was quenched by 
addition of a saturated aqueous NaHCO3 solution and extracted with DCM. The combined 
organic layers were washed with dist. water, dried over MgSO4, filtered and concentrated in 
vacuo. The crude residue was dissolved in dry DMF (50.0 ml) and sodium nitrite (8.00 g, 
116 mmol, 10 eq.) was added. The reaction mixture was stirred overnight at 70°C under a 
nitrogen atmosphere. Diethyl ether was added and the organic layer was washed with brine 
and dist. water, dried over MgSO4, filtered and concentrated in vacuo. The crude product was 
chromatographed on silica gel (cyclohexane/ethyl acetate, 7:1 → 5:1) to give lyxofuranose 
derivative 43 (2.51 g, 5.86 mmol, 50%) as a white solid. TLC (cyclohexane/ethyl acetate, 4:1): 
Rf = 0.22; 1H NMR (500 MHz, CDCl3, 300 K): δ = 7.72-7.68 (m, 4H, aryl-Hortho), 4.45-7.35 (m, 
6H, aryl-Hmeta, aryl-Hpara), 5.72 (d, 3J1,2 = 4.1 Hz, 1H, H-1), 4.62 (dd, 3J1,2 = 4.1 Hz, 
3J2,3 = 5.9 Hz, 1H, H-2), 4.34 (ddd~q, 3J2,3 = 5.9 Hz, 3J3,4 = 5.9 Hz, 3J3,OH = 5.9 Hz, 1H, H-3), 
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4.19-4.12 (m, 2H, H-4, H-5a), 3.89 (dd, 3J4,5b = 5.1 Hz, 2J5a,5b = 9.5 Hz, 1H, H-5b), 3.06 (d, 
3J3,OH = 6.4 Hz, 1H, OH), 1.43, 1.36 (s each, 3H each, O2C(CH3)2), 1.07 (s, 9H, C(CH3)3) ppm. 
3-Azido-5-O-tert-butyldiphenylsilyl-3-deoxy-1,2-O-isopropylidene-β-D-arabinofuranose (44)282 
The reported synthesis282 was modified according to the following procedure: The lyxofuranose 
derivative 43 (1.50 g, 3.50 mmol) was dissolved in dry DCM (15.0 ml). The solution was cooled 
with an ice bath and supplemented with dry pyridine (900 µl, 11.2 mmol, 3 eq.) and 
Tf2O (1.20 ml, 7.14 mmol, 2 eq.). The reaction mixture was stirred for 4.5 h under a nitrogen 
atmosphere. The reaction was quenched by addition of a saturated aqueous NaHCO3 solution 
and extracted with DCM. The combined organic layers were washed with dist. water, dried 
over MgSO4, filtered, concentrated in vacuo and co-evaporated with toluene. The crude 
residue was dissolved in dry DMF (50.0 ml) and sodium azide (1.20 g, 18.5 mmol, 5 eq.) was 
added. It was stirred for 5 h at 80°C and overnight at rt under a nitrogen atmosphere. Diethyl 
ether was added and the organic layer was washed with brine and dist. water, dried over 
MgSO4, filtered and concentrated in vacuo. Silica gel chromatography 
(cyclohexane/ethyl acetate, 20:1) gave the azido derivative 44 (1.19 g, 2.63 mmol, 75%) as a 
colorless oil. TLC (cyclohexane/ethyl acetate, 18:1): Rf = 0.27; 1H NMR (500 MHz, CDCl3, 
300 K): δ = 7.69-7.65 (m, 4H, aryl-Hortho), 7.46-7.37 (m, 6H, aryl-Hmeta, aryl-Hpara), 5.84 (d, 
3J1,2 = 4.0 Hz, 1H, H-1), 4.56 (dd~d, 3J1,2 = 4.0 Hz, 1H, H-2), 4.25 (dd~d, 3J3,4 = 2.7 Hz, 1H, 
H-3), 4.11 (ddd, 3J3,4 = 2.9 Hz, 3J4,5a = 8.0 Hz, 3J4,5b = 5.0 Hz, 1H, H-4), 3.84 (dd, 3J4,5a = 8.1 Hz, 
2J5a,5b = 10.3 Hz, 1H, H-5a), 3.79 (dd, 3J4,5b = 5.0 Hz, 2J5a,5b = 10.4 Hz, 1H, H-5b), 1.35, 1.29 (s 
each, 3H each, O2C(CH3)2), 1.08 (s, 9H, C(CH3)3) ppm.  
3-Azido-3-deoxy-1,2-O-isopropylidene-β-D-arabinofuranose (45)                  
The azido sugar 44 (1.30 g, 2.86 mmol) was dissolved in dry THF (25.0 ml) and supplemented 
with tetra-N-butylammonium fluoride (TBAF, 1 M solution in THF, 6.00 ml, 6.00 mmol, 2 eq.). 
The reaction mixture was stirred for 45 min at rt under a nitrogen atmosphere and concentrated 
in vacuo. The crude product was chromatographed on silica gel (cyclohexane/ethyl acetate, 
3:1 → 2:1) to give 45 (549 mg, 2.56 mmol, 90%) as a white solid. 
TLC (cyclohexane/ethyl acetate, 3:1): Rf = 0.14; rotation value: [α]22𝐷  = - 0.79 (c = 0.5, CH2Cl2);
  
1H NMR (500 MHz, CDCl3, 300 K): δ = 5.87 (d, 3J1,2 = 4.1 Hz, 1H, H-1), 4.64 (dd, 3J1,2 = 4.1 Hz, 
3J2,3 = 1.5 Hz, 1H, H-2), 4.06 (ddd~dt, 3J3,4 = 3.9 Hz, 3J4,5a = 5.4 Hz, 3J4,5b = 5.4 Hz, 1H, H-4), 
4.03 (dd, 3J2,3 = 1.4 Hz, 3J3,4 = 3.8 Hz, 1H, H-3), 3.80 (dd, 3J4,5a = 5.6 Hz, 2J5a,5b = 11.8 Hz, 1H, 
H-5a), 3.78 (dd, 3J4,5b = 5.1 Hz, 2J5a,5b = 11.8 Hz, 1H, H-5b), 2.06 (s, 1H, OH), 1.55, 1.35 (s 
each, 3H each, O2C(CH3)2) ppm; 13C NMR (125 MHz, CDCl3, 300 K): δ = 113.5 (O2C(CH3)2), 
105.4 (C-1), 85.5 (C-2), 85.0 (C-4), 65.5 (C-3), 62.3 (C-5), 27.1, 26.4 (O2C(CH3)2 each) ppm; 
IR (ATR-IR): Ṽ = 3440, 2988, 2941, 2100, 1458, 1379, 1313, 1247, 1211, 1162, 1083, 1060, 
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1014, 949, 857, 837, 812, 780, 693, 615, 552, 519; ESI-MS:m/z = 238.082, [M+Na]+ (calc. 
238.127 for C8H13O5+Na).  
1,2-O-Isopropylidene-α-D-xylofuranose (46)283                                                     
D-Xylose (4.00 g, 26.7 mmol) was dissolved in dry acetone (100 ml) and concentrated 
sulphuric  acid (4.00 ml) was added. The reaction was stirred for 30 min at rt under a nitrogen 
atmosphere. A solution of Na2CO3 (5.20 g) in dist. water (44.8 ml) was added dropwise under 
cooling with an ice bath and the mixture was stirred for further 3 h. Solid Na2CO3 (2.80 g) was 
added, Na2SO4 was filtered off and washed with acetone. The combined filtrates were 
evaporated. Silica gel chromatography (cyclohexane/ethyl acetate, 1:1) gave the 
xylofuranose 46 (3.70 g, 19.5 mmol, 73%) as colorless crystals. TLC (cyclohexane/ethyl 
acetate, 1:1): Rf = 0.13; 1H NMR (500 MHz, CDCl3, 300 K, TMS): δ = 5.98 (d, 3J1,2 = 3.7 Hz, 
1H, H-1), 4.52 (dd~d, 3J1,2 = 3.7 Hz, 1H, H-2), 4.32 (dd~d, 3J3,4 = 2.8 Hz, 1H, H-3), 4.18-4.15 
(m, 1H, H-4), 4.12 (dd, 3J4,5a = 3.9 Hz, 2J5a,5b = 12.5 Hz, 1H, H-5a), 4.03 (dd, 3J4,5b = 2.8 Hz, 
2J5a,5b = 12.5 Hz, 1H, H-5b), 3.25 (s, 1H, OH), 1.48, 1.32 (s each, 3H each, O2C(CH3)2) ppm. 
5-O-tert-Butyldiphenylsilyl-1,2-O-isopropylidene-α-D-xylofuranose (47)284,285                
The reported synthesis284,285 was modified according to the following procedure: The 
arabinofuranose derivative 46 (3.00 g, 15.8 mmol) was dissolved in dry pyridine (25.0 ml) and 
TBDPSCl (4.00 ml, 15.4 mmol, 1 eq.) was added. The reaction was stirred for 3.5 h at rt under 
a nitrogen atmosphere. After neutralization with a saturated aqueous NaHCO3 solution the 
resulting mixture was extracted with DCM. The combined organic layers were dried over 
MgSO4, filtered and concentrated in vacuo. The crude product was chromatographed on silica 
gel (cyclohexane/ethyl acetate, 1:1) to give 47 (6.47 g, 15.1 mmol, 96%) as a white solid. 
TLC (cyclohexane/ethyl acetate, 1:1): Rf = 0.55; 1H NMR (500 MHz, CDCl3, 300 K, TMS): δ = 
7.73-7.71 (m, 2H, aryl-Hortho), 7.69-7.67 (m, 2H, aryl-Hortho), 7.47-7.38 (m, 6H, aryl-Hmeta, 
aryl-Hpara), 6.01 (d, 3J1,2 = 3.7 Hz, 1H, H-1), 4.55 (dd~d, 3J1,2 = 3.7 Hz, 1H, H-2), 4.37 (dd~d, 
3J3,4 = 2.2 Hz, 1H, H-3), 4.15-4.13 (m, 1H, H-4), 4.12-4.09 (m, 2H, H-5a, H-5b), 4.02 (s, 1H, 
OH), 1.47, 1.33 (s each, 3H each, O2C(CH3)2), 1.05 (s, 9H, C(CH3)3) ppm.  
3-Azido-5-O-tert-butyldiphenylsilyl-3-deoxy-1,2-O-isopropylidene-α-D-ribofuranose (48)284,285 
The reported synthesis284,285 was modified according to the following procedure: The 
arabinofuranose derivative 47 (4.00 g, 9.33 mmol) was dissolved in dry DCM (30.0 ml). The 
solution was cooled with an ice bath and supplemented with dry pyridine (2.70 ml, 33.3 mmol, 
3.6 eq.) and Tf2O (4.00 ml, 23.3 mmol, 2.5 eq.). The reaction mixture was stirred for 5 h under 
a nitrogen atmosphere. The reaction was quenched by addition of a saturated aqueous 
NaHCO3 solution and extracted with DCM. The combined organic layers were washed with 
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dist. water, dried over MgSO4, filtered, concentrated in vacuo and co-evaporated with toluene. 
The crude residue was dissolved in dry DMF (50.0 ml) and supplemented with sodium azide 
(3.00 g, 46.3 mmol, 5 eq.). The reaction mixture was stirred for 5 h at 80°C and overnight at rt 
under a nitrogen atmosphere. Diethyl ether was added and the organic layer was washed with 
brine and dist. water, dried over MgSO4, filtered and concentrated in vacuo. Silica gel 
chromatography (cyclohexane/ethyl acetate, 18:1) gave the azido derivative 48 (1.93 g, 
4.25 mmol, 46%) as a white solid. TLC (cyclohexane/ethyl acetate, 18:1): Rf = 0.17; 1H NMR 
(500 MHz, CDCl3, 300 K, TMS): δ = 7.71-7.67 (m, 4H, aryl-Hortho), 7.45-7.37 (m, 6H, aryl-Hmeta, 
aryl-Hpara), 5.84 (d, 3J1,2 = 3.7 Hz, 1H, H-1), 4.78-4.75 (m, 1H, H-2), 4.15 (ddd~dt, 3J3,4 = 9.4 Hz, 
3J4,5a = 2.8 Hz, 3J4,5b = 2.8 Hz, 1H, H-4),  3.99 (dd, 3J4,5a = 2.6 Hz, 2J5a,5b = 11.9 Hz, 1H, H-5a), 
3.79 (dd, 3J4,5b = 3.0 Hz, 2J5a,5b = 11.9 Hz, 1H, H-5b), 3.74 (dd, 3J2,3 = 4.7 Hz, 3J3,4 = 9.4 Hz, 1H, 
H-3), 1.58, 1.39 (s each, 3H each, O2C(CH3)2), 1.08 (s, 9H, C(CH3)3) ppm. 
3-Azido-3-deoxy-1,2-O-isopropylidene-α-D-ribofuranose (49)284,285                  
The reported synthesis284,285 was modified according to the following procedure: The 
azido sugar 48 (1.70 g, 3.75 mmol) was dissolved in dry THF (25.0 ml) and supplemented with 
TBAF (1 M solution in THF, 7.80 ml, 7.80 mmol, 2 eq.). The reaction mixture was stirred for 
45 min at rt under a nitrogen atmosphere and concentrated in vacuo. The crude product was 
chromatographed (cyclohexane/ethyl acetate, 3:1 → 2:1) to give 49 (765 mg, 3.56 mmol, 95%) 
as a white solid. TLC (cyclohexane/ethyl acetate, 3:1): Rf = 0.08; 1H NMR (500 MHz, CDCl3, 
300 K, TMS): δ = 5.81 (d, 3J1,2 = 3.7 Hz, 1H, H-1), 4.75 (dd~t, 3J1,2 = 4.1 Hz, 3J2,3 = 4.1 Hz, 1H, 
H-2), 4.13 (ddd~dt, 3J3,4 = 9.6 Hz, 3J4,5a = 2.7 Hz, 3J4,5b = 2.7 Hz, 1H, H-4), 4.00 (dd, 
3J4,5a = 2.4 Hz, 2J5a,5b = 12.7 Hz, 1H, H-5a), 3.71 (dd, 3J4,5b = 3.0 Hz, 2J5a,5b = 12.7 Hz, 1H, 
H-5b), 3.60 (dd, 3J2,3 = 4.7 Hz, 3J3,4 = 9.6 Hz, 1H, H-3), 1.89 (s, 1H, OH), 1.58, 1.37 (s each, 
3H each, O2C(CH3)2) ppm. 
5-O-Tosyl-1,2,3-tri-O-acetyl-α,β-D-arabinofuranose (50)286                     
The reported synthesis286 was modified according to the following procedure: The 
arabinofuranose derivative 14 (2.00 g, 7.25 mmol) was dissolved in dry pyridine (20.0 ml). The 
reaction was cooled with an ice bath and tosyl chloride (TsCl, 3.00 g, 15.6 mmol, 2 eq.) was 
added slowly. The reaction was warmed to rt and stirred overnight under a nitrogen 
atmosphere. After addition of a saturated aqueous NaHCO3 solution the resulting mixture was 
extracted with DCM. The combined organic layer was dried over MgSO4, filtered and 
concentrated in vacuo. The crude product was chromatographed on silica gel 
(cyclohexane/ethyl acetate, 3:1 → 2:1) to give 50 (3.00 g, 6.98 mmol, 96%) as a colorless oil 
(α:β ratio = 2:1 by integration of the 1H NMR spectrum). TLC (cyclohexane/ethyl acetate, 2:1): 
Rf = 0.13; 1H NMR (500 MHz, CDCl3, 300 K, TMS): δ = 7.79 (qd, 3Jmeta,ortho = 8.4 Hz, 
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4Jmeta,CH3 = 1.9 Hz, 2H, aryl-Hmeta (α,β)), 7.34 (d, 3Jmeta,ortho = 8.0 Hz, 2H, aryl-Hortho (α,β)), 6.33 
(d, 3J1,2 = 3.9 Hz, 1H, H-1 (β)), 6.11 (d~s, 1H, H-1 (α)), 5.31-5.29 (m, 2H, H-2 (β), H-3 (β)), 5.15 
(dd~d, 3J2,3 = 1.4 Hz, 1H, H-2 (α)), 5.00-4.98 (m, 1H, H-3 (α)), 4.30 (ddd~q, 3J3,4 = 4.2 Hz, 
3J4,5a = 4.2 Hz, 3J4,5b= 4.2 Hz, 1H, H-4 (α)), 4.28 (dd, 3J4,5a = 6.3 Hz, 2J5a,5b = 10.0 Hz, 1H, 
H-5a (β)), 4.27 (dd, 3J4,5a = 4.2 Hz, 2J5a,5b = 11.2 Hz, 1H, H-5a (α)), 4.24 (dd, 3J4,5b = 4.0 Hz, 
2J5a,5b = 11.0 Hz, 1H, H-5b (α)), 4.19 (dd, 3J4,5b = 6.3 Hz, 2J5a,5b = 10.4 Hz, 1H, H-5b (β)), 
4.17-4.14 (m, 1H, H-4 (β)), 2.44 (s, 6H, aryl-CH3 (α,β)) 2.10, 2.09, 2.08 (s each, 3H each, 
COCH3 (α)), 2.07, 2.06, 2.04 (s each, 3H each, COCH3 (β)) ppm. 
5-Azido-5-deoxy-1,2,3-tri-O-acetyl-α,β-D-arabinofuranose (51)286                  
The reported synthesis286 was modified according to the following procedure: To a stirring 
solution of the tosylated molecule 50 (2.50 g, 5.81 mmol) in dry DMF (50.0 ml) sodium azide 
(1.50 g, 23.3 mmol, 4 eq.) was added. The reaction mixture was heated to 70°C and stirred for 
5 h under a nitrogen atmosphere. Dist. water was added and the reaction mixture was 
extracted with diethyl ether. The combined organic layer was dried over MgSO4, filtered and 
concentrated in vacuo. The crude product was chromatographed on silica gel 
(cyclohexane/ethyl acetate, 2:1) to give the azido sugar 51 (1.48 g, 4.92 mmol, 85%) as a 
colorless oil (α:β ratio = 2.5:1 by integration of the 1H NMR spectrum). 
TLC (cyclohexane/ethyl acetate, 2:1): Rf = 0.28; 1H NMR (500 MHz, CDCl3, 300 K, TMS): 
δ = 6.41-6.39 (m, 1H, H-1 (β)), 6.22 (d~s, 1H, H-1 (α)), 5.39-5.35 (m, 2H, H-2 (β), H-3 (β)), 
5.22 (dd~d, 3J2,3 = 1.5 Hz, 1H, H-2 (α)), 5.04 (ddd, 3J2,3 = 1.4 Hz, 3J3,4 = 4.7 Hz, 4J = 0.7 Hz, 1H, 
H-3 (α)), 4.23 (ddd~dt, 3J3,4 = 4.7 Hz, 3J4,5a = 3.3 Hz, 3J4,5b= 4.7 Hz, 1H, H-4 (α)), 4.12 (ddd~dt, 
3J3,4 = 3.6 Hz, 3J4,5a = 3.6 Hz, 3J4,5b = 6.2 Hz, 1H, H-4 (β)), 3.68 (dd, 3J4,5a = 3.3 Hz, 
2J5a,5b = 13.4 Hz, 1H, H-5a (α)), 3.60 (dd, 3J4,5a = 3.7 Hz, 2J5a,5b = 13.3 Hz, 1H, H-5a (β)), 
3.46 (dd, 3J4,5b = 6.3 Hz, 2J5a,5b = 13.3 Hz, 1H, H-5b (β)), 3.45 (dd, 3J4,5b = 4.8 Hz, 
2J5a,5b = 13.4 Hz, 1H, H-5b (α)), 2.14, 2.12, 2.11 (s each, 3H each, COCH3 (α)), 2.11, 2.10, 2.08 
(s each, 3H each, COCH3 (β)) ppm.  
3-Azido-3-deoxy-1,2,5-tri-O-acetyl-α,β-D-arabinose (52)                   
The azido arabinose 38 (50.0 mg, 290 µmol) was dissolved in dry pyridine (4.00 ml) and Ac2O 
(1.30 ml, 13.8 mmol, 48 eq.) was added. The reaction mixture was stirred for 2 h at rt under a 
nitrogen atmosphere and concentrated in vacuo. The crude product was chromatographed on 
silica gel (cyclohexane/ethyl acetate, 4:1) to give the acetylated azido sugar 52 (69.0 mg, 
230 µmol, 82%) as a colorless oil (α-pyranose: β-pyranose: furanose ratio = 3:3:1 according 
to integration of the 1H NMR spectrum). TLC (cyclohexane/ethyl acetate/methanol, 1:1:0.25): 
Rf = 0.62; rotation value: [α]22𝐷  = -83.0° (c = 0.42, CH2Cl2);
 1H NMR (only resonances of α- and 
β-pyranose are listed, not the resonances of the minor furanose) (500 MHz, CDCl3, 300 K): δ 
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= 6.33 (d, 3J1,2 = 3.5 Hz, 1H, H-1 (β)), 5.65 (d, 3J1,2 = 6.6 Hz, 1H, H-1 (α)), 5.34 (dd, 
3J1,2 = 3.5 Hz, 3J2,3 = 10.9 Hz, 1H, H-2 (β)), 5.29-5.25 (m, 2H, H-2 (α), H-4 (β)), 5.23 (ddd~dt, 
3J3,4 = 2.2 Hz, 3J4,5a = 3.7 Hz, 3J4,5b = 3.7 Hz, 1H, H-4 (α)), 4.07 (dd, 3J4,5a = 3.9 Hz, 
2J5a,5b = 12.9 Hz, 1H, H-5a (α)), 3.97 (dd, 3J4,5a = 1.5 Hz, 2J5a,5b = 13.2 Hz, 1H, H-5a (β)), 3.94 
(dd, 3J2,3 = 10.9 Hz, 3J3,4 = 3.2 Hz, 1H, H-3 (β)), 3.85 (dd, 3J4,5b = 2.0 Hz, 2J5a,5b = 13.3 Hz, 1H, 
H-5b (β)), 3.72 (dd, 3J4,5b = 2.2 Hz, 2J5a,5b = 13.1 Hz, 1H, H-5b (α)), 3.69 (dd, 3J2,3 = 9.2 Hz, 
3J3,4 = 3.8 Hz, 1H, H-3 (α)), 2.17, 2.16, 2.15, 2.13, 2.12, 2.10 (s each, 3H each, COCH3 (α,β)) 
ppm; 13C NMR (only resonances of α- and β-pyranose are listed, not the resonances of the 
minor furanose) (125 MHz, CDCl3, 300 K): δ = 170.1, 169.7, 169.7, 169.2, 169.1, 168.9 (6 
COCH3), 92.0 (C-1 (α)), 89.6 (C-1 (β)), 69.3 (C-4 (β)), 68.7 (C-4 (α)), 68.4 (C-2 (α)), 68.0 
(C-2 (β)), 64.0 (C-5 (α)), 62.7 (C-5 (β)), 60.2 (C-3 (α)),  56.8 (C-3 (β)), 20.9, 20.9, 20.8, 20.7, 
20.6 (6 COCH3) ppm; IR (ATR-IR): Ṽ = 2099.41, 1738.74, 1436.54, 1371.97, 1210.01, 
1054.11, 1031.92, 1002.80, 937.11, 760.29, 731.76, 645.27, 600.70, 551.32, 502.02, 460.37; 
HRMS (ESI-MS): m/z = 324.0802, [M+Na]+ (calc. 324.0808 for C11H15N3O7+Na). 
3-Azido-3-deoxy-1,2,5-tri-O-acetyl-α,β-D-ribose (53)                   
The azido ribose 39 (48.0 mg, 270 µmol) was dissolved in dry pyridine (4.00 ml) and Ac2O 
(1.30 ml, 13.8 mmol, 50 eq.) was added. The reaction mixture was stirred for 2 h at rt and 
concentrated in vacuo. Silica gel chromatography (cyclohexane/ethyl acetate, 4:1) gave the 
acetylated azido sugar 53 (52.0 mg, 170 µmol, 98%) as a colorless oil (α-pyranose: 
β-pyranose: β-furanose ratio = 1:6:1 by integration of the 1H NMR spectrum). 
TLC (cyclohexane/ethyl acetate/methanol, 1:1:0.25): Rf = 0.64; rotation value: [α]22𝐷  = - 2.38° 
(c = 0.33, CH2Cl2); 1H NMR (only resonances of β-pyranose are listed, minor α-pyranose and 
furanose resonances are not shown) (500 MHz, CDCl3, 300 K): δ = 5.97 (d, 3J1,2 = 5.5 Hz, 1H, 
H-1 (β)), 5.11 (ddd~dt, 3J3,4 = 3.9 Hz, 3J4,5a = 3.9 Hz, 3J4,5b = 6.4 Hz, 1H, H-4 (β)), 5.01 (dd, 
3J1,2 = 5.5 Hz, 3J2,3 = 3.6 Hz, 1H, H-2 (β)), 4.09 (dd~t, 3J2,3 = 3.5 Hz, 3J3,4 = 3.5 Hz, 1H, H-3 (β)), 
3.92 (dd, 3J4,5a = 4.1 Hz, 2J5a,5b = 12.3 Hz, 1H, H-5a (β)) 3.89 (dd, 3J4,5b = 6.4 Hz, 
2J5a,5b = 12.2 Hz, 1H, H-5b (β)), 2.16, 2.15, 2.11 (s each, 3H each, COCH3 (β)) ppm; 13C NMR 
(only resonances of β-pyranose are listed, minor α-pyranose and furanose resonances are not 
shown) (125 MHz, CDCl3, 300 K): δ = 169.9, 169.6, 168.7 (3 COCH3 (β)), 90.2 (C-1 (β)), 68.7 
(C-2 (β)), 67.4 (C-4 (β)), 62.4 (C-5 (β)), 57.4 (C-3 (β)) 20.8, 20.8, 20.7 (3 COCH3 (β)) ppm; IR 
(ATR-IR): Ṽ = 3473, 2936, 2108, 1741, 1432, 1369, 1208, 1138, 1043, 1013, 952, 882, 723, 
601, 550, 438; HRMS (ESI-MS): m/z = 324.0795, [M+Na]+ (calc. 324.0808 for 
C11H15N3O7+Na). 
5-Deoxy-5-iodo-1,2,3-tri-O-acetyl-α,β-D-arabinofuranose (54)286             
The reported synthesis286 was modified according to the following procedure: To a stirring 
solution of the tosylated molecule 50 (1.00 g, 2.33 mmol) in dry DMF (20.0 ml) sodium iodine 
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(1.40 g, 9.6 mmol, 4. eq.) was added. The reaction mixture was heated to 80°C and stirred for 
5 h under a nitrogen atmosphere. Dist. water was added and the reaction mixture was 
extracted with diethyl ether. The combined organic layers were dried over MgSO4, filtered and 
concentrated in vacuo. The crude product was chromatographed on silica gel 
(cyclohexane/ethyl acetate, 2:1) to give the azido sugar 54 (709 mg, 1.84 mmol, 79%) as a 
colorless oil (α:β ratio = 2:1 by integration of the 1H NMR spectrum). 
TLC (cyclohexane/ethyl acetate, 2:1): Rf = 0.28; 1H NMR (500 MHz, CDCl3, 300 K): δ = 6.40 
(d, 3J1,2 = 4.2 Hz,  1H, H-1 (β)), 6.21 (d~s, 1H, H-1 (α)), 5.36 (dd, 3J1,2 = 4.8 Hz, 3J2,3 = 6.6 Hz,  
1H, H-2 (β)), 5.34 (dd, 3J2,3 = 6.5 Hz, 3J3,4 = 4.3 Hz,  1H,  H-3 (β)), 5.21 (dd~d, 3J2,3 = 1.7 Hz, 
1H, H-2 (α)), 5.00 (dd, 3J2,3 = 1.7 Hz, 3J3,4 = 4.7 Hz, 1H, H-3 (α)), 4.25-4.17 (m, 2H, H-4 (α,β)), 
3.47-3.34 (m, 4H, H-5a (α,β), H-5b (α,β)), 2.13, 2.12, 2.11 (s each, 3H each, COCH3 (α)), 2.11, 
2.10, 2.08 (s each, 3H each, COCH3 (β)) ppm.  
5-Deoxy-5-iodo-α,β-D-arabinofuranose (55)                                 
The iodo derivative 58 (250 mg, 650 µmol) was dissolved in a sodium methoxide/methanol 
solution (10 mM, 5 ml) and stirred for 1 h at rt under a nitrogen atmosphere. After neutralization 
with Amberlite IR120 ion exchange resin and concentration in vacuo at a low heat (max. 30°C), 
the crude product was chromatographed on silica gel (cyclohexane/ethyl acetate/methanol, 
1:1:0.25) and lyophilized to give the product 41 (150 mg, 580 µmol, 89%) as a white solid 
(α:β ratio = 1.5:1 by integration of the 1H NMR spectrum). TLC 
(cyclohexane/ethyl acetate/methanol, 1:1:0.25): Rf = 0.3; rotation value: [α]22𝐷  = + 17.5° 
(c = 0.21, MeOH); 1H NMR (500 MHz, D2O, 300 K): δ = 5.27 (d, 3J1,2 = 4.7 Hz, 1H, H-1 (β)), 
5.23 (d, 3J1,2 = 3.0 Hz, 1H, H-1 (α)), 4.06 (dd, 3J1,2 = 4.7 Hz, 3J2,3 = 7.2 Hz, 1H, H-2 (β)), 4.03 
(dd, 3J1,2 = 3.0 Hz, 3J2,3 = 4.8 Hz, 1H, H-2 (α)), 3.99-3.95 (m, 2 H, H-3 (β), H-4 (α)), 3.90 (dd, 
3J2,3 = 4.8 Hz, 3J3,4 = 6.2 Hz, 1H, H-3 (α)), 3.82 (ddd~dt, 3J3,4 = 6.7 Hz, 3J4,5a = 5.4 Hz, 
3J4,5b= 6.9 Hz, 1H, H-4 (β)), 3.45 (dd, 3J4,5a = 4.8 Hz, 2J5a,5b = 11.0 Hz, 1H, H-5a (α)), 3.44 (dd, 
3J4,5a = 5.3 Hz, 2J5a,5b = 10.6 Hz, 1H, H-5a (β)), 3.34 (dd, 3J4,5b = 5.8 Hz, 2J5a,5b = 11.0 Hz, 1H, 
H-5b (α)), 3.31 (dd, 3J4,5b = 7.1 Hz, 2J5a,5b = 10.6 Hz, 1H, H-5b (β)) ppm;  13C NMR (125 MHz, 
D2O, 300 K): δ = 101.1 (C-1 (α)), 95.3 (C-1 (β)), 81.6 (C-4 (α)), 81.4 (C-2 (α)), 80.7 (C-4 (β)), 
79.2 (C-3 (α)), 77.9 (C-3 (β)), 76.4 (C-2 (β)), 7.1 (C-5 (β)), 6.5 (C-5 (α))  ppm.  
3-O-Allyl-5-O-tert-butyldiphenylsilyl-1,2-O-isopropylidene-β-D-arabinofuranose (56)            
The arabinofuranose derivative 42 (1.00 g, 2.33 mmol) was dissolved in dry DMF (40.0 ml). 
The solution was cooled with an ice bath and sodium hydride (NaH, 108 mg, 4.50 mmol, 2 eq.) 
was slowly added. The reaction was stirred for 30 min under ice cooling and a nitrogen 
atmosphere. Allyl bromide (650 µl, 7.52 mmol, 3 eq.) was added and the reaction stirred for 
3.5 h at rt. After addition of dist. water the resulting mixture was extracted with diethyl ether. 
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The combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. The 
crude product was chromatographed on silica gel (cyclohexane/ethyl acetate, 6:1) to give the 
fully protected sugar 56 (741 mg, 1.58 mmol, 64%) as a colorless oil. 
TLC (cyclohexane/ethyl acetate, 4:1): Rf = 0.55; rotation value: [α]25𝐷  = - 0.30° (c = 0.5, CH2Cl2); 
 
1H NMR (500 MHz, CDCl3, 300 K): δ = 7.69-7.65 (m, 6H, aryl-Hmeta, aryl-Hpara), 7.45-7.35 (m, 
4H, aryl-Hortho), 5.92 (ddt, 3JOCHa,CH=CH2 = 5.5 Hz, 3JOCHb,CH=CH2 = 5.5 Hz, 
3JCH=CH2,CH=CH2cis = 10.5 Hz, 3JCH=CH2,CH=CH2trans = 17.2 Hz, 1H, CH=CH2), 5.87 (d, 3J1,2 = 4.1 Hz, 
1H, H-1), 5.32 (dq, 4JOCHa,CH=CH2trans = 1.6 Hz, 4JOCHb,CH=CH2trans = 1.6 Hz, 
3JCH=CH2,CH=CH2trans = 17.2 Hz, 2JCH=CH2cis,CH=CH2trans = 1.6 Hz, 1H, CH=CH2,trans), 5.22 (ddd, 
4JOCH2,CH=CH2cis = 2.9 Hz, 3JCH=CH2,CH=CH2cis = 10.4 Hz, 2JCH=CH2cis,CH=CH2trans = 1.3 Hz, 1H, 
CH=CH2,cis), 4.60 (dd~d, 3J1,2 = 4.1 Hz, 1H, H-2), 4.18-4.14 (m, 2H, H-3, H-4), 4.13-4.05 (m, 
2H, OCHa, OCHb), 3.84-4.05 (m, 2H, H-5a, H-5b), 1.34, 1.29 (s each, 3H each, O2C(CH3)2), 
1.07 (s, 9H, C(CH3)3) ppm; 13C NMR (125 MHz, CDCl3, 300 K): δ = 135.6 (aryl-Cortho), 134.0 
(CH=CH2), 133.3, 133.2 (aryl-Cipso), 129.7 (aryl-Cpara), 127.7 (aryl-Cmeta), 117.5 (CH=CH2), 
112.4 (O2C(CH3)2), 105.7 (C-1), 85.3 (C-4), 85.1 (C-2), 82.7 (C-3), 70.6 (OCH2), 63.5 (C-5), 
27.0, 26.1 (O2C(CH3)2), 26.8 (OSi(C6H5)2C(CH3)3), 19.2 (OSi(C6H5)2C(CH3)3) ppm; 
ESI-MS: m/z = 491.4, [M+Na]+ (calc. 491.2 for C27H36O5Si+Na). 
3-O-Allyl-1,2-O-isopropylidene-β-D-arabinofuranose (57)                                                     
The product 57 was obtained by a different synthetic route as described in literature:363 The 
arabinofuranose derivative 56 (500 mg, 1.07 mmol) was dissolved in dry THF (20.0 ml) and 
supplemented with TBAF (1 M solution in THF, 3.50 ml, 3.50 mmol, 3.3 eq.). The reaction 
mixture was stirred for 1 h at rt under a nitrogen atmosphere and concentrated in vacuo. The 
crude product was chromatographed on silica gel (cyclohexane/ethyl acetate, 2:1 → 1:1) to 
give 57 (220 mg, 960 µmol, 90%) as a colorless oil. TLC (cyclohexane/ethyl acetate, 4:1): Rf = 
0.04; 1H NMR (500 MHz, CDCl3, 300 K): δ = 5.94-5.85 (m, 1H, CH=CH2), 5.90 (d, 
3J1,2 = 4.3 Hz, 1H, H-1), 5.31 (dq, 4JOCHa,CH=CH2trans = 1.6 Hz, 4JOCHb,CH=CH2trans = 1.6 Hz, 
3JCH=CH2,CH=CH2trans = 17.2 Hz, 2JCH=CH2cis,CH=CH2trans = 1.6 Hz, 1H, CH=CH2,trans), 5.23 (ddd, 
4JOCH2,CH=CH2cis = 2.8 Hz,  3JCH=CH2,CH=CH2cis = 10.4 Hz, 2JCH=CH2cis,CH=CH2trans = 1.3 Hz, 1H, 
CH=CH2,cis), 4.62 (dd, 3J1,2 = 4.1 Hz, 3J2,3 = 0.8 Hz, 1H, H-2), 4.17-4.13 (m, 1H, H-4), 4.10 (ddt, 
2JOCHa,OCHb = 12.7 Hz, 3JOCHa,CH=CH2 = 5.5 Hz, 4JOCHa,CH=CH2cis = 1.4 Hz,  4JOCHa,CH=CH2trans = 1.4 Hz,  
1H, OCHa), 4.04 (ddt, 2JOCHa,OCHb = 12.7 Hz, 3JOCHb,CH=CH2 = 5.7 Hz, 4JOCHb,CH=CH2cis = 1.4 Hz,  
4JOCHb,CH=CH2trans = 1.4 Hz,  1H, OCHb), 3.92 (dd, 3J2,3 = 0.7 Hz, 3J3,4 = 3.4 Hz, 1H, H-3), 
3.77-3.75 (m, 2H, H-5a, H-5b), 2.06 (s, 1H, OH), 1.53, 1.34 (s each, 3H each, O2C(CH3)2) ppm. 
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3-O-[6’-N-(tert-Butoxycarbonyl)amino-4’-thiahexyl]-1,2-O-isopropylidene-β-D-arabinofuranose 
(58)                    
The arabinofuranose derivative 57 (100 mg, 430 µmol) and Boc protected cysteamine 72 
(300 mg, 2.00 mmol, 4.7 eq.) were dissolved in dry methanol (23.0 ml) and 2,2-dimethoxy-
2-phenylacetophenone (DPAP, 33.0 mg, 130 µmol, 0.3 eq.) was added. The reaction mixture 
was degassed with nitrogen and stirred for 1 h at rt under a nitrogen atmosphere while 
irradiating at λmax 365 nm. After concentration in vacuo, the crude product was 
chromatographed on silica gel (cyclohexane/ethyl acetate, 2:1 → 1:1) to give 58 (159 mg, 
390 µmol, 91%) as a colorless oil. TLC (cyclohexane/ethyl acetate, 1:1): Rf = 0.29; rotation 
value: [α]25
𝐷
 = + 6.90° (c = 0.5, CH2Cl2); 1H NMR (500 MHz, CDCl3, 300 K): δ = 5.88 (d, 
3J1,2 = 4.1 Hz, 1H, H-1), 4.92 (s, 1H, NH),  4.59 (dd, 3J1,2 = 4.1 Hz, 3J2,3 = 0.8 Hz, 1H, H-2), 
4.14-4.08 (m, 1H, H-4), 3.86 (dd, 3J2,3 = 0.7 Hz, 3J3,4 = 3.3 Hz, 1H, H-3), 3.75 (dd, 3J4,5 = 5.6 Hz, 
3J5,OH = 1.5 Hz, 2H, H-5a, H-5b), 3.66 (dt, 2JOCHa,OCHb = 9.4 Hz, 3JOCHa,OCH2CHa = 6.0 Hz, 
3JOCHa,OCH2CHb = 6.0 Hz, 1H, OCHa), 3.57 (dt, 2JOCHa,OCHb = 9.4 Hz, 3JOCHb,OCH2CHa = 6.0 Hz, 
3JOCHb,OCH2CHb = 6.0 Hz, 1H, OCHb),  3.30 (d, 3JSCH2,CH2NHBoc = 4.2 Hz, 2H, CH2NHBoc), 2.62 (dt, 
2JSCHa/CHaS, SCHb/CHbS = 11.9 Hz, 3JSCHa,b/CHa,bS,CHaNHBoc/OCH2CHa = 6.9 Hz, 
3JSCHa,b/CHa,bS,CHbNHBoc/OCH2CHb = 6.9 Hz, 4H, SCH2, CH2S), 1.97 (s, 1H, OH), 1.88-1.82 (m, 2H, 
OCH2CH2) 1.53, 1.33 (s each, 3H each, O2C(CH3)2), 1.44 (s, 9H, COOC(CH3)3) ppm; 13C NMR 
(125 MHz, CDCl3, 300 K): δ = 155.8 (COOC(CH3)3), 112.8 (O2C(CH3)2), 105.5 (C-1), 85.6 
(C-4), 85.1 (C-2), 83.5 (C-3), 79.5 (COOC(CH3)3), 68.0 (OCH2), 62.7 (C-5), 39.8 (CH2NHBoc), 
32.2 (CH2S), 29.5 (OCH2CH2), 28.4 (COOC(CH3)3), 28.3 (SCH2), 27.1, 26.3 (O2C(CH3)2) ppm; 
ESI-MS: m/z = 430.1, [M+Na]+ (calc. 430.2 for C18H33NO7S+Na). 
3-O-(6’-Amino-4’-thiahexyl)-α,β-D-arabinose (59)                 
Thiahexyl derivative 58 (75.0 mg, 180 µmol) was dissolved in DCM (15.0 ml), cooled with ice 
and supplemented with dist. water (2.00 ml) and TFA (7.00 ml, 91.5 mmol, 500 eq.). The 
reaction mixture was stirred for 2 h and concentrated in vacuo. The product 59 was 
co-evaporated with toluene and lyophilized to give a light yellow oil (68.0 mg, 180 µmol, quant.) 
(α-pyranose: β-pyranose: furanose ratio = 6:3:1 by integration of the 1H NMR spectrum); TLC 
(methylene chloride/methanol, 4:1): Rf = 0.22; rotation value: [α]25𝐷  = - 35.8° (c = 0.6, MeOH); 
1H NMR (only resonances of α- and β-pyranose are listed, not the resonances of the minor 
furanose): (500 MHz, D2O, 300 K): δ = 5.18 (d, 3J1,2 = 3.7 Hz, 1H, H-1 (β)), 4.46 (d, 
3J1,2 = 7.8 Hz, 1H, H-1 (α)), 4.15-4.13 (m, 1H, H-4 (β)), 4.12-4.08 (m, 1H, H-4 (α)), 3.95 (dd, 
3J4,5a = 1.4 Hz, 2J5a,5b = 12.8 Hz, 1H, H-5a (β)), 3.87 (dd, 3J4,5a = 2.2 Hz, 2J5a,5b = 13.1 Hz, 1H, 
H-5a (α)), 3.80 (dd, 3J1,2 = 3.7 Hz, 3J2,3 = 10.0 Hz, 1H, H-2 (β)),  3.78-3.65 (m, 3H, OCHa (α), 
OCH2 (β)), 3.63-3.54 (m, 4H, H-3 (β), H-5b (α), H-5b (β), OCHb (α)), 3.47 (dd, 3J1,2 = 7.8 Hz, 
3J2,3 = 9.8 Hz, 1H, H-2 (α)), 3.38 (dd, 3J2,3 = 10.1 Hz, 3J3,4 = 3.7 Hz, 1H, H-3 (α)), 3.18 (t, 
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3JSCHa,CH2NH2 = 6.6 Hz, 3JSCHb,CH2NH2 = 6.6 Hz, 4H, CH2NH2 (α,β)), 2.81 (t, 3JSCHa,CH2NH2 = 6.6 Hz, 
3JSCHb,CH2NH2 = 6.6 Hz, 4H, SCH2 (α,β)), 2.65 (t, 3JOCH2CHa,CH2S = 7.3 Hz, 3JOCH2CHb,CH2S  = 7.3 Hz, 
2H, CH2S (α)), 2.60 (t, 3JOCH2CHa,CH2S = 7.2 Hz, 3JOCH2CHb,CH2S  = 7.2 Hz, 2H, CH2S (β)), 1.89-1.81 
(m, 1H, 4H, OCH2CH2 (α,β)) ppm; 13C NMR (125 MHz, D2O, 300 K): δ = 96.8 (C-1 (β)), 92.6 
(C-1 (α)), 80.4 (C-3 (α)), 76.6 (C-3 (β)), 70.9 (C-2 (α)),  67.7, 67.5 (OCH2 (α,β)), 67.4 (C-2 (β)),  
66.3 (C-5 (α)), 65.6 (C-4 (β)), 65.0 (C-4 (α)), 62.4 (C-5 (β)), 38.9, 38.3 (CH2NH2 (α,β)), 28.7, 
28.6 (SCH2 (α,β)), 28.2 (OCH2CH2 (α,β)), 27.3 (CH2S (α,β)) ppm; HRMS (ESI-MS): 
m/z = 268.1221, [M+H]+ (calc. 268.1213 for C10H22NO5S+H). 
5-O-tert-Butyldiphenylsilyl-1,2-O-isopropylidene-α-D-ribofuranose (60)                             
The product 60 was obtained by a different synthetic route as described in literature:298 The 
xylofuranose derivative 47 (4.00 g, 9.32 mmol) was dissolved in dry DCM (40.0 ml). The 
solution was cooled with an ice bath and supplemented with dry pyridine (2.40 ml, 29.8 mmol, 
3 eq.) and Tf2O (4.00 ml, 23.8 mmol, 2.5 eq.). The reaction mixture was stirred for 3 h under a 
nitrogen atmosphere. The reaction was quenched by addition of a saturated aqueous NaHCO3 
solution and extracted with DCM. The combined organic layers were washed with dist. water, 
dried over MgSO4, filtered and concentrated in vacuo. The crude residue was dissolved in dry 
DMF (50.0 ml) and sodium nitrite (9.00 g, 131 mmol, 14 eq.) was added. The reaction mixture 
was stirred overnight at 70°C under a nitrogen atmosphere. Diethyl ether was added and the 
organic layer was washed with brine and dist. water, dried over MgSO4, filtered and 
concentrated in vacuo. The crude product was chromatographed on silica gel 
(cyclohexane/ethyl acetate, 6:1 → 5:1) to give ribofuranose derivative 60 (1.60 g, 3.73 mmol, 
40%) as a colorless solid. TLC (cyclohexane/ethyl acetate, 4:1): Rf = 0.30; 1H NMR (500 MHz, 
CDCl3, 300 K, TMS): δ = 7.71-7.68 (m, 4H, aryl-Hortho), 7.44-7.36 (m, 6H, aryl-Hmeta, aryl-Hpara), 
5.85 (d, 3J1,2 = 3.8 Hz, 1H, H-1), 4.60 (dd, 3J1,2 = 3.9 Hz, 3J2,3 = 5.2 Hz, 1H, H-2), 4.14 (dd, 
3J2,3 = 5.2 Hz, 3J3,4 = 8.3 Hz, 1H, H-3), 3.98-3.94 (m, 1H, H-4), 3.88-3.83 (m, 2H, H-5a, H-5b), 
2.11 (s, 1H, OH), 1.56, 1.39 (s each, 3H each, O2C(CH3)2), 1.05 (s, 9H, C(CH3)3) ppm.  
3-O-Allyl-5-O-tert-butyldiphenylsilyl-1,2-O-isopropylidene-α-D-ribofuranose (61)             
The ribofuranose derivative 60 (1.00 g, 2.33 mmol) was dissolved in dry DMF (40.0 ml). The 
solution was cooled with an ice bath and sodium hydride (NaH, 108 mg, 4.50 mmol, 2 eq.) was 
slowly added. The reaction was stirred for 30 min under ice cooling and a nitrogen atmosphere. 
Allyl bromide (650 µl, 7.52 mmol, 3 eq.) was added and the reaction stirred for 3.5 h at rt. After 
addition of dist. water the resulting mixture was extracted with diethyl ether. The combined 
organic layers were dried over MgSO4, filtered and concentrated in vacuo. The crude product 
was chromatographed on silica gel (cyclohexane/ethyl acetate, 6:1) to give the fully protected 
sugar 61 (873 mg, 1.87 mmol, 80%) as a colorless oil. TLC (cyclohexane/ethyl acetate, 4:1): 
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Rf = 0.55; rotation value: [α]23𝐷  = + 68.3° (c = 0.4, CH2Cl2); 
1H NMR (500 MHz, CDCl3, 300 K): 
δ = 7.73-7.66 (m, 4H, aryl-Hortho), 7.45-7.35 (m, 6H, aryl-Hmeta, aryl-Hpara), 5.96 (ddt, 
3JOCHa,CH=CH2 = 5.9 Hz, 3JOCHb,CH=CH2 = 5.9 Hz, 3JCH=CH2,CH=CH2cis = 10.4 Hz, 
3JCH=CH2,CH=CH2trans = 16.2 Hz, 1H, CH=CH2), 5.79 (d, 3J1,2 = 3.6 Hz, 1H, H-1), 5.31 (ddd, 
4JOCH2,CH=CH2trans = 3.1 Hz, 3JCH=CH2,CH=CH2trans = 17.2 Hz, 2JCH=CH2cis,CH=CH2trans = 1.5 Hz, 1H, 
CH=CH2,trans), 5.22 (ddd, 4JOCH2,CH=CH2cis = 2.6 Hz, 3JCH=CH2,CH=CH2cis = 17.2 Hz, 
2JCH=CH2cis,CH=CH2trans = 1.2 Hz, 1H, CH=CH2,cis), 4.65 (dd, 3J1,2 = 3.6 Hz, 3J2,3 = 3.6 Hz, 1H, H-2), 
4.21 (ddt, 2JOCHa,OCHb = 12.8 Hz, 3JOCHa,CH=CH2 = 5.8 Hz, 4JOCHa,CH=CH2cis = 1.3 Hz,  
4JOCHa,CH=CH2trans = 1.3 Hz,  1H, OCHa), 4.11 (ddt, 2JOCHa,OCHb = 12.8 Hz, 3JOCHb,CH=CH2 = 5.8 Hz, 
4JOCHb,CH=CH2cis = 1.3 Hz,  4JOCHb,CH=CH2trans = 1.3 Hz,  1H, OCHb), 4.14-4.04 (m, 2H, H-3, H-4), 
4.02-3.98 (m, 1H, H-5a), 3.82 (dd, 3J4,5b = 2.4 Hz, 2J5a,5b = 11.8 Hz, 1H, H-5b), 1.58, 1.38 
(s each, 3H each, O2C(CH3)2), 1.05 (s, 9H, C(CH3)3) ppm; 13C NMR (125 MHz, CDCl3, 300 K): 
δ = 135.7, 135.6 (aryl-Cortho), 134.8, 134.6 (CH=CH2), 133.6, 133.2 (aryl-Cipso), 129.7, 129.6 
(aryl-Cpara), 127.7, 127.6 (aryl-Cmeta), 117.9 (CH=CH2), 112.9 (O2C(CH3)2), 104.0 (C-1), 79.4 
(C-4), 77.8 (C-2), 76.8 (C-3), 71.7 (OCH2), 61.7 (C-5), 26.9, 26.6 (O2C(CH3)2), 26.8 
(OSi(C6H5)2C(CH3)3), 19.4 (OSi(C6H5)2C(CH3)3) ppm; ESI-MS: m/z = 491.3, [M+Na]+ 
(calc. 491.2 for C27H36O5Si+Na). 
3-O-Allyl-1,2-O-isopropylidene-α-D-ribofuranose (62)                                                   
The product 62 was obtained by a different synthetic route as described in literature:364 The 
ribofuranose derivative 61 (800 mg, 1.71 mmol) was dissolved in dry THF (20.0 ml) and 
supplemented with TBAF (1 M solution in THF, 3.50 ml, 3.50 mmol, 2.0 eq.). The reaction 
mixture was stirred for 1 h at rt under a nitrogen atmosphere and concentrated in vacuo. The 
crude product was chromatographed on silica gel (cyclohexane/ethyl acetate, 2:1 → 1:1) to 
give 62 (390 mg, 1.70 mmol, 99%) as a colorless oil. TLC (cyclohexane/ethyl acetate, 4:1): 
Rf = 0.04; 1H NMR (500 MHz, CDCl3, 300 K): δ = 5.95 (ddt, 3JOCHa,CH=CH2 = 5.9 Hz, 
3JOCHb,CH=CH2 = 5.9 Hz, 3JCH=CH2,CH=CH2cis = 10.3 Hz, 3JCH=CH2,CH=CH2trans = 17.2 Hz, 1H, CH=CH2), 
5.74 (d, 3J1,2 = 3.6 Hz, 1H, H-1), 5.32 (dq, 4JOCHa,CH=CH2trans = 1.6 Hz, 4JOCHb,CH=CH2trans = 1.6 Hz, 
3JCH=CH2,CH=CH2trans = 17.2 Hz, 2JCH=CH2cis,CH=CH2trans = 1.6 Hz, 1H, CH=CH2,trans), 5.23 (ddd, 
4JOCH2,CH=CH2cis = 2.8 Hz,  3JCH=CH2,CH=CH2cis = 10.3 Hz, 2JCH=CH2cis,CH=CH2trans = 1.2 Hz, 1H, 
CH=CH2,cis), 4.62 (dd~t, 3J1,2 = 4.0 Hz, 3J2,3 = 4.0 Hz, 1H, H-2), 4.20 (ddt, 2JOCHa,OCHb = 12.7 Hz, 
3JOCHa,CH=CH2 = 5.7 Hz, 4JOCHa,CH=CH2cis = 1.4 Hz,  4JOCHa,CH=CH2trans = 1.4 Hz,  1H, OCHa), 
4.12-4.05 (m, 2H, H-4, OCHb), 3.94 (dd, 3J4,5a = 2.5 Hz, 2J5a,5b = 12.5 Hz, 1H, H-5a), 3.83 (dd, 
3J2,3 = 4.3 Hz, 3J3,4 = 9.1 Hz, 1H, H-3), 3.67 (dd, 3J4,5b = 3.0 Hz, 2J5a,5b = 12.5 Hz, 1H, H-5b),  
1.84 (s, 1H, OH), 1.57, 1.36 (s each, 3H each, O2C(CH3)2) ppm. 
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3-O-[6’-N-(tert-Butoxycarbonyl)amino-4’-thiahexyl]-1,2-O-isopropylidene-α-D-ribofuranose 
(63)                     
The ribofuranose derivative 62 (150 mg, 650 µmol) and Boc protected cysteamine 72 (460 mg, 
3.07 mmol, 4.7 eq.)  were dissolved in dry methanol (23.0 ml) and catalytic amounts of 
azobisisobutyronitrile (AIBN) were added. The reaction mixture was stirred for 6 h at 70°C 
under a nitrogen atmosphere. After addition of DCM the organic layer was washed with brine 
and dist. water, dried over MgSO4, filtered and concentrated in vacuo. The crude product was 
chromatographed on silica gel (cyclohexane/ethyl acetate, 1:1) to give thiahexyl derivative 63 
(160 mg, 390 µmol, 60%) as a colorless oil. TLC (cyclohexane/ethyl acetate, 1:1): Rf = 0.09; 
rotation value: [α]23
𝐷
 = + 59.0° (c = 0.3, CH2Cl2); 1H NMR (500 MHz, CDCl3, 300 K): δ = 5.76 (d, 
3J1,2 = 3.7 Hz, 1H, H-1), 4.96 (s, 1H, NH),  4.64 (dd~t, 3J1,2 = 4.0 Hz, 3J2,3 = 4.0 Hz, 1H, H-2), 
4.04 (ddd~dt, 3J3,4 = 9.1 Hz, 3J4,5a = 2.7 Hz, 3J4,5b = 2.7 Hz,  1H, H-4), 3.94 (dd, 3J4,5a = 2.5 Hz, 
2J5a,5b= 12.4 Hz, 1H, H-5a), 3.80 (dd, 3J2,3 = 4.4 Hz, 3J3,4 = 9.0 Hz, 1H, H-3), 3.81-3.76 (m, 1H, 
OCHa), 3.68 (dd, 3J4,5b = 2.9 Hz, 2J5a,5b= 12.4 Hz, 1H, H-5b), 3.57 (dt, 2JOCHa,OCHb = 9.5 Hz, 
3JOCHb,OCH2CHa = 5.7 Hz, 3JOCHb,OCH2CHb = 6.8 Hz, 1H, OCHb), 3.32-3.27 (m, 2H, 
CH2NHBoc), 2.62 (t, 3JSCHa,b/CHa,bS,CHaNHBoc/OCH2CHa = 7.1 Hz, 3JSCHa,b/CHa,bS,CHbNHBoc/OCH2CHb 
= 7.1 Hz, 4H, SCH2, CH2S), 1.84 (s, 1H, OH), 1.93-1.84 (m, 2H, OCH2CH2) 1.56, 1.35 (s each, 
3H each, O2C(CH3)2), 1.44 (s, 9H, COOC(CH3)3) ppm; 13C NMR (125 MHz, CDCl3, 300 K): δ = 
155.8 (COOC(CH3)3), 113.1 (O2C(CH3)2), 104.1 (C-1), 79.5 (COOC(CH3)3), 78.6 (C-4), 77.8 
(C-2), 77.5 (C-3), 68.7 (OCH2), 60.5 (C-5), 39.9 (CH2NHBoc), 32.3 (CH2S), 29.7 (OCH2CH2), 
28.4 (COOC(CH3)3), 28.2 (SCH2), 26.8, 26.5 (O2C(CH3)2) ppm; ESI-MS: m/z = 430.2, [M+Na]+ 
(calc. 430.2 for C18H33NO7S+Na). 
3-O-(6’-Amino-4’-thiahexyl)-α,β-D-ribose (64)                        
Thiahexyl derivative 63 (90.0 mg, 220 µmol) was dissolved in DCM (15.0 ml), cooled with ice 
and supplemented with dist. water (2.00 ml) and TFA (7.00 ml, 91.5 mmol, 400 eq.). The 
reaction mixture was stirred for 2 h and concentrated in vacuo. The product 64 was 
co-evaporated with toluene and lyophilized to give a light yellow oil (83.0 mg, 220 µmol, quant.) 
(α-pyranose: β-pyranose: α-furanose: β-furanose ratio = 4:4:1:2 by integration of the 1H NMR 
spectrum). TLC (methylene chloride/methanol, 4:1): Rf = 0.25; rotation value: [α]23𝐷  = - 3.37° 
(c = 0.2, MeOH); 1H NMR (500 MHz, D2O, 300 K): δ = 5.29 (d, 3J1,2 = 4.1 Hz, 1H, H-1f (α)), 5.20 
(d, 3J1,2 = 1.6 Hz, 1H, H-1f (β)), 4.99 (d, 3J1,2 = 4.7 Hz, 1H, H-1py (α)), 4.71 (1H, H-1py (β)), 4.16 
(dd, 3J1,2 = 4.1 Hz, 3J2,3 = 5.6 Hz, 1H, H-2f (α)), 4.13-4.07 (m, 2H, H-2f (β), H-4f (β)), 3.99-3.92 
(m, 4H, H-2py (α), H-2py (β), H-4f (α), H-4py (α)), 3.89 (dd, 3J4,5a = 3.7 Hz, 2J5a,5b = 12.8 Hz, 1H, 
H-5apy (α)),  3.87 (dd, 3J4,5a = 3.4 Hz, 2J5a,5b = 12.2 Hz, 1H, H-5apy (β)), 3.83 (t, 3J2,3 = 5.4 Hz, 
3J3,4 = 5.4 Hz, 1H, H-3f (β)), 3.76-3.53 (m, 18H, H-3f (α), H-3py (α,β), H-4py (β)), H-5af (α,β), 
H-5bf (α,β), H-5bpy (α,β), OCH2,f (α,β), OCH2,py (α,β)),  2.83-2.79 (m, 8H, CH2NH2,f (α,β), 
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CH2NH2,py (α,β)), 2.65 (t, 3JOCH2CHa,CH2S = 6.5 Hz, 3JOCH2CHb,CH2S  = 6.5 Hz, 8H, SCH2,f (α,β), 
SCH2,py (α,β)), 2.68-2.61 (m, 8H, CH2Sf (α,β), CH2Spy (α,β)), 1.91-1.82 (m, 8H, OCH2CH2,f (α,β), 
OCH2CH2,py (α,β)) ppm; 13C NMR (125 MHz, D2O, 300 K): δ = 163.0, 162.7 (CF3COO-), 117.4, 
115.2 (CF3COO-), 101.3 (C-1f (β)), 96.3 (C-1f (α)), 94.3 (C-1py (α)), 93.9 (C-1py (β)), 81.3 (C-4f 
(β)), 80.9, 78.3, 77.7, 76.3, 75.2 (C-4f (α), C-4py (α,β), C-3f (α,β), C-3py (β)), 73.2 (C-2f (β)), 70.1 
(C-3py (α)), 70.0 (C-2f (α)), 69.4, 69.2, 69.1, 69.0, 67.8 ((C-2py (β), OCH2,f (α,β), OCH2,py(α,β)), 
67.1 (C-2py (α)), 66.1 (C-5f (β)), 63.3 (C-5py(α)), 62.6 (C-5py(β)), 61.5 (C-5f (α)), 38.3 
(CH2NH2,f (α,β), CH2NH2,py (α,β)), 28.8, 28.6 (SCH2,f (α,β), SCH2,py (α,β)), 28.5, 28.2 
(OCH2CH2,f (α,β), OCH2CH2,py (α,β)), 27.4, 27.3 (CH2Sf (α,β), CH2Spy (α,β)) ppm; HRMS (ESI-
MS): m/z = 268.1221, [M+H]+ (calc. 268.1213 for C10H22NO5S+H).                              
5-O-tert-Butyldiphenylsilyl-1,2-O-isopropylidene-3-O-methoxymethyl-β-D-arabinofuranose 
(65)                    
The arabinofuranose derivative 42 (2.00 g, 4.66 mmol) was dissolved in 
N,N-diisopropylethylamine (DIPEA, 30.0 ml) and TBAI (3.50 g, 9.48 mmol, 2 eq.) and 
chloromethyl methyl ether (MOMCl, 5.20 ml, 68.5 mmol, 15 eq.) were added. The reaction 
mixture was stirred under a nitrogen atmosphere for 2 h at 60°C and concentrated in vacuo. 
Ethyl acetate was added and the organic layer was washed with dist. water, dried over MgSO4, 
filtered and concentrated in vacuo. The crude product was chromatographed on silica gel 
(cyclohexane/ethyl acetate, 4:1) to give the fully protected sugar 65 (1.91 g, 4.05 mmol, 87%) 
as colorless oil. TLC (cyclohexane/ethyl acetate, 4:1): Rf = 0.36; rotation value: [α]25𝐷  = + 7.30° 
(c = 0.5, CH2Cl2); 1H NMR (600 MHz, CDCl3, 300 K): δ = 7.72-7.63 (m, 4H, aryl-Hortho), 
7.47-7.31 (m, 6H, aryl-Hmeta, aryl-Hpara), 5.88 (d, 3J1,2 = 4.0 Hz, 1H, H-1), 4.74, 4.70 (d each, 
2JOCHaOCH3,OCHbOCH3 = 6.7 Hz, 1H each, OCH2OCH3), 4.60 (dd~d, 3J1,2 = 4.0 Hz, 1H, H-2), 4.41 
(dd~d, 3J3,4 = 2.2 Hz, 1H, H-3), 4.17 (ddd, 3J3,4 = 2.2 Hz, 3J4,5a = 6.0 Hz,  3J4,5b = 7.9 Hz,  1H, H-4), 
3.83 (dd, 3J4,5a = 5.5 Hz,  2J5a,5b = 12.3 Hz,  1H, H-5a), 3.78 (dd, 3J4,5b = 7.3 Hz,  2J5a,5b = 13.2 Hz,  
1H, H-5b), 3.39 (s, 3H, OCH2OCH3), 1.33, 1.29 (s each, 3H each, O2C(CH3)2), 1.07 (s, 9H, 
C(CH3)3) ppm; 13C NMR (125 MHz, CDCl3, 300 K): δ = 135.6, 135.5 (aryl-Cortho), 133.2, 133.1 
(aryl-Cipso), 129.7, 129.6 (aryl-Cpara), 127.7, 127.6 (aryl-Cmeta), 112.4 (O2C(CH3)2), 105.8 (C-1), 
95.5 (OCH2OCH3), 86.0 (C-4), 85.3 (C-2), 80.0 (C-3), 63.4 (C-5), 55.7 (OCH2OCH3), 26.9, 26.0 
(O2C(CH3)2), 26.8 (OSi(C6H5)2C(CH3)3), 19.2 (OSi(C6H5)2C(CH3)3) ppm; ESI-MS: m/z = 495.5, 
[M+Na]+ (calc. 495.2 for C26H36O6Si+Na). 
1,2-O-Isopropylidene-3-O-methoxymethyl-β-D-arabinofuranose (66)        
The arabinofuranose derivative 65 (3.00 g, 6.36 mmol) was dissolved in dry THF (50.0 ml) and 
supplemented with TBAF (1 M solution in THF, 14.0 ml, 14.0 mmol, 2 eq.). The reaction 
mixture was stirred for 1 h at rt under a nitrogen atmosphere and concentrated in vacuo. The 
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crude product was chromatographed on silica gel (cyclohexane/ethyl acetate, 2:1 → 1:2) to 
give the product 66 (1.45 g, 6.20 mmol, 97%) as a colorless oil. TLC (cyclohexane/ethyl 
acetate, 4:1): Rf = 0.07; rotation value: [α]25𝐷  = + 33.2° (c = 0.5, CH2Cl2); 
1H NMR (500 MHz, 
CDCl3, 300 K): δ = 5.88 (d, 3J1,2 = 4.0 Hz, 1H, H-1), 4.72, 4.67 (d each, 2JOCHaOCH3,OCHbOCH3 
= 6.8 Hz, 1H each, OCH2OCH3), 4.62 (dd, 3J1,2 = 4.0 Hz, 3J2,3 = 0.6 Hz, 1H, H-2), 4.14-4.10 (m, 
2H, H-3, H-4), 3.77 (dd, 3J4,5a = 6.2 Hz, 2J5a,5b = 11.7 Hz, 1H, H-5a), 3.73 (dd, 3J4,5b = 4.8 Hz, 
2J5a,5b = 11.7 Hz, 1H, H-5b), 3.38 (s, 3H, OCH2OCH3), 2.24 (s, 1H, OH), 1.52, 1.32 (s each, 3H 
each, O2C(CH3)2) ppm; 13C NMR (125 MHz, CDCl3, 300 K): δ = 112.9 (O2C(CH3)2), 105.5 
(C-1), 95.5 (OCH2OCH3), 85.9 (C-3), 85.7 (C-2), 80.7 (C-4), 62.7 (C-5), 55.8 (OCH2OCH3), 
27.1, 26.3 (O2C(CH3)2) ppm; ESI-MS: m/z = 257.2, [M+Na]+ (calc. 257.1 for C10H18O6+Na). 
5-O-Allyl-1,2-O-isopropylidene-3-O-methoxymethyl-β-D-arabinofuranose (67)       
The arabinofuranose derivative 66 (500 mg, 2.14 mmol) was dissolved in dry DMF (40.0 ml). 
The solution was cooled with an ice bath and sodium hydride (NaH, 100 mg, 4.17 mmol, 2 eq.) 
was slowly added. The reaction was stirred for 30 min under ice cooling and a nitrogen 
atmosphere. Allyl bromide (580 µl, 6.71 mmol, 3 eq.) was added and the reaction stirred 
overnight at rt. After addition of dist. water the resulting mixture was extracted with diethyl 
ether. The combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. 
The crude product was chromatographed on silica gel (cyclohexane/ethyl acetate, 4:1) to give 
the fully protected sugar 67 (520 mg, 1.90 mmol, 89%) as a colorless liquid. 
TLC (cyclohexane/ethyl acetate, 4:1): Rf = 0.45; rotation value: [α]25𝐷  = + 16.3° (c = 0.5, 
CH2Cl2); 1H NMR (500 MHz, CDCl3, 300 K): δ = 5.94-5.85 (m, 1H, CH=CH2), 5.88 (d, 
3J1,2 = 3.9 Hz, 1H, H-1), 5.27 (dq, 4JOCHa,CH=CH2trans = 1.6 Hz, 4JOCHb,CH=CH2trans = 1.6 Hz, 
3JCH=CH2,CH=CH2trans = 17.3 Hz, 2JCH=CH2cis,CH=CH2trans = 1.6 Hz, 1H, CH=CH2,trans), 5.17 (ddd, 
4JOCH2,CH=CH2cis = 2.9 Hz,  3JCH=CH2,CH=CH2cis = 10.4 Hz, 2JCH=CH2cis,CH=CH2trans = 1.3 Hz, 1H, 
CH=CH2,cis), 4.71, 4.68 (d each, 2JOCHaOCH3,OCHbOCH3 = 6.8 Hz, 1H each, OCH2OCH3), 4.60 
(dd~d, 3J1,2 = 4.0 Hz, 1H, H-2), 4.18-4.13 (m, 2H, H-3, H-4), 4.04 (ddt, 2JOCHa,OCHb = 6.0 Hz, 
3JOCHa,CH=CH2 = 4.7 Hz, 4JOCHa,CH=CH2cis = 1.4 Hz,  4JOCHa,CH=CH2trans = 1.4 Hz,  2H, OCHa, OCHb), 
3.62 (dd~d, 3J4,5 = 6.1 Hz, 2H, H-5a, H-5b), 3.38 (s, 3H, OCH2OCH3), 1.52, 1.33 (s each, 3H 
each, O2C(CH3)2) ppm; 13C NMR (125 MHz, CDCl3, 300 K): δ = 134.6 (CH=CH2), 117.1 
(CH=CH2), 112.9 (O2C(CH3)2), 105.6 (C-1), 95.7 (OCH2OCH3), 85.5 (C-2), 84.1 (C-3), 80.6 
(C-4), 72.3 (OCH2), 70.1 (C-5), 55.7 (OCH2OCH3), 27.1, 26.3 (O2C(CH3)2) ppm; ESI-MS: 
m/z = 297.3, [M+Na]+ (calc. 297.1 for C13H22O6+Na). 
5-O-Allyl-α,β-D-arabinofuranose (68)                
The fully protected sugar 67 (900 mg, 3.28 mmol) was dissolved in DCM (30.0 ml), cooled with 
ice and supplemented with dist. water (3.00 ml) and TFA (15.0 ml, 196 mmol, 60 eq.). The 
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reaction mixture was stirred for 1 h under ice cooling and for 1 h at 40°C while concentrating 
in vacuo. The crude product was chromatographed on silica gel 
(cyclohexane/ethyl acetate/methanol, 4:4:1) to give the arabinofuranose derivative 68 
(520 mg, 2.74 mmol, 84%) as a colorless oil (α-furanose: β-furanose = 3:2 by integration of the 
1H NMR spectrum). TLC (cyclohexane/ethyl acetate/methanol, 4:4:1): Rf = 0.20, 0.14; rotation 
value: [α]23
𝐷
 = + 25.8° (c = 0.5, MeOH); 1H NMR (500 MHz, MeOH-d4, 300 K): δ = 6.00-5.91 (m, 
2H, CH=CH2 (α,β)), 5.32 (ddd, 4JOCH2,CH=CH2trans = 3.5 Hz, 3JCH=CH2,CH=CH2trans = 17.3 Hz, 
2JCH=CH2cis,CH=CH2trans = 1.7 Hz, 2H, CH=CH2,trans (α,β)), 5.21 (d, 3J1,2 = 3.7 Hz, 1H, H-1 (β)), 
5.22-5.18 (m, 2H, CH=CH2,cis (α,β)), 5.15 (d, 3J1,2 = 2.3 Hz, 1H, H-1 (α)), 4.14 (ddd~dt, 
3J3,4 = 6.0 Hz, 3J4,5a = 3.4 Hz, 3J4,5b = 5.9 Hz, 1H, H-4 (α)), 4.10-4.06 (m, 5H, H-4 (β), OCH2 
(α,β)), 3.98 (dd~t, 3J2,3 = 6.1 Hz, 3J3,4 = 6.1 Hz, 1H, H-3 (β)), 3.98-3.80 (m, 3H, H-2 (α,β), H-3 
(α)), 3.68 (dd, 3J4,5a = 3.4 Hz, 2J5a,5b = 10.7 Hz, 2H, H-5a (α,β)), 3.59 (dd, 3J4,5b = 5.7 Hz, 
2J5a,5b = 10.7 Hz, 2H, H-5b (α,β)) ppm; 13C NMR (125 MHz, MeOH-d4, 300 K): δ = 136.0 
(CH=CH2 (β)), 135.9 (CH=CH2 (α)), 117.4 (CH=CH2 (α,β)), 103.6 (C-1 (α)), 97.6 (C-1 (β)), 83.7 
(C-4 (α,β)), 83.6 (C-2 (α)), 82.4 (C-2 (β)), 78.6 (C-3 (α)), 77.3 (C-3 (β)), 73.3 (OCH2 (α,β)), 71.6 
(C-5 (α,β)) ppm.  
5-O-[6’-N-(tert-Butoxycarbonyl)amino-4’-thiahexyl]-α,β-D-arabinofuranose (69)                 
The arabinofuranose derivative 68 (130 mg, 680 µmol) and Boc protected cysteamine 72 
(475 mg, 3.17 mmol, 4.7 eq.) were dissolved in dry methanol (35.0 ml) and 2,2-dimethoxy-
2-phenylacetophenone (DPAP, 52.0 mg, 200 µmol, 0.3 eq.) was added. The reaction mixture 
was degassed with nitrogen and stirred 1 h at rt under a nitrogen atmosphere while irradiating 
at λmax 365 nm. After concentration in vacuo, the crude product was chromatographed on silica 
gel (methylene chloride/methanol, 18:1 → 15:1) to give 69 (187 mg, 510 µmol, 75%) as a 
colorless oil (α-furanose: β-furanose = 2:1 by integration of the 1H NMR spectrum). TLC 
(cyclohexane/ethyl acetate/methanol, 4:4:1): Rf = 0.125; rotation value: [α]25𝐷  = + 17.5° (c = 0.3, 
MeOH); 1H NMR (500 MHz, MeOH-d4, 300 K): δ = 5.21 (d, 3J1,2 = 4.4 Hz, 1H, H-1 (β)), 5.15 
(d~dd, 3J1,2 = 2.4 Hz, 4J1,3 = 0.4 Hz,  1H, H-1 (α)), 4.13 (ddd~dt, 3J3,4 = 5.8 Hz, 3J4,5a = 3.4 Hz, 
3J4,5b = 3.4 Hz,  1H, H-4 (α)), 3.98 (dd~t, 3J2,3 = 6.2 Hz, 3J3,4 = 6.2 Hz, 1H, H-3 (β)), 3.93 (dd, 
3J1,2 = 2.4 Hz, 3J2,3 = 4.2 Hz, 1H, H-2 (α)), 3.91 (dd, 3J1,2 = 4.4 Hz, 3J2,3 = 6.4 Hz, 1H, H-2 (β)), 
3.88 (dd, 3J2,3 = 4.3 Hz, 3J3,4 = 6.0 Hz, 1H, H-3 (α)), 3.85-3.81 (m, 1H, H-4 (β)), 3.67-3.56 (m, 
8H, H-5a,b (α,β), OCH2 (α,β)), 3.24 (t, 3JSCHa,CH2NHBoc = 7.1 Hz, 3JSCHb,CH2NHBoc = 7.1 Hz, 4H, 
CH2NHBoc (α,β)), 2.68-2.60 (m, 8H, SCH2 (α,β), CH2S (α,β)), 1.91-1.84 (m, 4H, OCH2CH2 
(α,β)) 1.47 (s, 18H, COOC(CH3)3 (α,β)) ppm; 13C NMR (125 MHz, CDCl3, 300 K): δ = 158.4 
(COOC(CH3)3 (α,β)), 103.6 (C-1 (α)), 97.6 (C-1 (β)), 83.7 (C-4 (α)), 83.6 (C-2 (α)), 82.4 (C-4 
(β)), 801 (C-2 (β)), 78.6 (C-3 (α)), 77.3 (C-3 (β)), 74.0 (C-5 (α)), 72.2 (C-5 (β)), 70.9 (OCH2 
(α,β)), 70.8 (COOC(CH3)3 (α,β)), 41.4 (CH2NHBoc (α,β)), 32.6 (CH2S (α,β)), 30.9 (OCH2CH2 
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(α,β)), 29.3 (SCH2 (α,β)), 28.8 (COOC(CH3)3 (α,β)) ppm; ESI-MS: m/z = 390.1, [M+Na]+ 
(calc. 390.2 for C15H29NO7S+Na). 
5-O-(6’-Amino-4’-thiahexyl)-α,β-D-arabinofuranose (70)           
Thiahexyl derivative 69 (75.0 mg, 200 µmol) was dissolved in DCM (15.0 ml), cooled with ice 
and supplemented with dist. water (2.00 ml) and TFA (7.00 ml, 91.5 mmol, 460 eq.). The 
reaction mixture was stirred for 7 h under ice cooling and concentrated in vacuo. The 
product 70 was co-evaporated with toluene and lyophilized to give a colorless oil (76.0 mg, 
200 µmol, quant.) ((α-furanose: β-furanose = 3:2 by integration of the 1H NMR spectrum). TLC 
(methylene chloride/methanol, 4:1): Rf = 0.29; rotation value: [α]23𝐷  = + 7.71° (c = 0.2, MeOH); 
1H NMR (500 MHz, D2O, 300 K): δ = 5.23 (d, 3J1,2 = 4.6 Hz, 1H, H-1 (β)), 5.18 (d, 3J1,2 = 2.7 Hz, 
1H, H-1 (α)), 4.14 (ddd~dt, 3J3,4 = 6.4 Hz, 3J4,5a = 3.0 Hz, 3J4,5b = 6.4 Hz, 1H, H-4 (α)), 4.02 (dd, 
3J1,2 = 4.6 Hz, 3J2,3 = 7.3 Hz, 1H, H-2 (β)), 3.97 (dd, 3J1,2 = 2.7 Hz, 3J2,3 = 4.4 Hz, 1H, H-2 (α)), 
3.95 (dd~t, 3J2,3 = 7.3 Hz, 3J3,4 = 7.3 Hz, 1H, H-3 (β)), 3.89 (dd, 3J2,3 = 4.4 Hz, 3J3,4 = 6.4 Hz, 1H, 
H-3 (α)),  3.85 (ddd~dt, 3J3,4 = 7.2 Hz, 3J4,5a = 3.1 Hz, 3J4,5b = 7.1 Hz, 1H, H-4 (β)), 3.70-3.54 (m, 
8H, H-5a,b (α,β), OCH2 (α,β)), 3.17 (t, 3JOCH2CHa,CH2S = 6.t Hz, 3JOCH2CHb,CH2S  = 6.7 Hz, 4H, 
CH2NH2 (α,β)), 2.81 (t, 3JOCH2CHa,CH2S = 6.7 Hz, 3JOCH2CHb,CH2S  = 6.7 Hz, 4H, SCH2 (α,β)), 2.61 (t, 
3JOCH2CHa,CH2S = 7.3 Hz, 3JOCH2CHb,CH2S  = 7.3 Hz, 4H, CH2S (α,β)), 1.88-1.80 (m, 4H, OCH2CH2 
(α,β)) ppm; 13C NMR (125 MHz, D2O, 300 K): δ = 101.2 (C-1 (α)), 95.4 (C-1 (β)), 81.6 (C-4 (α)), 
81.3 (C-2 (α)), 79.6 (C-4 (β)), 76.1 (C-3 (α)), 76.0 (C-2 (β)), 74.7 (C-3 (β)), 71.8 (C-5 (β)), 70.2 
(C-5 (α)), 69.7 (OCH2 (α)), 69.6 (OCH2 (β)), 38.3 (CH2NH2 (α,β)), 28.4 (SCH2 (α,β)), 28.2 
(OCH2CH2 (α,β)), 27.3 (CH2Sf (α,β)) ppm;  
2-N-(tert-Butoxycarbonyl)amino-ethanethiol (72)297                    
Cysteamine hydrochloride (10.0 g, 87.7 mmol) was suspended in DCM (800 ml) and 
supplemented with di-tert-butyl dicarbonate (19.2 g, 88.0 mmol, 1 eq.). Triethylamine (22.0 ml, 
158 mmol, 1.8 eq.) was slowly added and the reaction mixture was stirred 6 h at rt. The crude 
product was washed with hydrochloric acid (0.5 M), brine and dist. water, dried over MgSO4, 
filtered and concentrated in vacuo. The Boc-protected cysteamine 72 (10.1 g, 87.8 mmol, 
quant.) was obtained as a colorless liquid. TLC (cyclohexane/ethyl acetate/methanol, 4:4:1): 
Rf = 0.75; 1H NMR (200 MHz, CDCl3, 300 K): δ = 4.94 (s, 1H, NHBoc), 3.35-3.20 (m, 2H, 
CH2NHBoc), 2.62 (dt, 3JHSCH2,HSCH2 = 8.3 Hz, 3JHSCH2,CHaNHBoc = 6.5 Hz, 3JHSCH2,CHbNHBoc = 6.5 Hz, 
2H, HSCH2), 1.43 (s, 9H, COOC(CH3)3), 2.62 (t, 3JHSCH2,HSCHa = 8.5 Hz, 3JHSCH2,HSCHb = 8.5 Hz, 
2H, HSCH2) ppm. 
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S-Acetyl-2-N-(tert-butylcarbonyl)amino-ethanethiol (73)                    
The product 73 was obtained by a different synthetic route as described in literature:365 The 
Boc-protected cysteamine 72 (3.00 g, 26.1 mmol) was dissolved in dry pyridine (40.0 ml) and 
Ac2O (4.00 ml, 42.5 mmol, 1.6 eq.) was added. The reaction mixture was stirred for 4 h at rt 
and concentrated in vacuo. Silica gel chromatography (cyclohexane/ethyl acetate, 4:1) gave 
the fully protected cysteamine derivative 73 (4.06 g, 23.5 mmol, 90%) as a colorless solid. 
TLC (cyclohexane/ethyl acetate, 4:1): Rf = 0.4; 1H NMR (500 MHz, CDCl3, 300 K): δ = 4.80 (s, 
1H, NHBoc), 3.29 (s, 2H, CH2NHBoc), 2.99 (t, 3JAcSCH2,CHaNHBoc = 6.6 Hz, 
3JAcSCH2,CHbNHBoc = 6.6 Hz, 2H,AcSCH2), 2.34 (s, 3H, COCH3), 2.34 (s, 9H, COOC(CH3)3) ppm. 
S-Acetyl-2-amino-ethanethiol (74)366                       
The fully protected cysteamine derivative 73 (1.00 g, 5.78 mmol) was dissolved in DCM 
(100 ml) and supplemented with TFA (15.0 ml, 196 mmol, 34 eq.). The reaction mixture was 
stirred for 1 h at rt and concentrated in vacuo. The product 74 was co-evaporated with toluene 
and a colorless oil was obtained (1.34 g, 5.75 mmol, 99%). TLC (methylene chloride/methanol, 
4:1): Rf = 0.64; 1H NMR (500 MHz, MeOH-d4, 300 K): δ = 3.20-3.13 (m, 4H, NH2C2H4SAc), 
2.42 (s, 3H, COCH3) ppm.  
 
 
References 
 
159 
 
4    References 
1. World Health Organization. Global tuberculosis report 2015 (2015). 
2. World Health Organization. Implementing the WHO Stop TB strategy. A handbook for national tuberculosis 
control programmes (2008). 
3. Nyendak, M. R., Lewinsohn, D. A., Lewinsohn, D. M. New diagnostic methods for tuberculosis. 
Curr Opin Infect Dis 22, 174-182 (2009). 
4. Parsons, L. M. et al. Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and 
opportunities Clin Microbiol Rev 24, 314-350 (2011). 
5. Greco, S., Girardi, E., Navarra, A., Saltini, C. Current evidence on diagnostic accuracy of commercially based 
nucleic acid amplification tests for the diagnosis of pulmonary tuberculosis Thorax 61, 783-790 (2006). 
6. Ling, D. I., Flores, L. L., Riley, L. W., Pai, M. Commercial nucleic-acid amplification tests for diagnosis of 
pulmonary tuberculosis in respiratory specimens: meta-analysis and meta-regression PloS One 3, e1536 
(2008). 
7. Boehme, C. C. et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Eng J Med 363, 
1005-1015 (2010). 
8. Lacoma, A. et al. GenoType MTBDRplus assay for molecular detection of rifampin and isoniazid resistance in 
Mycobacterium tuberculosis strains and clinical samples. J Clin Microbiol 46, 3660-3667 (2008). 
9. Arnold, C. et al. Single-nucleotide polymorphism-based differentiation and drug resistance detection in 
Mycobacterium tuberculosis from isolates or directly from sputum. Clin Microbiol Infect 11, 122-130 (2005). 
10. Andersen, P., Munk, M. E., Pollock, J. M., Doherty, T. M. Specific immune-based diagnosis of tuberculosis. 
Lancet 356, 1099-1104 (2000). 
11. Huebner, R. E., Schein, M. F., Bass, J. B. The tuberculin skin test. Clin Infect Dis 17, 968-975 (1993). 
12. Van Pinxteren, L. A. H., Ravn, P., Agger, E. M., Pollock, J., Andersen, P. Diagnosis of tuberculosis based on 
the two specific antigens ESAT-6 and CFP10. Clin Diagn Lab Immunol 7, 155-160 (2000). 
13. Ravn, P. et al. Prospective evaluation of a whole-blood test using Mycobacterium tuberculosis-specific 
antigens ESAT-6 and CFP-10 for diagnosis of active tuberculosis. Clin Diagn Lab Immunol 12, 491-496 
(2005). 
14. Walzl, G., Ronacher, K., Djoba Siawaya, J. F., Dockrell, H. M. Biomarkers for TB treatment response: 
challenges and future strategies. J Infect 57, 103-109 (2008). 
15. Wallis, R. S. et al. Induction of the antigen 85 complex of Mycobacterium tuberculosis in sputum: a 
determinant of outcome in pulmonary tuberculosis treatment. J Infect Dis 178, 1115-1121 (1998). 
16. Pereira Arias-Bouda, L. M. et al. Development of antigen detection assay for diagnosis of tuberculosis using 
sputum samples. J Clin Microbiol 38, 2278-2283 (2000). 
17. Hamasur, B. et al. Rapid diagnosis of tuberculosis by detection of mycobacterial lipoarabinomannan in urine. 
J Microbiol Methods 45, 41-52 (2001). 
18. Boehme, C. et al. Detection of mycobacterial lipoarabinomannan with an antigen-capture ELISA in 
unprocessed urine of Tanzanian patients with suspected tuberculosis. Trans R Soc Trop Med Hyg 99, 
893-900 (2005). 
References 
 
160 
 
19. Minion, J. et al. Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and meta-analysis. 
Eur Respir J 38, 1398-1405 (2011). 
20. Yang, C. M., Hsu, C. H., Lee, C. M., Wang, F. C. Intense uptake of [F-18]-fluoro-2 deoxy-D-glucose in active 
pulmonary tuberculosis. Ann Nucl Med 17, 407-410 (2003). 
21. Chen, R. Y. et al. PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant 
tuberculosis. Sci Transl Med. 6, 265ra166 (2014). 
22. Russell, D. G., Barry, C. E. 3rd, Flynn, J. L. Tuberculosis: what we don't know can, and does, hurt us. 
Science 328, 852-856 (2010). 
23. Capon, A. W. Streptomycin, PAS and isoniazid in the treatment of pulmonary tuberculosis. Can Med Assoc J 
70, 62-67 (1954). 
24. Falzon, D. et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 
update. Eur Respir J 38, 516-528 (2011). 
25. Ling, L. L. et al. A new antibiotic kills pathogens without detectable resistance. Nature 517, 455-459 (2015). 
26. Gomez, J. E., McKinney, J. D. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis 84, 
29-44 (2004). 
27. Nathan, C., Barry, C. E. 3rd TB drug development: immunology at the table. Immunol Rev 264, 308-318 
(2015). 
28. Kremer, L. S., Besra, G. S. Current status and future development of antitubercular chemotherapy. 
Expert Opin Investig Drugs 11, 1033-1049 (2002). 
29. Suarez, J. et al. An oxyferrous heme/protein-based radical intermediate is catalytically competent in the 
catalase reaction of Mycobacterium tuberculosis catalase-peroxidase (KatG). J Biol Chem 284, 7017-7029 
(2009). 
30. Lee, R. E., Mikusova, K., Brennan, P. J., Besra, G. S. Synthesis of the arabinose donor β-D-arabinofuranosyl-
1-monophosphoryldecaprenol, development of a basic arabinosyl-transferase assay, and identification of 
ethambutol as an arabinosyl transferase inhibitor. J Am Chem Soc 117, 11829-11832 (1995). 
31. Calvori, C., Frontali, L., Leoni, L., Tecce, G. Effect of rifamycin on protein synthesis. Nature 207, 417-418 
(1965). 
32. Shi, W. et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 333, 1630-1632 
(2011). 
33. Koch, R. Die Ätiologie der Tuberkulose. Berliner Klinische Wochenschrift, 428-445 (1882). 
34. Cole, S. T. et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome 
sequence. Nature 393, 537–544 (1998). 
35. de Jong, B. C., Antonio, M. & Gagneux, S. Mycobacterium africanum-review of an important cause of human 
tuberculosis in West Africa. PLoS Negl Trop Dis 4, e744 (2010). 
36. Fabre, M. et al. Molecular characteristics of "Mycobacterium canettii" the smooth Mycobacterium tuberculosis 
bacilli. Infect Genet Evol 10, 1165-1173 (2010). 
37. Koeck, J. L. et al. Clinical characteristics of the smooth tubercle bacilli 'Mycobacterium canettii' infection 
suggest the existence of an environmental reservoir. Clin Microbiol Infect 17, 1013-1019 (2011). 
References 
 
161 
 
38. Smith, N. H. et al. Ecotypes of the Mycobacterium tuberculosis complex. J Theor Biol 239, 220-225 (2006). 
39. Grange, J. M. Mycobacterium bovis infection in human beings. Tuberculosis 81, 71-77 (2001). 
40. Smith, N. H., Gordon, S. V., de la Rua-Domenech, R., Clifton-Hadley, R. S., Hewinson, R. G. Bottlenecks and 
broomsticks: the molecular evolution of Mycobacterium bovis. Nat Rev Microbiol 4, 670-681 (2006). 
41. Gagneux, S., Small, P. M. Global phylogeography of Mycobacterium tuberculosis and implications for 
tuberculosis product development. Lancet Infect Dis 7, 328-337 (2007). 
42. Brosch, R. et al. A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc Natl Acad 
Sci USA 99, 3684-3689 (2002). 
43. Gagneux, S. Host-pathogen coevolution in human tuberculosis. Phil Trans R Soc B 367, 850-859 (2012). 
44. Brudey, K. et al. Mycobacterium tuberculosis complex genetic diversity: mining the fourth international 
spoligotyping database (SpolDB4) for classification, population genetics and epidemiology. BMC Microbiol 6, 
23 (2006). 
45. Gagneux, S. et al. Variable host-pathogen compatibility in Mycobacterium tuberculosis. 
Proc Natl Acad Sci USA 103, 2869-2873 (2006). 
46. Reiling, N. et al. Clade-specific virulence patterns of Mycobacterium tuberculosis complex strains in human 
primary macrophages and aerogenically infected mice. mBio 4, e00250-13 (2013). 
47. Homolka, S., Niemann, S., Russell, D. G., Rohde, K. H. Functional genetic diversity among Mycobacterium 
tuberculosis complex clinical isolates: delineation of conserved core and lineage-specific transcriptomes 
during intracellular survival. PLoS Pathog 6, e1000988 (2010). 
48. Comas, I. et al. Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with 
modern humans. Nat Genet 45, 1176-1182 (2013). 
49. Barry, C. E. 3rd Interpreting cell wall ‘virulence factors’ of Mycobacterium tuberculosis. Trends Microbiol 9, 
237-241 (2001). 
50. Olsen, G. J., Woese, C. R. Ribosimal RNA: a key to phylogeny. FASEB J 7, 113-123 (1993). 
51. Woese, C. R. Bacterial evolution. Microbiol Rev 51, 221-271 (1987). 
52. Fu, L. M., Fu-Liu, C. S. Is Mycobacterium tuberculosis a closer relative to Gram-positive or Gram-negative 
bacterial pathogens? Tuberculosis 82, 85-90 (2002). 
53. Hoffmann, C., Leis, A., Niederweis, M., Plitzko, J. M., Engelhardt, H. Disclosure of the mycobacterial outer 
membrane: cryo-electron tomography and vitreous sections reveal the lipid bilayer structure. 
Proc Natl Acad Sci USA 105, 3963-3967 (2008). 
54. Zuber, B. et al. Direct visualization of the outer membrane of mycobacteria and corynebacteria in their native 
state. J Bacteriol 190, 5672-5680 (2008). 
55. Brennan, P. J., Crick, D. C. The cell-wall core of Mycobacterium tuberculosis in the context of drug Discovery. 
Curr Top Med Chem 7, 475-488 (2007). 
56. Wietzerbin, J. et al. Occurrence of D-alanyl-D-meso-diaminopimelic acid and meso-diaminopimelyl-meso-
diaminopimelic acid interpeptide linkages in the peptidoglycan of mycobacteria. Biochemistry 13, 3471-3476 
(1974). 
References 
 
162 
 
57. Schleifer, K. H., Kandler, O. Peptidoglycan types of bacterial cell walls and their taxonomic implications. 
Bacteriol Rev 36, 407-477 (1972). 
58. McNeil, M., Daffe, M., Brennan, P. J. Evidence of the nature of the link between the arabinogalactan and 
peptidoglycan of the mycobacterial cell wall. J Biol Chem 265, 18200-18206 (1990). 
59. Daffe, M., Brennan, P. J., McNeil, M. Predominant structural features of the cell wall arabinogalactan of 
Mycobacterium tuberculosis as revealed through characterization of oligoglycosyl alditol fragments by gas 
chromatography/mass spectrometry and by 1H and 13C NMR analyses. J Biol Chem 265, 6734-6743 (1990). 
60. McNeil, M., Daffe, M., Brennan, P. J. Location of the mycolyl ester substituents in the cell walls of 
mycobacteria. J Biol Chem 266, 13217-13223 (1991). 
61. Hong, S. et al. Ultralong C100 mycolic acids support the assignment of Segniliparus as a new bacterial 
genus. PloS One 7, e39017 (2012). 
62. Barry, C. E. 3rd et al. Mycolic acids: structure, biosynthesis and physiological functions. Prog Lipid Res 37, 
143-179 (1998). 
63. Besra, G. S., Brennan, P. J. The mycobacterial cell wall: biosynthesis of arabinogalactan and 
lipoarabinomannan. Biochem Soc Trans 25, 845-850 (1997). 
64. Marrakchi, H., Lanéelle, M. A., Daffé, M. Mycolic acids: structures, biosynthesis, and beyond. Chem Biol 21, 
67-85 (2014). 
65. Hunter, S. W., Brennan, P. J. Evidence for the presence of a phosphatidylinositol anchor on the 
lipoarabinomannan and lipomannan of Mycobacterium tuberculosis. J Biol Chem 265, 9272-9279 (1990). 
66. Korduláková, J. et al. Identification of the required acyltransferase step in the biosynthesis of the 
phosphatidylinositol mannosides of mycobacterium species. J Biol Chem 278, 36285-36295 (2003). 
67. Hsu, F. F., Turk, J., Owens, R. M., Rhoades, E. R., Russell, D. G. Structural characterization of phosphatidyl-
myo-inositol mannosides from Mycobacterium bovis Bacillus Calmette Gúerin by multiple-stage quadrupole 
ion-trap mass spectrometry with electrospray ionization. II. Monoacyl- and diacyl-PIMs. 
J Am Soc Mass Spectrom 18, 479-492 (2007). 
68. Briken, V., Porcelli, S. A., Besra, G. S., Kremer, L. Mycobacterial lipoarabinomannan and related lipoglycans: 
from biogenesis to modulation of the immune response. Mol Microbiol 53, 391-403 (2004). 
69. Nigou, J., Gilleron, M.,  Puzo, G. Lipoarabinomannans: from structure to biosynthesis. Biochimie 85, 153-166 
(2003). 
70. Chatterjee, D., Khoo, K. H. The surface glycopeptidolipids of mycobacteria: structures and biological 
properties. Cell Mol Life Sci 58, 2018-2042 (2001). 
71. Khoo, K. H., Dell, A., Morris, H. R., Brennan, P. J., Chaterjee, D. Inositol phosphate capping of the 
nonreducing termini of lipoarabiniomannan from rapidly growing strains of Mycobacterium. J Biol Chem 270, 
12380-12389 (1995). 
72. Guerardel, Y. et al. Structural study of lipomannan and lipoarabinomannan from Mycobacterium chelonae. 
Presence of unusual components with alpha 1,3-mannopyranose side chains. J Biol Chem 277, 30635-30648 
(2002). 
73. Fujiwara, N. Distribution of antigenic glycolipids among Mycobacterium tuberculosis strains and their 
contribution to virulence. Kekkaku 72, 193-205 (1997). 
References 
 
163 
 
74. Sarathy, J. P., Dartois, V., Lee, E. J. D. The role of transport mechanisms in Mycobacterium tuberculosis drug 
resistance and tolerance. Pharmaceuticals 5, 1210-1235 (2012). 
75. Elbein, A. D., Pan, Y. T., Pastuszak, I., Carroll, D. New insights on trehalose: a multifunctional molecule. 
Glycobiology 13, 17R-27R (2003). 
76. Berg, S., Kaur, D., Jackson, M., Brennan, P. J. The glycosyltransferases of Mycobacterium tuberculosis - 
roles in the synthesis of arabinogalactan, lipoarabinomannan, and other glycoconjugates. Glycobiology 17, 
35-56R (2007). 
77. Webb, K. M., DiRuggiero, J. Role of Mn2+ and compatible solutes in the radiation resistance of thermophilic 
bacteria and archaea. Archaea 2012, 845756 (2012). 
78. Lee, J. et al. Trehalose glycopolymers as excipients for protein stabilization. Biomacromolecules 14, 
2561-2569 (2013). 
79. Iturriaga, G., Suárez, R., Nova-Franco, B. Trehalose metabolism: from osmoprotection to signaling. 
Int J Mol Sci 10, 3793–3810 (2009). 
80. Lang, R. Recognition of the mycobacterial cord factor by Mincle: relevance for granuloma formation and 
resistance to tuberculosis. Front Immunol 4, 5 (2013). 
81. Billi, D., Potts, M. Life and death of dried prokaryotes. Res Microbiol 153, 7-12 (2002). 
82. Nobre, A., Alarico, S., Maranha, A., Mendes, V., Empadinhas, N. The molecular biology of mycobacterial 
trehalose in the quest for advanced tuberculosis therapies. Microbiology 160, 1547-1570 (2014). 
83. De Smet, K. A., Weston, A., Brown, I. N., Young, D. B., Robertson, B. D. Three pathways for trehalose 
biosynthesis in mycobacteria. Microbiology 146, 199-208 (2000). 
84. Tahlan, K. et al. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in 
mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother 56, 
1797-1809 (2012). 
85. Grzegorzewicz, A. E. et al. Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma 
membrane. Nat Chem Biol 8, 334-341 (2012). 
86. Sathyamoorthy, N., Takayama, K. Purification and characterization of a novel mycolic acid exchange enzyme 
from Mycobacterium smegmatis. J Biol Chem  262, 13417-13423 (1987). 
87. Kalscheuer, R., Weinrick, B., Veeraraghavan, U., Besra, G. S., Jacobs, W. R. Trehalose-recycling ABC 
transporter LpqY-SugA-SugB-SugC is essential for virulence of Mycobacterium tuberculosis. 
Proc Natl Acad Sci USA 107, 21761-21766 (2010). 
88. Swarts, B. M. et al. Probing the mycobacterial trehalome with bioorthogonal chemistry. J Am Chem Soc 134, 
16123-16126 (2012). 
89. Fincher, G. B., Stone, B. A., Clarke, A. E. Arabinogalactan-Proteins: Structure, Biosynthesis, and Function. 
Ann Rev Plant Physiol 34, 47-70 (1983). 
90. Dobson, D. E. et al. Identification of genes encoding arabinosyltransferases (SCA) mediating developmental 
modifications of lipophosphoglycan required for sand fly transmission of Leishmania major. J Biol Chem 278, 
28840-28848 (2003). 
91. Goswami, M., Dobson, D. E., Beverley, S. M., Turco, S. J. Demonstration by heterologous expression that 
the Leishmania SCA1 gene encodes an arabinopyranosyltransferase. Glycobiology 16, 230-236 (2006). 
References 
 
164 
 
92. Guha-Niyogi, A., Sullivan, D. R., Turco, S. J. Glycoconjugate structures of parasitic protozoa. Glycobiology 
11, 45R-59R (2001). 
93. Previato, J. O., Mendonca-Previato, L., Lewanczuk, R. Z., Travassos, L. R., Gorin, P. A. J. Crithidia spp.: 
structural comparison of polysaccharides for taxonomic significance. Exp Parasitol 53, 170-178 (1982). 
94. Xavier Da Dilveira, E., Jones, C., Wait, R., Previato, J. O., Mendonca-Previato, L. Glycoinositol phospholipids 
from Endotrypanum species express epitopes in common with saccharide side chains of the 
lipophosphoglycan from Leishmania major. Biochem J 329, 665-673 (1998). 
95. Levin, D. H., Racker, E. Condensation of Arabinose 5-Phosphate and Phosphorylenol Pyrovate by 2-Keto-3-
deoxy-8-phosphooctonic Acid Synthetase. J Biol Chem 234, 2532-2539 (1959). 
96. McNeil, M., Wallner, S. J., Hunter, S. W., Brennan, P. J. Demonstration that the galactosyl and arabinosyl 
residues in the cell-wall arabinogalactan of Mycobacterium leprae and Mycobacterium tuberculosis are 
furanoid. Carbohydr Res 166, 299-308 (1987). 
97. Wolucka, B. A. Biosynthesis of D-arabinose in mycobacteria - a novel bacterial pathway with implications for 
antimycobacterial therapy. FEBS J 275, 2691-2711 (2008). 
98. Wojtkiewicz, B., Szmidzinski, R., Jezierska, A., Cocito, C. Identification of a salvage pathway for D-arabinose 
in Mycobacterium smegmatis. Eur J Biochem 172, 197-203 (1988). 
99. Izumori, K., Waltanabe, Y., Sugimoto, S. Evolution of D-arabinose, L-xylose and L-ribose utilization in 
Mycobacterium smegmatis: mutants with a novel enzyme "pentose reductase". Agric Bioi Chem 44, 
1443-1446 (1980). 
100.Niederweis, M. Nutrient acquisition by mycobacteria. Microbiology 154, 679-692 (2008). 
101.Schlesinger, L. S. et al. Determinants of phagocytosis, phagosome biogenesis and autophagy for 
Mycobacterium tuberculosis. In Handbook of Tuberculosis: Immunology and Cell Biology Edn 2 Vol. 2 (eds 
Kaufmann, S. H. E., Rubin, E.), 1-22 (WILEY-VCH, Weinheim, 2008). 
102.Vergne, I., Gilleron, M., Nigou, J. Manipulation of the endocytic pathway and phagocyte functions by 
Mycobacterium tuberculosis lipoarabinomannan. Front Cell Infect Microbiol 4, 187 (2015). 
103.Kleinnijenhuis, J., Oosting, M., Joosten, L. A., Netea, M. G., van Crevel, R. Innate immune recognition of 
Mycobacterium tuberculosis. Clin Dev Immunol 2011, 405310 (2011). 
104.Hossain, M. M., Norazmi, M.N. Pattern recognition receptors and cytokines in Mycobacterium tuberculosis 
infection - the double-edged sword? Biomed Res Int 2013, 179174 (2013). 
105.Gaynor, C. D., McCormack, F. X., Voelker, D. R., McGowan, S. E., Schlesinger, L. S. Pulmonary surfactant 
protein A mediates enhanced phagocytosis of Mycobacterium tuberculosis by a direct interaction with human 
macrophages. J Immunol 155, 5343-5351 (1995). 
106.Garred, P., Harboe, M., Oettinger, T., Koch, C., Svejgaard, A. Dual role of mannan-binding protein in 
infections: another case of heterosis? Eur J lmmunogenet 21, 125-131 (1994). 
107.Tailleux, L. et al. DC-SIGN induction in alveolar macrophages defines privileged target host cells for 
mycobacteria in patients with tuberculosis. PLoS Med 2, e381 (2005). 
108.Tailleux, L. et al. DC-SIGN is the major Mycobacterium tuberculosis receptor on human dendritic cells. 
J Exp Med 197, 121-127 (2003). 
References 
 
165 
 
109.van de Veerdonk, F. L. et al. Mycobacterium tuberculosis induces IL-17A responses through TLR4 and 
dectin-1 and is critically dependent on endogenous IL-1. J Leukoc Biol 88, 227-232 (2010). 
110.Yadav, M., Schorey, J. S. The beta-glucan receptor dectin-1 functions together with TLR2 to mediate 
macrophage activation by mycobacteria. Blood 108, 3168-3175 (2006). 
111.Yonekawa, A. et al. Dectin-2 is a direct receptor for mannose-capped lipoarabinomannan of mycobacteria. 
Immunity 41, 402-413 (2014). 
112.Ishikawa, E. et al. Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin 
Mincle. J Expl Med 206, 2879-2888 (2009). 
113.Lobato-Pascual, A., Saether, P. C., Fossum, S., Dissen, E., Daws, M. R. Mincle, the receptor for 
mycobacterial cord factor, forms a functional receptor complex with MCL and FcεRI-γ. Eur J Immunol 43, 
3167-3174 (2013). 
114.Richardson, M. B., Williams, S. J. MCL and Mincle: C-type lectin receptors that sense damaged self and 
pathogen-associated molecular patterns. Front Immunol 5, 288 (2014). 
115.Schlesinger, L. S., Hull, S. R., Kaufman, T. M. Binding of the terminal mannosyl units of lipoarabinomannan 
from a virulent strain of Mycobacterium tuberculosis to human macrophages. J Immunol 152, 4070-4079 
(1994). 
116.Schlesinger, L. S. Macrophage phagocytosis of virulent but not attenuated strains of Mycobacterium 
tuberculosis is mediated by mannose receptors in addition to complement receptors. J Immunol 150, 
2920-2930 (1993). 
117.Schlesinger, L. S., Kaufman, T. M., lyer, S., Hull, S. R., Marchiando, L. K. Differences in mannose receptor-
mediated uptake of lipoarabinomannan from virulent and attenuated strains of Mycobacterium tuberculosis by 
human macrophages. J Immunol 157, 4568-4575 (1996). 
118.Torrelles, J. B., Azad, A. K., Schlesinger, L. S. Fine discrimination in the recognition of individual species of 
phosphatidyl-myo-inositol mannosides from Mycobacterium tuberculosis by C-type lectin pattern recognition 
receptors. J Immunol 177, 1805-1816 (2006). 
119.Torrelles, J. B., Schlesinger, L. S. Diversity in Mycobacterium tuberculosis mannosylated cell wall 
determinants impacts adaptation to the host. Tuberculosis 90, 84-93 (2010). 
120.Nigou, J. et al. Mannan chain length controls lipoglycans signaling via and binding to TLR2. J Immunol 180, 
6696-6702 (2008). 
121.Quesniaux, V. J. et al. Toll-like receptor 2 (TLR2)-dependent-positive and TLR2-independent-negative 
regulation of proinflammatory cytokines by mycobacterial lipomannans. J Immunol 172, 4425-4434 (2004). 
122.Reiling, N., Ehlers, S., Hölscher, C. MyDths and un-TOLLed truths: sensor, instructive and effector immunity 
to tuberculosis. Immunol Lett 116, 15-23 (2008). 
123.Geurtsen, J. et al. Identification of mycobacterial alpha-glucan as a novel ligand for DC-SIGN: involvement of 
mycobacterial capsular polysaccharides in host immune modulation. J Immunol 183, 5221-5231 (2009). 
124.Geijtenbeek, T. B. et al. Mycobacteria target DC-SIGN to suppress dendritic cell function. J Exp Med 197, 
7-17 (2002). 
125.Pitarque, S. et al. Deciphering the molecular bases of Mycobacterium tuberculosis binding to the lectin 
DC-SIGN reveals an underestimated complexity. Biochem J 392, 615-624 (2005). 
References 
 
166 
 
126.Dinadayala, P. et al. Revisiting the structure of the anti-neoplastic glucans of Mycobacterium bovis Bacille 
Calmette-Guerin. Structural analysis of the extracellular and boiling water extract-derived glucans of the 
vaccine substrains. J Biol Chem 279, 12369-12378 (2004). 
127.Russell, D. G., Purdy, G. E., Owens, R. M., Rohde, K. H., Yates, R. M. Mycobacterium tuberculosis and the 
four-minute phagosome. ASM News 71, 459-463 (2005). 
128.Mishra, A. K., Driessen, N. N., Appelmelk, B. J. & Besra, G. S. Lipoarabinomannan and related 
glycoconjugates: structure, biogenesis and role in Mycobacterium tuberculosis physiology and host-pathogen 
interaction. FEMS Microbiol Rev 35, 1126-1157 (2011). 
129.Kang, P. B. et al. The human macrophage mannose receptor directs Mycobacterium tuberculosis 
lipoarabinomannan-mediated phagosome biogenesis. J Exp Med 202, 987-999 (2005). 
130.Malik, Z. A., Iyer, S. S., Kusner, D. J. Mycobacterium tuberculosis phagosomes exhibit altered calmodulin-
dependent signal transduction. Contribution to inhibition of phagosome-lysosome fusion and intracellular 
survival in human macrophages. J Immunol 166, 3392-3401 (2001). 
131.Malik, Z. A., Denning, G. M., Kusner, D. J. Inhibition of Ca2+ signaling by Mycobacterium tuberculosis is 
associated with reduced phagosome-lysosome fusion and increased survival within human macrophages. J 
Exp Med 191, 287-302 (2000). 
132.Vergne, I., Chua, J. & Deretic, V. Tuberculosis toxin blocking phagosome maturation inhibits a novel 
Ca2+/calmodulin-PI3K hVPS34 cascade. J Exp Med 198, 653-659 (2003). 
133.Kyei, G. B. et al. Rab14 is critical for maintenance of Mycobacterium tuberculosis phagosome maturation 
arrest. EMBO J 25, 5250-5259 (2006). 
134.Axelrod, S. et al. Delay of phagosome maturation by a mycobacterial lipid is reversed by nitric oxide. 
Cell Microbiol 10, 1530-1545 (2008). 
135.Seto, S., Tsujimura, K., Koide, Y. Rab GTPases regulating phagosome maturation are differentially recruited 
to mycobacterial phagosomes. Traffic 12, 407-420 (2011). 
136.Steinhäuser, C. et al. Lipid-labeling facilitates a novel magnetic isolation procedure to characterize pathogen-
containing phagosomes. Traffic 14, 321-336 (2013). 
137.Rojas, M., Garcia, L. F., Nigou, J., Puzo, G. & Olivier, M. Mannosylated lipoarabinomannan antagonizes 
Mycobacterium tuberculosis–induced macrophage apoptosis by altering Ca2+-dependent cell signaling. 
J Infect Dis 182, 240-251 (2000). 
138.Maiti, D., Bhattacharyya, A., Basu, J. Lipoarabinomannan from Mycobacterium tuberculosis promotes 
macrophage survival by phosphorylating Bad through a phosphatidylinositol 3-kinase/Akt pathway. 
J Biol Chem 276, 329-333 (2001). 
139.Dao, D. N. et al. Mycobacterium tuberculosis lipomannan induces apoptosis and interleukin-12 production in 
macrophages. Infect Immun 72, 2067-2074 (2004). 
140.Vignal, C. et al. Lipomannans, but not lipoarabinomannans, purified from Mycobacterium chelonae and 
Mycobacterium kansasii induce TNF- and IL-8 secretion by a CD14-Toll-like receptor 2-dependent 
mechanism. J Immunol 171, 2014-2023 (2003). 
141.Torrelles, J. B. et al. Identification of Mycobacterium tuberculosis clinical isolates with altered phagocytosis by 
human macrophages due to a truncated lipoarabinomannan. J Biol Chem 283, 31417-31428 (2008). 
References 
 
167 
 
142.Amin, A. G. et al. EmbA is an essential arabinosyltransferase in Mycobacterium tuberculosis. Microbiology 
154, 240-248 (2008). 
143.Goude, R., Amin, A. G., Chatterjee, D., Parish, T. The critical role of embC in Mycobacterium tuberculosis. 
J Bacteriol 190, 4335-4341 (2008). 
144.Esko, J. D., Sharon, N. Microbial lectins: hemagglutinins, adhesins, and toxins. In Essentials of Glycobiology. 
Edn 2 (eds. Varki et al.), 489-500 (Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press, 2009). 
145.Kundu, M., Basu, J., Chakrabarti, P. Purification and characterization of an extracellular lectin from 
Mycobacterium smegmatis. FEBS Lett 256, 207-210 (1989). 
146.Goswami, S., Sarkar, S., Basu, J., Kundu, M., Chakrabarti, P. Mycotin. A lectin involved in the adherence of 
mycobacteria to macrophages. FEBS Lett 355, 183-186 (1994). 
147.Anton, V., Roug, P., Daffé, M. Identification of the sugars involved in mycobacterial cell aggregation. 
FEMS Microbiol Lett 144, 167-170 (1996). 
148.Singh, D. D., Chandran, D., Jeyakani, J., Chandran, N. Scanning the genome of Mycobacterium tuberculosis 
to identify potential lectins. Protein Pept Lett 14, 683-691 (2007). 
149.Abhinav, K. V., Sharma, A., Vijayan, M. Identification of mycobacterial lectins from genomic data. Proteins 81, 
644-657 (2013). 
150.Steingart, K. R. et al. Sputum processing methods to improve the sensitivity of smear microscopy for 
tuberculosis: a systematic review. Lancet Infect Dis 6, 664-674 (2006). 
151.Yeager, H. Jr., Lacy, J., Smith, L. R., Lemaistre, C. A. Quantitative studies of mycobacterial populations in 
sputum and saliva. Am Rev Respir Dis 95, 998-1004 (1967). 
152.Zar, H. J. et al. Sputum induction for the diagnosis of pulmonary tuberculosis in infants and young children in 
an urban setting in South Africa. Arch Dis Child 82, 305-308 (2000). 
153.Owens, S. et al. Nasopharyngeal aspiration for diagnosis of pulmonary tuberculosis. Arch Dis Child 92, 
693-696 (2007). 
154.Marais, B. J., Pai, M. Specimen collection methods in the diagnosis of childhood tuberculosis. 
Indian J Med Microbiol 24, 249-251 (2006). 
155.Lunawat, P. P. et al. Detection of acid fast bacilli in saliva using papanicolaou stain induced fluorescence 
method versus fluorochrome staining: an evaluative study. J Int Oral Health 7, 115-120 (2015). 
156.Holani, A. G. et al. Demonstration of Mycobacterium tuberculosis in sputum and saliva smears of tuberculosis 
patients using Ziehl Neelsen and flurochrome staining - a comparative study. J Clin Diagn Res 8, ZC42-ZC45 
(2014). 
157.Mediero, G. G., Gallardo, R. V., Del Molino, M. L. P., Dios, P. D. Evaluation of two commercial nucleic acid 
amplification kits for detecting Mycobacterium tuberculosis in saliva samples. Oral Dis 21, 451-455 (2015). 
158.Yassen, G., Noori, J., Yas, N. S. Detection of acid fast bacilli in the saliva of patients having pulmonary 
tuberculosis. J Bagh College Dentistry 24, 59-62 (2012). 
159.Neild, N., Dunkley, E. V. The role of the saliva in the transmission of tubercle. Lancet 173, 1096-1098 (1909). 
160.Stratmann, J., Strommenger, B., Stevenson, K., Gerlach, G. F. Development of a peptide-mediated capture 
PCR for detection of Mycobacterium avium subsp. paratuberculosis in milk. J Clin Microbiol 40, 4244-4250 
(2002). 
References 
 
168 
 
161.Garbaccio, S. G., Cataldi, A. A. Evaluation of an immunomagnetic capture method followed by PCR to detect 
Mycobacterium bovis in tissue samples from cattle. Rev Argent Microbiol 42, 247-253 (2010). 
162.Arutyunov, D. et al. Mycobacteriophage cell binding proteins for the capture of mycobacteria. Bacteriophage 
4, e960346 (2014). 
163.Hunter, D. M., Lim, D. V. An IMS/ATP assay for the detection of Mycobacterium tuberculosis in urine. 
Tuberc Res Treat 2012, 292605 (2012). 
164.Sweeney, F. P. et al. Immunomagnetic recovery of Mycobacterium bovis from naturally infected 
environmental samples. Lett Appl Microbiol 43, 364-369 (2006). 
165.Grant, I. R., Ball, H. J., Rowe, M. T. Isolation of Mycobacterium paratuberculosis from milk by 
immunomagnetic separation. Appl Environ Microbiol 64, 3153-3158 (1998). 
166.Wilson, S., Lane, A., Rosedale, R., Stanley, C. Concentration of Mycobacterium tuberculosis from sputum 
using ligand-coated magnetic beads. Int J Tuberc Lung Dis 14, 1164-1168 (2010). 
167.Wang, X. et al. Bead capture increases the sensitivity of sputum microscopy for the diagnosis of tuberculosis 
in Beijing, China. Trans R Soc Trop Med Hyg 107, 741-743 (2013). 
168.Ghodbane, R., Drancourt, M. Magnetic bead protocol for culturing Mycobacterium tuberculosis from sputum 
specimens. J Clin Microbiol 51, 1578-1579 (2013). 
169.Kang, J. H. et al. An extracorporeal blood-cleansing device for sepsis therapy. Nat Med 20, 1211-1216 
(2014). 
170.Hartmann, M. et al. Saccharide-modified nanodiamond conjugates for the efficient detection and removal of 
pathogenic bacteria. Chemistry 18, 6485-6492 (2012). 
171.Qi, Z. et al. Multivalency at interfaces: supramolecular carbohydrate-functionalized graphene derivatives for 
bacterial capture, release, and disinfection. Nano Lett 15, 6051-6057 (2015). 
172.Carr, S. W., Pickup, K. M., Smith, P. M., Schilling, K. M. Oral care compositions. US Patent 5824292 filed 
12 Apr. 1996, and issued 20 Oct. 1998.  
173.Lau, A., Eason, R., Brevnow, M., Li, H., Hacker, K. Magnetic beads having surface glycoconjugates and use 
thereof. US Patent PCT/US2011/048693 filed 22 Aug. 2011, and issued 23 Feb. 2012. 
174.Wang, H., Ng, T. B. First report of an arabinose-specific fungal lectin. Biochem Biophys Res Commun 337, 
621-625 (2005). 
175.Sudakevitz, D., Imberty, A., Gilbos-Garber, N. Production, properties and specificity of a bew bacterial 
L-fucose- and D-arabinose-binding lectin of the plant aggressive pathogen Ralstonia solanacearum, and its 
comparison to related plant and microbial lectins. J Biochem 132, 353-358 (2002). 
176.Adam, J. et al. Engineering of PA-IIL lectin from Pseudomonas aeruginosa - Unravelling the role of the 
specificity loop for sugar preference. BMC Struct Biol 7, 36 (2007). 
177.Stanley, P., Schachter, H., Taniguchi, N. N-Glycans. In Essentials of Glycobiology. Edn 2 (eds. Varki et al.), 
101-114 (Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press, 2009). 
178.Knight, S. D., Bouckaert, J. Structure, function, and assembly of type 1 fimbriae. Top Curr Chem 288, 67-107 
(2009). 
179.Hartmann, M., Lindhorst, T. K. The bacterial lectin FimH, a target for drug discovery - Carbohydrate inhibitors 
of type-1 fimbriae-mediated bacterial adhesion. Eur J Org Chem 2011, 3583-3609 (2011). 
References 
 
169 
 
180.Lindhorst, T. K., Kötter, S., Krallmann-Wenzel, U., Ehlers, S. Trivalent α-D-mannoside clusters as inhibitors of 
type-1 fimbriae-mediated adhesion of Escherichia coli. Structural variation and biotinylation. J Chem Soc 1, 
823-831 (2001). 
181.Bonner, W. Isomers of tetra-O-acetyl-D-mannopyranose. J Am Chem Soc 80, 3372-3378 (1958). 
182.Dahmén, J. et al. 2-Bromoethyl glycosides: synthesis and characterisation. Carbohydr Res 116, 303-307 
(1983). 
183.Zemplén, G., Pacsu, E. Über die Verseifung acetylierter Zucker und verwandter Substanzen. 
Ber Dtsch Chem Ges 62, 1613-1614 (1929). 
184.Lindhorst, T. K. Essentials of Carbohydrate Chemistry and Biochemistry. Edn 3 (WILEY-VCH, Weinheim, 
2007). 
185.Kam, B. L., Barascut, J. L., Imbach, J. L. A general method of synthesis and isolation, and an 
NMR-spectroscopic study, of tetra-O-acetyl-D-aldopento-furanoses. Carbohydr Res 69, 135-142 (1979). 
186.Pathak, A. K., Pathak, V., Bansal, N., Maddry, J. A., Reynolds, R. C. Synthesis of a fluorescent 
arabinofuranosyl disaccharide: a probe for arabinosyltransferase activity in Mycobacterium tuberculosis. 
Tetrahedron Lett 42, 979-982 (2001). 
187.Westphal, O., Feier, H. Darstellung künstlicher Antigene mit determinanten Zuckergruppen, II. Mitteil.: 
Synthese der p-Aminophenyl-O-α-glykoside von L-Fucose, L-Rhamnose, D-galaktose und D-Mannose. 
Eur J Inorg Chem 89, 582-588 (1956). 
188.Legler, G., Stiitz, A. E., Immich, H. Synthesis of 1,5-dideoxy-1,5-imino-D-arabinitol (5-nor-L-fuco-1-
deoxynojirimycin) and its application for the affinity purification and characterisation of α-L-fucosidase. 
Carbohydr Res 272, 17-30 (1995). 
189.Koenigs, W., Knorr, E. Über einige Derivate des Traubenzuckers und der Galaktose. Ber Dtsch Chem Ges 
34, 957-981 (1901). 
190.Bloch, H., Sorkin, E., Erlenmeyer, H. A toxic lipid component of the tubercle bacillus (cord factor). I. Isolation 
from petroleum ether extracts of young bacterial cultures. Am Rev Tuberc 67, 629-643 (1953). 
191.Glickman, M. S., Cox, J. S., Jacobs, W. R. Jr. A novel mycolic acid cyclopropane synthetase is required for 
cording, persistence, and virulence of Mycobacterium tuberculosis. Mol Cell 5, 717-727 (2000). 
192.Backus, K. M. et al. Uptake of unnatural trehalose analogs as a reporter for Mycobacterium tuberculosis. 
Nat Chem Biol 7, 228-235 (2011). 
193.Wang, M., Tu, P. F., Xu, Z. D., Yu, X. L., Yang, M. Design and synthesis of guanidinoglycosides directed 
against the TAR RNA of HIV-1. Helv Chim Acta 86, 2637-2644 (2003). 
194.Jezo, I. Aminoderivate der Saccharose und der α,α-Trehalose. I. Herstellung von 6-Desoxy-6-amino- und 
6,6'-Didesoxy-6,6'-diaminoderivaten. Chem zvesti 25, 364-368 (1971). 
195.Sizovs, A. et al. Poly(trehalose): sugar-coated nanocomplexes promote stabilization and effective polyplex-
mediated siRNA delivery. J Am Chem Soc 135, 15417-15424 (2013). 
196.Hartmann, M., Horst, A. K., Klemm, P., Lindhorst, T. K. A kit for the investigation of live Escherichia coli cell 
adhesion to glycosylated surfaces. Chem Commun 46, 330-332 (2010). 
197.Calmette, A., Plotz, H. Protective inoculation against tuberculosis with BCG. Am Rev Tuberc 19, 567-572 
(1929). 
References 
 
170 
 
198.Sumner, J. B., Howell, S. F. The identification of the hemagglutinin of the jack bean with Concanavalin A. 
J Bacteriol 32, 227–237 (1936). 
199.Nogueira, L. et al. Mycobacterium tuberculosis Rv1419 encodes a secreted 13 kDa lectin with immunological 
reactivity during human tuberculosis. Eur J Immunol 40, 744-753 (2010). 
200.Patra, D. et al. Cloning, expression, purification, crystallization and preliminary X-ray studies of a secreted 
lectin (Rv1419) from Mycobacterium tuberculosis. Acta Crystallogr Sect F Struct Biol Cryst Commun 66, 
1662-1665 (2010). 
201.Patra, D., Sharma, A., Chandran, D., Vijayan, M. Cloning, expression, purification, crystallization and 
preliminary X-ray studies of the mannose-binding lectin domain of MSMEG_3662 from Mycobacterium 
smegmatis. Acta Crystallogr Sect F Struct Biol Cryst Commun 67, 596-599 (2011). 
202.Sewón, L. A., Karjalainen, S. M., Söderling, E., Lapinleimu, H., Simell, O. Associations between salivary 
calcium and oral health. J Clin Periodontol 25, 913-919 (1998). 
203.Smith, E., Collins, I. Photoaffinity labeling in target- and binding-site identification. Future Med Chem 7, 
159-183 (2015). 
204.Vodovozova, E. L. Photoaffinity labeling and its application in structural biology. Biochemistry  72, 1-20 
(2007). 
205.Sumranjit, J., Chung, S. J. Recent advances in target characterization and identification by photoaffinity 
probes. Molecules 18, 10425-10451 (2013). 
206.Pham, N. D., Parker, R. B., Kohler, J. J. Photocrosslinking approaches to interactome mapping. 
Curr Opinin Chem Biol 17, 90-101 (2013). 
207.Dubinsky, L., Krom, B. P., Meijler, M. M. Diazirine based photoaffinity labeling. Bioorg Med Chem 20, 
554-570 (2012). 
208.Yu, S. H. et al. Metabolic labeling enables selective photocrosslinking of O-GlcNAc-modified proteins to their 
binding partners. Proc Natl Acad Sci USA 109, 4834-4839 (2012). 
209.Hashimoto, M., Hatanaka, Y. Recent progress in diazirine-based photoaffinity labeling. Eur J Org Chem 
2008, 2513-2523 (2008). 
210.Yu, S. H., Wands, A. M., Kohler, J. J. Photoaffinity probes for studying carbohydrate biology. 
J Carbohydr Chem 31, 325-352 (2012). 
211.Bond, M. R., Whitman, C. M., Kohler, J. J. Metabolically incorporated photocrosslinking sialic acid covalently 
captures a ganglioside-protein complex. Mol BioSyst 6, 1796-1799 (2010). 
212.Bond, M. R. et al. Metabolism of diazirine-modified N-acetylmannosamine analogues to photo-cross-linking 
sialosides. Bioconjug Chem 22, 1811-1823 (2011). 
213.Tanaka, Y., Kohler, J. J. Photoactivatable crosslinking sugars for capturing glycoprotein interactions. 
J Am Chem Soc 130, 3278-3279 (2008). 
214.Robinette, D., Neamati, N., Tomer, K. B., Borchers, C. H. Photoaffinity labeling combined with mass 
spectrometric approaches as a tool for structural proteomics. Expert Rev Proteomics 3, 399-408 (2006). 
215.Sokurenko, E. V., Vogel, V., Thomas, W. E. Catch-bond mechanism of force-enhanced adhesion: 
counterintuitive, elusive, but … widespread? Cell Host Microbe 4, 314-323 (2008). 
References 
 
171 
 
216.Thomas, W. E., Trintchina, E., Forero, M., Vogel, V., Sokurenko, E. V. Bacterial Adhesion to Target Cells 
Enhanced by Shear Force. Cell 109, 913-923 (2002). 
217.Interlandi, G., Thomas, W. E. The catch bond mechanism between von Willebrand factor and platelet surface 
receptors investigated by molecular dynamics simulations. Proteins 78, 2506-2522 (2010). 
218.Rakshit, S., Zhang, Y., Manibog, K., Shafraz, O., Sivasankar, S. Ideal, catch, and slip bonds in cadherin 
adhesion. Proc Natl Acad Sci USA 109, 18815-18820 (2012). 
219.Dwir, O., Kansas, G. S., Alon, R. An activated L-selectin mutant with conserved equilibrium binding properties 
but enhanced ligand recognition under shear flow. J Biol Chem 275, 18682-18691 (2000). 
220.Thomas, W. E., Nilsson, L. M., Forero, M., Sokurenko, E. V., Vogel, V. Shear-dependent 'stick-and-roll' 
adhesion of type-1 fimbriated Escherichia coli. Mol Microbiol 53, 1545-1557 (2004). 
221.Thielbeer, F., Donaldson, K., Bradley, M. Zeta potential mediated reaction monitoring on nano and 
microparticles. Bioconjugate Chem 22, 144-150 (2011). 
222.Kang, E. T., Tan, K. L., Kato, K., Uyama, Y., Ikada, Y. Surface modification and functionalization of 
polytetrafluoroethylene films. Macromolecules 29, 6872-6879 (1996). 
223.Stanley, C. J., Wilson, S. M. Capture of micro-organisms. US Patent EP2588863 A1 filed 29 Jun. 2011, and 
issued 8 Mai. 2013. 
224.Feinberg, H. et al. Mechanism for recognition of an unusual mycobacterial glycolipid by the macrophage 
receptor Mincle. J Biol Chem 288, 28457-28465 (2013). 
225.Behra, M. et al. Magnetic porous sugar-functionalized PEG microgels for efficient isolation and removal of 
bacteria from solution. Biomacromolecules 14, 1927-1935 (2013). 
226.Sanares, A. M. E., King, N. M., Itthagarun, A., Wong, H. M. Chewing gum as a medium for the delivery of 
anticariogenic therapeutic agents: a review. Hong Kong Dent J 6, 13-22 (2009). 
227.Imfeld, T. Chewing gum - facts and fiction: A review of gum-chewing and oral health. Crit Rev Oral Biol Med 
10, 405-419 (1999). 
228.Meinel, L., Schnabelrauch, M., Schlottig, F. Diagnostic chewing gum for pathogens. Patent WO2013132058 
filed 8 Mar. 2012, and issued 12 Sep. 2013. 
229.Allen, N. Microsoft's Bill Gates invests in chewing gum and chocolate in fight against malaria. The Telegraph 
(2009). 
230.Beatty, W. L. et al. Trafficking and release of mycobacterial lipids from infected macrophages. Traffic 1, 
235-247 (2000). 
231.Kong, Y. et al. Imaging tuberculosis with endogenous beta-lactamase reporter enzyme fluorescence in live 
mice. Proc Natl Acad Sci USA 107, 12239-12244 (2010). 
232.Xie, H. et al. Rapid point-of-care detection of the tuberculosis pathogen using a BlaC-specific fluorogenic 
probe. Nat Chem 4, 802-809 (2012). 
233.Cheng, Y. et al. Fluorogenic probes with substitutions at the 2 and 7 positions of cephalosporin are highly 
BlaC-specific for rapid Mycobacterium tuberculosis detection. Angew Chem Int Ed 53, 9360-9364 (2014). 
234.Song, H., Sandie, R., Wang, Y., Andrade-Navarro, M. A., Niederweis, M. Identification of outer membrane 
proteins of Mycobacterium tuberculosis. Tuberculosis 88, 526-544 (2008). 
References 
 
172 
 
235.Stover, C. K. et al. New use of BCG for recombinant vaccines. Nature 351, 456-460 (1991). 
236.Hillemann, D., Warren, R., Kubica, T., Rüsch-Gerdes, S., Niemann, S. Rapid detection of Mycobacterium 
tuberculosis Beijing genotype strains by real-time PCR. J Clin Microbiol 44, 302-306 (2006). 
237.Amaike, M., Kobayashi, H., Shinkai, S. New organogelators bearing both sugar and cholesterol units: an 
approach toward molecular design of universal gelators. Bull Chem Soc Jpn 73, 2553-2558 (2000). 
238.Dumont, A., Malleron, A., Awwad, M., Dukan, S., Vauzeilles, B. Click-mediated labeling of bacterial 
membranes through metabolic modification of the lipopolysaccharide inner core. Angew Chem 124, 
3197-3200 (2012). 
239.Sadamoto, R. et al. Cell-wall engineering of living bacteria. J Am Chem Soc 124, 9018-9019 (2002). 
240.Tra, V. N., Dube, D. H. Glycans in pathogenic bacteria - potential for targeted covalent therapeutics and 
imaging agents. Chem Commun 50, 4659-4673 (2014). 
241.Dube, D. Metabolic oligosaccharide engineering as a tool for glycobiology. Curr Opin Chem Biol 7, 616-625 
(2003). 
242.Laughlin, S. T., Bertozzi, C. R. Metabolic labeling of glycans with azido sugars and subsequent glycan-
profiling and visualization via Staudinger ligation. Nat Protoc 2, 2930-2944 (2007). 
243.Mahal, L. K., Yarema, K. J., Bertozzi, C. R. Engineering chemical reactivity on cell surfaces through 
oligosaccharide biosynthesis. Science 276, 1125-1128 (1997). 
244.Saxon, E., Bertozzi, C. R. Cell surface engineering by a modified Staudinger reaction. Science 287, 
2007-2010 (2000). 
245.Keppler, O. T., Horstkorte, R., Pawlita, M., Schmidt, C., Reutter, W. Biochemical engineering of the N-acetyl 
side chain of sialic acid: biological implications. Glycobiology 11, 11R-18R (2001). 
246.Keppler, O. T. et al. Biosynthetic modulations of sialic acid dependent virus-receptor Interactions of two 
primate polyoma viruses. J Biol Chem 270, 1308-1314 (1995). 
247.Sletten, E. M., Bertozzi, C. R. From mechanism to mouse: a tale of two bioorthogonal reactions. 
Acc Chem Res 44, 666-676 (2011). 
248.Prescher, J. A., Bertozzi, C. R. Chemistry in living systems. Nat Chem Biol 1, 12-21 (2005). 
249.Sletten, E. M., Bertozzi, C. R. Bioorthogonal chemistry: fishing for selectivity in a sea of functionality. 
Angew Chem Int Ed 48, 6974-6998 (2009). 
250.Ramil, C. P., Lin, Q. Bioorthogonal chemistry: strategies and recent developments. Chem Commun 49, 
11007-11022 (2013). 
251.Lim, R. K. V., Lin, Q. Bioorthogonal chemistry: recent progress and future directions. Chem Commun 46, 
1589-1600 (2010). 
252.Hangauer, M. J., Bertozzi, C. R. A FRET-based fluorogenic phosphine for live-cell imaging with the 
Staudinger ligation. Angew Chem Int Ed 47, 2394-2397 (2008). 
253.Rostovtsev, V. V., Green, L. G., Fokin, V. V., Sharpless, K. B. A Stepwise Huisgen cycloaddition process: 
Copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes. Angew Chem 114, 2708-2711 
(2002). 
References 
 
173 
 
254.Tornøe, C. W., Christensen, C., Meldal, M. Peptidotriazoles on Solid Phase. [1,2,3]-Triazoles by regiospecific 
copper(I)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides. J Org Chem 67, 3057-3064 
(2002). 
255.Presolski, S. I., Hong, V., Cho, S.-H., Finn, M. G. Tailored ligand acceleration of the Cu-catalyzed azide-
alkyne cycloaddition reaction: practical and mechanistic implications. J Am Chem Soc 132, 14570-14576 
(2010). 
256.Gaetke, L., Chow, C. K. Copper toxicity, oxidative stress, and antioxidant nutrients. Toxicology 189, 147-163 
(2003). 
257.Zödl, B., Zeiner, M., Marktl, W., Steffan, I., Ekmekcioglu, C. Pharmacological levels of copper exert toxic 
effects in Caco-2 cells. Biol Trace Elem Res  96, 143-152 (2003). 
258.Kennedy, D. C. et al. Cellular consequences of copper complexes used to catalyze bioorthogonal click 
reactions. J Am Chem Soc 133, 17993-18001 (2011). 
259.Hong, V., Steinmetz, N. F., Manchester, M., Finn, M. G. Labeling live cells by copper-catalyzed alkyne-azide 
click chemistry. Bioconjug Chem 21, 1912-1916 (2010). 
260.Chan, T. R., Hilgraf, R., Sharpless, K. B., Fokin, V. V. Polytriazoles as copper(I)-stabilizing ligands in 
catalysis. Org Lett 6, 2853-2855 (2004). 
261.Besanceney-Webler, C. et al. Increasing the efficacy of bioorthogonal click reactions for bioconjugation: a 
comparative study. Angew Chem 50, 8051-8056 (2011). 
262.Michaels, H. A., Zhu, L. Ligand-assisted, copper(II) acetate-accelerated azide-alkyne cycloaddition. 
Chem Asian J 6, 2825-2834 (2011). 
263.Wang, W. et al. Sulfated ligands for the copper(I)-catalyzed azide-alkyne cycloaddition. Chem Asian J 6, 
2796-2802 (2011). 
264.Agard, N. J., Prescher, J. A. & Bertozzi, C. R. A strain-promoted [3 + 2] azide-alkyne cycloaddition for 
covalent modification of biomolecules in living systems. J Am Chem Soc 126, 15046-15047 (2004). 
265.Baskin, J. M. et al. Copper-free click chemistry for dynamic in vivo imaging. Proc Natl Acad Sci USA 104, 
16793-16797 (2007). 
266.Wittig, G., Krebs, A. Zur Existenz niedergliedriger Cycloalkine, I. Eur J Inorg Chem 94, 3260-3275 (1961). 
267. de Almeida, G., Townsend, L. C., Bertozzi, C. R. Synthesis and reactivity of dibenzoselenacycloheptynes. 
Org Lett 15, 3038-3041 (2013). 
268.Debets, M. F. et al. Aza-dibenzocyclooctynes for fast and efficient enzyme PEGylation via copper-free (3+2) 
cycloaddition. Chem Commun 46, 97-99 (2010). 
269.Chigrinova, M. et al. Rearrangements and addition reactions of biarylazacyclooctynones and the implications 
to copper-free click chemistry. Org Biomol Chem 11, 3436-3441 (2013). 
270.Dehnert, K. W. et al. Imaging the sialome during zebrafish development with copper-free click chemistry. 
Chembiochem 13, 353-357 (2012). 
271.Dehnert, K. W. et al. Metabolic labeling of fucosylated glycans in developing zebrafish. ACS Chem Biol 6, 
547-552 (2011). 
272.Laughlin, S. T., Baskin, J. M., Amacher, S. L., Bertozzi, C. R. In vivo imaging of membrane-associated 
glycans in developing zebrafish. Science 320, 664-667 (2008). 
References 
 
174 
 
273.Laughlin, S. T., Bertozzi, C. R. In vivo imaging of Caenorhabditis elegans glycans. ACS Chem Biol 4, 
1068-1072 (2009). 
274.Chang, P. V. et al. Copper-free click chemistry in living animals. Proc Natl Acad Sci USA 107, 1821-1826 
(2010). 
275.Nauman, D. A., Bertozzi, C. R. Kinetic parameters for small-molecule drug delivery by covalent cell surface 
targeting. Biochim Biophys Acta. 1568, 147-154 (2001). 
276.Dirksen, A., Hackeng, T. M., Dawson, P. E. Nucleophilic catalysis of oxime ligation. Angew Chem Int Ed 45, 
7581-7584 (2006). 
277.Li, J. et al. Ligand-free palladium-mediated site-specific protein labeling inside Gram-negative bacterial 
pathogens. J Am Chem Soc 135, 7330-7338 (2013). 
278.Patterson, D. M., Nazarova, L. A., Xie, B., Kamber, D. N., Prescher, J. A. Functionalized cyclopropenes as 
bioorthogonal chemical reporters. J Am Chem Soc 134, 18638-18643 (2012). 
279.Song, W. et al. A metabolic alkene reporter for spatiotemporally controlled imaging of newly synthesized 
proteins in mammalian cells. ACS Chem Biol 5, 875–885 (2010). 
280.Li, Q., Dong, T., Liu, X., Lei, X. A bioorthogonal ligation enabled by click cycloaddition of o-quinolinone 
quinone methide and vinyl thioether. J Am Chem Soc 135, 4996-4999 (2013). 
281.Doboszewski, B., Herdewijn, P. Carbohydrate chiral-pool approach to four enantiomerically pure 
2-naphthylmethyl 3-hydroxy-2-methylbutanoates. Tetrahedron 64, 5551-5562 (2008). 
282.Elliott, R. P. et al. Attempted ring contraction of α-triflates of 3-azido- and 3-fluoro-γ-lactones to oxetanes. 
Tetrahedron 1, 715-718 (1990). 
283.Moravcov, J., Capkova, J., Stanek, J. One-pot synthesis of 1,2-O-isopropylidene-α-D-xylofuranose. 
Carbohydr Res 263, 61-66 (1994). 
284.Botta, O., Moyroud, E., Lobato, C., Strazewski, P. Synthesis of 3'-azido- and 3'-amino-3'-deoxyadenosine in 
both enantiomeric forms. Tetrahedron 54, 13529-13546 (1998). 
285.McDevitt, J. P., Lansbury, P. T. Glycosamino acids. New building blocks for combinatorial synthesis. 
J Am Chem Soc 118, 3818-3828 (1996). 
286.Smellie, I. A., Bhakta, S., Sim, E., Fairbanks, A. J. Synthesis of putative chain terminators of mycobacterial 
arabinan biosynthesis. Org Biomol Chem 5, 2257-2266 (2007). 
287.Tracy, B. P., Gaida, S. M., Papoutsakis, E. T. Flow cytometry for bacteria. Enabling metabolic engineering, 
synthetic biology and the elucidation of complex phenotypes. Curr Opin Biotechnol 21, 85-99 (2010). 
288.Michelucci, A. et al. Immune-responsive gene 1 protein links metabolism to immunity by catalyzing itaconic 
acid production. Proc Natl Acad Sci USA 110, 7820-7825 (2013). 
289.Khoo, K. H., Tang, J. B., Chatterjee, D. Variation in mannose-capped terminal arabinan motifs of 
lipoarabinomannans from clinical isolates of Mycobacterium tuberculosis and Mycobacterium avium complex. 
J Biol Chem 276, 3863-3871 (2001). 
290.Chatterjee, D., Lowell, K., Rivoire, B., McNeil, M. R., Brennan, P. J. Lipoarabinomannan of Mycobacterium 
tuberculosis. J Biol Chem 267, 6234-6239 (1992). 
291.Venisse, A., Berjeaud, J. M., Chaurand, P., Gilleron, M., Puzo, G. Structural features of lipoarabinomannan 
from Mycobacterium bovis BCG. J Biol Chem 268, 12401-12411 (1993). 
References 
 
175 
 
292.Ortalo-Magné, A., Andersen, A. B., Daffé, M. The outermost capsular arabinomannans and other 
mannoconjugates of virulent and avirulent tubercle bacilli. Microbiology 142, 927-935 (1996). 
293.Fratti, R. A., Backer, J. M., Gruenberg, J., Corvera, S., Deretic, V. Role of phosphatidylinositol 3-kinase and 
Rab5 effectors in phagosomal biogenesis and mycobacterial phagosome maturation arrest. J Cell Biol 154, 
631-644 (2001). 
294.Sturgill-Koszycki, S. et al. Lack of acidification in Mycobacterium phagosomes produced by exclusion of the 
visicular proton-ATPase. Science 263, 678-681 (1994). 
295.Bozyczko-Coyne, D., McKenna, B. W., Connors, T. J., Neff, N. T. A rapid fluorometric assay to measure 
neuronal survival in vitro. J Neurosci Methods 50, 205-216 (1993). 
296.Charrier, C. et al. Cysteamine (Lynovex), a novel mucoactive antimicrobial & antibiofilm agent for the 
treatment of cystic fibrosis. Orphanet J Rare Dis 9, 189-200 (2014). 
297.Suzuki, T. et al. Design, synthesis, and biological activity of folate receptor-targeted prodrugs of thiolate 
histone deacetylase inhibitors. Bioorg Med Chem Lett 17, 4208-4212 (2007). 
298.Straten, N. C. R., van der Marel, G. A., van Boom, J. H. An Expeditious Route to the Synthesis of 
Adenophostin A. Tetrahedron Lett 37, 3599-3602 (1996). 
299.Fessele, C., Lindhorst, T. K. Effect of aminophenyl and aminothiahexyl α-D-glycosides of the manno-, gluco-, 
and galacto-series on type-1 fimbriae-mediated adhesion of Escherichia coli. Biology 2, 1135-1149 (2013). 
300.Dheda, K. et al. Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients 
using urine and sputum samples. PloS One 5, e9848 (2010). 
301.Slayden, R. A., Lee, R. E., Barry, C. E. 3rd Isoniazid affects multiple components of the type II fatty acid 
synthase system of Mycobacterium tuberculosis. Mol Microbiol 38, 514-525 (2000). 
302.Siegrist, M. S. et al. D-Amino acid chemical reporters reveal peptidoglycan dynamics of an intracellular 
pathogen. ACS Chem Biol 8, 500-505 (2013). 
303.Edson, N. L. The intermediary metabolism of the mycobacteria. Bacteriol Rev. 15, 147-182 (1951). 
304.Izumori, K., Yamanaka, K., Elbein, D. Pentose metabolism in Mycobacterium smegmatis: Specificity of 
induction of pentose isomerases. J Bacteriol 128, 587-591 (1976). 
305.Titgemeyer, F. et al. A genomic view of sugar transport in Mycobacterium smegmatis and Mycobacterium 
tuberculosis. J Bacteriol 189, 5903-5915 (2007). 
306.Braibant, M., Gilot, P., Content, J. The ATP binding cassette (ABC) transport systems of Mycobacterium 
tuberculosis. FEMS Microbiol Rev 24, 449-467 (2000). 
307.Wolucka, B. A., McNeil, M. R., de Hoffmann, E. Chojnacki, T., Brennan, P. J. Recognition of the lipid 
intermediate for arabinogalactadkabinomannan biosynthesis and its relation to the mode of action of 
ethambutol on mycobacteria. J Biol Chem 269, 23328-23335 (1994). 
308.Basso, L. A. et al. Purine nucleoside phosphorylase from Mycobacterium tuberculosis. Analysis of inhibition 
by a transition-state analogue and dissection by parts. Biochemistry 40, 8196-8203 (2001). 
309.Sigrell, J. A., Cameron, A. D., Jones, T. A., Mowbray, S. L. Purification, characterization, and crystallization of 
Escherichia coli ribokinase. Protein Sci 6, 2474-2476 (1997). 
References 
 
176 
 
310.Reddy, M. C. et al. High resolution crystal structures of Mycobacterium tuberculosis adenosine kinase: 
insights into the mechanism and specificity of this novel prokaryotic enzyme. J Biol Chem 282, 27334-27342 
(2007). 
311.Sassetti, C. M., Boyd, D. H., Rubin, E. J. Genes required for mycobacterial growth defined by high density 
mutagenesis. Mol Microbiol 48, 77-84 (2003). 
312.Winkler, C., Denker, K., Wortelkamp, S., Sickmann, A. Silver- and Coomassie-staining protocols: detection 
limits and compatibility with ESI MS. Electrophoresis 28, 2095-2099 (2007). 
313.Ragas, A., Roussel, L., Puzo, G., Rivière, M. The Mycobacterium tuberculosis cell-surface glycoprotein apa 
as a potential adhesin to colonize target cells via the innate immune system pulmonary C-type lectin 
surfactant protein A. J Biol Chem 282, 5133-5142 (2007). 
314.Dobos, K. M., Khoo, K. H., Swiderek, K. M., Brennan, P. J., Belisle, J. T. Definition of the full extent of 
glycosylation of the 45-kilodalton glycoprotein of Mycobacterium tuberculosis. J Bacteriol 178, 2498-2506 
(1996). 
315.Smith, G. T., Sweredoski, M. J., Hess, S. O-linked glycosylation sites profiling in Mycobacterium tuberculosis 
culture filtrate proteins. J Proteomics 97, 296-306 (2014). 
316.Foley, H. N., Stewart, J. A., Kavunja, H. W., Rundell, S. R., Swarts, B. M. Bioorthogonal chemical reporters 
for selective in situ probing of mycomembrane components in mycobacteria. Angew Chem 128, 2093-2097 
(2016). 
317.Lowery, R., Gibson, M. I., Thompson, R. L., Fullam, E. Deuterated carbohydrate probes as 'label-free' 
substrates for probing nutrient uptake in mycobacteria by nuclear reaction analysis. Chem Commun 51, 
4838-4841 (2015). 
318.Russell, D. G. et al. Mycobacterium tuberculosis wears what it eats. Cell Host Microbe 8, 68-76 (2010). 
319.Homolka, S., Niemann, S., Russell, D. G., Rohde, K. H., Deretic, V. Functional genetic diversity among 
Mycobacterium tuberculosis complex clinical isolates. Delineation of conserved core and lineage-specific 
transcriptomes during intracellular survival. PLoS Pathog 6, e1000988 (2010). 
320.Meredith, T. C., Aggarwal, P., Mamat, U., Lindner, B., Woodard, R. W. Redefining the requisite 
lipopolysaccharide structure in Escherichia coli. ACS Chem Biol 1, 33-42 (2006). 
321.Ray, P. H. Purification and characterization of 3-deoxy-D-manno-octulosonate 8-phosphate synthetase from 
Escherichia coli. J Bacteriol 141, 635-644 (1980). 
322.Cech, D., Wang, P. F., Holler, T. P., Woodard, R. W. Analysis of the arabinose-5-phosphate isomerase of 
Bacteroides fragilis provides insight into regulation of single-domain arabinose phosphate isomerases. J 
Bacteriol 196, 2861-2868 (2014). 
323.Horecker, B. L. The pentose phosphate pathway. J Biol Chem 277, 47965-47971 (2002). 
324.Xavier Da Silveira, E., Jones, C., Wait, R., Previato, J. O., Mendonca-Previato, L. Glycoinositol phospholipids 
from Endotrypanum species express epitopes in common with saccharide side chains of the 
lipophosphoglycan from Leishmania major. Biochem J 329, 665-673 (1998). 
325.Pimenta, P. F. et al. Stage-specific adhesion of Leishmania promastigotes to the sandfly midgut. Science 
256, 1812-1815 (1992). 
326.Kamhawi, S. et al. A role for insect galectins in parasite survival. Cell 119, 329-341 (2004). 
References 
 
177 
 
327.Novozhilova, N. M., Bovin, N. V. D-Arabinose methabolism: characterization of bifunctional arabinokinase/ 
pyrophosphorylase of Leishmania major. Acta Naturae, 81-83 (2009). 
328.Meniche, X. et al. Subpolar addition of new cell wall is directed by DivIVA in mycobacteria. 
Proc Natl Acad Sci USA 111, E3243-51 (2014). 
329.Hett, E. C., Rubin, E. J. Bacterial growth and cell division: a mycobacterial perspective. 
Microbiol Mol Biol Rev  72, 126-156 (2008). 
330.Thanky, N. R., Young, D. B., Robertson, B. D. Unusual features of the cell cycle in mycobacteria: polar-
restricted growth and the snapping-model of cell division. Tuberculosis  87, 231-236 (2007). 
331.Plocinski, P. et al. Mycobacterium tuberculosis CwsA interacts with CrgA and Wag31, and the CrgA-CwsA 
complex is involved in peptidoglycan synthesis and cell shape determination. J Bacteriol. 194, 6398-6409 
(2012). 
332.Vergne, I., Chua, J., Singh, S. B., Deretic, V. Cell biology of Mycobacterium tuberculosis phagosome. 
AnnuRev Cell Dev Biol 20, 367–394 (2004). 
333.Russell, D. G. Mycobacterium tuberculosis: here today, and here tomorrow. Nat Rev Mol Cell Biol 2, 569-577 
(2001). 
334.Clemens, D. L., Lee, B. Y., Horwitz, M. A. Deviant expression of Rab5 on phagosomes containing the 
intracellular pathogens Mycobacterium tuberculosis and Legionella pneumophila is associated with altered 
phagosomal fate. Infect Immun 68, 2671-2684 (2000). 
335.Via, L. E. et al. Arrest of mycobacterial phagosome maturation is caused by a block in vesicle fusion between 
stages controlled by Rab5 and Rab7. J Biol Chem 272, 13326-13331 (1997). 
336.Ullrich, H. J., Beatty, W. L., Russell, D. G. Direct delivery of procathepsin D to phagosomes. Implications for 
phagosome biogenesis and parasitism by Mycobacterium. Eur J Cell Biol 78, 739-748 (1999). 
337.Via, L. E. et al. Effects of cytokines on mycobacterial phagosome maturation. J Cell Sci 111, 897-905 (1998). 
338.Sukumar, N., Tan, S., Aldridge, B. B., Russell, D. G., Salgame, P. Exploitation of Mycobacterium tuberculosis 
reporter strains to probe the impact of vaccination at sites of infection. PLoS Pathog 10, e1004394 (2014). 
339.Tan, S., Sukumar, N., Abramovitch, R. B., Parish, T., Russell, D. G. Mycobacterium tuberculosis responds to 
chloride and pH as synergistic cues to the immune status of its host cell. PLoS Pathog 9, e1003282 (2013). 
340.Kaplan, G. et al. Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed 
immunity. Infect Immun 71, 7099-7108 (2003). 
341.Keener, A. B. Oldie but goodie: Repurposing penicillin for tuberculosis. Nat Med 20, 976-978 (2014). 
342.Prosser, G. A., de Carvalho, L. P. Kinetic mechanism and inhibition of Mycobacterium tuberculosis D-alanine: 
D-alanine ligase by the antibiotic D-cycloserine. FEBS J 280, 1150-1166 (2013). 
343.Kaewsapsak, P., Esonu, O., Dube, D. H. Recruiting the host's immune system to target Helicobacter pylori's 
surface glycans. Chembiochem 14, 721-726 (2013). 
344.Memmel, E., Homann, A., Oelschlaeger, T. A., Seibel, J. Metabolic glycoengineering of Staphylococcus 
aureus reduces its adherence to human T24 bladder carcinoma cells. Chem Commun 49, 7301-7303 (2013). 
345.McEnaney, P. J., Parker, C. G., Zhang, A. X., Spiegel, D. A. Antibody-recruiting molecules: an emerging 
paradigm for engaging immune function in treating human disease. ACS Chem Biol 7, 1139-1151 (2012). 
References 
 
178 
 
346.Brown, S. B., Brown, E. A., Walker, I. The present and future role of photodynamic therapy in cancer 
treatment. Lancet Oncol 5, 497-508 (2004). 
347.Davis, M. E., Chen, Z. G., Shin, D. M. Nanoparticle therapeutics: an emerging treatment modality for cancer. 
Nat Rev Drug Discov 7, 771-782 (2008). 
348.O’Connor, A. E., Gallagher, W. M., Byrne, A. T. Porphyrin and nonporphyrin photosensitizers in oncology. 
Preclinical and clinical advances in photodynamic therapy. Photochem Photobiol 85, 1053-1074 (2009). 
349.Josefsen, L. B., Boyle, R. W. Unique diagnostic and therapeutic roles of porphyrins and phthalocyanines in 
photodynamic therapy, imaging and theranostics. Theranostics 2, 916-966 (2012). 
350.Moan, J., Berg, K. The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet 
oxygen. Photochem Photobiol 53, 549-553 (1991). 
351.Sharma, S. K. et al. Drug discovery of antimicrobial photosensitizers using animal models. Curr Pharm Des 
17, 1303-1319 (2011). 
352.Sperandio, F. F., Huang, Y. Y., Hamblin, M. R. Antimicrobial photodynamic therapy to kill Gram-negative 
bacteria. Recent Pat Antiinfect Drug Discov 8, 108-120 (2013). 
353.Wardlaw, J. L., Sullivan, T. J., Lux, C. N., Austin, F. W. Photodynamic therapy against common bacteria 
causing wound and skin infections. Vet J 192, 374-377 (2012). 
354.Verma, R. K. et al. Inhalable microparticles containing nitric oxide donors: saying NO to intracellular 
Mycobacterium tuberculosis. Mol Pharm 9, 3183-3189 (2012). 
355.Verma, R. K. et al. Inhalable microparticles of nitric oxide donors induce phagosome maturation and kill 
Mycobacterium tuberculosis. Tuberculosis 93, 412-417 (2013). 
356.Doane, T. L., Burda, C. The unique role of nanoparticles in nanomedicine: imaging, drug delivery and 
therapy. Chem Soc Rev 41, 2885-2911 (2012). 
357.Norman, R. S., Stone, J. W., Gole, A., Murphy, C. J., Sabo-Attwood, T. L. Targeted photothermal lysis of the 
pathogenic bacteria, Pseudomonas aeruginosa, with gold nanorods. Nano Lett 8, 302-306 (2008). 
358.Wirth, T. et al. Origin, spread and demography of the Mycobacterium tuberculosis complex. PLoS Pathog 4, 
e1000160 (2008). 
359.Zelmer, A. et al. A new in vivo model to test anti-tuberculosis drugs using fluorescence imaging. J Antimicrob 
Chemother 67, 1948-1960 (2012). 
360.Carroll, P. et al. Sensitive detection of gene expression in mycobacteria under replicating and non-replicating 
conditions using optimized far-red reporters. PloS One 5, e9823 (2010). 
361.Dubray, G., Bezard, G. A Highly sensitive periodic acid-silver stain for 1,2-diol groups of glycoproteins and 
polysaccharides in polyacrylamide gels. Anal Biochem 119, 325-329 (1982). 
362.Tsai, C. M., Frasch, C. E. A Sensitive Silver Stain for Detecting Lipopolysaccharides in Polyacrylamide Gels. 
Anal Biochem 119, 115-119 (1982). 
363.Hashimoto, H., Izumi, M. A Facile synthesis of 5-thio-L-fucose and 3-O-allyl-L-fucose triacetate from D-
arabinose. Chem Lett 21, 25-28 (1992). 
364.Machado, I. C., Alonso, O. M. & Bencomo, V. V. A new approach to the ribosylribitol intermediate for the 
synthesis of Haemophilus influenzae type B oligosaccharides. J Carbohydr Chem 13, 465-474 (1994). 
References 
 
179 
 
365.Vedejs, E., Stults, J. S. Synthesis of azocine derivatives from thio aldehyde Diels-Alder adducts. J Org Chem 
53, 2226-2232 (1988). 
366.Roy, B. C., Mallik, S. Synthesis of conjugated diacetylene, metal-chelating monomers for polymerizable 
monolayer assemblies. Org Lett 3, 1877-1879 (2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 
 
I 
 
5 Appendix  
5.1 NMR spectra 
1H and 13C NMR spectra of new compounds and 1H NMR of known molecules, which were 
used for metabolic labeling:  
 
Figure 56. 1H NMR spectrum (500 MHz, MeOH-d4, 300 K) of p-aminophenyl α-D-arabinofuranoside (1). 
 
 
Figure 57. 13C NMR spectrum (125 MHz, MeOH-d4, 300 K) of p-aminophenyl α-D-arabinofuranoside (1). 
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Figure 59. 13C NMR spectrum (125 MHz, CDCl3, 300 K) of 5-O-tert-butyldimethylsilyl-1,2,3-tri-O-acetyl-
α,β-D-arabinofuranose (13). 
 
 
Figure 58. 1H NMR spectrum (500 MHz, CDCl3, 300 K) of 5-O-tert-butyldimethylsilyl-1,2,3-tri-O-acetyl-
α,β-D-arabinofuranose (13). 
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Figure 60. 1H NMR spectrum (500 MHz, CDCl3, 300 K) of 5-O-benzoyl-1,2,3-tri-O-acetyl-α,β-D-arabinofuranose 
(19).  
 
 
Figure 61. 13C NMR spectrum (125 MHz, CDCl3, 300 K) of 5-O-benzoyl-1,2,3-tri-O-acetyl-α,β-D-arabinofuranose 
(19).  
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Figure 62. 1H NMR spectrum (500 MHz, CDCl3, 300 K) of 5-O-benzoyl-2,3-di-O-acetyl-α,β-D-arabinofuranose 
(20). 
 
 
Figure 63. 13C NMR spectrum (125 MHz, CDCl3, 300 K) of 5-O-benzoyl-2,3-di-O-acetyl-α,β-D-arabinofuranose 
(20). 
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Figure 64. 1H NMR spectrum (500 MHz, CDCl3, 300 K) of p-nitrophenyl 5-O-benzoyl-2,3-di-O-acetyl-
α-D-arabinofuranoside (22). 
 
 
Figure 65. 13C NMR spectrum (125 MHz, CDCl3, 300 K) of p-nitrophenyl 5-O-benzoyl-2,3-di-O-acetyl-
α-D-arabinofuranoside (22). 
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Figure 66. 1H NMR spectrum (500 MHz, MeOH-d4, 300 K) of p-nitrophenyl α-D-arabinofuranoside (23). 
 
 
 
Figure 67. 13C NMR spectrum (125 MHz, MeOH-d4, 300 K) of p-nitrophenyl α-D-arabinofuranoside (23). 
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Figure 68. 1H NMR spectrum (500 MHz, CDCl3, 300 K) of 6-azido-6-deoxy-2,3,4,2’,3’,4’,6’-hepta-O-acetyl-
α,α-D-trehalose (27). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 
 
VIII 
 
 
 
Figure 69. 1H NMR spectrum (500 MHz, D2O, 300 K) of 6-azido-6-deoxy-α,α-D-trehalose (28). 
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Figure 70. 1H NMR spectrum (500 MHz, D2O, 300 K) of 3-azido-3-deoxy-α,β-D-arabinose (38). 
 
 
 
 
Figure 71. 13C NMR spectrum (125 MHz, D2O, 300 K) of 3-azido-3-deoxy-α,β-D-arabinose (38). 
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Figure 72. 1H NMR spectrum (500 MHz, D2O, 300 K) of 3-azido-3-deoxy-α,β-D-ribose (39). 
 
 
 
 
 
 
Figure 73. 13C NMR spectrum (125 MHz, D2O, 300 K) of 3-azido-3-deoxy-α,β-D-ribose (39). 
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Figure 74. 1H NMR spectrum (500 MHz, D2O, 300 K) of 5-azido-5-deoxy-α,β-D-arabinofuranose (40). 
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Figure 75. 1H NMR spectrum (500 MHz, CDCl3, 300 K) of 3-azido-3-deoxy-1,2-O-isopropylidene-
β-D-arabinofuranose (45). 
 
 
 
Figure 76. 13C NMR spectrum (125 MHz, CDCl3, 300 K) of 3-azido-3-deoxy-1,2-O-isopropylidene-
β-D-arabinofuranose (45). 
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Figure 77. 1H NMR spectrum (500 MHz, CDCl3, 300 K) of 5-azido-5-deoxy-1,2,3-tri-O-acetyl-
α,β-D-arabinofuranose (51). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 
 
XIV 
 
 
 
Figure 78. 1H NMR spectrum (500 MHz, CDCl3, 300 K) of 3-azido-3-deoxy-1,2,5-tri-O-acetyl-
α,β-D-arabinose (52). 
 
 
 
Figure 79. 13C NMR spectrum (125 MHz, CDCl3, 300 K) of 3-azido-3-deoxy-1,2,5-tri-O-acetyl-
α,β-D-arabinose (52). 
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Figure 80. 1H NMR spectrum (500 MHz, CDCl3, 300 K) of 3-azido-3-deoxy-1,2,5-tri-O-acetyl-α,β-D-ribose (53). 
 
 
 
Figure 81. 13C NMR spectrum (125 MHz, CDCl3, 300 K) of 3-azido-3-deoxy-1,2,5-tri-O-acetyl-α,β-D-ribose (53). 
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Figure 82. 1H NMR spectrum (500 MHz, D2O, 300 K) of 5-deoxy-5-iodo-α,β-D-arabinofuranose (55). 
 
 
 
 
 
Figure 83. 13C NMR spectrum (125 MHz, D2O, 300 K) of 5-deoxy-5-iodo-α,β-D-arabinofuranose (55). 
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Figure 84. 1H NMR spectrum (500 MHz, CDCl3, 300 K) of 3-O-allyl-5-O-tert-butyldiphenylsilyl-
1,2-O-isopropylidene-β-D-arabinofuranose (56). 
 
 
Figure 85. 13C NMR spectrum (125 MHz, CDCl3, 300 K) of 3-O-allyl-5-O-tert-butyldiphenylsilyl-
1,2-O-isopropylidene-β-D-arabinofuranose (56). 
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Figure 86. 1H NMR spectrum (500 MHz, CDCl3, 300 K) of 3-O-[6’-N-(tert-butoxycarbonyl)amino-4’-thiahexyl]-
1,2-O-isopropylidene-β-D-arabinofuranose (58). 
 
 
 
Figure 87. 13C NMR spectrum (125 MHz, CDCl3, 300 K) of 3-O-[6’-N-(tert-butoxycarbonyl)amino-4’-thiahexyl]-
1,2-O-isopropylidene-β-D-arabinofuranose (58). 
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Figure 88. 1H NMR spectrum (500 MHz, D2O, 300 K) of 3-O-(6’-amino-4’-thiahexyl)-α,β-D-arabinose (59). 
 
 
 
 
 
 
 
Figure 89. 13C NMR spectrum (125 MHz, D2O, 300 K) of 3-O-(6’-amino-4’-thiahexyl)-α,β-D-arabinose (59). 
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Figure 90. 1H NMR spectrum (500 MHz, CDCl3, 300 K) of 3-O-allyl-5-O-tert-butyldiphenylsilyl-
1,2-O-isopropylidene-α-D-ribofuranose (61). 
 
 
Figure 91. 13C NMR spectrum (125 MHz, CDCl3, 300 K) of 3-O-allyl-5-O-tert-butyldiphenylsilyl-
1,2-O-isopropylidene-α-D-ribofuranose (61). 
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Figure 92. 1H NMR spectrum (500 MHz, CDCl3, 300 K) of 3-O-[6’-N-(tert-butoxycarbonyl)amino-4’-thiahexyl]-
1,2-O-isopropylidene-α-D-ribofuranose (63). 
 
 
Figure 93. 13C NMR spectrum (125 MHz, CDCl3, 300 K) of 3-O-[6’-N-(tert-butoxycarbonyl)amino-4’-thiahexyl]-
1,2-O-isopropylidene-α-D-ribofuranose (63). 
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Figure 94. 1H NMR spectrum (500 MHz, D2O, 300 K) of 3-O-(6’-amino-4’-thiahexyl)-α,β-D-ribose (64). 
 
 
 
 
 
 
 
Figure 95. 13C NMR spectrum (125 MHz, D2O, 300 K) of 3-O-(6’-amino-4’-thiahexyl)-α,β-D-ribose (64). 
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Figure 96. 1H NMR spectrum (500 MHz, CDCl3, 300 K) of 5-O-tert-butyldiphenylsilyl-1,2-O-isopropylidene-
3-O-methoxymethyl-β-D-arabinofuranose (65). 
 
 
Figure 97. 13C NMR spectrum (125 MHz, CDCl3, 300 K) of 5-O-tert-butyldiphenylsilyl-1,2-O-isopropylidene-
3-O-methoxymethyl-β-D-arabinofuranose (65). 
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Figure 98. 1H NMR spectrum (500 MHz, CDCl3, 300 K) of 1,2-O-isopropylidene-3-O-methoxymethyl-
β-D-arabinofuranose (66). 
 
 
Figure 99. 13C NMR spectrum (125 MHz, CDCl3, 300 K) of 1,2-O-isopropylidene-3-O-methoxymethyl-
β-D-arabinofuranose (66). 
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Figure 100. 1H NMR spectrum (500 MHz, CDCl3, 300 K) of 5-O-allyl-1,2-O-isopropylidene-3-O-methoxymethyl-
β-D-arabinofuranose (67). 
 
 
Figure 101. 13C NMR spectrum (125 MHz, CDCl3, 300 K) of 5-O-allyl-1,2-O-isopropylidene-3-O-methoxymethyl-
β-D-arabinofuranose (67). 
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Figure 102. 1H NMR spectrum (500 MHz, MeOH-d4, 300 K) of 5-O-allyl-α,β-D-arabinofuranose (68). 
 
 
 
Figure 103. 13C NMR spectrum (125 MHz, MeOH-d4, 300 K) of 5-O-allyl-α,β-D-arabinofuranose (68). 
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Figure 104. 1H NMR spectrum (500 MHz, MeOH-d4, 300 K) of 5-O-[6’-N-(tert-butoxycarbonyl)amino-
4’-thiahexyl]-α,β-D-arabinofuranose (69). 
 
 
Figure 105. 13C NMR spectrum (125 MHz, MeOH-d4, 300 K) of 5-O-[6’-N-(tert-butoxycarbonyl)amino-
4’-thiahexyl]-α,β-D-arabinofuranose (69). 
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Figure 106. 1H NMR spectrum (500 MHz, D2O, 300 K) of 5-O-(6’-amino-4’-thiahexyl)-α,β-D-arabinofuranose 
(70). 
 
 
 
 
 
 
 
Figure 107. 13C NMR spectrum (125 MHz, D2O, 300 K) of 5-O-(6’-amino-4’-thiahexyl)-α,β-D-arabinofuranose 
(70). 
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5.2 Abbreviations 
 
Ab 1 Primary antibody 
Ab 2 Secondary antibody 
ABC ATP-binding cassette 
Ac Acetyl 
Ac3AraAz 3-Azido-3-deoxy-1,2,5-tri-O-acetyl-α,β-D-arabinose 
Ac5AraAz 5-Azido-5-deoxy-1,2,3-tri-O-acetyl-α,β-D-arabinofuranose 
AcManNAz Acetylated N-azidoacetyl-mannosamine  
Ac3RiboAz 3-Azido-3-deoxy-1,2,5-tri-O-acetyl-α,β-D-ribose 
Ac6TreAz 2,3,4,2’,3’,4’,6’-Hepta-O-acetyl-6-azido-α,α-D-trehalose  
Ac2O Acetic anhydride  
AcOH Acetic acid 
ADK Adenosine kinase 
AG Arabinogalactan  
Ag85 Antigen 85  
AIBN Azobisisobutyronitrile  
D-Ala D-Alanine 
L-Ala L-Alanine 
AMP Adenosine monophosphate 
APS Ammonium persulfate 
3AraAz 3-azido-3-deoxy-α,β-D-arabinose  
5AraAz 5-azido-5-deoxy-α,β-D-arabinofuranose 
α-D-Araf  α-D-Arabinofuranoside 
5AraI 5-Deoxy-5-iodo-α,β-D-arabinofuranose 
AraLAM Non-capped LAM 
Arap  D-Arabinopyranose 
Ara5P Arabinose-5-phosphate  
ATP Adenosine triphosphate 
Bad Bcl-2-associated death promoter  
BBQ BlackBerry  
Bcl-2 B-cell lymphoma 2  
BCG Bacillus Calmette-Guérin 
BlaC β-Lactamase C 
Boc tert-Butyloxycarbonyl  
Boc2O di-tert-Butyl dicarbonate 
BP filter Band-pass filter 
BSA Bovine serum albumin  
calc. Calculated 
Calcein AM Acetomethoxy derivate of calcein  
CAMK II Ca2+/calmodulin-dependent protein kinase II 
CAS Central Asian  
CDC Centers for Disease Control and Prevention  
CDCl3, Chloroform-d1 Deuterated chloroform 
cfu Colony forming units  
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CMP Cytidine monophosphate  
ConA Concanavalin A  
COSY Correlation spectroscopy 
CSP Cell surface proteins  
CT Computed tomography  
ct (RT-PCR) Cyle threshold  
C-type  Calcium-dependent 
CyTOF Cytometry by time of flight  
d (NMR) Doublet  
pDADMAC poly-Diallyldimethyl ammonium chloride  
DAP meso-Diaminopimelate 
DAPI 4′,6-Diamidino-2-phenylindole  
DBU 1,8-Diazabicycloundec-7-ene 
DC Dendritic cell 
DCM Dichloromethane  
DC-SIGN DC-specific intercellular adhesion molecule 3-grabbing nonintegrin 
Dectin Dendritic cell-specific C-type lectin  
dest. Distilled 
DETA/NO Diethylenetriamine nitric oxide  
DIBO Dibenzocyclooctyne  
DIPEA N,N-Diisopropylethylamine  
DMF Dimethylformamide  
DMSO Dimethylsulfoxide  
DNA Deoxyribonucleic acid 
dNTPs Deoxynucleoside triphosphates  
DPAP 2,2-Dimethoxy-2-phenyl-acetophenone  
D2O Deuterium oxide 
EAI East African Indian  
ECL Enhanced chemiluminescence 
E. coli Escherichia coli 
EDC 1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide  
EDTA Ethylenediaminetetraacetate  
EEA1 Early endosome antigene 1  
ELISA Enzyme-linked immunosorbent  
ESI-MS Electrospray ionization mass spectrometry  
Et2O Diethyl ether 
FAM Fluorescein  
FDG 2-Deoxy-2-(18F)fluoro-D-glucose 
FDT 2-Deoxy-2-(18F)fluoro-D-trehalose  
FCS Fetal calf serum  
FI Fluorescence intensity 
FITC Fluorescein isothiocyanate  
FRET Fluorescence resonance energy transfer  
FSC Forward scatter 
β-D-Galf β-D-Galactofuranoside 
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Gc Glycolyl 
GFP Green fluorescent protein 
α-D-Glcp α-D-Glucopyranoside 
α/β-D-GlcNAc N-Acetyl-α/β-D-glucosamine 
GPIL Glycosylphosphatidylinositol lipids  
GTPase Enzyme, which binds and hydrolyzes guanosine triphosphate (GTP) 
HBSS Hank’s balanced salt solution  
hEGF Human epidermal growth factor  
HEPES 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid  
hMDM Human monocyte-derived macrophages  
HMEC Human mammary epithelial cells  
HMBC Heteronuclear multiple-bond correlation spectroscopy  
HMM Human macrophage medium  
HOEtBr 2-Bromoethanol 
HOEtCl 2-Chloroethanol 
HRMS  High-resolution mass spectrometry 
HSQC Heteronuclear single-quantum correlation spectroscopy  
IFN-γ Interferon-γ 
IgA Immunoglobulins A 
IgG Immunoglobulins G 
IGRA Interferon-γ release assay  
IR  Infrared 
ISMN Isosorbide mononitrate 
D-IsoGln D-Isoglutamine 
J Coupling constant (in hertz (Hz)) 
k Reaction rate constant 
Kdo 3-Deoxy-D-manno-octulosonic acid  
KdoAz Azide-modified Kdo  
LAM (lipoglycan) Lipoarabinomannan  
LAM (Mtb family) Latin American Mediterranean  
LAMP-1 Lysosome-associated membrane protein 1  
LBB Lectin binding buffer  
LM Lipomannan  
L. major Leishmania major 
LPG Lipophosphoglycan  
LPS Lipopolysaccharide  
LRM Low range marker  
m (NMR) Multiplet 
M. Mycobacterium 
m.p. Melting points  
MA Mycolic acids  
ManLAM Mannosylated LAM 
α-D-Manp  α-D-Mannopyranoside 
mAGP Mycolyl-arabinogalactan-peptidoglycan  
MBL Mannose-binding lectin  
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MCL Macrophage C-type lectin  
M-CSF Macrophage colony stimulating factor  
MDR Multi-drug resistant 
MeOH Methanol  
MES 2-(N-morpholino)ethanesulfonic acid  
Methanol-d4 Deuterated methanol 
MFI Mean fluorescence intensity 
Mid-log phase Middle logarithmic phase 
Mincle Macrophage inducible C-type lectin  
MmpL3 Mycobacterial membrane protein large 3  
MOE Metabolic oligosaccharide engineering  
MOI Multiplicity of infection  
MOMCl Chloromethyl methyl ether  
MR Mannose receptor  
MRT Magnetic resonance tomography  
Msg Mycobacterium smegmatis  
Mtb Mycobacterium tuberculosis 
MTBC Mycobacterium tuberculosis complex  
β-D-MurNAc/Gc N-Acetyl-/N-glycolyl-β-D-muramic acid 
m/z Mass-to-charge ratio 
MVL Microcystis viridis lectin 
MWCO  Molecular weight cut-off 
NAD Nicotinamide adenine dinucleotide 
NaOAc Sodium acetate 
NaOMe Sodium methoxide 
NGS Normal goat serum  
NHS N-Hydroxysuccinimide  
NMR Nuclear magnetic resonance 
pNO2PhOH p-Nitrophenol 
NRC National Reference Center  
OADC Oleic acid, albumin, dextrose, catalase 
OD Optical density  
OtsA Trehalose-6-phosphate synthase  
OtsB Trehalose-6-phosphate phosphatase  
PAL Photoaffinity labeling  
PAS Periodic acid-Schiff reaction  
PBMC Peripheral blood mononuclear cells  
PBS Phosphate buffered saline  
PBSB PBS supplemented with BSA 
PCR Polymerase chain reaction 
Pd/C Palladium on charcoal 
PEG Polyethylene glycol 
PEP Phosphoenolpyruvate  
PET Positron emission tomography  
PFA Paraformaldehyde  
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PG Peptidoglycan  
PGL Phenolic glycolipids  
PI Phosphatidylinositol  
PI3K Phosphatidylinositol 3 kinase  
PILAM Phosphate-capped LAM 
PIM Phosphatidylinositol mannosides  
PI3P Phosphatidylinositol 3-phosphate  
ppm Parts per million 
PRRs Pattern recognition receptors  
PVDF Polyvinylidene fluoride  
q (NMR) Quartet 
QD Quantum dots  
quant. Quantitative 
Rab5 Ras-related in brain 5  
Rf Retention factor 
RFI Relative fluorescence intensity 
α-D-Rhap α-D-Rhamnopyranoside 
3RiboAz 3-Azido-3-deoxy-α,β-D-ribose  
RIFA Rifampicin  
RK Ribokinase  
RLU Relative light units 
RNA Ribonucleic acid 
RNS Reactive nitrogen species  
ROS Reactive oxygen species  
rt Room temperature 
RT-PCR Real-time PCR  
R-type Ricin-type 
Ru5P Ribulose 5-phosphate  
s (NMR) Singlet 
SD Standard deviation 
SDS Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis  
SEM Standard error of the mean 
S-HRP Streptavidin-horseradish peroxidase  
SL Sulfolipids  
sMTL-13 13 kDa large lectin from Mtb 
SNP Sodium nitroprusside  
SOD Superoxide dismutase  
SP-A Surfactant proteins A  
SPAAC Strain promoted azide-alkyne cycloaddition 
SSC Sideward scatter 
SugABC ATP-dependent sugar transporter  
t (NMR) Triplet  
Taq Thermus aquaticus  
Tb Tuberculosis 
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TBAI Tetrabutylammonium iodide  
TBAF tetra-N-Butylammonium fluoride  
TBDMSCl tert-Butyl-dimethylsilyl chloride  
TBDPSCl tert-Butyl-diphenylsilyl chloride  
TBO Toluidine blue O  
TBS Tris-buffered saline  
TDM Trehalose 6,6'-dimycolate  
TEMED N,N,N′,N′-Tetramethylethylenediamine  
TFA Trifluoroacetic acid  
Tf2O Trifluoromethanesulfonic anhydride  
TGN trans-Golgi network 
THF Terahydrofuran  
TLC Thin layer chromatography  
TLRs Toll-like receptors  
TMM Trehalose 6-monomycolate  
TMS Tetramethylsilane  
TOF-MS Time-of-flight mass spectrometry 
T6P Trehalose-6-phosphate  
trHbN NO detoxifying truncated hemoglobin  
6TreAz 6-Azido-6-deoxy-D-trehalose  
Tris Tris(hydroxymethyl)aminomethane  
TreY Maltooligosyltrehalose synthase  
TreZ Maltooligosyltrehalose trehalohydrolase  
TsCl Tosyl chloride 
p-TsOH p-Toluenesulfonic acid  
TST Tuberculin skin test 
T-TBS TBS supplemented with Tween 20 
UDP Uracil-diphosphate 
UDP-MurNAc uridine diphosphate N-acetylmuramic acid  
UK United Kingdom 
USA United States of America 
UV Ultraviolet 
WHO World Health Organization 
XDR Extensively-drug resistant 
YAK YakimaYellow  
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